CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
5825488,58254886,6,F,20070831.0,20121225.0,20050624,20130104,EXP,,JP-ABBOTT-03P-087-0212201-00,ABBOTT,,28.0,YR,,M,Y,,,20130104.0,,MD,COUNTRY NOT SPECIFIED,JP,EFAVIRENZ;EFAVIRENZ/EMTRICITABIN/TENOFOVIR DISOPROX FUM,Hepatitis C;Hyperglycaemia,58254886.0,HO,,,58254886.0,1.0,20020123.0,20040309.0,,,58254886.0,1.0,HIV infection
6334520,63345204,4,F,20060909.0,20131212.0,20070615,20131217,EXP,,US-GILEAD-2007-0012398,GILEAD,,27.0,YR,,F,Y,,,20131217.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pregnancy;Ultrasound antenatal screen abnormal,,,,,63345204.0,1.0,20061128.0,20070604.0,,,63345204.0,1.0,HIV infection
6334643,63346434,4,F,,20131212.0,20070615,20131216,EXP,,US-GILEAD-2007-0012399,GILEAD,,,,,M,Y,3.57,KG,20131216.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital naevus,63346434.0,CA,,,63346434.0,1.0,20061128.0,20070604.0,,,63346434.0,1.0,HIV infection
6821483,68214833,3,F,20081112.0,20131212.0,20081125,20131217,EXP,,US-GILEAD-2008-0019105,GILEAD,,27.0,YR,,F,Y,,,20131217.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Stillbirth,68214833.0,OT,,,68214833.0,1.0,20081009.0,,,,68214833.0,1.0,HIV infection
7370455,73704554,4,F,20091130.0,20160819.0,20100429,20160826,EXP,,US-GILEAD-2010-0028688,GILEAD,,40.0,YR,A,F,Y,,,20160826.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Amniocentesis abnormal;Maternal exposure during pregnancy,73704554.0,OT,,,73704554.0,1.0,20091201.0,20091101.0,,,73704554.0,1.0,HIV infection
7370594,73705944,4,F,20100311.0,20160822.0,20100429,20160825,EXP,,US-GILEAD-2010-0028690,GILEAD,,,,,,Y,,,20160825.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Klinefelter's syndrome,73705944.0,OT,,,73705944.0,1.0,20091201.0,20100327.0,,,73705944.0,1.0,HIV infection
7371076,73710763,3,F,20100317.0,20160822.0,20100429,20160830,EXP,,US-GILEAD-2010-0028676,GILEAD,,36.0,YR,A,F,Y,,,20160830.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Intrauterine infection;Maternal exposure during pregnancy,73710763.0,OT,,,73710763.0,1.0,20100219.0,20100201.0,,,73710763.0,1.0,HIV infection
7451576,74515765,5,F,20100602.0,20151023.0,20100701,20151105,EXP,,US-GILEAD-2010-0030045,GILEAD,,0.0,DY,,F,Y,2.95,KG,20151105.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acrochordon;Foetal exposure during pregnancy,74515765.0,CA,,,74515765.0,1.0,20090903.0,20090924.0,,,74515765.0,1.0,HIV infection
7640015,76400152,2,F,200901.0,20151028.0,20101026,20151112,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-15345911,BRISTOL MYERS SQUIBB,,44.0,YR,,F,Y,,,20151112.0,,CN,IT,IT,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI;SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Normal newborn,76400152.0,OT,,,76400152.0,1.0,2007.0,200904.0,,,76400152.0,1.0,HIV infection
7752886,77528866,6,F,20100722.0,20151026.0,20110107,20151216,EXP,,US-GILEAD-2011-0034854,GILEAD,,30.0,YR,A,F,Y,,,20151216.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,77528866.0,OT,,,,,,,,,77528866.0,1.0,HIV infection
7752911,77529116,6,F,,20151026.0,20110107,20151112,EXP,,US-GILEAD-2011-0034856,GILEAD,,25.0,WK,I,F,Y,0.3,KG,20151112.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction;Wolf-Hirschhorn syndrome,77529116.0,CA,,,,,,,,,77529116.0,1.0,HIV infection
8159073,815907314,14,F,201108.0,20160125.0,20110927,20160201,EXP,,GB-GILEAD-2011-0044197,GILEAD,,1.0,DY,N,M,Y,,,20160201.0,,CN,GB,GB,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital teratoma;Conjunctival haemorrhage;Cryptorchism;Facial paresis;Foetal exposure during pregnancy;Respiratory distress,815907314.0,CA,,,815907314.0,1.0,20100915.0,20110913.0,,,815907314.0,1.0,HIV infection
8169345,81693452,2,F,20100327.0,20151119.0,20111005,20160118,EXP,,US-GILEAD-2010-0029365,GILEAD,,26.0,YR,A,F,Y,,,20160118.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Caesarean section;Maternal exposure during pregnancy;Premature delivery;Twin pregnancy,81693452.0,OT,,,81693452.0,1.0,20100518.0,20100518.0,,,81693452.0,1.0,HIV infection
8383331,83833314,4,F,20101120.0,20160114.0,20120201,20160120,EXP,GB-MHRA-ADR 21453021,GB-GILEAD-2011-0044189,GILEAD,,37.0,YR,A,F,Y,,,20160120.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Headache;Live birth;Maternal exposure during pregnancy,83833314.0,OT,,,83833314.0,1.0,20100301.0,20110913.0,,,83833314.0,1.0,HIV infection
8394813,83948134,4,F,20111218.0,20130219.0,20120207,20130222,EXP,,GB-GILEAD-2012-0049923,GILEAD,,40.0,YR,,M,Y,,,20130222.0,,MD,CA,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal failure;Respiratory failure;Septic shock;Systemic candida;Vascular pseudoaneurysm,83948134.0,DE,,,83948134.0,1.0,20110331.0,20111217.0,,,83948134.0,1.0,HIV infection
8536392,85363924,4,F,20120413.0,20130805.0,20120430,20130809,EXP,,DK-GILEAD-2012-0053980,GILEAD,,24.0,YR,,F,Y,,,20130809.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicide attempt,85363924.0,OT,,,85363924.0,1.0,20120306.0,20120412.0,,,85363924.0,1.0,HIV infection
8625796,86257964,4,F,20120605.0,20130104.0,20120620,20130111,EXP,,US-GILEAD-2012-0056643,GILEAD,,29.0,YR,,M,Y,,,20130111.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Syncope,86257964.0,HO,,,86257964.0,1.0,20110303.0,,,,86257964.0,1.0,HIV infection
8812196,88121962,2,F,20120805.0,20130318.0,20120927,20130320,EXP,,US-GILEAD-2012-0061757,GILEAD,,25.0,YR,,M,Y,,,20130320.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar I disorder,88121962.0,HO,,,88121962.0,1.0,20100803.0,,,,88121962.0,1.0,HIV infection
8912091,89120916,6,F,20121102.0,20130122.0,20121115,20150630,EXP,,US-BMSGILMSD-2012-0064557,GILEAD,,48.0,YR,A,M,Y,86.62,KG,20150630.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypophosphataemia,89120916.0,OT,,,89120916.0,1.0,201109.0,20121119.0,,,89120916.0,1.0,HIV infection
8940550,89405505,5,F,20121106.0,20130123.0,20121203,20130201,EXP,,UG-GILEAD-2012-0065023,GILEAD,,33.0,YR,,F,Y,,,20130212.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Disseminated tuberculosis;Sepsis,89405505.0,HO,,,89405505.0,1.0,20121025.0,20121106.0,,,89405505.0,1.0,HIV infection
8970961,89709612,2,F,20121102.0,20130103.0,20121217,20130104,EXP,,CH-GILEAD-2012-0066261,GILEAD,,50.0,YR,,F,Y,,,20130104.0,,MD,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumococcal bacteraemia,89709612.0,HO,,,89709612.0,1.0,20120309.0,,,,89709612.0,1.0,HIV infection
8976020,89760202,2,F,20121115.0,20130130.0,20121219,20130207,EXP,,US-GILEAD-2012-0066298,GILEAD,,47.0,YR,,M,Y,,,20130207.0,,MD,US,US,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetic nephropathy;Renal failure acute,89760202.0,HO,,,89760202.0,1.0,20100722.0,20120111.0,,,89760202.0,1.0,HIV infection
8984199,89841993,3,F,20121218.0,20121228.0,20121226,20130102,EXP,,MW-009507513-1212MWI009263,MERCK,,22.0,YR,,F,Y,58.9,KG,20130101.0,,CN,MW,MW,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Neutrophil count decreased,89841993.0,OT,,,89841993.0,1.0,20120614.0,20121204.0,,,89841993.0,1.0,HIV infection
8999393,89993932,2,F,20121102.0,20130125.0,20130103,20130129,EXP,,CH-GILEAD-2012-0065175,GILEAD,,50.0,YR,,F,Y,,,20130129.0,,MD,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Necrobiosis,89993932.0,HO,,,89993932.0,1.0,20120309.0,,,,89993932.0,1.0,HIV infection
9001647,90016472,2,F,20121213.0,20130724.0,20130107,20130726,EXP,,US-BMSGILMSD-2013-0067460,GILEAD,,40.0,YR,,M,Y,,,20130726.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Transient ischaemic attack,90016472.0,HO,,,90016472.0,1.0,20100131.0,,,,90016472.0,1.0,HIV infection
9003339,90033393,3,F,201210.0,20130308.0,20130108,20130313,EXP,,MW-GILEAD-2013-0067253,GILEAD,,21.0,,,F,Y,,,20130313.0,,MD,MW,MW,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Hepatitis;Hepatitis acute;Kaposi's sarcoma;Malaria;Salmonella sepsis,90033393.0,HO,,,90033393.0,1.0,20121018.0,20121230.0,,,90033393.0,1.0,HIV infection
9007042,90070421,1,I,20121212.0,20130104.0,20130110,20130110,EXP,,US-GILEAD-2013-0067436,GILEAD,,40.0,YR,,F,Y,,,20130110.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dehydration;Vomiting,90070421.0,HO,,,90070421.0,1.0,20111220.0,,,,90070421.0,1.0,HIV infection
9008615,90086152,2,F,20120716.0,20130121.0,20130111,20130326,EXP,,US-BMSGILMSD-2013-0067559,GILEAD,,28.0,YR,,F,Y,,,20130325.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Polyhydramnios;Premature delivery,90086152.0,OT,,,90086152.0,1.0,20120206.0,20120206.0,,,90086152.0,1.0,HIV infection
9012850,90128502,2,F,20121211.0,20130823.0,20130114,20130830,EXP,,US-BMSGILMSD-2013-0067672,GILEAD,,40.0,YR,,M,Y,,,20130830.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Orchitis;Renal failure acute,90128502.0,OT,,,90128502.0,1.0,2009.0,20121211.0,,,90128502.0,1.0,HIV infection
9092648,90926484,4,F,20130201.0,20130418.0,20130218,20130423,EXP,,KE-GILEAD-2013-0069920,GILEAD,,28.0,YR,,F,Y,,,20130423.0,,MD,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Gastroenteritis;Renal failure acute,90926484.0,OT,,,90926484.0,1.0,20130104.0,20130131.0,,,90926484.0,1.0,Acquired immunodeficiency syndrome
9105614,91056141,1,I,,20130219.0,20130220,20130220,EXP,,US-BMSGILMSD-2012-0063039,GILEAD,,,,,NS,Y,,,20130220.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Endothelial dysfunction,91056141.0,OT,,,,,,,,,91056141.0,1.0,HIV infection
9133082,91330821,1,I,201101.0,20130219.0,20130301,20130301,EXP,,US-GILEAD-2013-0070307,GILEAD,,,,,F,Y,,,20130301.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Dizziness;Encephalitis,91330821.0,OT,,,91330821.0,1.0,201101.0,,,,91330821.0,1.0,HIV infection
9149547,91495471,1,I,20121218.0,,20130228,20130228,DIR,,,,,68.0,YR,,M,N,100.0,KG,20130216.0,,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Angioedema;Dysphagia;Dyspnoea;Hypersensitivity;Local swelling;No therapeutic response;Obstructive airways disorder;Pyrexia;Rash macular;Throat tightness,91495471.0,RI,91495471.0,HP,91495471.0,1.0,20121203.0,20121217.0,,,91495471.0,1.0,HIV infection
9149554,91495541,1,I,20121217.0,,20130228,20130228,DIR,,,,,68.0,YR,,M,N,103.4,KG,20130216.0,,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dysphagia;Dyspnoea;Hypersensitivity;Local swelling;No therapeutic response;Pyrexia;Rash macular;Swollen tongue;Throat tightness,91495541.0,RI,91495541.0,HP,91495541.0,1.0,20121203.0,20121217.0,,,91495541.0,1.0,HIV infection
9165317,91653171,1,I,20121206.0,,20130314,20130314,DIR,,,,,24.0,YR,,M,N,,,20130305.0,,OT,US,,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Coagulopathy;Drug-induced liver injury;Hepatic failure;Jaundice cholestatic;Liver transplant,91653171.0,LT,,,91653171.0,1.0,20111201.0,20121122.0,,,91653171.0,1.0,HIV infection
9175955,91759551,1,I,20110527.0,20130308.0,20130320,20130320,EXP,,FR-GILEAD-2013-0072036,GILEAD,,46.0,YR,,M,Y,,,20130320.0,,MD,FR,FR,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatotoxicity;Transaminases increased,91759551.0,OT,,,91759551.0,1.0,20020107.0,20111216.0,,,91759551.0,1.0,HIV infection
9188174,91881741,1,I,,20130313.0,20130325,20130325,EXP,,US-BMSGILMSD-2013-0071819,GILEAD,,,,,F,Y,,,20130325.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Osteoporosis,91881741.0,OT,,,91881741.0,1.0,200808.0,200908.0,,,91881741.0,1.0,HIV infection
9234054,92340542,2,F,20120830.0,20130411.0,20130416,20130418,EXP,,FR-GILEAD-2013-0073238,GILEAD,,50.0,YR,,F,Y,,,20130708.0,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Gamma-glutamyltransferase increased;Transaminases increased,92340542.0,OT,,,92340542.0,1.0,20120202.0,20120907.0,,,92340542.0,1.0,HIV infection
9252653,92526531,1,I,20130329.0,20130422.0,20130424,20130424,EXP,,GB-GILEAD-2013-0074046,GILEAD,,38.0,YR,,M,Y,,,20130424.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Circulatory collapse;Dehydration;Loss of consciousness,92526531.0,HO,,,92526531.0,1.0,20120103.0,,,,92526531.0,1.0,HIV infection
9259215,92592151,1,I,20130126.0,20130424.0,20130426,20130426,EXP,,GB-GILEAD-2013-0074162,GILEAD,,34.0,YR,,M,Y,,,20130426.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal colic,92592151.0,HO,,,92592151.0,1.0,20121011.0,,,,92592151.0,1.0,HIV infection
9264323,92643231,1,I,,20130424.0,20130430,20130430,EXP,,BW-GILEAD-2013-0074309,GILEAD,,,,,NS,Y,,,20130430.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome,92643231.0,DE,,,,,,,,,92643231.0,1.0,HIV infection
9322562,93225621,1,I,20130112.0,20130524.0,20130531,20130531,EXP,,GB-BMSGILMSD-2013-0075821,GILEAD,,39.0,YR,,F,Y,,,20130531.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,93225621.0,OT,,,,,,,,,93225621.0,1.0,HIV infection
9385909,93859091,1,I,20130106.0,20130628.0,20130705,20130705,EXP,,US-GILEAD-2013-0068608,GILEAD,,35.0,YR,,M,Y,,,20130705.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bronchitis,93859091.0,HO,,,93859091.0,1.0,20121217.0,20121218.0,,,93859091.0,1.0,HIV infection
9451234,94512343,3,F,20130311.0,20140221.0,20130809,20140226,EXP,,US-GILEAD-2013-0080841,GILEAD,,0.0,DY,,F,Y,3.35,KG,20140226.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital anomaly,94512343.0,CA,,,94512343.0,1.0,20120618.0,20130128.0,,,94512343.0,1.0,HIV infection
9505157,95051575,5,F,20130523.0,20160905.0,20130906,20160912,EXP,,ZA-GILEAD-2013-0082749,GILEAD,,53.0,YR,A,F,Y,52.0,KG,20160912.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Death;Gastroenteritis,95051575.0,OT,,,95051575.0,1.0,20130513.0,20130730.0,,,95051575.0,1.0,HIV infection
9522978,95229781,1,I,20130805.0,20130909.0,20130913,20130913,EXP,,TH-GILEAD-2013-0083072,GILEAD,,56.0,YR,,M,Y,,,20130913.0,,MD,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea infectious;Strongyloidiasis,95229781.0,HO,,,95229781.0,1.0,20130627.0,,,,95229781.0,1.0,HIV infection
9565250,95652501,1,I,,20130820.0,20130930,20130930,EXP,,US-BMSGILMSD-2013-0084003,GILEAD,,59.0,YR,,M,Y,,,20130930.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Pathogen resistance,95652501.0,OT,,,,,,,,,95652501.0,1.0,HIV infection
9575882,95758824,4,F,20130831.0,20131231.0,20131001,20140106,EXP,,US-GILEAD-2013-0079906,GILEAD,,42.0,YR,,M,Y,107.9,KG,20140106.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression suicidal,95758824.0,HO,,,95758824.0,1.0,20090729.0,20130618.0,,,95758824.0,1.0,HIV infection
9644015,96440151,1,I,20131011.0,20131017.0,20131024,20131024,EXP,,US-GILEAD-2013-0085874,GILEAD,,24.0,YR,,F,Y,,,20131024.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,96440151.0,OT,,,96440151.0,1.0,20131008.0,20130927.0,,,96440151.0,1.0,HIV infection
9696985,96969851,1,I,,20131112.0,20131119,20131119,EXP,,CA-GILEAD-2013-0087681,GILEAD,,,,,NS,Y,,,20131119.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,96969851.0,OT,,,,,,,,,96969851.0,1.0,HIV infection
9696986,96969861,1,I,,20131112.0,20131119,20131119,EXP,,CA-GILEAD-2013-0087685,GILEAD,,,,,NS,Y,,,20131119.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,96969861.0,OT,,,,,,,,,96969861.0,1.0,HIV infection
9696987,96969871,1,I,,20131112.0,20131119,20131119,EXP,,CA-GILEAD-2013-0087680,GILEAD,,,,,NS,Y,,,20131119.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,96969871.0,OT,,,,,,,,,96969871.0,1.0,HIV infection
9696988,96969881,1,I,,20131112.0,20131119,20131119,EXP,,CA-GILEAD-2013-0087682,GILEAD,,,,,NS,Y,,,20131119.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,96969881.0,OT,,,,,,,,,96969881.0,1.0,HIV infection
9696990,96969901,1,I,,20131112.0,20131119,20131119,EXP,,CA-GILEAD-2013-0087673,GILEAD,,,,,NS,Y,,,20131119.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,96969901.0,OT,,,,,,,,,96969901.0,1.0,HIV infection
9702857,97028573,3,F,20131025.0,20140213.0,20131121,20140217,EXP,,DE-GILEAD-2013-0088299,GILEAD,,35.0,YR,,M,Y,70.0,KG,20140217.0,N,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Grand mal convulsion,97028573.0,OT,,,97028573.0,1.0,20120222.0,,,,97028573.0,1.0,HIV infection
9705475,97054751,1,I,,20131112.0,20131122,20131122,EXP,,CA-GILEAD-2013-0088484,GILEAD,,,,,NS,Y,,,20131122.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Genotype drug resistance test positive;Virologic failure,97054751.0,OT,,,,,,,,,97054751.0,1.0,HIV infection
9705479,97054791,1,I,,20131112.0,20131122,20131122,EXP,,CA-GILEAD-2013-0088486,GILEAD,,,,,NS,Y,,,20131122.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Genotype drug resistance test positive;Virologic failure,97054791.0,OT,,,,,,,,,97054791.0,1.0,HIV infection
9705480,97054801,1,I,,20131112.0,20131122,20131122,EXP,,CA-GILEAD-2013-0088478,GILEAD,,,,,NS,Y,,,20131122.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Genotype drug resistance test positive;Virologic failure,97054801.0,OT,,,,,,,,,97054801.0,1.0,HIV infection
9705481,97054811,1,I,,20131112.0,20131122,20131122,EXP,,CA-GILEAD-2013-0088485,GILEAD,,,,,NS,Y,,,20131122.0,,MD,CA,CA,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Genotype drug resistance test positive;Virologic failure,97054811.0,OT,,,,,,,,,97054811.0,1.0,HIV infection
9705832,97058321,1,I,,20131118.0,20131122,20131122,EXP,,BF-GILEAD-2013-0088274,GILEAD,,,,,NS,Y,,,20131121.0,,OT,BF,BF,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal failure,97058321.0,DE,,,,,,,,,97058321.0,1.0,HIV infection
9709281,97092811,1,I,20130801.0,20131114.0,20131125,20131125,EXP,,DE-GILEAD-2013-0088290,GILEAD,,,,,F,Y,73.0,KG,20131125.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion threatened;Pregnancy,97092811.0,OT,,,,,,,,,97092811.0,1.0,HIV infection
9719145,97191452,2,F,20131104.0,20131125.0,20131127,20131203,EXP,,MW-GILEAD-2013-0088593,GILEAD,,36.0,YR,,M,Y,60.0,KG,20131203.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,97191452.0,HO,,,97191452.0,1.0,20121024.0,,,,97191452.0,1.0,HIV infection
9742969,97429691,1,I,,20131205.0,20131210,20131210,EXP,,FR-BMSGILMSD-2013-0089538,GILEAD,,50.0,YR,,M,Y,,,20131210.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Off label use;Renal failure,97429691.0,OT,,,,,,,,,97429691.0,1.0,HIV infection
9746158,97461583,3,F,20091119.0,20091204.0,20131211,20150722,PER,,US-BMSGILMSD-2009-0025758,GILEAD,,43.0,YR,,F,Y,,,20150722.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aspartate aminotransferase increased,97461583.0,OT,,,97461583.0,1.0,20090731.0,20091031.0,,,97461583.0,1.0,HIV infection
9746463,97464633,3,F,201310.0,20160905.0,20131211,20160909,EXP,,ZA-GILEAD-2013-0089120,GILEAD,,52.0,YR,A,M,Y,63.0,KG,20160909.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dyspnoea,97464633.0,DE,,,97464633.0,1.0,20130605.0,,,,97464633.0,1.0,HIV infection
9786701,97867011,1,I,,20131220.0,20131227,20131227,EXP,,IT-GILEAD-2013-0090640,GILEAD,,31.0,YR,,M,Y,,,20131227.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dyslipidaemia;Lipoatrophy;Mitochondrial toxicity,97867011.0,OT,,,,,,,,,97867011.0,1.0,HIV infection
9819665,98196653,3,F,201202.0,20140113.0,20140115,20140123,EXP,,US-BMSGILMSD-2013-0081579,GILEAD,,29.0,YR,,F,Y,,,20140123.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Deafness;Immune reconstitution inflammatory syndrome,98196653.0,OT,,,98196653.0,1.0,201212.0,,,,98196653.0,1.0,HIV infection
9823287,98232873,3,F,,20180614.0,20140116,20180723,PER,,US-009507513-1401USA003256,MERCK,,31.0,YR,,F,Y,,,20180723.0,,OT,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy,,,,,,,,,,,98232873.0,1.0,HIV infection
9829841,98298411,1,I,,20140106.0,20140120,20140120,PER,,US-009507513-1401USA006638,MERCK,,31.0,YR,,F,Y,,,20140120.0,N,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,,,,,,,98298411.0,1.0,HIV infection
9847155,98471553,3,F,20131105.0,20140227.0,20140127,20150722,PER,,US-BMSGILMSD-2014-0093029,GILEAD,,54.0,YR,A,M,Y,,,20150722.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,98471553.0,OT,,,98471553.0,1.0,20101017.0,,,,98471553.0,1.0,HIV infection
9859936,98599362,2,F,20131101.0,20140214.0,20140131,20140221,EXP,,TH-GILEAD-2014-0093075,GILEAD,,27.0,YR,,M,Y,50.5,KG,20140221.0,N,MD,TH,TH,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Humerus fracture,98599362.0,HO,,,98599362.0,1.0,20130206.0,20130206.0,,,98599362.0,1.0,HIV infection
9859943,98599434,4,F,20140512.0,20150127.0,20140131,20150203,EXP,,GB-GILEAD-2014-0093204,GILEAD,,40.0,YR,A,F,Y,,,20150203.0,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alpha 1 foetoprotein;Stillbirth,98599434.0,OT,,,,,,,,,98599434.0,1.0,HIV infection
9860022,98600225,5,F,,20150421.0,20140131,20150429,EXP,,GB-GILEAD-2014-0093213,GILEAD,,,,,F,Y,,,20150429.0,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cytomegalovirus test positive;Polyhydramnios;Trisomy 21,98600225.0,OT,,,98600225.0,1.0,20130818.0,20140512.0,,,98600225.0,1.0,HIV infection
9886886,98868869,9,F,20121213.0,20170420.0,20140210,20170424,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-17227166,BRISTOL MYERS SQUIBB,,34.0,YR,,F,Y,38.0,KG,20170424.0,,CN,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Burning sensation;Diarrhoea;Hypokalaemia;Hyponatraemia;Malaise;Muscular weakness;Neutropenia;Pyrexia;Vomiting,98868869.0,OT,,,98868869.0,1.0,20121115.0,20131107.0,,,98868869.0,1.0,HIV infection
9892010,98920103,3,F,,20140226.0,20140212,20150722,PER,,US-GILEAD-2014-0094090,GILEAD,,48.0,YR,A,F,Y,61.22,KG,20150722.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional product misuse,,,,,,,,,,,98920103.0,1.0,Acquired immunodeficiency syndrome
9914941,99149414,4,F,20140106.0,20140520.0,20140220,20140523,EXP,,US-GILEAD-2014-0093157,GILEAD,,59.0,YR,,M,Y,79.5,KG,20140523.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Delirium,99149414.0,OT,,,99149414.0,1.0,20131028.0,20140112.0,,,99149414.0,1.0,HIV infection
9924000,99240003,3,F,20140121.0,20140228.0,20140225,20140311,EXP,,ZA-GILEAD-2014-0095009,GILEAD,,36.0,YR,,F,Y,54.5,KG,20140310.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal death,99240003.0,DE,,,99240003.0,1.0,20131021.0,,,,99240003.0,1.0,HIV infection
9929973,99299732,2,F,,20140423.0,20140227,20140428,EXP,,US-BMSGILMSD-2014-0095210,GILEAD,,,,,M,Y,,,20140428.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise,99299732.0,HO,,,,,,,,,99299732.0,1.0,Acquired immunodeficiency syndrome
9976054,99760541,1,I,,20140301.0,20140306,20140306,EXP,,US-GILEAD-2014-0096036,GILEAD,,,,,M,Y,,,20140306.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,99760541.0,OT,,,,,,,,,99760541.0,1.0,HIV infection
9976286,99762861,1,I,20131128.0,20140226.0,20140306,20140306,EXP,,US-BMSGILMSD-2014-0095749,GILEAD,,61.0,YR,,M,Y,,,20140306.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Immobile;Nerve compression,99762861.0,HO,,,,,,,,,99762861.0,1.0,HIV infection
10004695,100046952,2,F,20130518.0,20140307.0,20140312,20140312,EXP,,MW-GILEAD-2013-0077075,GILEAD,,35.0,YR,,M,Y,59.1,KG,20140312.0,N,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Sepsis,100046952.0,LT,,,100046952.0,1.0,20130614.0,20130213.0,,,100046952.0,1.0,Acquired immunodeficiency syndrome
10012940,100129402,2,F,,20140319.0,20140314,20140320,EXP,,US-GILEAD-2014-0096398,GILEAD,,,,,F,Y,2.95,KG,20140320.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,No adverse event,,,,,100129402.0,1.0,,20130808.0,,,100129402.0,1.0,HIV infection
10033274,100332742,2,F,20140203.0,20140319.0,20140324,20140324,EXP,,ZA-GILEAD-2014-0095219,GILEAD,,21.0,YR,,F,Y,53.5,KG,20140324.0,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome;Kaposi's sarcoma,100332742.0,HO,,,100332742.0,1.0,20131031.0,,,,100332742.0,1.0,HIV infection
10042046,100420462,2,F,,20140411.0,20140327,20140414,EXP,,US-GILEAD-2014-0097628,GILEAD,,34.0,YR,,M,Y,,,20140414.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive;Virologic failure,100420462.0,OT,,,100420462.0,1.0,,201401.0,,,100420462.0,1.0,HIV infection
10045817,100458171,1,I,2008.0,20140320.0,20140328,20140328,EXP,,US-GILEAD-2014-0097594,GILEAD,,28.0,YR,,M,Y,,,20140328.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Loss of consciousness,100458171.0,OT,,,100458171.0,1.0,2008.0,,,,100458171.0,1.0,HIV infection
10051456,100514562,2,F,,20140411.0,20140401,20140414,EXP,,US-GILEAD-2014-0098136,GILEAD,,39.0,YR,,M,Y,,,20140414.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pathogen resistance;Virologic failure,100514562.0,OT,,,100514562.0,1.0,,201312.0,,,100514562.0,1.0,HIV infection
10051473,100514731,1,I,,20140326.0,20140401,20140401,EXP,,US-GILEAD-2014-0098152,GILEAD,,31.0,YR,,M,Y,,,20140401.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Drug ineffective;Drug resistance;Virologic failure,100514731.0,OT,,,100514731.0,1.0,,201403.0,,,100514731.0,1.0,HIV infection
10051501,100515011,1,I,,20140327.0,20140401,20140401,EXP,,US-BMSGILMSD-2014-0098259,GILEAD,,46.0,YR,,M,Y,,,20140401.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Insomnia;Pathogen resistance;Virologic failure,100515011.0,OT,,,100515011.0,1.0,,201401.0,,,100515011.0,1.0,HIV infection
10051734,100517341,1,I,,20140327.0,20140401,20140401,EXP,,US-BMSGILMSD-2014-0098251,GILEAD,,,,,M,Y,,,20140401.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,100517341.0,DE,,,,,,,,,100517341.0,1.0,HIV infection
10055016,100550161,1,I,,20140327.0,20140402,20140402,EXP,,US-GILEAD-2014-0098269,GILEAD,,55.0,YR,,M,Y,,,20140402.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Pathogen resistance,100550161.0,OT,,,100550161.0,1.0,,201402.0,,,100550161.0,1.0,HIV infection
10056413,100564131,1,I,20120612.0,20140327.0,20140403,20140403,EXP,,US-BMSGILMSD-2014-0098286,GILEAD,,59.0,YR,,M,Y,,,20140403.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bladder cancer,100564131.0,OT,,,,,,,,,100564131.0,1.0,HIV infection
10066778,100667783,3,F,20140330.0,20140513.0,20140408,20140515,EXP,,UG-GILEAD-2014-0099059,GILEAD,,47.0,YR,,F,Y,,,20140515.0,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,100667783.0,DE,,,100667783.0,1.0,20140121.0,20140329.0,,,100667783.0,1.0,HIV infection
10070832,100708321,1,I,,20140408.0,20140410,20140410,EXP,,US-GILEAD-2014-0099281,GILEAD,,,,,F,Y,,,20140410.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness,100708321.0,OT,,,,,,,,,100708321.0,1.0,HIV infection
10085099,100850992,2,F,,20140411.0,20140417,20140417,EXP,,US-BMSGILMSD-2014-0098152,GILEAD,,31.0,YR,,M,Y,,,20140417.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Drug ineffective;Drug resistance;Virologic failure,100850992.0,OT,,,100850992.0,1.0,,201403.0,,,100850992.0,1.0,HIV infection
10085309,100853092,2,F,20140324.0,20140717.0,20140417,20140723,EXP,,US-GILEAD-2014-0099707,GILEAD,,34.0,YR,,F,Y,,,20140723.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion missed,100853092.0,OT,,,100853092.0,1.0,20140228.0,20140220.0,,,100853092.0,1.0,HIV infection
10096170,100961705,5,F,20140312.0,20141014.0,20140422,20141017,EXP,,MW-GILEAD-2014-0097032,GILEAD,,28.0,YR,A,F,Y,50.2,KG,20141017.0,N,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Immune reconstitution inflammatory syndrome associated tuberculosis,100961705.0,OT,,,100961705.0,1.0,20140227.0,,,,100961705.0,1.0,HIV infection
10097196,100971962,2,F,20140127.0,20140423.0,20140422,20140428,EXP,,US-GILEAD-2014-0100246,GILEAD,,39.0,YR,,F,Y,,,20140428.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,100971962.0,OT,,,,,,,,,100971962.0,1.0,HIV infection
10100769,101007693,3,F,20140220.0,20140507.0,20140423,20140509,EXP,,ZA-GILEAD-2014-0095930,GILEAD,,24.0,YR,,F,Y,88.6,KG,20140509.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pelvic inflammatory disease;Renal failure acute,101007693.0,OT,,,101007693.0,1.0,20130411.0,20140220.0,,,101007693.0,1.0,HIV infection
10133482,101334822,2,F,,20140421.0,20140428,20140428,EXP,,US-BMSGILMSD-2014-0098125,GILEAD,,47.0,YR,,M,Y,,,20140428.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Drug resistance;Viral mutation identified;Virologic failure,101334822.0,OT,,,101334822.0,1.0,20100706.0,20131121.0,,,101334822.0,1.0,HIV infection
10145041,101450411,1,I,20140208.0,20140423.0,20140501,20140501,EXP,,US-GILEAD-2014-0100766,GILEAD,,40.0,YR,,F,Y,,,20140430.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,101450411.0,OT,,,101450411.0,1.0,20140108.0,20140107.0,,,101450411.0,1.0,HIV infection
10155701,101557015,5,F,20140103.0,20160822.0,20140506,20160826,EXP,,UG-GILEAD-2014-0101523,GILEAD,,41.0,YR,A,M,Y,73.0,KG,20160826.0,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia;Bacteraemia;Kaposi's sarcoma;Urinary tract infection,101557015.0,OT,,,101557015.0,1.0,20130724.0,20140423.0,,,101557015.0,1.0,HIV infection
10161197,101611972,2,F,,20160404.0,20140508,20160407,PER,,US-GILEAD-2014-0101721,GILEAD,,53.0,YR,A,M,Y,,,20160407.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Nightmare,,,,,,,,,,,101611972.0,1.0,HIV infection
10161198,101611981,1,I,20140405.0,20140506.0,20140508,20140508,EXP,,ZA-GILEAD-2014-0101839,GILEAD,,32.0,YR,,F,Y,93.0,KG,20140508.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Sudden death,101611981.0,DE,,,101611981.0,1.0,20130510.0,,,,101611981.0,1.0,HIV infection
10181810,101818103,3,F,20100217.0,20140516.0,20140519,20140521,EXP,,FR-GILEAD-2010-0029949,GILEAD,,31.0,YR,,F,Y,,,20140521.0,N,OT,SN,SN,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Placenta praevia;Pregnancy,101818103.0,OT,,,101818103.0,1.0,20090827.0,20100613.0,,,101818103.0,1.0,HIV infection
10202591,102025912,2,F,,20150421.0,20140528,20150501,EXP,,GB-GILEAD-2014-0103166,GILEAD,,,,,M,Y,,,20150501.0,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Congenital anomaly;Twin reversed arterial perfusion sequence malformation,102025912.0,CA,,,102025912.0,1.0,20131105.0,20140123.0,,,102025912.0,1.0,HIV infection
10233705,102337051,1,I,,20140606.0,20140612,20140612,EXP,,US-BMSGILMSD-2014-0104707,GILEAD,,,,,M,Y,,,20140612.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Road traffic accident,102337051.0,HO,,,,,,,,,102337051.0,1.0,Acquired immunodeficiency syndrome
10245044,102450441,1,I,20140519.0,20140612.0,20140618,20140618,EXP,,VN-GILEAD-2014-0105527,GILEAD,,52.0,YR,,M,Y,,,20140618.0,N,MD,VN,VN,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,102450441.0,DE,,,102450441.0,1.0,20140506.0,20140519.0,,,102450441.0,1.0,HIV infection
10245412,102454121,1,I,20140505.0,20140612.0,20140618,20140618,EXP,,VN-GILEAD-2014-0105528,GILEAD,,40.0,YR,,M,Y,,,20140618.0,N,MD,VN,VN,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,102454121.0,HO,,,102454121.0,1.0,20131226.0,20140505.0,,,102454121.0,1.0,HIV infection
10263507,102635072,2,F,20140603.0,20140807.0,20140626,20140813,EXP,,AR-GILEAD-2014-0106810,GILEAD,,36.0,YR,A,M,Y,64.5,KG,20140813.0,N,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional self-injury,102635072.0,OT,,,102635072.0,1.0,20130721.0,20140603.0,,,102635072.0,1.0,HIV infection
10265687,102656871,1,I,20140606.0,20140624.0,20140627,20140627,EXP,,US-BMSGILMSD-2014-0106832,GILEAD,,25.0,YR,,M,Y,,,20140627.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,102656871.0,DE,,,,,,,,,102656871.0,1.0,Acquired immunodeficiency syndrome
10271631,102716313,3,F,20140621.0,20140723.0,20140701,20140728,EXP,,US-GILEAD-2014-0107470,GILEAD,,37.0,YR,A,F,Y,65.4,KG,20140908.0,N,MD,SZ,SZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome;Premature labour,102716313.0,DE,,,102716313.0,1.0,20140611.0,,,,102716313.0,1.0,HIV infection
10295788,102957885,5,F,,20150216.0,20140710,20150227,EXP,,US-GILEAD-2014-0107713,GILEAD,,,,N,F,Y,2.38,KG,20150227.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Unevaluable event,102957885.0,CA,,,102957885.0,1.0,20131005.0,20140623.0,,,102957885.0,1.0,HIV infection
10308252,103082522,2,F,20140131.0,20140711.0,20140716,20140725,EXP,,US-GILEAD-2014-0108664,GILEAD,,22.0,YR,,F,Y,,,20140725.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Complication of pregnancy,103082522.0,OT,,,103082522.0,1.0,20120625.0,20140128.0,,,103082522.0,1.0,HIV infection
10345808,103458082,2,F,20140304.0,20140908.0,20140728,20140910,EXP,,US-GILEAD-2014-0110138,GILEAD,,0.0,YR,N,M,Y,,,20140910.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Polydactyly,103458082.0,CA,,,103458082.0,1.0,20131209.0,20140710.0,,,103458082.0,1.0,HIV infection
10375974,103759741,1,I,,20140801.0,20140811,20140811,EXP,,GB-GILEAD-2014-0110975,GILEAD,,30.0,YR,A,F,Y,,,20140811.0,N,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,103759741.0,OT,,,103759741.0,1.0,20140405.0,,,,103759741.0,1.0,HIV infection
10376054,103760541,1,I,,20140807.0,20140811,20140811,EXP,,US-BMSGILMSD-2014-0111468,GILEAD,,30.0,YR,A,M,Y,,,20140811.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Nausea,103760541.0,OT,,,,,,,,,103760541.0,1.0,HIV infection
10382748,103827482,2,F,2014.0,20140820.0,20140813,20140825,EXP,,US-GILEAD-2014-0111709,GILEAD,,51.0,YR,A,M,Y,,,20140825.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood cholesterol increased;Myocardial infarction,103827482.0,OT,,,103827482.0,1.0,,2014.0,,,103827482.0,1.0,HIV infection
10393648,103936482,2,F,20140730.0,20140813.0,20140819,20150722,PER,,US-GILEAD-2014-0112056,GILEAD,,56.0,YR,A,M,Y,,,20150722.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pruritus;Rash,,,,,103936482.0,1.0,20140730.0,,,,103936482.0,1.0,HIV infection
10411318,104113181,1,I,,20140822.0,20140826,20140826,EXP,,US-BMSGILMSD-2014-0113134,GILEAD,,41.0,YR,A,F,Y,,,20140826.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Loss of consciousness;Unevaluable event,104113181.0,HO,,,,,,,,,104113181.0,1.0,HIV infection
10416273,104162732,2,F,,20131031.0,20140828,20150722,PER,,US-GILEAD-2013-0086862,GILEAD,,40.0,YR,A,M,Y,,,20150722.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Decreased appetite;Dizziness,,,,,,,,,,,104162732.0,1.0,HIV infection
10534658,105346581,1,I,,20141020.0,20141022,20141022,EXP,,US-BMSGILMSD-2014-0119447,GILEAD,,,,,M,Y,,,20141022.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dementia,105346581.0,OT,,,,,,,,,105346581.0,1.0,HIV infection
10546081,105460815,5,F,20140926.0,20150128.0,20141027,20150202,EXP,,UG-GILEAD-2014-0119476,GILEAD,,42.0,YR,A,M,Y,59.0,KG,20150202.0,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Electrolyte imbalance;Malaria,105460815.0,LT,,,105460815.0,1.0,20140804.0,,,,105460815.0,1.0,HIV infection
10546087,105460872,2,F,20141004.0,20141114.0,20141027,20141118,EXP,,GB-GILEAD-2014-0119488,GILEAD,,46.0,YR,A,F,Y,64.9,KG,20141118.0,N,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional overdose,105460872.0,HO,,,105460872.0,1.0,20110802.0,,,,105460872.0,1.0,HIV infection
10555837,105558371,1,I,,20140807.0,20141030,20141030,EXP,,ES-GILEAD-2014-0120440,GILEAD,,,,,M,Y,,,20141030.0,N,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neuropsychiatric syndrome,105558371.0,OT,,,105558371.0,1.0,200809.0,,,,105558371.0,1.0,HIV infection
10561657,105616574,4,F,20141016.0,20141119.0,20141103,20150128,EXP,,ZW-GILEAD-2014-0120772,GILEAD,,30.0,YR,A,F,Y,,,20150128.0,N,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma,105616574.0,HO,,,105616574.0,1.0,20130902.0,20141022.0,,,105616574.0,1.0,HIV infection
10561718,105617181,1,I,,20141021.0,20141103,20141103,EXP,,FR-GILEAD-2014-0120085,GILEAD,,,,,,Y,,,20141103.0,N,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pain in extremity;Weight increased,105617181.0,OT,,,105617181.0,1.0,2011.0,,,,105617181.0,1.0,HIV infection
10566050,105660501,1,I,20140214.0,,20141104,20141104,DIR,,,,,72.0,YR,,M,N,97.0,KG,20140415.0,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Acute kidney injury,105660501.0,LT,105660501.0,HP,105660501.0,1.0,20140101.0,20140214.0,,,105660501.0,1.0,HIV infection
10567030,105670302,2,F,20141005.0,20150820.0,20141105,20150825,EXP,,FR-GILEAD-2014-0121194,GILEAD,,51.0,YR,A,M,Y,112.5,KG,20150825.0,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,105670302.0,OT,,,105670302.0,1.0,20100726.0,,,,105670302.0,1.0,HIV infection
10567034,105670341,1,I,201406.0,20141021.0,20141105,20141105,EXP,,FR-BMSGILMSD-2014-0121725,GILEAD,,61.0,YR,A,M,Y,,,20141105.0,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute hepatitis C;Depressed mood;Gastroenteritis;Nausea,105670341.0,OT,,,105670341.0,1.0,20090629.0,20140930.0,,,105670341.0,1.0,HIV infection
10567093,105670931,1,I,,20140721.0,20141105,20141105,EXP,,ES-GILEAD-2014-0120405,GILEAD,,54.0,YR,A,M,Y,,,20141105.0,N,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatitis C,105670931.0,OT,,,105670931.0,1.0,200803.0,,,,105670931.0,1.0,HIV infection
10567207,105672071,1,I,201309.0,20141030.0,20141105,20141105,EXP,,US-BMSGILMSD-2014-0121388,GILEAD,,46.0,YR,A,F,Y,,,20141105.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Leprosy;Pruritus;Pruritus allergic,105672071.0,OT,,,,,,,,,105672071.0,1.0,HIV infection
10588774,105887741,1,I,,20141106.0,20141117,20141117,EXP,,US-BMSGILMSD-2014-0122812,GILEAD,,,,A,,Y,,,20141117.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,105887741.0,OT,,,105887741.0,1.0,2011.0,,,,105887741.0,1.0,HIV infection
10591095,105910952,2,F,,20141111.0,20141118,20141120,EXP,,IL-GILEAD-2014-0122673,GILEAD,,,,,,Y,,,20141120.0,N,OT,IL,IL,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diaphragmatic hernia;Gastrointestinal disorder,105910952.0,CA,,,105910952.0,1.0,20140506.0,20140619.0,,,105910952.0,1.0,HIV infection
10591369,105913691,1,I,,20141113.0,20141118,20141118,EXP,,US-GILEAD-2014-0123016,GILEAD,,66.0,YR,E,M,Y,,,20141118.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chemotherapy,105913691.0,OT,,,,,,,,,105913691.0,1.0,HIV infection
10635697,106356971,1,I,20141118.0,20141202.0,20141205,20141205,EXP,,VN-GILEAD-2014-0125538,GILEAD,,36.0,YR,A,M,Y,,,20141205.0,N,MD,VN,VN,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis,106356971.0,OT,,,106356971.0,1.0,20141110.0,,,,106356971.0,1.0,HIV infection
10641942,106419421,1,I,,20141202.0,20141209,20141209,EXP,,US-BMSGILMSD-2014-0125491,GILEAD,,45.0,YR,A,M,Y,,,20141209.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cognitive disorder,106419421.0,OT,,,,,,,,,106419421.0,1.0,HIV infection
10661479,106614791,1,I,,20141202.0,20141216,20141216,EXP,,2014HINLIT1051,HETERO,,45.0,YR,,M,N,,,20141215.0,N,OT,IN,,LAMIVUDINE+STAVUDINE+EFAVIRENZ (LAMIVUDINE+STAVUDINE+EFAVIRENZ),Angina pectoris;Cardiomyopathy;Gastritis;Immune system disorder;Mitral valve incompetence;Pulmonary tuberculosis;Treatment failure;Tuberculosis;Viral load increased,106614791.0,OT,106614791.0,FGN,106614791.0,1.0,200204.0,2005.0,91.0,DAY,106614791.0,1.0,HIV infection
10662531,106625312,2,F,20131003.0,20141223.0,20141218,20150113,EXP,,US-BMSGILMSD-2014-0127745,GILEAD,,23.0,YR,A,F,Y,,,20150113.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,106625312.0,1.0,20140620.0,,,,106625312.0,1.0,HIV infection
10662826,106628263,3,F,20140620.0,20150122.0,20141218,20150310,EXP,,US-GILEAD-2014-0127543,GILEAD,,,,N,F,Y,3.1,KG,20150310.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Foetal exposure during pregnancy;Foetal malformation,106628263.0,CA,,,106628263.0,1.0,20140620.0,20140710.0,,,106628263.0,1.0,HIV infection
10663163,106631631,1,I,,20141215.0,20141218,20141218,EXP,,US-BMSGILMSD-2014-0127932,GILEAD,,50.0,YR,A,F,Y,,,20141218.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Malaise,106631631.0,OT,,,,,,,,,106631631.0,1.0,HIV infection
10675075,106750751,1,I,20141204.0,20141209.0,20141224,20141224,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-002068,BRISTOL MYERS SQUIBB,,30.0,YR,,M,Y,59.8,KG,20141224.0,N,CN,MW,MW,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Acidosis;Ascites;Blood albumin decreased;Blood pressure diastolic increased;Generalised oedema;Heart rate increased;Hyponatraemia;Micturition frequency decreased;Normochromic normocytic anaemia;Pericardial effusion;Pleural effusion;Right ventricular failure,106750751.0,OT,,,106750751.0,1.0,20141204.0,20141205.0,,,106750751.0,1.0,Antiretroviral therapy
10683900,106839001,1,I,,20141226.0,20141230,20141230,EXP,,US-GILEAD-2014-0129282,GILEAD,,25.0,YR,A,M,Y,,,20141230.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,106839001.0,OT,,,,,,,,,106839001.0,1.0,HIV infection
10707713,107077131,1,I,,20150102.0,20150113,20150113,EXP,,US-GILEAD-2015-0130366,GILEAD,,75.0,YR,E,M,Y,,,20150113.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood glucose decreased;Blood pressure inadequately controlled;Diabetes mellitus;Haemoglobin decreased;Infected skin ulcer;Localised infection;Osteomyelitis;Speech disorder,107077131.0,OT,,,,,,,,,107077131.0,1.0,HIV infection
10721346,107213461,1,I,,20150113.0,20150119,20150119,EXP,,US-BMSGILMSD-2015-0132183,GILEAD,,67.0,YR,E,M,Y,,,20150119.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bladder cancer;Prostate cancer,107213461.0,OT,,,,,,,,,107213461.0,1.0,HIV infection
10723666,107236661,1,I,,20150114.0,20150120,20150120,EXP,,US-BMSGILMSD-2015-0132386,GILEAD,,62.0,YR,A,M,Y,,,20150120.0,N,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise,107236661.0,HO,,,,,,,,,107236661.0,1.0,HIV infection
10731170,107311701,1,I,20141128.0,20150116.0,20150122,20150122,EXP,,US-GILEAD-2015-0132837,GILEAD,,66.0,YR,E,M,Y,,,20150122.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,107311701.0,OT,,,,,,,,,107311701.0,1.0,HIV infection
10733012,107330121,1,I,,20150116.0,20150123,20150123,EXP,,US-BMSGILMSD-2015-0132942,GILEAD,,38.0,YR,A,M,Y,,,20150123.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,AIDS dementia complex;Myelopathy,107330121.0,HO,,,,,,,,,107330121.0,1.0,HIV infection
10734286,107342863,3,F,20141205.0,20150209.0,20150123,20150213,EXP,,ZA-GILEAD-2014-0128682,GILEAD,,47.0,YR,A,M,Y,110.5,KG,20150213.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Pneumonia,107342863.0,DE,,,107342863.0,1.0,20140709.0,20141204.0,,,107342863.0,1.0,HIV infection
10746135,107461351,1,I,20141117.0,20150121.0,20150128,20150128,EXP,,BW-BMSGILMSD-2015-0133689,GILEAD,,38.0,YR,A,F,Y,,,20150128.0,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,107461351.0,OT,,,107461351.0,1.0,20120611.0,,,,107461351.0,1.0,HIV infection
10749941,107499411,1,I,20140903.0,20150126.0,20150129,20150129,EXP,,US-BMSGILMSD-2015-0134293,GILEAD,,57.0,YR,A,M,Y,,,20150129.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,107499411.0,OT,,,,,,,,,107499411.0,1.0,Acquired immunodeficiency syndrome
10750185,107501853,3,F,20140103.0,20160822.0,20150129,20160830,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-004640,BRISTOL MYERS SQUIBB,,41.0,YR,,M,Y,73.0,KG,20160830.0,,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute kidney injury;Anaemia;Bacteraemia;Disease progression;Urinary tract infection,107501853.0,OT,,,107501853.0,1.0,20130725.0,20131106.0,,,107501853.0,1.0,Antiretroviral therapy
10752198,107521981,1,I,1983.0,20150121.0,20150130,20150130,EXP,,US-GILEAD-2015-0133756,GILEAD,,64.0,YR,A,M,Y,,,20150130.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Cognitive disorder;Gait disturbance;Hearing impaired;Malaise;Myocardial infarction;Nausea;Neoplasm malignant;Neuropathy peripheral;Pain;Spinal column injury;Visual impairment,107521981.0,OT,,,,,,,,,107521981.0,1.0,HIV infection
10752212,107522121,1,I,,20150126.0,20150130,20150130,EXP,,US-BMSGILMSD-2015-0134700,GILEAD,,41.0,YR,A,M,Y,,,20150130.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,107522121.0,DE,,,,,,,,,107522121.0,1.0,HIV infection
10752478,107524781,1,I,,20150123.0,20150130,20150130,EXP,,US-BMSGILMSD-2015-0134568,GILEAD,,52.0,YR,A,M,Y,,,20150130.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,107524781.0,OT,,,,,,,,,107524781.0,1.0,HIV infection
10752506,107525061,1,I,,20150126.0,20150130,20150130,EXP,,US-GILEAD-2015-0134483,GILEAD,,45.0,YR,A,F,Y,,,20150130.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness,107525061.0,HO,,,,,,,,,107525061.0,1.0,HIV infection
10756420,107564201,1,I,,20150126.0,20150202,20150202,EXP,,US-GILEAD-2015-0134778,GILEAD,,31.0,YR,A,M,Y,,,20150202.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abscess limb,107564201.0,HO,,,,,,,,,107564201.0,1.0,HIV infection
10759869,107598691,1,I,,20150128.0,20150203,20150203,EXP,,US-BMSGILMSD-2015-0134972,GILEAD,,70.0,YR,E,M,Y,,,20150203.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,107598691.0,OT,,,,,,,,,107598691.0,1.0,HIV infection
10763906,107639063,3,F,20141119.0,20150305.0,20150204,20150312,EXP,,ZA-BMSGILMSD-2015-0135192,GILEAD,,29.0,YR,A,F,Y,,,20150312.0,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,107639063.0,OT,,,107639063.0,1.0,20140604.0,,,,107639063.0,1.0,HIV infection
10767739,107677391,1,I,,20150202.0,20150205,20150205,EXP,,US-BMSGILMSD-2015-0135653,GILEAD,,43.0,YR,A,M,Y,,,20150205.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Nightmare;Wrist fracture,107677391.0,HO,,,,,,,,,107677391.0,1.0,HIV infection
10783183,107831831,1,I,2014.0,20150204.0,20150210,20150210,EXP,,US-BMSGILMSD-2015-0136113,GILEAD,,48.0,YR,A,F,Y,,,20150210.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intestinal perforation,107831831.0,HO,,,,,,,,,107831831.0,1.0,HIV infection
10783185,107831851,1,I,,20150203.0,20150210,20150210,EXP,,US-BMSGILMSD-2015-0136133,GILEAD,,65.0,YR,E,F,Y,,,20150210.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Joint stiffness,107831851.0,HO,,,,,,,,,107831851.0,1.0,HIV infection
10794428,107944281,1,I,20131101.0,20141205.0,20150213,20150213,EXP,,UG-GILEAD-2014-0126150,GILEAD,,29.0,YR,A,M,Y,64.0,KG,20150213.0,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Dyspnoea;Malaise;Peripheral swelling;Pyrexia;Septic shock;Skin hyperpigmentation;Vomiting,107944281.0,HO,,,107944281.0,1.0,20140409.0,,,,107944281.0,1.0,HIV infection
10833190,108331901,1,I,,20150212.0,20150219,20150219,EXP,,US-BMSGILMSD-2015-0137763,GILEAD,,61.0,YR,A,M,Y,,,20150219.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lymphoma;Neoplasm malignant,108331901.0,OT,,,,,,,,,108331901.0,1.0,HIV infection
10833295,108332951,1,I,,20150210.0,20150219,20150219,EXP,,US-GILEAD-2015-0137401,GILEAD,,45.0,YR,A,M,Y,,,20150219.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Pathogen resistance,108332951.0,OT,,,,,,,,,108332951.0,1.0,HIV infection
10857041,108570411,1,I,,20150212.0,20150223,20150223,EXP,,US-BMSGILMSD-2015-0137726,GILEAD,,63.0,YR,A,M,Y,,,20150223.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,108570411.0,OT,,,108570411.0,1.0,2004.0,,,,108570411.0,1.0,HIV infection
10862465,108624654,4,F,20141011.0,20150521.0,20150224,20150729,EXP,,GB-GILEAD-2015-0137682,GILEAD,,51.0,YR,A,F,Y,66.0,KG,20150729.0,N,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,108624654.0,OT,,,108624654.0,1.0,20100617.0,,,,108624654.0,1.0,HIV infection
10865804,108658043,3,F,20140701.0,20150708.0,20150224,20150716,EXP,,UG-GILEAD-2014-0120166,GILEAD,,29.0,YR,A,F,Y,56.0,KG,20150716.0,N,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Abortion threatened;Amylase increased;Exposure during pregnancy;Upper respiratory tract infection;Vulvovaginal candidiasis,108658043.0,OT,,,108658043.0,1.0,20140701.0,20140923.0,,,108658043.0,1.0,HIV infection
10875397,108753972,2,F,20141119.0,20150317.0,20150227,20150324,EXP,,ZA-GILEAD-2015-0139347,GILEAD,,38.0,YR,A,F,Y,,,20150324.0,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,108753972.0,OT,,,108753972.0,1.0,20140625.0,,,,108753972.0,1.0,HIV infection
10881845,108818452,2,F,20140710.0,20150312.0,20150303,20150319,EXP,,MW-GILEAD-2015-0139377,GILEAD,,38.0,YR,A,M,Y,,,20150319.0,N,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis cryptococcal,108818452.0,HO,,,108818452.0,1.0,20140304.0,,,,108818452.0,1.0,HIV infection
10888950,108889501,1,I,201410.0,20150226.0,20150305,20150305,EXP,,US-BMSGILMSD-2015-0140194,GILEAD,,41.0,YR,A,M,Y,,,20150305.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Heart valve operation,108889501.0,OT,,,,,,,,,108889501.0,1.0,HIV infection
10894999,108949993,3,F,201501.0,20150318.0,20150306,20150323,EXP,,UG-GILEAD-2015-0140055,GILEAD,,38.0,YR,A,F,Y,68.7,KG,20150323.0,N,MD,UG,UG,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Uterine haemorrhage,108949993.0,OT,,,108949993.0,1.0,20131021.0,20131002.0,,,108949993.0,1.0,HIV infection
10902829,109028292,2,F,20150208.0,20150520.0,20150310,20150528,EXP,,US-GILEAD-2015-0140381,GILEAD,,50.0,YR,A,F,Y,80.3,KG,20150528.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Overdose;Suicide attempt,109028292.0,OT,,,109028292.0,1.0,20111216.0,,,,109028292.0,1.0,HIV infection
10902831,109028311,1,I,,20150302.0,20150310,20150310,EXP,,US-BMSGILMSD-2015-0140813,GILEAD,,71.0,YR,E,M,Y,,,20150310.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,109028311.0,OT,,,,,,,,,109028311.0,1.0,HIV infection
10902832,109028321,1,I,,20150303.0,20150310,20150310,EXP,,US-BMSGILMSD-2015-0140801,GILEAD,,66.0,YR,E,M,Y,,,20150310.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,109028321.0,OT,,,,,,,,,109028321.0,1.0,HIV infection
10905707,109057071,1,I,20140508.0,20150303.0,20150311,20150311,EXP,,IT-GILEAD-2015-0141152,GILEAD,"D?AVINO A, LASSANDRO A, LAMONICA S, PICCOLI B, FABBIANI M, MONDI A, GAGLIARDINI R, BORGHETTI A, FANTI L, PALLAVICINI F, CAUDA R, DI GIAMBENEDETTO S. PREVALENCE OF OSTEOPOROSIS AND PREDICTORS OF LOW BMD IN A COHORT OF HIV-1 INFECTED PATIENTS IN ROME: A POPULATION AT HIGH RISK. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2014;UNK:UNK",46.0,YR,A,M,Y,72.0,KG,20150311.0,N,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,109057071.0,OT,,,109057071.0,1.0,20090428.0,20140408.0,,,109057071.0,1.0,HIV infection
10926507,109265072,2,F,20141201.0,20150331.0,20150318,20150409,EXP,,ZA-GILEAD-2015-0141781,GILEAD,,28.0,YR,A,F,Y,61.6,KG,20150409.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Ruptured ectopic pregnancy,109265072.0,OT,,,109265072.0,1.0,20140324.0,,,,109265072.0,1.0,HIV infection
10932862,109328621,1,I,,20150312.0,20150320,20150320,EXP,,US-BMSGILMSD-2015-0142466,GILEAD,,41.0,YR,A,M,Y,,,20150320.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Overdose,109328621.0,HO,,,109328621.0,1.0,20150220.0,20150304.0,,,109328621.0,1.0,HIV infection
10936068,109360681,1,I,,20150313.0,20150320,20150320,EXP,,US-BMSGILMSD-2015-0142903,GILEAD,,43.0,YR,A,M,Y,,,20150320.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,109360681.0,OT,,,,,,,,,109360681.0,1.0,HIV infection
10983647,109836471,1,I,2015.0,20150325.0,20150403,20150403,EXP,,US-BMSGILMSD-2015-0145237,GILEAD,,45.0,YR,A,F,Y,,,20150403.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;CD4 lymphocytes abnormal;Diabetes mellitus;Drug ineffective;Drug resistance;HIV test positive;Hyperlipidaemia;Treatment noncompliance;Virologic failure,109836471.0,OT,,,109836471.0,1.0,201501.0,,,,109836471.0,1.0,HIV infection
11005236,110052361,1,I,20140512.0,20150217.0,20150409,20150409,EXP,,SZ-GILEAD-2015-0141083,GILEAD,,0.0,YR,,M,Y,3.5,KG,20150409.0,N,MD,SZ,SZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foot deformity,110052361.0,CA,,,110052361.0,1.0,20140512.0,,,,110052361.0,1.0,HIV infection
11021435,110214351,1,I,20150202.0,20150403.0,20150413,20150413,EXP,,ES-GILEAD-2015-0147410,GILEAD,,39.0,YR,A,F,Y,61.5,KG,20150413.0,N,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ectopic pregnancy,110214351.0,OT,,,110214351.0,1.0,20100628.0,,,,110214351.0,1.0,HIV infection
11022075,110220752,2,F,201501.0,20150421.0,20150413,20150504,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-020219,BRISTOL MYERS SQUIBB,,38.0,YR,,F,Y,68.0,KG,20150504.0,N,CN,US,UG,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Uterine haemorrhage,110220752.0,HO,,,110220752.0,1.0,20131021.0,20131002.0,,,110220752.0,1.0,HIV infection
11022204,110222043,3,F,20131030.0,20160905.0,20150413,20160913,EXP,ZA-ANRS-201500264,ZA-GILEAD-2015-0147988,GILEAD,,42.0,YR,A,M,Y,56.7,KG,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Gamma-glutamyltransferase increased;Hypokalaemia;Renal failure,110222043.0,DE,,,110222043.0,1.0,20130405.0,,,,110222043.0,1.0,HIV infection
11038596,110385961,1,I,,20150410.0,20150416,20150416,EXP,,US-BMSGILMSD-2015-0148761,GILEAD,,,,,M,Y,,,20150416.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Hip fracture,110385961.0,OT,,,,,,,,,110385961.0,1.0,HIV infection
11043901,110439011,1,I,,20150406.0,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02905,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN:A REVIEW OF ITS USE IN HIV-1 INFECTION. DRUGS. 2015;75:503-514,,,,,Y,,,20150417.0,N,OT,NZ,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Pneumonia,110439011.0,DE,,,,,,,,,110439011.0,1.0,HIV infection
11043906,110439061,1,I,,20150406.0,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02899,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN: A REVIEW OF ITS USE IN HIV-1 INFECTION.. DRUGS. DRUG;75:503-514,,,,,Y,,,20150417.0,N,OT,NZ,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Renal failure;Sepsis,110439061.0,DE,,,,,,,,,110439061.0,1.0,HIV infection
11045212,110452121,1,I,,20150406.0,20150417,20150417,EXP,,CA-CIPLA LTD.-2015CA02915,CIPLA,SARAH L. GREIG .EMMA D. DEEKS. ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE SINGLE-TABLET REGIMEN: A REVIEW OF ITS USE IN HIV-1 INFECTION.. DRUGS. DRUG;75:503-514,,,,,Y,,,20150418.0,N,,COUNTRY NOT SPECIFIED,CA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Cerebrovascular accident,110452121.0,OT,,,,,,,,,110452121.0,1.0,HIV infection
11048742,110487421,1,I,,20150407.0,20150420,20150420,EXP,,IN-CIPLA LTD.-2015IN02964,CIPLA,"PAL.A, SARKAR.S, SAHA.D, GUHA.S, SAHA.B, CHAKRAVARTY.R, CHAKRABARTI.S. HIGH INCIDENCE OF LAMIVUDINE-RESISTANCE ASSOCIATED VACCINE-ESCAPE HBV MUTANT AMONG HIV-COINFECTED PATIENTS ON PROLONGED ANTIRETROVIRAL ACTIVITY. ISSN. 2015;1359-6535:1-20",,,,,Y,,,20150420.0,N,OT,IN,IN,NEVIRAPINE/EFAVIRENZ,Death,110487421.0,DE,,,,,,,,,110487421.0,1.0,HIV infection
11048771,110487711,1,I,,20150407.0,20150420,20150420,EXP,,IN-CIPLA LTD.-2015IN02963,CIPLA,"PAL.A, SARKAR.S, SAHA.D, GUHA.S, SAHA.B, CHAKRAVARTY.R, CHAKRABARTI.S. HIGH INCIDENCE OF LAMIVUDINE-RESISTANCE ASSOCIATED VACCINE-ESCAPE HBV MUTANT AMONG HIV-COINFECTED PATIENTS ON PROLONGED ANTIRETROVIRAL ACTIVITY. ISSN. 2015;1359-6535",,,,,Y,,,20150420.0,N,OT,IN,IN,NEVIRAPINE/EFAVIRENZ,Fibrosis,110487711.0,OT,,,,,,,,,110487711.0,1.0,HIV infection
11055951,110559513,3,F,20150323.0,20150608.0,20150422,20150616,EXP,,ZA-GILEAD-2015-0149662,GILEAD,,32.0,YR,A,F,Y,83.8,KG,20150616.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Xanthoma,110559513.0,OT,,,110559513.0,1.0,20140407.0,20150302.0,,,110559513.0,1.0,HIV infection
11069342,110693421,1,I,20141216.0,20150421.0,20150427,20150427,EXP,,US-GILEAD-2015-0149983,GILEAD,,50.0,YR,A,M,Y,72.5,KG,20150427.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Schizoaffective disorder,110693421.0,HO,,,110693421.0,1.0,20100511.0,201411.0,,,110693421.0,1.0,HIV infection
11072967,110729671,1,I,,20150423.0,20150428,20150428,EXP,,US-BMSGILMSD-2015-0150542,GILEAD,,50.0,YR,A,M,Y,,,20150428.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ear deformity acquired;Hypersensitivity;Injury,110729671.0,HO,,,,,,,,,110729671.0,1.0,HIV infection
11090452,110904528,8,F,20140729.0,20150903.0,20150505,20150910,EXP,,ZA-GILEAD-2015-0151205,GILEAD,,35.0,YR,A,F,Y,,,20150910.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Dysmenorrhoea;Eosinophilia;Eye infection;Menorrhagia;Vaginal haemorrhage,110904528.0,OT,,,110904528.0,1.0,20140729.0,,,,110904528.0,1.0,HIV infection
11091473,110914731,1,I,2014.0,20150430.0,20150505,20150505,EXP,,US-BMSGILMSD-2015-0151744,GILEAD,,,,,F,Y,,,20150505.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,110914731.0,HO,,,,,,,,,110914731.0,1.0,HIV infection
11101158,111011582,2,F,201209.0,20150512.0,20150508,20150513,EXP,,US-BMSGILMSD-2015-0152313,GILEAD,,62.0,YR,A,M,Y,78.46,KG,20150513.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,111011582.0,OT,,,,,,,,,111011582.0,1.0,HIV infection
11101417,111014171,1,I,,20150430.0,20150508,20150508,EXP,,US-BMSGILMSD-2015-0151695,GILEAD,,,,,M,Y,,,20150508.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,111014171.0,OT,,,,,,,,,111014171.0,1.0,HIV infection
11107072,111070721,1,I,,20150508.0,20150512,20150512,EXP,,US-BMSGILMSD-2015-0152926,GILEAD,,45.0,YR,A,M,Y,,,20150512.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tuberculosis,111070721.0,LT,,,,,,,,,111070721.0,1.0,HIV infection
11111379,111113792,2,F,20150428.0,20150909.0,20150513,20150914,EXP,,UG-GILEAD-2015-0152101,GILEAD,,58.0,YR,A,M,Y,77.0,KG,20150914.0,N,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drowning,111113792.0,OT,,,111113792.0,1.0,20141208.0,20150427.0,,,111113792.0,1.0,HIV infection
11116909,111169095,5,F,20141031.0,20161227.0,20150515,20170103,EXP,,UG-GILEAD-2014-0123355,GILEAD,,36.0,YR,A,M,Y,56.0,KG,20170103.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,111169095.0,OT,,,111169095.0,1.0,20140328.0,20141117.0,,,111169095.0,1.0,HIV infection
11119425,111194253,3,F,,20180628.0,20150518,20180710,EXP,,ZA-CIPLA LTD.-2015ZA03809,CIPLA,"SOGBANMU OO, ADENIYI OV, FUENTES YO, TER GOON D.. VERY EARLY VIROLOGICAL FAILURE AND DRUG RESISTANCE MUTATIONS IN A WOMAN ON ANTIRETROVIRAL THERAPY IN EASTERN CAPE, SOUTH AFRICA: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2015?9:1 TO 9",,,,,Y,,,20180710.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Drug resistance;Virologic failure,111194253.0,OT,,,111194253.0,1.0,,201407.0,,,111194253.0,1.0,HIV infection
11122723,111227231,1,I,20150311.0,20150430.0,20150519,20150519,EXP,,UG-GILEAD-2015-0153986,GILEAD,,34.0,YR,A,F,Y,72.0,KG,20150519.0,N,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,111227231.0,OT,,,111227231.0,1.0,20140708.0,20141214.0,,,111227231.0,1.0,HIV infection
11142534,111425341,1,I,2010.0,20150520.0,20150527,20150527,EXP,,US-BMSGILMSD-2015-0154760,GILEAD,,36.0,YR,A,M,Y,,,20150527.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain neoplasm,111425341.0,DS,,,111425341.0,1.0,2010.0,,,,111425341.0,1.0,HIV infection
11147779,111477791,1,I,20150324.0,,20150528,20150528,DIR,,,,,75.0,YR,,M,N,69.1,KG,20150421.0,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Bile duct stone;Diverticulum;Drug-induced liver injury;Pancreatitis,111477791.0,HO,111477791.0,HP,111477791.0,1.0,20141001.0,20150324.0,,,111477791.0,1.0,HIV infection
11148863,111488631,1,I,,20150521.0,20150529,20150529,EXP,,US-BMSGILMSD-2015-0154933,GILEAD,,43.0,YR,A,F,Y,65.76,KG,20150529.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Headache;Hyperhidrosis;Malaise;Osteomyelitis bacterial;Tuberculosis,111488631.0,OT,,,,,,,,,111488631.0,1.0,HIV infection
11152243,111522433,3,F,20140714.0,20150817.0,20150601,20150825,EXP,,ZA-GILEAD-2014-0111067,GILEAD,,46.0,YR,A,F,Y,64.9,KG,20150825.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,111522433.0,OT,,,111522433.0,1.0,20121213.0,20140706.0,,,111522433.0,1.0,HIV infection
11154960,111549602,2,F,2014.0,20150609.0,20150529,20150617,EXP,,FR2015GSK056018,VIIV,,45.0,YR,,M,N,105.0,KG,20150616.0,N,MD,FR,,ATRIPLA (EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE),Blood creatinine increased;Renal failure,111549602.0,OT,111549602.0,HP,111549602.0,1.0,20141127.0,20150317.0,,,111549602.0,1.0,HIV infection
11157011,111570112,2,F,20150309.0,20150714.0,20150602,20150717,EXP,,GB-BMSGILMSD-2015-0155123,GILEAD,,54.0,YR,A,M,Y,93.0,KG,20150717.0,N,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malignant melanoma,111570112.0,OT,,,111570112.0,1.0,201406.0,,,,111570112.0,1.0,HIV infection
11166253,111662532,2,F,200811.0,20160303.0,20150605,20160314,EXP,,ES-CIPLA LTD.-2015ES04334,CIPLA,"MIRODDI M, CALAPAI G, CASCIARO M, CALAPAI F, NAVARRA M, GANGEMI S. MONTELUKAST-INDUCED ADVERSE DRUG REACTIONS: A REVIEW OF CASE REPORTS IN THE LITERATURE. PHARMACOLOGY. 2014?94:60 TO 70",,,,,Y,,,20160314.0,,OT,IT,ES,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Abnormal dreams;Confusional state;Disturbance in attention;Drug interaction;Drug intolerance;Irritability;Nightmare;Sleep disorder,111662532.0,OT,,,111662532.0,1.0,200707.0,201201.0,,,111662532.0,1.0,HIV infection
11169047,111690471,1,I,,20150602.0,20150605,20150605,EXP,,US-BMSGILMSD-2015-0156591,GILEAD,,47.0,YR,A,M,Y,,,20150605.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dementia,111690471.0,HO,,,,,,,,,111690471.0,1.0,HIV infection
11183985,111839851,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04548,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Kaposi's sarcoma,111839851.0,OT,,,,,,,,,111839851.0,1.0,HIV infection
11183986,111839861,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04545,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Kaposi's sarcoma,111839861.0,OT,,,,,,,,,111839861.0,1.0,HIV infection CDC category C
11184007,111840071,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04546,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Cervix carcinoma,111840071.0,OT,,,,,,,,,111840071.0,1.0,HIV infection CDC category C
11184390,111843901,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04551,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Molluscum contagiosum,111843901.0,OT,,,,,,,,,111843901.0,1.0,HIV infection
11184393,111843931,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04623,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Urogenital disorder,111843931.0,OT,,,,,,,,,111843931.0,1.0,HIV infection
11184399,111843991,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04549,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Toxoplasmosis,111843991.0,OT,,,,,,,,,111843991.0,1.0,HIV infection
11184403,111844031,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04622,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Adverse event,111844031.0,OT,,,,,,,,,111844031.0,1.0,HIV infection
11184411,111844111,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04624,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Skin toxicity,111844111.0,OT,,,,,,,,,111844111.0,1.0,HIV infection
11184415,111844151,1,I,,20150604.0,20150612,20150612,EXP,,ES-CIPLA LTD.-2015ES04625,CIPLA,"MIRO M.J, MANZARDO C, FERRER E, LONCA M, GUARDO A.C, PODZAMCZER D, DOMINGO P.ET.AL. IMMUNE RECONSTITUTION IN SEVERELY IMMUNOSUPPRESSED ANTIRETROVIRAL-NAIVE HIV-1-INFECTED PATIENTS STARTING EFAVIRENZ, LOPINAVIR-RITONAVIR, OR ATAZANAVIR-RITONAVIR PLUS TENOFOVIR/EMTRICITABINE: FINAL 48-WEEK RESULTS (THE ADVANZ-3 TRIAL). J ACQUIR IMMUNE DEFIC SYNDR. 2015;69:206-215",,,,,Y,,,20150612.0,N,OT,ES,ES,Tenofovir/Emtricitabine/Efavirenz,Laboratory test abnormal,111844151.0,OT,,,,,,,,,111844151.0,1.0,HIV infection
11196973,111969735,5,F,20141021.0,20150922.0,20150617,20151026,PER,,US-GILEAD-2015-0158008,GILEAD,,31.0,YR,A,F,Y,173.2,KG,20151026.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy,,,,,111969735.0,1.0,20120612.0,,,,111969735.0,1.0,HIV infection
11200116,1120011610,10,F,20141021.0,20160701.0,20150618,20160711,EXP,,US-BMSGILMSD-2015-0158849,GILEAD,,0.0,YR,N,M,Y,1.36,KG,20160711.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydronephrosis;Foetal exposure during pregnancy;Foetal megacystis;Pulmonary embolism;Pulmonary haemorrhage,1120011610.0,CA,,,1120011610.0,1.0,20141021.0,20150611.0,,,1120011610.0,1.0,HIV infection
11200772,112007721,1,I,20140917.0,20150610.0,20150618,20150618,EXP,,BW-BMSGILMSD-2015-0158227,GILEAD,,37.0,YR,A,F,Y,,,20150618.0,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,112007721.0,OT,,,112007721.0,1.0,20120730.0,,,,112007721.0,1.0,HIV infection
11203820,112038201,1,I,,20150616.0,20150619,20150619,EXP,,US-GILEAD-2015-0159102,GILEAD,,,,,M,Y,,,20150619.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Loss of consciousness,112038201.0,OT,,,,,,,,,112038201.0,1.0,HIV infection
11216235,112162351,1,I,,20150617.0,20150624,20150624,EXP,,US-CIPLA LTD.-2015US05019,CIPLA,"OVERTON ET, CHAN ES, BROWN TT, TEBAS P, MCCOMSEY GA, MELBOURNE KM, NAPOLI A, HARDIN WR, RIBAUDO HJ, YIN MT. VITAMIN D AND CALCIUM ATTENUATE BONE LOSS WITH ANTIRETROVIRAL THERAPY INITIATION: A RANDOMIZED TRIAL. ANN INTERN MED. 2015;162:815-24",,,,,Y,,,20150624.0,N,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Nephrolithiasis,112162351.0,OT,,,,,,,,,112162351.0,1.0,HIV infection
11222432,112224321,1,I,201506.0,20150421.0,20150626,20150626,EXP,,US-BMSGILMSD-2015-0150261,GILEAD,,25.0,YR,A,F,Y,,,20150626.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Drug dose omission;Dysphonia;Hearing aid user;Hearing impaired;Malaise;Nausea,112224321.0,HO,,,,,,,,,112224321.0,1.0,HIV infection
11229774,112297742,2,F,20150423.0,20150805.0,20150630,20150811,EXP,,US-BMSGILMSD-2015-0160600,GILEAD,,48.0,YR,A,M,Y,,,20150811.0,N,MD,US,US,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alcohol poisoning;Death;Pneumonia;Spinal fracture,112297742.0,HO,,,112297742.0,1.0,20150416.0,20150424.0,,,112297742.0,1.0,HIV infection
11232764,112327643,3,F,20150519.0,20150818.0,20150701,20150825,EXP,,ZA-GILEAD-2015-0159824,GILEAD,,32.0,YR,A,F,Y,114.8,KG,20150825.0,N,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Adenocarcinoma;Metastases to liver,112327643.0,HO,,,112327643.0,1.0,20111024.0,,,,112327643.0,1.0,HIV infection
11234093,112340931,1,I,,20150622.0,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05088,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Laryngeal pain,112340931.0,OT,,,,,,,,,112340931.0,1.0,HIV infection
11234094,112340941,1,I,,20150622.0,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05107,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz,Virologic failure,112340941.0,OT,,,,,,,,,112340941.0,1.0,HIV infection
11234095,112340951,1,I,,20150622.0,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05103,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112340951.0,OT,,,,,,,,,112340951.0,1.0,HIV infection
11234440,112344401,1,I,,20150622.0,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05106,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz,Virologic failure,112344401.0,OT,,,,,,,,,112344401.0,1.0,HIV infection
11234441,112344411,1,I,,20150622.0,20150702,20150702,EXP,,US-CIPLA LTD.-2015US05104,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150702.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Creatinine renal clearance decreased,112344411.0,OT,,,,,,,,,112344411.0,1.0,HIV infection
11235047,112350471,1,I,,20150325.0,20150702,20150702,EXP,,US-BMSGILMSD-2015-0145407,GILEAD,,32.0,YR,A,M,Y,,,20150702.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes abnormal;Drug ineffective;Drug resistance;HIV test positive;Virologic failure,112350471.0,OT,,,112350471.0,1.0,201412.0,,,,112350471.0,1.0,HIV infection
11237694,112376941,1,I,,20150622.0,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05114,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Pancreatitis acute,112376941.0,OT,,,,,,,,,112376941.0,1.0,HIV infection
11237696,112376961,1,I,,20150622.0,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05112,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Hepatitis acute,112376961.0,OT,,,,,,,,,112376961.0,1.0,HIV infection
11237697,112376971,1,I,,20150622.0,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05115,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112376971.0,OT,,,,,,,,,112376971.0,1.0,HIV infection
11237701,112377011,1,I,,20150622.0,20150703,20150703,EXP,,US-CIPLA LTD.-2015US05116,CIPLA,"DEJESUS E, YOUNG B, MORALES-RAMIREZ J.O, SLOAN L, WARD D.J, FLAHERTY J.F, EBRAHIMI R, MAA J, ET.AL.. SIMPLIFICATION OF ANTIRETROVIRAL THERAPY TO A SINGLE-TABLET REGIMEN CONSISTING OF EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE VERSUS UNMODIFIED ANTIRETROVIRAL THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED PATIENTS. J ACQUIR IMMUNE DEFIC SYNDR. 2009;51:163-174",,,,,Y,,,20150703.0,N,OT,US,US,EFAVIRENZ PLUS ZIDOVUDINE (ZDV)/LAMIVUDINE;Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Virologic failure,112377011.0,OT,,,,,,,,,112377011.0,1.0,HIV infection
11238562,112385623,3,F,20150528.0,20150917.0,20150706,20150923,EXP,,FR-GILEAD-2015-0160731,GILEAD,,45.0,YR,A,M,Y,65.0,KG,20150923.0,N,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cholecystitis,112385623.0,HO,,,112385623.0,1.0,20100605.0,,,,112385623.0,1.0,HIV infection
11245634,112456341,1,I,,20150629.0,20150707,20150707,EXP,,US-BMSGILMSD-2015-0161097,GILEAD,,59.0,YR,A,M,Y,,,20150707.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tuberculosis,112456341.0,OT,,,,,,,,,112456341.0,1.0,HIV infection
11274333,112743332,2,F,2015.0,20150724.0,20150715,20150730,EXP,,US-GILEAD-2015-0161669,GILEAD,,,,,M,Y,,,20150730.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Foetal megacystis,112743332.0,DE,,,112743332.0,1.0,20150320.0,20150519.0,,,112743332.0,1.0,HIV infection
11277775,112777751,1,I,,20150709.0,20150716,20150716,EXP,,US-BMSGILMSD-2015-0163015,GILEAD,,,,,M,Y,,,20150716.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amino acid level decreased;Staphylococcal infection,112777751.0,HO,,,,,,,,,112777751.0,1.0,HIV infection
11289331,112893311,1,I,20141003.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024153,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893311.0,OT,,,112893311.0,1.0,20130313.0,,,,112893311.0,1.0,HIV infection
11289334,112893341,1,I,,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024158,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Cleft lip and palate;Foetal exposure during pregnancy;Maternal drugs affecting foetus,112893341.0,OT,,,,,,,,,112893341.0,1.0,HIV infection
11289347,112893471,1,I,20140812.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024140,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ W/LAMIVUDINE/STAVUDINE,Abortion spontaneous;Exposure during pregnancy,112893471.0,OT,,,112893471.0,1.0,20140313.0,,,,112893471.0,1.0,HIV infection
11289348,112893481,1,I,20141006.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024148,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893481.0,OT,,,112893481.0,1.0,20140411.0,,,,112893481.0,1.0,HIV infection
11289358,112893581,1,I,20140526.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024154,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893581.0,OT,,,112893581.0,1.0,20130213.0,,,,112893581.0,1.0,HIV infection
11289359,112893591,1,I,20140922.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024155,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893591.0,OT,,,112893591.0,1.0,20131029.0,,,,112893591.0,1.0,HIV infection
11289360,112893601,1,I,20140926.0,20150707.0,20150721,20150721,EXP,,KE-MYLANLABS-2015M1024157,MYLAN,,,,,,Y,,,20150721.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,112893601.0,OT,,,112893601.0,1.0,20131113.0,,,,112893601.0,1.0,HIV infection
11289961,112899611,1,I,20150608.0,20150714.0,20150721,20150721,EXP,,US-GILEAD-2015-0163480,GILEAD,,53.0,YR,A,M,Y,115.9,KG,20150721.0,N,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction,112899611.0,OT,,,112899611.0,1.0,20110107.0,,,,112899611.0,1.0,HIV infection
11290164,112901641,1,I,2015.0,20150717.0,20150721,20150721,EXP,,US-BMSGILMSD-2015-0164176,GILEAD,,60.0,YR,A,M,Y,,,20150721.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Spinal fracture,112901641.0,OT,,,,,,,,,112901641.0,1.0,HIV infection
11290406,112904061,1,I,20140617.0,20150707.0,20150722,20150722,EXP,,KE-MYLANLABS-2015M1024156,MYLAN,,,,,,Y,,,20150722.0,N,OT,KE,KE,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Maternal drugs affecting foetus;Stillbirth,112904061.0,DE,,,112904061.0,1.0,20130109.0,,,,112904061.0,1.0,HIV infection
11307217,113072171,1,I,20150219.0,20150716.0,20150723,20150723,EXP,,ZA-BMSGILMSD-2015-0164444,GILEAD,,,,N,,Y,,,20150723.0,N,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypoplastic nasal cartilage;Limb reduction defect,113072171.0,OT,,,113072171.0,1.0,20150219.0,,,,113072171.0,1.0,HIV infection
11315198,113151981,1,I,,20150721.0,20150727,20150727,EXP,,US-BMSGILMSD-2015-0164539,GILEAD,,,,,M,Y,,,20150727.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Road traffic accident,113151981.0,OT,,,,,,,,,113151981.0,1.0,HIV infection
11316088,113160881,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0590,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFIVIR)",Abortion spontaneous;Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy,113160881.0,OT,113160881.0,FGN,113160881.0,1.0,20131029.0,,,,113160881.0,1.0,HIV infection
11316102,113161021,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0591,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy,113161021.0,OT,113161021.0,HP,113161021.0,1.0,20131113.0,,,,113161021.0,1.0,HIV infection
11316346,113163461,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0599,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Contraindicated drug administered;Maternal exposure during pregnancy;Pregnancy;Stillbirth,113163461.0,OT,113163461.0,FGN,113163461.0,1.0,20130109.0,,,,113163461.0,1.0,HIV infection
11316382,113163821,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0601,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,LAMIVUDINE+STAVUDINE+EFAVIRENZ (LAMIVUDINE+STAVUDINE+EFAVIRENZ),Abortion spontaneous;Maternal exposure during pregnancy,113163821.0,OT,113163821.0,HP,113163821.0,1.0,20140313.0,,,,113163821.0,1.0,HIV infection
11316588,113165881,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0612,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Maternal exposure during pregnancy,113165881.0,OT,113165881.0,FGN,113165881.0,1.0,20130213.0,,,,113165881.0,1.0,HIV infection
11316596,113165961,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0613,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ + LAMIVUDINE + TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR)",Abortion spontaneous;Maternal exposure during pregnancy,113165961.0,OT,113165961.0,FGN,113165961.0,1.0,20140411.0,,,,113165961.0,1.0,HIV infection
11316613,113166131,1,I,,20150709.0,20150724,20150724,EXP,,2015HINCT0614,HETERO,,,,,F,N,,,20150722.0,N,MD,KE,,"EFAVIRENZ+LAMIVUDINE+TENOFOVIR (EFAVIRENZ, LAMIVUDINE, TENOFOVIR) UNKNOWN",Abortion spontaneous;Maternal exposure during pregnancy,113166131.0,OT,113166131.0,FGN,113166131.0,1.0,20150313.0,,,,113166131.0,1.0,HIV infection
11321780,113217802,2,F,,20150727.0,20150729,20150805,EXP,,US-BMSGILMSD-2015-0165282,GILEAD,,50.0,YR,A,M,Y,,,20150805.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Road traffic accident,113217802.0,HO,,,,,,,,,113217802.0,1.0,HIV infection
11323551,113235511,1,I,,20141124.0,20150730,20150730,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2014GSK028624,VIIV,"JANARDHANAN M, AMBERKAR MB, VIDYSAGAR S, KUMARI M AND HOLLA SN. HYPERSENSITIVITY REACTION ASSOCIATED WITH ABACAVIR THERAPY IN AN INDIAN  HIV PATIENT- A CASE REPORT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2014;8 (9):1-2",44.0,YR,,M,Y,,,20150730.0,N,MD,IN,IN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Blood test abnormal;Decreased appetite;Fatigue;Headache;Hepatic function abnormal;Hypersensitivity;Pancytopenia;Pruritus;Rash;Skin lesion;Vomiting,113235511.0,OT,,,,,,,,,113235511.0,1.0,HIV infection
11325419,113254191,1,I,20150607.0,20150723.0,20150730,20150730,EXP,,BW-GILEAD-2015-0165113,GILEAD,,36.0,YR,A,F,Y,,,20150730.0,N,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,113254191.0,OT,,,113254191.0,1.0,20140219.0,,,,113254191.0,1.0,HIV infection
11331364,113313641,1,I,,20150727.0,20150803,20150803,EXP,,US-GILEAD-2015-0165308,GILEAD,,63.0,YR,A,M,Y,,,20150803.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion;Retinal detachment;Stress;Visual acuity reduced,113313641.0,OT,,,,,,,,,113313641.0,1.0,HIV infection
11342579,113425791,1,I,201504.0,20150729.0,20150805,20150805,EXP,,US-BMSGILMSD-2015-0165930,GILEAD,,43.0,YR,A,M,Y,,,20150805.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Road traffic accident,113425791.0,DS,,,,,,,,,113425791.0,1.0,HIV infection
11362999,113629991,1,I,20150714.0,,20150807,20150807,DIR,,,,,34.0,YR,,M,N,63.0,KG,20150715.0,Y,OT,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Neutropenic sepsis;Toxicity to various agents,113629991.0,LT,113629991.0,HP,113629991.0,1.0,20150305.0,20150713.0,,,113629991.0,1.0,HIV infection
11400950,114009501,1,I,20150702.0,20150602.0,20150820,20150820,EXP,,US-BMSGILMSD-2015-0162045,GILEAD,,45.0,YR,A,M,Y,53.61,KG,20150820.0,N,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Drug ineffective;Drug resistance;Treatment noncompliance,114009501.0,OT,,,114009501.0,1.0,20130418.0,20150702.0,,,114009501.0,1.0,HIV infection
11407070,114070702,2,F,20150709.0,20150827.0,20150821,20150904,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-054443,BRISTOL MYERS SQUIBB,,63.0,YR,,F,Y,44.0,KG,20150904.0,N,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia;Pneumonia,114070702.0,OT,,,114070702.0,1.0,20150603.0,20150708.0,,,114070702.0,1.0,HIV infection
11427734,114277341,1,I,,20150818.0,20150828,20150828,EXP,,GB-CIPLA LTD.-2015GB06837,CIPLA,"WONG D, WALMSLEY S, BAUMGARTEN A, BERENGUER J, FELIZARTA F, FLORENCE E, KHUONG-JOSSES M ET AL.. DOLUTEGRAVIR PLUS ABACAVIR/LAMIVUDINE FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL THERAPY NAIVE PATIENTS: WEEK 96 AND WEEK 144 RESULTS FROM THE SINGLE RANDOMIZED CLINICAL TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES",,,,,Y,,,20150828.0,N,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Virologic failure,114277341.0,OT,,,,,,,,,114277341.0,1.0,HIV infection
11427770,114277701,1,I,,20150818.0,20150828,20150828,EXP,,GB-CIPLA LTD.-2015GB06842,CIPLA,"WONG D, WALMSLEY S, BAUMGARTEN A, BERENGUER J, FELIZARTA F, FLORENCE E, KHUONG-JOSSES M ET AL.. DOLUTEGRAVIR PLUS ABACAVIR/LAMIVUDINE FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL THERAPY-NAIVE PATIENTS: WEEK 96 AND WEEK 144 RESULTS FROM THE SINGLE RANDOMIZED CLINICAL TRIAL. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES",,,,,Y,,,20150828.0,N,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Acute hepatitis C,114277701.0,OT,,,,,,,,,114277701.0,1.0,HIV infection
11432913,114329131,1,I,,20150824.0,20150828,20150828,EXP,,US-BMSGILMSD-2015-0169396,GILEAD,,50.0,YR,A,M,Y,,,20150828.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,114329131.0,HO,,,,,,,,,114329131.0,1.0,HIV infection
11473744,114737442,2,F,20150825.0,20151111.0,20150908,20151118,EXP,,ZW-GILEAD-2015-0170992,GILEAD,,43.0,YR,A,F,Y,52.0,KG,20151118.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal loss of weight;Anaemia,114737442.0,OT,,,114737442.0,1.0,20150603.0,20150805.0,,,114737442.0,1.0,HIV infection
11481725,114817251,1,I,201504.0,20150903.0,20150909,20150909,EXP,,US-GILEAD-2015-0170920,GILEAD,,46.0,YR,A,F,Y,,,20150909.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,114817251.0,OT,,,,,,,,,114817251.0,1.0,HIV infection
11515807,115158071,1,I,20150910.0,20150911.0,20150916,20150916,EXP,,US-BMSGILMSD-2015-0172189,GILEAD,,64.0,YR,,M,Y,,,20150916.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Fall;Neoplasm malignant;Peripheral swelling,115158071.0,OT,,,,,,,,,115158071.0,1.0,HIV infection
11525693,115256931,1,I,2013.0,20150914.0,20150918,20150918,EXP,,US-GILEAD-2015-0172208,GILEAD,,38.0,YR,A,M,Y,,,20150918.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,115256931.0,OT,,,,,,,,,115256931.0,1.0,HIV infection
11525986,115259861,1,I,,20150911.0,20150918,20150918,EXP,,US-BMSGILMSD-2015-0172096,GILEAD,,40.0,YR,A,M,Y,,,20150918.0,N,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal infection,115259861.0,HO,,,115259861.0,1.0,20100101.0,,,,115259861.0,1.0,HIV infection
11550264,115502644,4,F,20150622.0,20161102.0,20150924,20161107,EXP,,ZA-GILEAD-2015-0173671,GILEAD,,31.0,YR,A,F,Y,38.0,KG,20161107.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood alkaline phosphatase increased;Diarrhoea;Gamma-glutamyltransferase increased,115502644.0,OT,,,115502644.0,1.0,201505.0,,,,115502644.0,1.0,HIV infection
11585604,115856044,4,F,20150922.0,20151029.0,20151001,20151103,EXP,,UG-GILEAD-2015-0174732,GILEAD,,25.0,YR,A,F,Y,44.0,KG,20151103.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,115856044.0,HO,,,115856044.0,1.0,20150901.0,20150922.0,,,115856044.0,1.0,Kaposi's sarcoma AIDS related
11594589,115945891,1,I,201504.0,20150929.0,20151005,20151005,EXP,,US-BMSGILMSD-2015-0175040,GILEAD,,58.0,YR,A,M,Y,,,20151005.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,115945891.0,OT,,,,,,,,,115945891.0,1.0,HIV infection
11594898,115948984,4,F,20150115.0,20160613.0,20151005,20160615,EXP,,PE-GILEAD-2015-0174370,GILEAD,,,,,M,Y,,,20160615.0,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Foetal exposure during pregnancy,115948984.0,OT,,,115948984.0,1.0,20130612.0,,,,115948984.0,1.0,HIV infection
11608344,116083441,1,I,,20151001.0,20151007,20151007,EXP,,US-GILEAD-2015-0175342,GILEAD,,54.0,YR,A,M,Y,,,20151007.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness,116083441.0,OT,,,,,,,,,116083441.0,1.0,HIV infection
11613561,116135611,1,I,20150120.0,20151002.0,20151008,20151008,EXP,,ZA-BMSGILMSD-2015-0175575,GILEAD,,41.0,YR,A,F,Y,,,20151008.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,116135611.0,OT,,,116135611.0,1.0,20140107.0,,,,116135611.0,1.0,HIV infection
11613599,116135991,1,I,20150124.0,20151002.0,20151008,20151008,EXP,,ZA-BMSGILMSD-2015-0175551,GILEAD,,39.0,YR,A,F,Y,,,20151008.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,116135991.0,OT,,,116135991.0,1.0,20140703.0,,,,116135991.0,1.0,HIV infection
11621108,116211081,1,I,,20151008.0,20151012,20151012,EXP,,US-GILEAD-2015-0176313,GILEAD,,,,,F,Y,,,20151012.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;Neoplasm malignant,116211081.0,OT,,,,,,,,,116211081.0,1.0,HIV infection
11627357,116273571,1,I,,20151008.0,20151013,20151013,EXP,,US-BMSGILMSD-2015-0176409,GILEAD,,49.0,YR,A,M,Y,,,20151013.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abasia;Nervous system disorder,116273571.0,DS,,,,,,,,,116273571.0,1.0,HIV infection
11629566,116295663,3,F,20150217.0,20160905.0,20151014,20160908,EXP,,ZA-009507513-1510ZAF006032,MERCK,,66.0,YR,,M,Y,60.1,KG,20160908.0,,MD,ZA,ZA,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Cardiac failure congestive;Hypernatraemia,116295663.0,HO,,,116295663.0,1.0,20150211.0,20150224.0,,,116295663.0,1.0,HIV infection
11633134,116331344,4,F,20150217.0,20160905.0,20151015,20160909,EXP,,ZA-GILEAD-2015-0176579,GILEAD,,66.0,YR,E,M,Y,60.0,KG,20160909.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Cardiac failure congestive;Hypernatraemia;Renal impairment,116331344.0,DE,,,116331344.0,1.0,20150211.0,20150302.0,,,116331344.0,1.0,HIV infection
11641525,116415256,6,F,20150409.0,20160905.0,20151019,20160913,EXP,,ZA-GILEAD-2015-0176566,GILEAD,,35.0,YR,A,F,Y,69.5,KG,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Delirium;Gastroenteritis,116415256.0,OT,,,116415256.0,1.0,20141007.0,,,,116415256.0,1.0,HIV infection
11641566,116415662,2,F,20150926.0,20160905.0,20151019,20160913,EXP,,ZA-GILEAD-2015-0177198,GILEAD,,62.0,YR,A,M,Y,42.6,KG,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,116415662.0,OT,,,116415662.0,1.0,20150612.0,,,,116415662.0,1.0,HIV infection
11642065,116420652,2,F,2012.0,20151026.0,20151019,20151029,EXP,,US-GILEAD-2015-0177355,GILEAD,,44.0,YR,A,M,Y,,,20151029.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anal cancer,116420652.0,OT,,,116420652.0,1.0,2012.0,2013.0,,,116420652.0,1.0,HIV infection
11645010,116450101,1,I,201308.0,20151016.0,20151020,20151020,EXP,,US-GILEAD-2015-0177765,GILEAD,,,,,M,Y,,,20151020.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,116450101.0,OT,,,,,,,,,116450101.0,1.0,HIV infection
11657239,116572391,1,I,20150909.0,20151016.0,20151023,20151023,EXP,,ZA-GILEAD-2015-0177684,GILEAD,,32.0,YR,A,M,Y,58.0,KG,20151023.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional overdose;Suicide attempt,116572391.0,OT,,,116572391.0,1.0,20150909.0,20150909.0,,,116572391.0,1.0,HIV infection
11688093,116880932,2,F,,20151104.0,20151030,20151118,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073862,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151118.0,,OT,BE,BE,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neurotoxicity,116880932.0,OT,,,116880932.0,1.0,20090303.0,20111218.0,,,116880932.0,1.0,HIV infection
11691124,116911243,3,F,20100722.0,20160819.0,20151102,20160823,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15467632,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20160823.0,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Maternal exposure during pregnancy;Stillbirth,116911243.0,OT,,,,,,,,,116911243.0,1.0,Antiretroviral therapy
11693954,116939541,1,I,20150930.0,20151029.0,20151103,20151103,EXP,,GB-GILEAD-2015-0179845,GILEAD,,62.0,YR,A,M,Y,75.0,KG,20151103.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure acute;Myocardial infarction;Myocardial ischaemia,116939541.0,OT,,,116939541.0,1.0,20100120.0,,,,116939541.0,1.0,HIV infection
11701392,117013921,1,I,20100611.0,20111004.0,20151105,20151105,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16133720,BRISTOL MYERS SQUIBB,,30.0,YR,,F,Y,,,20151105.0,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,117013921.0,OT,,,117013921.0,1.0,20100422.0,20100611.0,,,117013921.0,1.0,Antiretroviral therapy
11702440,117024406,6,F,20151021.0,20190424.0,20151105,20190501,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074328,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,,,20190501.0,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Bacterial sepsis;Renal failure,117024406.0,HO,,,117024406.0,1.0,20150527.0,20150916.0,,,117024406.0,1.0,Kaposi's sarcoma AIDS related
11704123,117041231,1,I,,20151027.0,20151106,20151106,EXP,,GB-CIPLA LTD.-2015GB08334,CIPLA,"DYSON J. K., HUTCHINSON J., HARRISON, L., ROTIMI O., TINIAKOS D., FOSTER R G., ET AL.. LIVER TOXICITY ASSOCIATED WITH SOFOSBUVIR, AN NS5A INHIBITOR AND RIBAVIRIN USE. JOURNAL OF HEPATOLOGY. 2015?1 TO 21",,,,,Y,,,20151106.0,,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Jaundice;Multi-organ failure;Pneumonia klebsiella;Vomiting,117041231.0,DE,,,117041231.0,2.0,201407.0,,,,117041231.0,1.0,HIV infection
11730095,117300953,3,F,200508.0,20160202.0,20151112,20160210,EXP,,ES-GILEAD-2015-0181587,GILEAD,,52.0,YR,A,F,Y,52.0,KG,20160210.0,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Creatinine renal clearance decreased;Insomnia;Osteopenia;Osteoporosis,117300953.0,OT,,,117300953.0,1.0,200507.0,201312.0,,,117300953.0,1.0,HIV infection
11730827,117308271,1,I,201303.0,20151103.0,20151112,20151112,EXP,,ES-GILEAD-2015-0181254,GILEAD,,28.0,YR,A,F,Y,,,20151112.0,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neuropsychiatric syndrome,117308271.0,OT,,,117308271.0,1.0,201102.0,201304.0,,,117308271.0,1.0,HIV infection
11741847,117418471,1,I,20150908.0,,20151113,20151113,DIR,,,,,53.0,YR,,F,N,42.3,KG,20151110.0,Y,OT,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Neutropenia;White blood cell count decreased,117418471.0,LT,,,117418471.0,1.0,20150728.0,20150908.0,,,117418471.0,1.0,Kaposi's sarcoma AIDS related
11744743,117447437,7,F,20150115.0,20160614.0,20151116,20160617,EXP,,PE-GILEAD-2015-0174369,GILEAD,,31.0,YR,A,F,Y,82.0,KG,20160617.0,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Maternal exposure during pregnancy,117447437.0,OT,,,117447437.0,1.0,20130612.0,,,,117447437.0,1.0,HIV infection
11748512,117485121,1,I,,20151110.0,20151117,20151117,EXP,,US-BMSGILMSD-2015-0182340,GILEAD,,28.0,YR,A,M,Y,,,20151117.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug dose omission;Drug resistance,117485121.0,OT,,,117485121.0,1.0,,20151110.0,,,117485121.0,1.0,HIV infection
11751173,117511733,3,F,20151008.0,20151208.0,20151118,20151217,EXP,,US-GILEAD-2015-0182212,GILEAD,,60.0,YR,A,F,Y,88.89,KG,20151217.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoarthritis,117511733.0,HO,,,117511733.0,1.0,20130222.0,,,,117511733.0,1.0,HIV infection
11756888,117568881,1,I,,20151107.0,20151120,20151120,EXP,,GB-CIPLA LTD.-2015GB08587,CIPLA,"WILKINS E, COHEN C, TROTTIER B, ESSER S, SMITH D, HAAS B, ET AL.. PATIENT-REPORTED OUTCOMES IN THE SINGLE-TABLET REGIMEN (STAR) TRIAL OF RILPIVIRINE/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE VERSUS EFAVIRENZ/EMTRICITABINE/ TENOFOVIR DISOPROXIL FUMARATE IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 THROUGH 48 WEEKS OF TREATMENT. AIDS CARE. 2015?1-8",,,,,Y,,,20151120.0,,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Septic shock,117568881.0,DE,,,,,,,,,117568881.0,1.0,HIV infection
11769512,117695121,1,I,2015.0,20151116.0,20151123,20151123,EXP,,US-GILEAD-2015-0183012,GILEAD,,55.0,YR,A,F,Y,,,20151123.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Carotid artery occlusion;Cerebral thrombosis;Cerebrovascular accident;Transient ischaemic attack,117695121.0,HO,,,,,,,,,117695121.0,1.0,HIV infection
11775350,117753502,2,F,20100317.0,20160822.0,20151125,20160822,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15072168,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20160822.0,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,117753502.0,OT,,,117753502.0,1.0,20100219.0,20100201.0,,,117753502.0,1.0,Antiretroviral therapy
11779613,117796131,1,I,20150123.0,20151120.0,20151125,20151125,EXP,,ZA-BMSGILMSD-2015-0184328,GILEAD,,43.0,YR,A,F,Y,,,20151125.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,117796131.0,OT,,,,,,,,,117796131.0,1.0,HIV infection
11780712,117807121,1,I,20100701.0,20100520.0,20151126,20151126,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15116122,BRISTOL MYERS SQUIBB,,26.0,YR,,F,Y,,,20151126.0,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Abortion spontaneous;Caesarean section;Normal newborn;Premature delivery;Twin pregnancy,117807121.0,OT,,,117807121.0,1.0,20100518.0,20100518.0,,,117807121.0,1.0,HIV infection
11799099,117990991,1,I,,20151123.0,20151203,20151203,EXP,,US-GILEAD-2015-0184897,GILEAD,,51.0,YR,A,F,Y,,,20151203.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Spinal cord injury,117990991.0,DS,,,,,,,,,117990991.0,1.0,HIV infection
11809402,118094021,1,I,,20151130.0,20151208,20151208,EXP,,US-BMSGILMSD-2015-0185910,GILEAD,,50.0,YR,A,M,Y,,,20151207.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Viral infection,118094021.0,HO,,,,,,,,,118094021.0,1.0,HIV infection
11814242,118142422,2,F,20140806.0,20161227.0,20151209,20161229,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21301353,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,60.5,KG,20161229.0,,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,118142422.0,HO,,,118142422.0,1.0,20140328.0,20150919.0,,,118142422.0,1.0,Kaposi's sarcoma AIDS related
11824685,118246851,1,I,,20130722.0,20151210,20151210,EXP,,US-GILEAD-2015-0187248,GILEAD,,67.0,YR,E,M,Y,,,20151210.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,118246851.0,OT,,,,,,,,,118246851.0,1.0,HIV infection
11824709,118247092,2,F,20151112.0,20160107.0,20151210,20160112,EXP,,GB-GILEAD-2015-0186285,GILEAD,,34.0,YR,A,M,Y,74.2,KG,20160112.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Generalised tonic-clonic seizure,118247092.0,OT,,,118247092.0,1.0,20111111.0,,,,118247092.0,1.0,HIV infection
11828984,118289841,1,I,20151126.0,20151207.0,20151211,20151211,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-085816,BRISTOL MYERS SQUIBB,,36.0,YR,,F,Y,,,20151211.0,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Bacterial sepsis;Renal failure,118289841.0,DE,,,118289841.0,1.0,20150205.0,20150317.0,,,118289841.0,1.0,Antiretroviral therapy
11829226,118292261,1,I,20150217.0,20150218.0,20151211,20151211,EXP,,UG-GILEAD-2015-0175831,GILEAD,,32.0,YR,A,F,Y,55.0,KG,20151211.0,,MD,UG,UG,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Placenta praevia haemorrhage,118292261.0,HO,,,118292261.0,1.0,20140611.0,20150830.0,,,118292261.0,1.0,HIV infection
11841004,118410043,3,F,20150104.0,20151228.0,20151216,20151231,EXP,,UG-GILEAD-2015-0132067,GILEAD,,36.0,YR,A,M,Y,56.0,KG,20151231.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypotension;Pneumonia;Pyrexia,118410043.0,HO,,,118410043.0,1.0,20140319.0,20150103.0,,,118410043.0,1.0,Kaposi's sarcoma AIDS related
11860634,118606341,1,I,201411.0,20151215.0,20151222,20151222,EXP,,US-GILEAD-2015-0188884,GILEAD,,37.0,YR,A,F,Y,,,20151222.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,118606341.0,OT,,,118606341.0,1.0,20140625.0,20141210.0,,,118606341.0,1.0,HIV infection
11861222,118612221,1,I,,20151214.0,20151222,20151222,EXP,,US-GILEAD-2015-0188659,GILEAD,,57.0,YR,A,M,Y,,,20151222.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,118612221.0,OT,,,,,,,,,118612221.0,1.0,HIV infection
11861994,118619941,1,I,,20151216.0,20151222,20151222,EXP,,US-BMSGILMSD-2015-0189055,GILEAD,,48.0,YR,A,M,Y,,,20151222.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Non-Hodgkin's lymphoma,118619941.0,OT,,,,,,,,,118619941.0,1.0,HIV infection
11862089,118620891,1,I,20151209.0,,20151222,20151222,DIR,,,,,66.0,YR,,M,N,,,20151221.0,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Hyperkalaemia;Hypoaldosteronism,118620891.0,HO,118620891.0,HP,118620891.0,1.0,20100707.0,20151209.0,,,118620891.0,1.0,HIV infection
11863472,118634721,1,I,,20151215.0,20151223,20151223,EXP,,GB-CIPLA LTD.-2015GB09526,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151223.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug interaction,118634721.0,OT,,,,,,,,,118634721.0,1.0,HIV infection
11866308,118663081,1,I,20151116.0,20151218.0,20151223,20151223,EXP,,US-GILEAD-2015-0189536,GILEAD,,,,,M,Y,,,20151223.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,118663081.0,HO,,,,,,,,,118663081.0,1.0,HIV infection
11866624,118666241,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09523,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Neurotoxicity,118666241.0,OT,,,,,,,,,118666241.0,1.0,HIV infection
11866634,118666341,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09525,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Gastrointestinal toxicity,118666341.0,OT,,,,,,,,,118666341.0,1.0,HIV infection
11866635,118666351,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09524,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Intentional overdose;Neurotoxicity;Suicide attempt,118666351.0,OT,,,,,,,,,118666351.0,1.0,HIV infection
11866666,118666661,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09527,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118666661.0,OT,,,,,,,,,118666661.0,1.0,HIV infection
11866703,118667031,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09541,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118667031.0,OT,,,,,,,,,118667031.0,1.0,HIV infection
11866729,118667291,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09544,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118667291.0,OT,,,,,,,,,118667291.0,1.0,HIV infection
11866733,118667331,1,I,,20151215.0,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09547,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224.0,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity;Pneumocystis jirovecii pneumonia,118667331.0,OT,,,,,,,,,118667331.0,1.0,HIV infection
11877375,118773752,2,F,,20160201.0,20151229,20160211,EXP,,GB-BMSGILMSD-2015-0189399,GILEAD,,33.0,YR,A,M,Y,,,20160211.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder,118773752.0,OT,,,,,,,,,118773752.0,1.0,HIV infection
11883015,118830151,1,I,20151020.0,20151223.0,20151231,20151231,EXP,,UG-GILEAD-2015-0190043,GILEAD,,47.0,YR,A,F,Y,74.0,KG,20151231.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Sepsis,118830151.0,HO,,,118830151.0,1.0,20150907.0,20150921.0,,,118830151.0,1.0,HIV infection
11883068,118830682,2,F,,20160201.0,20151231,20160210,EXP,,GB-GILEAD-2015-0190541,GILEAD,,52.0,YR,A,M,Y,,,20160210.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug intolerance,118830682.0,OT,,,,,,,,,118830682.0,1.0,HIV infection
11883136,118831362,2,F,,20160201.0,20151231,20160211,EXP,,GB-GILEAD-2015-0190578,GILEAD,,42.0,YR,A,M,Y,,,20160211.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychiatric symptom,118831362.0,OT,,,,,,,,,118831362.0,1.0,HIV infection
11883137,118831372,2,F,,20160201.0,20151231,20160212,EXP,,GB-009507513-1512GBR014567,MERCK,,41.0,YR,,F,Y,,,20160212.0,,CN,US,GB,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Virologic failure,118831372.0,OT,,,118831372.0,1.0,20151001.0,20151001.0,,,118831372.0,1.0,HIV infection
11883161,118831612,2,F,,20160201.0,20151231,20160211,EXP,,GB-BMSGILMSD-2015-0190543,GILEAD,,32.0,YR,A,F,Y,,,20160211.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder,118831612.0,OT,,,,,,,,,118831612.0,1.0,HIV infection
11893597,118935972,2,F,201512.0,20160108.0,20160106,20160115,EXP,,US-BMSGILMSD-2015-0190585,GILEAD,,55.0,YR,A,M,Y,,,20160115.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis;Surgery,118935972.0,OT,,,,,,,,,118935972.0,1.0,HIV infection
11903551,119035512,2,F,,20151231.0,20160108,20160109,EXP,,US-GILEAD-2016-0191873,GILEAD,,34.0,YR,A,M,Y,,,20160108.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Hallucination;Headache;Nausea;Personality change;Unevaluable event,119035512.0,OT,,,119035512.0,1.0,2013.0,2013.0,,,119035512.0,1.0,HIV infection
11918053,119180531,1,I,,20160104.0,20160114,20160114,EXP,,US-GILEAD-2016-0191274,GILEAD,,61.0,YR,A,M,Y,,,20160114.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,119180531.0,OT,,,,,,,,,119180531.0,1.0,HIV infection
11921961,119219611,1,I,201512.0,20160108.0,20160115,20160115,EXP,,US-GILEAD-2016-0192083,GILEAD,,64.0,YR,A,F,Y,,,20160115.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Lower respiratory tract infection,119219611.0,OT,,,,,,,,,119219611.0,1.0,Acquired immunodeficiency syndrome
11921964,119219641,1,I,2009.0,20160108.0,20160115,20160115,EXP,,US-GILEAD-2016-0192094,GILEAD,,77.0,YR,E,M,Y,,,20160115.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,119219641.0,OT,,,,,,,,,119219641.0,1.0,HIV infection
11921989,119219891,1,I,,20160108.0,20160115,20160115,EXP,,US-GILEAD-2016-0191932,GILEAD,,51.0,YR,A,M,Y,,,20160115.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Varicose vein,119219891.0,HO,,,119219891.0,1.0,2010.0,201512.0,,,119219891.0,1.0,HIV infection
11922034,119220342,2,F,2015.0,20160121.0,20160115,20160127,EXP,,US-GILEAD-2016-0191910,GILEAD,,63.0,YR,A,M,Y,,,20160127.0,,MD,US,US,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthralgia;Candida infection;Dysphagia;Nausea;Oesophagitis;Oral fungal infection;Pyrexia;Viral infection;Vomiting,119220342.0,HO,,,119220342.0,1.0,20150501.0,,,,119220342.0,1.0,HIV infection
11926357,119263571,1,I,,20160112.0,20160119,20160119,EXP,,CH-CIPLA LTD.-2016CH00229,CIPLA,"AOURI M, BARCELO C, TERNON B, CAVASSINI M, ANAGNOSTOPOULOS A, DECOSTERD L ET AL. IN VIVO PROFILING AND DISTRIBUTION OF KNOWN AND NOVEL PHASE I AND PHASE II METABOLITES OF EFAVIRENZ IN PLASMA, URINE, AND CEREBROSPINAL FLUID. DRUG METABOLISM AND DISPOSITION. 2016?44:151-161",,,,,Y,,,20160119.0,,OT,CH,CH,Tenofovir/Emtricitabine/Efavirenz,Drug level increased;Neurotoxicity,119263571.0,OT,,,,,,,,,119263571.0,1.0,HIV test positive
11937333,119373331,1,I,2015.0,20160113.0,20160121,20160121,EXP,,US-GILEAD-2016-0193635,GILEAD,,49.0,YR,A,M,Y,,,20160121.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Wrist fracture,119373331.0,OT,,,,,,,,,119373331.0,1.0,HIV infection
11940055,119400555,5,F,20160112.0,20160125.0,20160122,20160128,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-003072,BRISTOL MYERS SQUIBB,,39.0,YR,,F,Y,73.6,KG,20160128.0,,OT,ZW,ZW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Sepsis,119400555.0,OT,,,119400555.0,1.0,20150818.0,20151208.0,,,119400555.0,1.0,Kaposi's sarcoma AIDS related
11952464,119524641,1,I,20160115.0,20160118.0,20160125,20160125,EXP,,US-GILEAD-2016-0193991,GILEAD,,50.0,YR,A,F,Y,,,20160125.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Dyspnoea;Pneumocystis jirovecii pneumonia,119524641.0,HO,,,,,,,,,119524641.0,1.0,HIV infection
11967531,119675314,4,F,20160112.0,20160201.0,20160127,20160205,EXP,,ZW-GILEAD-2016-0193802,GILEAD,,39.0,YR,A,F,Y,73.6,KG,20160205.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Sepsis,119675314.0,HO,,,119675314.0,1.0,20150818.0,20160117.0,,,119675314.0,1.0,HIV infection
11969910,119699103,3,F,20151130.0,20160913.0,20160128,20160914,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004607,BRISTOL MYERS SQUIBB,,27.0,YR,,F,Y,61.5,KG,20160914.0,,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute respiratory distress syndrome;Pyrexia,119699103.0,HO,,,119699103.0,1.0,20150408.0,20150501.0,,,119699103.0,1.0,Acquired immunodeficiency syndrome
11971701,119717011,1,I,,20160120.0,20160128,20160128,EXP,,US-BMSGILMSD-2016-0194540,GILEAD,,63.0,YR,A,F,Y,,,20160128.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypertension;Nervousness,119717011.0,OT,,,,,,,,,119717011.0,1.0,HIV infection
12001258,120012581,1,I,,20160129.0,20160204,20160204,EXP,,US-BMSGILMSD-2016-0196168,GILEAD,,46.0,YR,A,M,Y,,,20160204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip surgery,120012581.0,OT,,,,,,,,,120012581.0,1.0,HIV infection
12001270,120012701,1,I,,20160129.0,20160204,20160204,EXP,,US-GILEAD-2016-0195944,GILEAD,,54.0,YR,A,M,Y,,,20160204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure congestive;Chronic kidney disease;Hyperlipidaemia;Type 2 diabetes mellitus,120012701.0,OT,,,,,,,,,120012701.0,1.0,HIV infection
12005836,120058361,1,I,,20160202.0,20160205,20160205,EXP,,US-GILEAD-2016-0196236,GILEAD,,54.0,YR,A,F,Y,,,20160204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain injury;Physical assault,120058361.0,HO,,,,,,,,,120058361.0,1.0,HIV infection
12061046,120610461,1,I,2014.0,20160203.0,20160210,20160210,EXP,,US-GILEAD-2016-0196907,GILEAD,,61.0,YR,A,M,Y,,,20160210.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Cerebrovascular accident;Encephalopathy;HIV infection;Memory impairment;Neoplasm malignant;Treatment noncompliance,120610461.0,OT,,,,,,,,,120610461.0,1.0,HIV infection
12070911,120709111,1,I,20150928.0,20151001.0,20160211,20160211,EXP,,KE-GILEAD-2015-0175436,GILEAD,,27.0,YR,A,F,Y,46.2,KG,20160211.0,,MD,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Ascites;Pleural effusion,120709111.0,HO,,,120709111.0,1.0,20150917.0,20151209.0,,,120709111.0,1.0,Kaposi's sarcoma AIDS related
12070929,120709291,1,I,,20151214.0,20160211,20160211,EXP,,GB-GILEAD-2015-0189409,GILEAD,,,,,M,Y,,,20160211.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression;Intentional product misuse,120709291.0,OT,,,,,,,,,120709291.0,1.0,HIV infection
12071121,120711211,1,I,20160128.0,20160202.0,20160211,20160211,EXP,,MW-GILEAD-2016-0197007,GILEAD,,33.0,YR,A,M,Y,,,20160211.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaria,120711211.0,HO,,,120711211.0,1.0,20150824.0,20160127.0,,,120711211.0,1.0,HIV infection
12071257,120712571,1,I,20151102.0,20160204.0,20160211,20160211,EXP,,GB-GILEAD-2016-0196945,GILEAD,,64.0,YR,,M,Y,64.0,KG,20160211.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Feeding disorder;Gastrooesophageal reflux disease;Infection;Malaise;Oropharyngeal pain,120712571.0,HO,,,120712571.0,1.0,20090205.0,20160122.0,,,120712571.0,1.0,HIV infection
12091740,120917401,1,I,,20160211.0,20160218,20160218,EXP,,US-BMSGILMSD-2016-0198859,GILEAD,,49.0,YR,A,M,Y,,,20160218.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Decreased appetite;Diabetes mellitus;Nasal ulcer;Pyrexia;Vision blurred,120917401.0,OT,,,,,,,,,120917401.0,1.0,HIV infection
12099496,120994961,1,I,,20160208.0,20160222,20160222,EXP,,US-CIPLA LTD.-2016US01277,CIPLA,"BARIL J, ANGEL JB, GILL MJ, GATHE J, CAHN P, WYK J AND WALMSLEY S. DUAL THERAPY TREATMENT STRATEGIES FOR THE MANAGEMENT OF PATIENTS INFECTED WITH HIV: A SYSTEMATIC REVIEW OF CURRENT EVIDENCE IN ARV-NAIVE OR ARV-EXPERIENCED, VIROLOGICALLY SUPPRESSED PATIENTS. PLOS ONE. 2016?11(2):1-32",,,,,Y,,,20160222.0,,OT,CA,US,Tenofovir/Emtricitabine/Efavirenz,Adverse event,120994961.0,OT,,,,,,,,,120994961.0,1.0,HIV infection
12099778,120997781,1,I,2013.0,20160212.0,20160222,20160222,EXP,,US-BMSGILMSD-2016-0198941,GILEAD,,66.0,YR,E,M,Y,,,20160222.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,120997781.0,HO,,,,,,,,,120997781.0,1.0,HIV infection
12107273,121072732,2,F,20160201.0,20160217.0,20160223,20160301,EXP,,US-GILEAD-2016-0199362,GILEAD,,60.0,YR,A,F,Y,93.6,KG,20160301.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoarthritis,121072732.0,HO,,,121072732.0,1.0,20130222.0,,,,121072732.0,1.0,HIV infection
12116848,121168482,2,F,20151006.0,20160308.0,20160225,20160314,EXP,,ZW-GILEAD-2015-0176985,GILEAD,,51.0,YR,A,M,Y,69.0,KG,20160314.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gangrene;Leg amputation;Weight decreased,121168482.0,HO,,,121168482.0,1.0,20150305.0,20151005.0,,,121168482.0,1.0,Kaposi's sarcoma AIDS related
12117436,121174362,2,F,,20160418.0,20160225,20160426,EXP,,ZA-GILEAD-2016-0199644,GILEAD,,47.0,YR,A,F,Y,114.8,KG,20160426.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Metastases to liver,121174362.0,DE,,,121174362.0,1.0,20111024.0,,,,121174362.0,1.0,HIV infection
12117440,121174404,4,F,20160125.0,20160719.0,20160225,20160728,EXP,,ZA-GILEAD-2016-0199511,GILEAD,,49.0,YR,A,M,Y,81.8,KG,20160728.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cognitive disorder,121174404.0,HO,,,121174404.0,1.0,20130425.0,20160118.0,,,121174404.0,1.0,HIV infection
12119616,121196162,2,F,20160118.0,20160303.0,20160226,20160308,EXP,,ZW-GILEAD-2016-0194747,GILEAD,,36.0,YR,A,F,Y,43.0,KG,20160308.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Gastroenteritis;Hypocalcaemia,121196162.0,DE,,,121196162.0,1.0,20150514.0,20160117.0,,,121196162.0,1.0,Kaposi's sarcoma AIDS related
12129353,121293531,1,I,20130521.0,20130527.0,20160229,20160229,EXP,,MW-GILEAD-2013-0076855,GILEAD,,29.0,YR,A,M,Y,60.5,KG,20160229.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Cellulitis,121293531.0,HO,,,121293531.0,1.0,20130128.0,,,,121293531.0,1.0,Acquired immunodeficiency syndrome
12142962,121429621,1,I,,20160226.0,20160303,20160303,EXP,,US-GILEAD-2016-0201217,GILEAD,,51.0,YR,A,M,Y,,,20160303.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Mass,121429621.0,HO,,,,,,,,,121429621.0,1.0,HIV infection
12156246,121562461,1,I,201404.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009290,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Anaemia;Blood creatinine increased;CD4 lymphocytes decreased;Deafness;Dizziness;Haemorrhage;Headache;Renal failure;Viral load increased,121562461.0,OT,,,121562461.0,1.0,201404.0,20140623.0,,,121562461.0,1.0,Antiretroviral therapy
12156247,121562471,1,I,,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009295,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Blood creatine phosphokinase increased;CD4 lymphocytes abnormal;Confusional state;Decreased appetite;Dyspnoea;Fatigue;Jaundice;Rash;Weight decreased,121562471.0,HO,,,121562471.0,1.0,20140117.0,,,,121562471.0,1.0,Antiretroviral therapy
12156248,121562481,1,I,20140424.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009264,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Blood creatinine increased;CD4 lymphocytes decreased;Confusional state;Decreased appetite;Disturbance in attention;Dizziness;Dyspnoea;Fatigue;Haemoglobin decreased;Viral load increased;Weight decreased,121562481.0,HO,,,121562481.0,1.0,20140408.0,,,,121562481.0,1.0,Antiretroviral therapy
12156249,121562491,1,I,20150223.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009433,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Alanine aminotransferase abnormal;Blood creatinine increased;CD4 lymphocytes decreased;Rash,121562491.0,OT,,,121562491.0,1.0,20141230.0,,,,121562491.0,1.0,Antiretroviral therapy
12156250,121562501,1,I,,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009436,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Diarrhoea;Vomiting;Weight decreased,121562501.0,HO,,,121562501.0,1.0,20151012.0,,,,121562501.0,1.0,Antiretroviral therapy
12156252,121562521,1,I,,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009272,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Blood creatine phosphokinase increased;CD4 lymphocytes abnormal;Decreased appetite;Diarrhoea;Nausea;Viral load;Vomiting;Weight decreased,121562521.0,OT,,,121562521.0,1.0,2010.0,,,,121562521.0,1.0,Antiretroviral therapy
12156517,121565171,1,I,20140619.0,20160224.0,20160307,20160307,EXP,,ZA-MYLANLABS-2016M1009396,MYLAN,,,,,,Y,,,20160307.0,,OT,ZA,ZA,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Anaemia;Back pain;Blood creatinine increased;Decreased appetite;Dizziness;Dyspnoea;Oesophageal candidiasis;Weight decreased,121565171.0,HO,,,121565171.0,1.0,201303.0,,,,121565171.0,2.0,HIV infection
12156890,121568901,1,I,,20160226.0,20160307,20160307,EXP,,US-BMSGILMSD-2016-0201464,GILEAD,,54.0,YR,A,M,Y,,,20160307.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Hip arthroplasty,121568901.0,OT,,,121568901.0,1.0,201401.0,,,,121568901.0,1.0,HIV infection
12158992,121589921,1,I,20140405.0,20160224.0,20160308,20160308,EXP,,ZA-MYLANLABS-2016M1009282,MYLAN,,,,,,Y,,,20160308.0,,OT,ZA,ZA,TENOFOVIR DF/EFAVIRENZ/EMTRICITABINE TABLETS 300/600/200MG,Deafness;Tinnitus,121589921.0,DS,,,,,,,,,121589921.0,1.0,Antiretroviral therapy
12169549,121695491,1,I,20160229.0,20160304.0,20160310,20160310,EXP,,ZW-GILEAD-2016-0202475,GILEAD,,44.0,YR,A,F,Y,52.0,KG,20160310.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Weight decreased,121695491.0,OT,,,121695491.0,1.0,20150603.0,20150824.0,,,121695491.0,1.0,HIV infection
12188434,121884348,8,F,20160229.0,20161118.0,20160317,20161125,EXP,,ZW-GILEAD-2016-0203612,GILEAD,,39.0,YR,A,M,Y,61.5,KG,20161125.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alopecia;Anaemia;Gastroenteritis;Hyponatraemia;Tuberculosis;Weight decreased,121884348.0,OT,,,121884348.0,1.0,20160219.0,20160228.0,,,121884348.0,1.0,Kaposi's sarcoma AIDS related
12188441,121884411,1,I,201603.0,20160311.0,20160317,20160317,EXP,,US-BMSGILMSD-2016-0203264,GILEAD,,44.0,YR,A,M,Y,,,20160317.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood glucose increased;Hypertension,121884411.0,HO,,,,,,,,,121884411.0,1.0,HIV infection
12188459,121884592,2,F,,20160401.0,20160317,20160407,EXP,,DE-GILEAD-2016-0199098,GILEAD,,46.0,YR,A,M,Y,82.0,KG,20160407.0,,CN,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psoriasis,121884592.0,OT,,,121884592.0,1.0,200812.0,,,,121884592.0,1.0,HIV infection
12196850,121968501,1,I,,20160315.0,20160321,20160321,EXP,,US-GILEAD-2016-0204078,GILEAD,,59.0,YR,A,M,Y,,,20160321.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system lesion;Toxoplasmosis,121968501.0,HO,,,,,,,,,121968501.0,1.0,HIV infection
12200868,122008681,1,I,201602.0,20160317.0,20160322,20160322,EXP,,US-BMSGILMSD-2016-0204507,GILEAD,,41.0,YR,A,M,Y,,,20160322.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,122008681.0,OT,,,,,,,,,122008681.0,1.0,HIV infection
12209496,122094961,1,I,,20160301.0,20160324,20160324,EXP,,US-GILEAD-2016-0201984,GILEAD,,52.0,YR,A,M,Y,,,20160324.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Back pain;Renal disorder,122094961.0,OT,,,,,,,,,122094961.0,1.0,HIV infection
12213424,122134242,2,F,20160324.0,20160331.0,20160328,20160401,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-022994,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20160401.0,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia,122134242.0,OT,,,122134242.0,1.0,20151216.0,20160309.0,,,122134242.0,1.0,Acquired immunodeficiency syndrome
12215305,122153053,3,F,20150707.0,20161128.0,20160328,20161130,EXP,,ZA-BMSGILMSD-2016-0205223,GILEAD,,26.0,YR,A,F,Y,,,20161130.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,122153053.0,OT,,,122153053.0,1.0,20150302.0,,,,122153053.0,1.0,HIV infection
12219433,122194331,1,I,20160202.0,20160325.0,20160329,20160329,EXP,,ZA-GILEAD-2016-0205750,GILEAD,,25.0,YR,A,F,Y,65.0,KG,20160329.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastritis,122194331.0,HO,,,122194331.0,1.0,20151217.0,,,,122194331.0,1.0,HIV infection
12223186,122231862,2,F,20160323.0,20160411.0,20160330,20160414,EXP,,MW-GILEAD-2016-0205855,GILEAD,,34.0,YR,A,M,Y,,,20160414.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis;Malaria,122231862.0,OT,,,122231862.0,1.0,20150325.0,20160322.0,,,122231862.0,1.0,Kaposi's sarcoma AIDS related
12235868,122358685,5,F,20160117.0,20160713.0,20160404,20160720,EXP,,GB-BMSGILMSD-2016-0199508,GILEAD,,44.0,YR,A,M,Y,60.0,KG,20160720.0,,OT,GB,GB,BLINDED EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Traumatic intracranial haemorrhage,122358685.0,OT,,,122358685.0,1.0,20151223.0,,,,122358685.0,1.0,HIV infection
12239382,122393821,1,I,20150721.0,20160330.0,20160405,20160405,EXP,,US-BMSGILMSD-2016-0206544,GILEAD,,37.0,YR,A,F,Y,,,20160405.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,122393821.0,OT,,,,,,,,,122393821.0,1.0,HIV infection
12240484,122404841,1,I,,20160328.0,20160405,20160405,EXP,,US-GILEAD-2016-0206026,GILEAD,,57.0,YR,A,F,Y,,,20160405.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure;Renal impairment,122404841.0,OT,,,,,,,,,122404841.0,1.0,HIV infection
12242834,122428341,1,I,,20160330.0,20160406,20160406,EXP,,US-GILEAD-2016-0206511,GILEAD,,52.0,YR,A,M,Y,,,20160406.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;T-lymphocyte count decreased,122428341.0,HO,,,122428341.0,1.0,2000.0,,,,122428341.0,1.0,HIV infection
12243877,122438772,2,F,20160328.0,20160413.0,20160406,20160419,EXP,,ZW-GILEAD-2016-0206751,GILEAD,,54.0,YR,A,M,Y,,,20160419.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,122438772.0,DE,,,122438772.0,1.0,20150715.0,20160327.0,,,122438772.0,1.0,Kaposi's sarcoma AIDS related
12247223,122472232,2,F,20151214.0,20160415.0,20160407,20160419,EXP,,US-BMSGILMSD-2016-0206961,GILEAD,,41.0,YR,A,M,Y,58.96,KG,20160419.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ischaemic stroke,122472232.0,OT,,,122472232.0,1.0,2009.0,,,,122472232.0,1.0,HIV infection
12266073,122660731,1,I,,20160408.0,20160413,20160413,EXP,,US-BMSGILMSD-2016-0207958,GILEAD,,34.0,YR,A,M,Y,,,20160413.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fatigue;Fear;Feeling abnormal;Intentional product use issue;Malaise;Nasopharyngitis,122660731.0,HO,,,,,,,,,122660731.0,1.0,HIV infection
12274736,122747362,2,F,2006.0,20160414.0,20160415,20160420,EXP,,US-BMSGILMSD-2016-0208708,GILEAD,,56.0,YR,A,F,Y,,,20160420.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Colorectal cancer;Colostomy,122747362.0,OT,,,,,,,,,122747362.0,1.0,HIV infection
12283361,122833613,3,F,20160411.0,20160421.0,20160419,20160428,EXP,,MW-GILEAD-2016-0209071,GILEAD,,30.0,YR,A,M,Y,,,20160428.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,122833613.0,DE,,,122833613.0,1.0,20150612.0,20160410.0,,,122833613.0,1.0,Acquired immunodeficiency syndrome
12300436,123004361,1,I,,20160420.0,20160425,20160425,EXP,,GB-GILEAD-2016-0209655,GILEAD,,47.0,YR,A,M,Y,,,20160425.0,,PH,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,123004361.0,DE,,,,,,,,,123004361.0,1.0,HIV infection
12308286,123082865,5,F,20160202.0,20170328.0,20160426,20170404,EXP,,UG-GILEAD-2016-0210345,GILEAD,,56.0,YR,A,F,Y,65.0,KG,20170404.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Radius fracture;Ulna fracture,123082865.0,HO,,,123082865.0,1.0,20150709.0,,,,123082865.0,1.0,HIV infection
12311657,123116571,1,I,2016.0,20160121.0,20160427,20160427,EXP,,US-BMSGILMSD-2016-0194875,GILEAD,,35.0,YR,A,M,Y,92.97,KG,20160427.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteopenia;Renal impairment,123116571.0,OT,,,,,,,,,123116571.0,1.0,HIV infection
12315941,123159412,2,F,20150701.0,20160626.0,20160428,20160701,EXP,,VN-BMSGILMSD-2016-0210281,GILEAD,,45.0,YR,A,M,Y,,,20160701.0,,OT,VN,VN,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,123159412.0,OT,,,123159412.0,1.0,20140329.0,20150701.0,,,123159412.0,1.0,HIV infection
12320551,123205512,2,F,,20160505.0,20160429,20160510,EXP,,IT-GILEAD-2016-0211232,GILEAD,,66.0,YR,E,M,Y,,,20160510.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Hypertension,123205512.0,OT,,,123205512.0,1.0,2012.0,,,,123205512.0,1.0,HIV infection
12325357,123253572,2,F,,20160523.0,20160502,20160526,EXP,,US-BMSGILMSD-2016-0211538,GILEAD,,54.0,YR,A,M,Y,,,20160526.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Plasma cell myeloma,123253572.0,OT,,,123253572.0,1.0,20110428.0,,,,123253572.0,1.0,HIV infection
12335445,123354452,2,F,20160127.0,20160426.0,20160504,20160511,EXP,,ZW-GILEAD-2016-0211545,GILEAD,,28.0,YR,A,M,Y,69.9,KG,20160511.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,123354452.0,OT,,,123354452.0,1.0,20150702.0,20160407.0,,,123354452.0,1.0,Acquired immunodeficiency syndrome
12358914,123589142,2,F,,20160430.0,20160512,20160513,EXP,,US-CIPLA LTD.-2016US04759,CIPLA,"LENCI LT, CHIN EK, ALMEIDA DR. CENTRAL RETINAL ARTERY OCCLUSION IN A YOUNG HIV-INFECTED PATIENT ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. RETINAL CASES + BRIEF REPORTS. 2016;1 TO 3",,,,,Y,,,20160513.0,,OT,US,US,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Carotid arteriosclerosis;Carotid artery stenosis;Hypercholesterolaemia;Hypertriglyceridaemia;Retinal artery occlusion,123589142.0,DS,,,,,,,,,123589142.0,1.0,HIV infection
12364175,123641752,2,F,201012.0,20160523.0,20160512,20160526,EXP,,GB-GILEAD-2016-0213104,GILEAD,,70.0,YR,E,M,Y,75.0,KG,20160526.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chronic kidney disease;Glycosuria;Hypophosphataemia;Multiple-drug resistance;Nephropathy toxic;Proteinuria;Renal tubular disorder;Treatment failure;Viral mutation identified,123641752.0,OT,,,123641752.0,1.0,20131114.0,,,,123641752.0,1.0,HIV infection
12369097,123690971,1,I,20160307.0,20160409.0,20160513,20160513,EXP,,BR-HETERO LABS LTD-1052123,HETERO,,23.0,YR,,F,Y,,,20160513.0,,OT,BR,BR,EFAVIRENZ\ LAMIVUDINE \ TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,123690971.0,OT,,,123690971.0,1.0,20150817.0,,,,123690971.0,1.0,HIV infection
12369962,123699622,2,F,201408.0,20160607.0,20160516,20160614,EXP,,CA-GILEAD-2016-0213210,GILEAD,,62.0,YR,A,M,Y,81.63,KG,20160614.0,,MD,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Glomerulonephritis;Nephropathy toxic;Renal impairment;Sleep disorder,123699622.0,OT,,,123699622.0,1.0,20160218.0,201602.0,,,123699622.0,1.0,HIV infection
12383446,123834464,4,F,,20170608.0,20160518,20170619,EXP,,FR-BMSGILMSD-2016-0214004,GILEAD,,58.0,YR,A,M,Y,,,20170619.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporotic fracture;Renal tubular disorder,123834464.0,OT,,,123834464.0,1.0,2006.0,,,,123834464.0,1.0,HIV infection
12387276,123872762,2,F,,20160531.0,20160519,20160607,EXP,,US-BMSGILMSD-2016-0214089,GILEAD,,62.0,YR,A,M,Y,,,20160607.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,123872762.0,OT,,,123872762.0,1.0,2011.0,,,,123872762.0,1.0,HIV infection
12402966,124029661,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05075,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Death,124029661.0,DE,,,,,,,,,124029661.0,1.0,HIV infection
12402994,124029941,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05076,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Mental disorder,124029941.0,OT,,,,,,,,,124029941.0,1.0,HIV infection
12403009,124030091,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05109,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Nephropathy toxic,124030091.0,OT,,,,,,,,,124030091.0,1.0,HIV infection
12403015,124030151,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05103,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Burn oesophageal,124030151.0,OT,,,,,,,,,124030151.0,1.0,HIV infection
12403021,124030211,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05077,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Mental disorder;Treatment noncompliance,124030211.0,OT,,,,,,,,,124030211.0,1.0,HIV infection
12403041,124030411,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05137,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030411.0,OT,,,,,,,,,124030411.0,1.0,HIV infection
12403064,124030641,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05135,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030641.0,OT,,,,,,,,,124030641.0,1.0,HIV infection
12403067,124030671,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05110,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Psychiatric decompensation,124030671.0,OT,,,,,,,,,124030671.0,1.0,HIV infection
12403075,124030751,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05136,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124030751.0,OT,,,,,,,,,124030751.0,1.0,HIV infection
12403234,124032341,1,I,,20160510.0,20160525,20160525,EXP,,CH-CIPLA LTD.-2016CH05138,CIPLA,,,,,,Y,,,20160525.0,,OT,CH,CH,Efavirenz;Tenofovir/Emtricitabine/Efavirenz,Blood HIV RNA increased,124032341.0,OT,,,,,,,,,124032341.0,1.0,HIV infection
12404262,124042623,3,F,20130320.0,20160803.0,20160525,20160810,EXP,,IT-BMSGILMSD-2016-0215006,GILEAD,,55.0,YR,A,M,Y,112.0,KG,20160810.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteopenia;Osteoporosis,124042623.0,OT,,,124042623.0,1.0,20100524.0,,,,124042623.0,1.0,HIV infection
12404284,124042841,1,I,,20160519.0,20160525,20160525,EXP,,GB-BMSGILMSD-2016-0215042,GILEAD,,,,A,F,Y,,,20160525.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foot fracture,124042841.0,HO,,,,,,,,,124042841.0,1.0,HIV infection
12409468,124094681,1,I,,20160520.0,20160526,20160526,EXP,,US-GILEAD-2016-0215258,GILEAD,,54.0,YR,A,F,Y,,,20160526.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;Therapy cessation,124094681.0,HO,,,,,,,,,124094681.0,1.0,HIV infection
12433610,124336103,3,F,20160525.0,20160811.0,20160603,20160815,EXP,,DE-GILEAD-2016-0215798,GILEAD,,49.0,YR,A,M,Y,84.2,KG,20160815.0,,OT,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial fibrillation,124336103.0,OT,,,124336103.0,1.0,20150622.0,20160525.0,,,124336103.0,1.0,HIV infection
12439298,124392983,3,F,20160115.0,20160614.0,20160606,20160622,EXP,,IT-GILEAD-2016-0216502,GILEAD,,67.0,YR,E,M,Y,65.0,KG,20160622.0,,OT,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lumbar vertebral fracture;Osteoporosis,124392983.0,HO,,,124392983.0,1.0,20050620.0,20160609.0,,,124392983.0,1.0,HIV infection
12445087,124450871,1,I,20130801.0,20131114.0,20160607,20160607,EXP,,DE-BMSGILMSD-2013-0088290,GILEAD,,,,A,F,Y,73.0,KG,20160607.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Pregnancy,,,,,,,,,,,124450871.0,1.0,HIV infection
12456925,124569251,1,I,,20160603.0,20160610,20160610,EXP,,ZW-GILEAD-2016-0217550,GILEAD,,33.0,YR,A,F,Y,47.0,KG,20160610.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,124569251.0,DE,,,124569251.0,1.0,20160120.0,20160516.0,,,124569251.0,1.0,Kaposi's sarcoma AIDS related
12481920,124819201,1,I,20160405.0,20160610.0,20160620,20160620,EXP,,US-GILEAD-2016-0218879,GILEAD,,,,,F,Y,,,20160620.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Parathyroid disorder;Viral infection,124819201.0,HO,,,,,,,,,124819201.0,1.0,HIV infection
12486495,124864951,1,I,,20160613.0,20160621,20160621,EXP,,US-BMSGILMSD-2016-0219037,GILEAD,,47.0,YR,A,M,Y,,,20160621.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Multiple fractures;Road traffic accident;Swelling,124864951.0,HO,,,,,,,,,124864951.0,1.0,HIV infection
12490356,124903563,3,F,20160613.0,20160708.0,20160622,20160714,EXP,,MW-GILEAD-2016-0219942,GILEAD,,38.0,YR,A,M,Y,,,20160714.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Bacterial sepsis;Disseminated tuberculosis,124903563.0,HO,,,124903563.0,1.0,20150717.0,20160612.0,,,124903563.0,1.0,Acquired immunodeficiency syndrome
12505909,125059092,2,F,,20160712.0,20160628,20160713,EXP,,GB-BMSGILMSD-2016-0220050,GILEAD,,,,,M,Y,,,20160713.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,125059092.0,OT,,,,,,,,,125059092.0,1.0,HIV infection
12506557,125065571,1,I,,20160621.0,20160628,20160628,EXP,,US-BMSGILMSD-2016-0220325,GILEAD,,,,,M,Y,,,20160628.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthralgia;Ascites;Hepatic cirrhosis;Liver disorder;Neuropathy peripheral;Splenomegaly;T-lymphocyte count decreased,125065571.0,OT,,,125065571.0,1.0,19950106.0,,,,125065571.0,1.0,HIV infection
12528907,125289073,3,F,20160421.0,20161103.0,20160705,20161109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-034189,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,60.0,KG,20161109.0,,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Encephalitis;Neutropenia,125289073.0,HO,,,125289073.0,1.0,20151021.0,20160329.0,,,125289073.0,1.0,Acquired immunodeficiency syndrome
12537541,125375411,1,I,,20160628.0,20160707,20160707,EXP,,US-BMSGILMSD-2016-0221435,GILEAD,,66.0,YR,E,M,Y,,,20160707.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Hypertension,125375411.0,OT,,,,,,,,,125375411.0,1.0,HIV infection
12538327,125383271,1,I,,20160628.0,20160707,20160707,EXP,,US-BMSGILMSD-2016-0221256,GILEAD,,56.0,YR,A,M,Y,,,20160707.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood glucose increased;Cardiac arrest;Myocardial infarction;Stent placement,125383271.0,OT,,,,,,,,,125383271.0,1.0,HIV infection
12566773,125667732,2,F,20160707.0,20160722.0,20160718,20160729,EXP,,ZW-GILEAD-2016-0223808,GILEAD,,52.0,YR,A,M,Y,,,20160729.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Sepsis,125667732.0,HO,,,125667732.0,1.0,20150305.0,20150916.0,,,125667732.0,1.0,Kaposi's sarcoma AIDS related
12566853,125668531,1,I,,20160711.0,20160718,20160718,EXP,,ZA-BMSGILMSD-2016-0223383,GILEAD,,27.0,YR,A,F,Y,,,20160718.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,125668531.0,OT,,,125668531.0,1.0,20150302.0,,,,125668531.0,1.0,HIV infection
12571446,125714462,2,F,,20161121.0,20160719,20161125,EXP,,US-GILEAD-2016-0223728,GILEAD,,56.0,YR,A,F,Y,,,20161125.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypersensitivity;Osteoporosis,125714462.0,OT,,,125714462.0,1.0,,200811.0,,,125714462.0,1.0,HIV infection
12575241,125752411,1,I,20160707.0,20160714.0,20160720,20160720,EXP,,IT-BMSGILMSD-2016-0223757,GILEAD,,59.0,YR,A,M,Y,79.0,KG,20160720.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Osteoporosis,125752411.0,OT,,,125752411.0,1.0,20081010.0,,,,125752411.0,1.0,HIV infection
12598438,125984383,3,F,20140227.0,20160822.0,20160726,20160830,EXP,,CH-BMSGILMSD-2016-0225011,GILEAD,,57.0,YR,A,M,Y,49.4,KG,20160830.0,,MD,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,125984383.0,OT,,,125984383.0,1.0,20111111.0,20150115.0,,,125984383.0,1.0,HIV infection
12604563,126045634,4,F,201508.0,20160825.0,20160728,20160830,EXP,,IL-GILEAD-2016-0224992,GILEAD,,50.0,YR,A,M,Y,84.5,KG,20160830.0,,OT,IL,IL,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Gastrointestinal disorder;Nausea;Osteoporosis;Proteinuria,126045634.0,OT,,,126045634.0,1.0,200802.0,201201.0,,,126045634.0,1.0,HIV infection
12611183,126111831,1,I,,20160725.0,20160801,20160801,EXP,,IT-GILEAD-2016-0225417,GILEAD,,39.0,YR,A,M,Y,118.6,KG,20160801.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,126111831.0,OT,,,126111831.0,1.0,20081206.0,,,,126111831.0,1.0,HIV infection
12617512,126175121,1,I,20160125.0,20160728.0,20160803,20160803,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-062932,BRISTOL MYERS SQUIBB,,49.0,YR,,M,Y,81.8,KG,20160803.0,,OT,ZA,ZA,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Cognitive disorder,126175121.0,HO,,,126175121.0,2.0,20130425.0,20160118.0,,,126175121.0,1.0,HIV infection
12627469,126274692,2,F,20160513.0,20161222.0,20160805,20161227,EXP,,AR-GILEAD-2016-0226029,GILEAD,,42.0,YR,A,M,Y,93.0,KG,20161227.0,,OT,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion,126274692.0,HO,,,126274692.0,1.0,20100713.0,,,,126274692.0,1.0,HIV infection
12638646,126386461,1,I,,20160805.0,20160809,20160809,EXP,,GB-BMSGILMSD-2016-0227025,GILEAD,,,,,M,Y,,,20160809.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,126386461.0,HO,,,,,,,,,126386461.0,1.0,HIV infection
12638946,126389461,1,I,20160718.0,20160804.0,20160809,20160809,EXP,,AR-GILEAD-2016-0226961,GILEAD,,45.0,YR,A,M,Y,85.0,KG,20160809.0,,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Enteritis,126389461.0,HO,,,126389461.0,1.0,20101122.0,,,,126389461.0,1.0,HIV infection
12657071,126570712,2,F,20150210.0,20160810.0,20160816,20190401,EXP,,US-GILEAD-2016-0224170,GILEAD,,52.0,YR,A,M,Y,75.28,KG,20190401.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal failure,126570712.0,OT,,,126570712.0,3.0,20140514.0,20160314.0,,,126570712.0,1.0,HIV infection
12658027,126580272,2,F,,20161026.0,20160816,20161104,EXP,,AT-GILEAD-2016-0228187,GILEAD,,,,,,Y,,,20161104.0,,MD,AT,AT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,126580272.0,OT,,,,,,,,,126580272.0,1.0,HIV infection
12665990,126659901,1,I,,20160809.0,20160818,20160818,EXP,,GB-GILEAD-2016-0228639,GILEAD,,,,,M,Y,,,20160818.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,126659901.0,OT,,,,,,,,,126659901.0,1.0,HIV infection
12668385,126683852,2,F,20150720.0,20160921.0,20160819,20160930,EXP,,ZA-GILEAD-2016-0229579,GILEAD,,33.0,YR,A,F,Y,51.5,KG,20160930.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Maternal exposure during pregnancy,126683852.0,OT,,,126683852.0,1.0,20150720.0,,,,126683852.0,1.0,HIV infection
12668500,126685002,2,F,20151129.0,20160905.0,20160819,20160913,EXP,,ZA-GILEAD-2016-0229638,GILEAD,,74.0,YR,E,M,Y,,,20160913.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,126685002.0,HO,,,126685002.0,1.0,20141006.0,,,,126685002.0,1.0,Prophylaxis against HIV infection
12668501,126685012,2,F,20130211.0,20160921.0,20160819,20160928,EXP,,ZA-GILEAD-2016-0229582,GILEAD,,27.0,YR,A,F,Y,73.9,KG,20160928.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126685012.0,OT,,,126685012.0,1.0,20130702.0,,,,126685012.0,1.0,HIV infection
12668506,126685062,2,F,20150327.0,20160905.0,20160819,20160913,EXP,,ZA-GILEAD-2016-0229583,GILEAD,,64.0,YR,A,F,Y,,,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cervix carcinoma,126685062.0,OT,,,126685062.0,1.0,20130925.0,,,,126685062.0,1.0,HIV infection
12668511,126685112,2,F,,20160905.0,20160819,20160913,EXP,,ZA-GILEAD-2016-0229538,GILEAD,,,,,F,Y,45.3,KG,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cervix carcinoma,126685112.0,DE,,,126685112.0,1.0,20131122.0,,,,126685112.0,1.0,HIV infection
12668514,126685142,2,F,20130505.0,20160921.0,20160819,20160928,EXP,,ZA-GILEAD-2016-0229633,GILEAD,,22.0,YR,A,F,Y,70.5,KG,20160928.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Pregnancy,126685142.0,OT,,,126685142.0,1.0,20130702.0,,,,126685142.0,1.0,Antiretroviral therapy
12668516,126685162,2,F,20150606.0,20160905.0,20160819,20160913,EXP,,ZA-GILEAD-2016-0229658,GILEAD,,25.0,YR,A,M,Y,53.3,KG,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Mental disorder,126685162.0,HO,,,126685162.0,1.0,20150224.0,,,,126685162.0,1.0,HIV infection
12668524,126685244,4,F,20160120.0,20160914.0,20160819,20160920,EXP,,ZA-GILEAD-2016-0229611,GILEAD,,58.0,YR,A,M,Y,43.0,KG,20160920.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Diabetes mellitus,126685244.0,DE,,,126685244.0,1.0,20130508.0,,,,126685244.0,1.0,Prophylaxis against HIV infection
12668529,126685292,2,F,20150401.0,20160921.0,20160819,20160928,EXP,,ZA-GILEAD-2016-0229634,GILEAD,,34.0,YR,A,F,Y,,,20160928.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,126685292.0,OT,,,126685292.0,1.0,20150219.0,,,,126685292.0,1.0,HIV infection
12668544,126685442,2,F,20150702.0,20160905.0,20160819,20160914,EXP,,ZA-GILEAD-2016-0229645,GILEAD,,21.0,YR,A,F,Y,49.3,KG,20160914.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder,126685442.0,HO,,,126685442.0,1.0,20150612.0,201507.0,,,126685442.0,1.0,HIV infection
12668547,126685472,2,F,20141204.0,20160921.0,20160819,20160929,EXP,,ZA-GILEAD-2016-0229585,GILEAD,,25.0,YR,A,F,Y,53.1,KG,20160929.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,126685472.0,OT,,,126685472.0,1.0,20141104.0,20141107.0,,,126685472.0,1.0,Antiretroviral therapy
12668565,126685652,2,F,20150212.0,20160905.0,20160819,20160914,EXP,,ZA-GILEAD-2016-0229742,GILEAD,,60.0,YR,A,M,Y,170.0,KG,20160914.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis;Pulmonary tuberculosis;Renal failure,126685652.0,HO,,,126685652.0,1.0,20141009.0,20150617.0,,,126685652.0,1.0,HIV infection
12668566,126685662,2,F,20150831.0,20160905.0,20160819,20160914,EXP,,ZA-GILEAD-2016-0229683,GILEAD,,27.0,YR,A,M,Y,64.1,KG,20160914.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,126685662.0,HO,,,126685662.0,1.0,20150625.0,20150901.0,,,126685662.0,1.0,HIV infection
12668567,126685673,3,F,20150827.0,20160908.0,20160819,20160920,EXP,,ZA-GILEAD-2016-0229697,GILEAD,,32.0,YR,A,F,Y,57.0,KG,20160920.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypochromic anaemia,126685673.0,OT,,,126685673.0,1.0,20150519.0,,,,126685673.0,1.0,HIV infection
12668570,126685702,2,F,20130206.0,20160921.0,20160819,20160930,EXP,,ZA-GILEAD-2016-0229584,GILEAD,,21.0,YR,A,F,Y,,,20160930.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death of relative;Exposure during pregnancy;Premature delivery,126685702.0,OT,,,126685702.0,1.0,20121008.0,,,,126685702.0,1.0,HIV infection
12668664,126686642,2,F,20160122.0,20160905.0,20160819,20160914,EXP,,ZA-GILEAD-2016-0229613,GILEAD,,54.0,YR,A,F,Y,89.9,KG,20160914.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal failure,126686642.0,OT,,,126686642.0,1.0,20130503.0,20160122.0,,,126686642.0,1.0,HIV infection
12671717,126717174,4,F,20150129.0,20161122.0,20160822,20161130,EXP,,ZA-GLAXOSMITHKLINE-ZA2016JPN120644,GLAXOSMITHKLINE,,43.0,YR,,F,Y,,,20161130.0,,MD,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Gamma-glutamyltransferase increased,126717174.0,OT,,,126717174.0,1.0,20110825.0,20150209.0,,,126717174.0,1.0,HIV infection
12671944,126719444,4,F,20150129.0,20161122.0,20160822,20161130,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016JPN120644,VIIV,,43.0,YR,,F,Y,,,20161130.0,,MD,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Gamma-glutamyltransferase increased,126719444.0,OT,,,126719444.0,1.0,20110825.0,20150209.0,,,126719444.0,1.0,HIV infection
12674277,126742774,4,F,20140501.0,20160926.0,20160822,20161005,EXP,,ZA-GILEAD-2016-0229726,GILEAD,,28.0,YR,A,F,Y,82.0,KG,20161005.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126742774.0,OT,,,126742774.0,1.0,20140117.0,,,,126742774.0,1.0,HIV infection
12674657,126746572,2,F,20130109.0,20160921.0,20160822,20160929,EXP,,ZA-GILEAD-2016-0229567,GILEAD,,29.0,YR,A,F,Y,77.9,KG,20160929.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126746572.0,OT,,,126746572.0,1.0,20120606.0,20120606.0,,,126746572.0,1.0,HIV infection
12675283,126752832,2,F,20150727.0,20160905.0,20160822,20160913,EXP,,ZA-GILEAD-2016-0229615,GILEAD,,53.0,YR,A,F,Y,,,20160913.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Dyspnoea;Gamma-glutamyltransferase increased;Headache,126752832.0,OT,,,126752832.0,1.0,20150625.0,,,,126752832.0,1.0,Antiretroviral therapy
12676420,126764202,2,F,20130109.0,20160921.0,20160823,20160930,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016121903,VIIV,,29.0,YR,,F,Y,77.9,KG,20160930.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Caesarean section;Exposure during pregnancy;Normal newborn,126764202.0,OT,,,126764202.0,1.0,20110917.0,20120606.0,,,126764202.0,1.0,HIV infection
12676465,126764652,2,F,20130109.0,20160921.0,20160823,20160930,EXP,,ZA-GLAXOSMITHKLINE-ZA2016121903,GLAXOSMITHKLINE,,29.0,YR,,F,Y,77.9,KG,20160930.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Caesarean section;Exposure during pregnancy;Normal newborn,126764652.0,OT,,,126764652.0,1.0,20110917.0,20120606.0,,,126764652.0,1.0,HIV infection
12677080,126770802,2,F,,20160912.0,20160823,20160919,EXP,,ZA-GILEAD-2016-0229581,GILEAD,,31.0,YR,A,F,Y,74.12,KG,20160919.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,126770802.0,OT,,,126770802.0,1.0,20141104.0,,,,126770802.0,1.0,Antiretroviral therapy
12677880,126778801,1,I,,20160817.0,20160823,20160823,EXP,,US-GILEAD-2016-0229315,GILEAD,,38.0,YR,A,M,Y,,,20160823.0,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Chest pain,126778801.0,HO,,,,,,,,,126778801.0,1.0,HIV infection
12678578,126785781,1,I,,20160815.0,20160823,20160823,EXP,,GB-BMSGILMSD-2016-0229406,GILEAD,"HAMZAH L, TIRABOSCH J, IVESON H, TOBY M, MANT C, CASON J, BURLING K, WANDOLO E, JENDRULEK I, TAYLOR C, IBRAHIM F, KULASEGARAM R, TEAGUE A, POST F, FOX J. EFFECTS ON VITAMIN D, BONE AND THE KIDNEY OF SWITCHING FROM FIXED-DOSE TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE/EFAVIRENZ TO DARUNAVIR/RITONAVIR MONOTHERAPY: A RANDOMIZED, CONTROLLED TRIAL (MIDAS). ANTIVIRAL THERAPY.. 2016;21:287-296",,,A,,Y,,,20160823.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hyperparathyroidism secondary,126785781.0,OT,,,,,,,,,126785781.0,1.0,HIV infection
12678598,126785981,1,I,20130503.0,20160804.0,20160823,20160823,EXP,,ZA-GILEAD-2016-0229684,GILEAD,,31.0,YR,A,F,Y,,,20160823.0,,OT,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126785981.0,OT,,,126785981.0,2.0,20110317.0,20130826.0,,,126785981.0,1.0,HIV infection
12685521,126855211,1,I,,20160817.0,20160825,20160825,EXP,,MX-GILEAD-2016-0229456,GILEAD,CRUZ-RODRIGUEZ A. TENOFOVIR AND ITS RELATION TO OSTEOPOROSIS IN HIV PATIENTS. MED INT M?X. 2015;31:150-154,,,A,,Y,,,20160825.0,,OT,MX,MX,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,126855211.0,OT,,,,,,,,,126855211.0,1.0,HIV infection
12687626,126876268,8,F,20160802.0,20171227.0,20160825,20180104,EXP,,UG-GILEAD-2016-0227055,GILEAD,,37.0,YR,A,M,Y,49.0,KG,20180104.0,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,126876268.0,HO,,,126876268.0,1.0,20140319.0,20160801.0,,,126876268.0,1.0,Kaposi's sarcoma AIDS related
12693020,126930201,1,I,,20140616.0,20160829,20160829,EXP,,US-CIPLA LTD.-2014US00582,CIPLA,"LUNI FK, KHAN AR, PRASHAR R, VETTETH S, DUGGAN JM. FANCONI SYNDROME AND ANTIRETROVIRALS: IT IS NEVER TOO LATE. AMERICAN JOURNAL OF THERAPEUTICS. 2016;23:E558 TO E560",,,,,Y,,,20160829.0,,OT,US,US,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Acute kidney injury;Asthenia;Depression;Diarrhoea;Fanconi syndrome acquired;Hypotension;Multiple organ dysfunction syndrome;Nausea;Respiratory failure;Staphylococcal bacteraemia;Subcutaneous abscess;Treatment noncompliance;Vomiting,126930201.0,OT,,,126930201.0,1.0,1996.0,2006.0,,,126930201.0,1.0,Antiretroviral therapy
12694331,126943311,1,I,19990702.0,19990705.0,20160829,20160829,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0681,BRISTOL MYERS SQUIBB,,33.0,YR,,F,Y,,,20160829.0,,OT,ES,ES,EFAVIRENZ;EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Affect lability;Aggression;Disinhibition;Irritability;Judgement impaired;Mania;Overdose;Psychotic disorder;Suicide attempt;Thinking abnormal,126943311.0,HO,,,126943311.0,1.0,19990630.0,19990703.0,,,126943311.0,1.0,HIV infection
12695546,126955462,2,F,20140916.0,20160921.0,20160829,20160930,EXP,,ZA-GILEAD-2016-0229667,GILEAD,,31.0,YR,A,F,Y,45.6,KG,20160930.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Breast feeding;Caesarean section;Exposure during pregnancy;Normal newborn,126955462.0,OT,,,126955462.0,2.0,20140829.0,,,,126955462.0,1.0,HIV infection
12695989,126959892,2,F,20150118.0,20160921.0,20160829,20160928,EXP,,ZA-GILEAD-2016-0229556,GILEAD,,40.0,YR,A,F,Y,61.1,KG,20160928.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126959892.0,OT,,,126959892.0,1.0,20130604.0,,,,126959892.0,1.0,HIV infection
12705608,127056082,2,F,20150413.0,20160901.0,20160901,20160906,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069259,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20160906.0,,OT,ZA,ZA,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Death,127056082.0,OT,,,127056082.0,1.0,20070622.0,20141125.0,,,127056082.0,1.0,HIV infection
12708238,127082382,2,F,20160802.0,20171227.0,20160901,20171228,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-065651,BRISTOL MYERS SQUIBB,,37.0,YR,,M,Y,49.0,KG,20171228.0,,CN,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute kidney injury;Anaemia;Dehydration,127082382.0,DE,,,127082382.0,2.0,20140319.0,20160802.0,,,127082382.0,1.0,Kaposi's sarcoma AIDS related
12721910,127219102,2,F,20140428.0,20160905.0,20160907,20160914,EXP,,ZA-GILEAD-2016-0229635,GILEAD,,26.0,YR,A,F,Y,,,20160914.0,,OT,ZA,ZA,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure during pregnancy,127219102.0,OT,,,127219102.0,3.0,2007.0,,,,127219102.0,1.0,HIV infection
12725431,127254312,2,F,20160819.0,20160906.0,20160908,20160914,EXP,,US-BMSGILMSD-2016-0231776,GILEAD,,62.0,YR,A,M,Y,,,20160914.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ankle fracture,127254312.0,OT,,,,,,,,,127254312.0,1.0,HIV infection
12732749,127327492,2,F,20151105.0,20160908.0,20160912,20160920,EXP,,ZW-GILEAD-2016-0231809,GILEAD,,33.0,YR,A,F,Y,75.1,KG,20160920.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,127327492.0,OT,,,127327492.0,1.0,20151105.0,20160224.0,,,127327492.0,1.0,Kaposi's sarcoma AIDS related
12733750,127337501,1,I,20140414.0,20140512.0,20160912,20160912,EXP,,ZA-GILEAD-2014-0102606,GILEAD,,53.0,YR,A,M,Y,40.5,KG,20160912.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Diarrhoea,127337501.0,DE,,,127337501.0,1.0,20140414.0,20140414.0,,,127337501.0,1.0,HIV infection
12735992,127359921,1,I,20130109.0,20160804.0,20160913,20160913,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069863,BRISTOL MYERS SQUIBB,,29.0,YR,,F,Y,,,20160913.0,,CN,FR,ZA,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Caesarean section;Maternal exposure during pregnancy;Normal newborn,127359921.0,OT,,,127359921.0,1.0,20110917.0,20120606.0,,,127359921.0,1.0,HIV infection
12740298,127402981,1,I,20140320.0,20160905.0,20160913,20160913,EXP,,ZA-GILEAD-2016-0233009,GILEAD,,26.0,YR,A,F,Y,46.6,KG,20160913.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis,127402981.0,HO,,,127402981.0,1.0,20120921.0,,,,127402981.0,1.0,HIV infection
12740301,127403011,1,I,20151007.0,20151016.0,20160913,20160913,EXP,,UG-GILEAD-2015-0178817,GILEAD,,27.0,YR,A,M,Y,53.0,KG,20160913.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Decreased appetite;Diarrhoea;Gastroenteritis;Leukoplakia;Malaise;Oral candidiasis;Vomiting,127403011.0,HO,,,127403011.0,1.0,20140207.0,20151006.0,,,127403011.0,1.0,HIV infection
12740378,127403782,2,F,20140527.0,20160922.0,20160913,20160929,EXP,,ZA-GILEAD-2016-0232542,GILEAD,,43.0,YR,A,M,Y,,,20160929.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cholecystitis acute;Gamma-glutamyltransferase increased;Hepatic enzyme abnormal;Physical assault;Pulmonary tuberculosis,127403782.0,OT,,,127403782.0,1.0,20130417.0,,,,127403782.0,1.0,HIV infection
12740396,127403962,2,F,20141006.0,20161006.0,20160913,20161010,EXP,,ZA-GILEAD-2016-0232652,GILEAD,,38.0,YR,A,F,Y,51.4,KG,20161010.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127403962.0,DE,,,127403962.0,1.0,20141002.0,20141012.0,,,127403962.0,1.0,HIV infection
12740444,127404441,1,I,20150810.0,20160804.0,20160913,20160913,EXP,,ZA-GILEAD-2016-0229604,GILEAD,,51.0,YR,A,M,Y,,,20160913.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Confusional state;Pulmonary tuberculosis,127404441.0,HO,,,127404441.0,1.0,2013.0,,,,127404441.0,1.0,HIV infection
12741772,127417722,2,F,20140527.0,20160922.0,20160914,20160930,EXP,,ZA-GLAXOSMITHKLINE-ZA2016133779,GLAXOSMITHKLINE,,43.0,YR,,M,Y,,,20160930.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Cholecystitis acute;Gamma-glutamyltransferase increased;Hepatic enzyme abnormal;Physical assault;Pulmonary tuberculosis,127417722.0,DE,,,127417722.0,1.0,20110316.0,,,,127417722.0,1.0,HIV infection
12741774,127417742,2,F,20141006.0,20161006.0,20160914,20161011,EXP,,ZA-GLAXOSMITHKLINE-ZA2016133781,GLAXOSMITHKLINE,,38.0,YR,,F,Y,51.4,KG,20161011.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127417742.0,OT,,,127417742.0,1.0,2013.0,20141012.0,,,127417742.0,1.0,HIV infection
12741889,127418892,2,F,20140527.0,20160922.0,20160914,20160930,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016133779,VIIV,,43.0,YR,,M,Y,,,20160930.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Cholecystitis acute;Gamma-glutamyltransferase increased;Hepatic enzyme abnormal;Physical assault;Pulmonary tuberculosis,127418892.0,DE,,,127418892.0,1.0,20110316.0,,,,127418892.0,1.0,HIV infection
12741891,127418912,2,F,20141006.0,20161006.0,20160914,20161011,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016133781,VIIV,,38.0,YR,,F,Y,51.4,KG,20161011.0,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127418912.0,OT,,,127418912.0,1.0,2013.0,20141012.0,,,127418912.0,1.0,HIV infection
12742870,127428702,2,F,20140519.0,20160905.0,20160914,20160916,EXP,,ZA-GILEAD-2016-0232440,GILEAD,,59.0,YR,A,M,Y,50.7,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis;Pulmonary tuberculosis,127428702.0,OT,,,,,,,,,127428702.0,1.0,HIV infection
12744141,127441411,1,I,20150716.0,20160804.0,20160914,20160914,EXP,,ZA-GILEAD-2016-0229663,GILEAD,,34.0,YR,A,M,Y,44.0,KG,20160914.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Gastroenteritis,127441411.0,HO,,,127441411.0,1.0,20100220.0,,,,127441411.0,1.0,HIV infection
12747472,127474721,1,I,20150129.0,20160804.0,20160915,20160915,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-069242,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,,,20160915.0,,OT,ZA,ZA,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Gamma-glutamyltransferase increased,127474721.0,OT,,,127474721.0,1.0,20110825.0,20150209.0,,,127474721.0,1.0,HIV infection
12747764,127477641,1,I,,20160909.0,20160915,20160915,EXP,,US-BMSGILMSD-2016-0233181,GILEAD,,51.0,YR,A,F,Y,,,20160915.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Pneumocystis jirovecii pneumonia,127477641.0,HO,,,,,,,,,127477641.0,1.0,HIV infection
12748818,127488182,2,F,20140429.0,20161006.0,20160915,20161011,EXP,,ZA-GILEAD-2016-0232499,GILEAD,,41.0,YR,A,M,Y,67.5,KG,20161011.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,127488182.0,LT,,,127488182.0,1.0,20131104.0,20160508.0,,,127488182.0,1.0,HIV infection
12751409,127514091,1,I,20141127.0,20160905.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0232503,GILEAD,,51.0,YR,A,M,Y,55.0,KG,20160915.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis;Meningitis cryptococcal,127514091.0,OT,,,127514091.0,1.0,20141023.0,,,,127514091.0,1.0,HIV infection
12753032,127530321,1,I,20150606.0,20160905.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0233575,GILEAD,,26.0,YR,A,M,Y,,,20160915.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Mental disorder,127530321.0,HO,,,127530321.0,1.0,20150617.0,20150606.0,,,127530321.0,1.0,Antiretroviral therapy
12754282,127542821,1,I,20150919.0,20160804.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0229601,GILEAD,,53.0,YR,A,M,Y,42.5,KG,20160915.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gamma-glutamyltransferase increased;Pulmonary tuberculosis,127542821.0,OT,,,127542821.0,1.0,20131204.0,,,,127542821.0,1.0,HIV infection
12754486,127544861,1,I,20140804.0,20160905.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0232384,GILEAD,,56.0,YR,A,F,Y,47.6,KG,20160915.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Cough;Pyrexia;Tuberculosis,127544861.0,HO,,,127544861.0,1.0,20131101.0,,,,127544861.0,1.0,HIV infection
12754541,127545411,1,I,20160211.0,20160905.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0232774,GILEAD,,45.0,YR,A,F,Y,149.0,KG,20160915.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Extrapulmonary tuberculosis,127545411.0,HO,,,127545411.0,1.0,20150414.0,,,,127545411.0,1.0,HIV infection
12754707,127547071,1,I,20160618.0,20160905.0,20160915,20160915,EXP,,ZA-GILEAD-2016-0232496,GILEAD,,42.0,YR,A,M,Y,,,20160915.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome associated tuberculosis,127547071.0,DE,,,127547071.0,1.0,20160523.0,,,,127547071.0,1.0,HIV infection
12754910,127549101,1,I,20150817.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233288,GILEAD,,57.0,YR,A,F,Y,,,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cervix carcinoma,127549101.0,OT,,,127549101.0,1.0,20130701.0,,,,127549101.0,1.0,HIV infection
12754968,127549681,1,I,20130724.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233276,GILEAD,,59.0,YR,A,M,Y,69.0,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,127549681.0,OT,,,127549681.0,2.0,20130705.0,,,,127549681.0,1.0,HIV infection
12754978,127549781,1,I,20160322.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233259,GILEAD,,51.0,YR,A,F,Y,77.7,KG,20160916.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Type 2 diabetes mellitus,127549781.0,HO,,,127549781.0,1.0,20121115.0,,,,127549781.0,1.0,HIV infection
12755049,127550491,1,I,20121010.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233253,GILEAD,,38.0,YR,A,F,Y,80.6,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthma,127550491.0,HO,,,127550491.0,1.0,20120411.0,,,,127550491.0,1.0,HIV infection
12755119,127551191,1,I,20151029.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233185,GILEAD,,56.0,YR,A,F,Y,52.7,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Infection;Sepsis,127551191.0,HO,,,127551191.0,1.0,20150422.0,20150919.0,,,127551191.0,1.0,HIV infection
12756258,127562581,1,I,20160301.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0232746,GILEAD,,42.0,YR,A,F,Y,,,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis,127562581.0,HO,,,,,,,,,127562581.0,1.0,HIV infection
12756268,127562681,1,I,20140801.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233074,GILEAD,,,,,M,Y,41.0,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis,127562681.0,HO,,,127562681.0,1.0,20140731.0,,,,127562681.0,1.0,HIV infection
12756285,127562851,1,I,20150319.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233068,GILEAD,,57.0,YR,A,F,Y,41.5,KG,20160916.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malnutrition;Pulmonary tuberculosis,127562851.0,HO,,,127562851.0,1.0,20141031.0,20150326.0,,,127562851.0,1.0,HIV infection
12756301,127563011,1,I,20160523.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0233014,GILEAD,,36.0,YR,A,F,Y,50.0,KG,20160916.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis,127563011.0,OT,,,127563011.0,1.0,20150204.0,,,,127563011.0,1.0,HIV infection
12756370,127563701,1,I,20130501.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0232495,GILEAD,,46.0,YR,A,F,Y,,,20160916.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Confusional state;Peptic ulcer;Pneumonia;Pulmonary tuberculosis,127563701.0,DE,,,127563701.0,1.0,20120628.0,,,,127563701.0,1.0,HIV infection
12756374,127563741,1,I,20140816.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0232491,GILEAD,,56.0,YR,A,F,Y,69.6,KG,20160916.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Dysuria;Tachypnoea,127563741.0,HO,,,127563741.0,1.0,20130510.0,,,,127563741.0,1.0,HIV infection
12756376,127563761,1,I,20160323.0,20160905.0,20160916,20160916,EXP,,ZA-GILEAD-2016-0232780,GILEAD,,50.0,YR,A,F,Y,53.5,KG,20160916.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tuberculosis,127563761.0,HO,,,127563761.0,1.0,20130809.0,,,,127563761.0,1.0,HIV infection
12756377,127563772,2,F,2013.0,20160912.0,20160916,20160923,EXP,,ZA-GILEAD-2016-0232808,GILEAD,,62.0,YR,A,M,Y,65.2,KG,20160923.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Joint swelling,127563772.0,HO,,,127563772.0,1.0,20141201.0,,,,127563772.0,1.0,HIV infection
12756380,127563802,2,F,20140801.0,20161012.0,20160916,20161019,EXP,,ZA-GILEAD-2016-0232533,GILEAD,,20.0,YR,A,M,Y,41.0,KG,20161019.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis;Malnutrition;Tuberculosis gastrointestinal,127563802.0,OT,,,127563802.0,1.0,20140731.0,,,,127563802.0,1.0,HIV infection
12759439,127594392,2,F,20141209.0,20161004.0,20160919,20161010,EXP,,ZA-GILEAD-2016-0232907,GILEAD,,37.0,YR,A,F,Y,,,20161010.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute psychosis,127594392.0,HO,,,127594392.0,1.0,20121130.0,,,,127594392.0,1.0,HIV infection
12759469,127594691,1,I,20160228.0,20160905.0,20160919,20160919,EXP,,ZA-GILEAD-2016-0232917,GILEAD,,71.0,YR,E,F,Y,66.4,KG,20160919.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis,127594691.0,HO,,,127594691.0,1.0,20140819.0,20160228.0,,,127594691.0,1.0,HIV infection
12760619,127606191,1,I,20131225.0,20160905.0,20160919,20160919,EXP,,ZA-GILEAD-2016-0232934,GILEAD,,26.0,YR,A,M,Y,60.7,KG,20160919.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Wrist fracture,127606191.0,OT,,,127606191.0,1.0,20121017.0,,,,127606191.0,1.0,HIV infection
12767460,127674601,1,I,20150416.0,20150420.0,20160921,20160921,EXP,,UG-GILEAD-2015-0150161,GILEAD,,45.0,YR,A,M,Y,52.0,KG,20160921.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis cryptococcal,127674601.0,DS,,,127674601.0,1.0,20150407.0,20150416.0,,,127674601.0,1.0,Kaposi's sarcoma AIDS related
12780948,127809484,4,F,20160909.0,20161025.0,20160926,20161102,EXP,,MW-GILEAD-2016-0234387,GILEAD,,31.0,YR,A,M,Y,58.0,KG,20161102.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome associated tuberculosis,127809484.0,HO,,,127809484.0,1.0,20160728.0,20160908.0,,,127809484.0,1.0,Acquired immunodeficiency syndrome
12781829,127818291,1,I,20131019.0,20160905.0,20160926,20160926,EXP,,ZA-GILEAD-2016-0233277,GILEAD,,48.0,YR,A,F,Y,81.0,KG,20160926.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Uterine leiomyoma,127818291.0,HO,,,127818291.0,1.0,20150715.0,,,,127818291.0,1.0,HIV infection
12786689,127866893,3,F,20160828.0,20170203.0,20160927,20170210,EXP,,MW-GILEAD-2016-0233550,GILEAD,,50.0,YR,A,M,Y,41.7,KG,20170210.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Pulmonary tuberculosis,127866893.0,HO,,,127866893.0,1.0,20160816.0,20160816.0,,,127866893.0,1.0,Kaposi's sarcoma AIDS related
12786932,127869321,1,I,20160815.0,20160818.0,20160927,20160927,EXP,,MW-GILEAD-2016-0230079,GILEAD,,25.0,YR,A,F,Y,,,20160927.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial infection,127869321.0,DE,,,127869321.0,1.0,20140507.0,20160814.0,,,127869321.0,1.0,HIV infection
12787367,127873671,1,I,,20160916.0,20160928,20160928,EXP,,BR-HETERO LABS LTD-1057792,HETERO,,,,,F,Y,,,20160928.0,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Congenital umbilical hernia;Foetal exposure during pregnancy,127873671.0,OT,,,127873671.0,1.0,20160302.0,20160818.0,,,127873671.0,1.0,HIV infection
12787620,127876201,1,I,,20160915.0,20160928,20160928,EXP,,CA-CIPLA LTD.-2016US18765,CIPLA,,,,,,Y,,,20160928.0,,OT,CN,CA,Tenofovir/Emtricitabine/Efavirenz,Renal failure;Sepsis,127876201.0,DE,,,,,,,,,127876201.0,1.0,HIV infection
12787658,127876581,1,I,,20160915.0,20160928,20160928,EXP,,CA-CIPLA LTD.-2016US18766,CIPLA,,,,,,Y,,,20160928.0,,OT,CN,CA,Tenofovir/Emtricitabine/Efavirenz,Pneumonia,127876581.0,DE,,,,,,,,,127876581.0,1.0,HIV infection
12789253,127892531,1,I,2013.0,20160907.0,20160928,20160928,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-077950,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160928.0,,OT,CA,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Live birth;Maternal exposure during pregnancy,,,,,,,,,,,127892531.0,1.0,HIV infection
12795134,127951342,2,F,20151015.0,20160922.0,20160929,20161011,EXP,,ZA-GILEAD-2016-0229134,GILEAD,,29.0,YR,A,F,Y,96.6,KG,20161011.0,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Maternal exposure during pregnancy;Prolonged labour,127951342.0,OT,,,127951342.0,1.0,20120816.0,,,,127951342.0,1.0,HIV infection
12796543,127965431,1,I,2012.0,20160907.0,20160929,20160929,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-077951,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20160929.0,,OT,CA,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Live birth;Maternal exposure during pregnancy,,,,,,,,,,,127965431.0,1.0,HIV infection
12796547,127965471,1,I,20141110.0,20160905.0,20160929,20160929,EXP,,ZA-GILEAD-2016-0232398,GILEAD,,60.0,YR,A,F,Y,67.0,KG,20160929.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cough;Malnutrition;Night sweats;Pleural effusion,127965471.0,OT,,,127965471.0,1.0,20130606.0,,,,127965471.0,1.0,HIV infection
12798946,127989461,1,I,20160822.0,20160825.0,20160930,20160930,EXP,,ZW-GILEAD-2016-0231062,GILEAD,,53.0,YR,A,F,Y,59.0,KG,20160930.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Creatinine renal clearance decreased,127989461.0,OT,,,127989461.0,1.0,20150120.0,20160615.0,,,127989461.0,1.0,HIV infection
12799647,127996471,1,I,201209.0,20160804.0,20160930,20160930,EXP,,ZA-GILEAD-2016-0229602,GILEAD,,35.0,YR,A,F,Y,,,20160930.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood pressure increased;Delivery;Maternal exposure during pregnancy;Normal newborn,127996471.0,HO,,,127996471.0,1.0,20130314.0,,,,127996471.0,1.0,HIV infection
12804079,128040793,3,F,20120415.0,20170217.0,20161003,20170301,EXP,,UG-GILEAD-2014-0093655,GILEAD,,33.0,YR,A,F,Y,38.0,KG,20170301.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Burning sensation;Diarrhoea;Hypokalaemia;Hyponatraemia;Malaise;Muscular weakness;Oedema peripheral;Pyrexia;Skin hyperpigmentation;Vomiting,128040793.0,HO,,,128040793.0,1.0,20121114.0,20140122.0,,,128040793.0,1.0,HIV infection
12804522,128045221,1,I,20130206.0,20160921.0,20161003,20161003,EXP,,ZA-GILEAD-2016-0235500,GILEAD,,1.0,DY,N,,Y,,,20161003.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Premature baby,128045221.0,DE,,,128045221.0,1.0,20121008.0,,,,128045221.0,1.0,HIV infection
12808470,128084703,3,F,20160909.0,20170223.0,20161004,20170228,EXP,,PE-GILEAD-2016-0235852,GILEAD,,39.0,YR,A,F,Y,54.0,KG,20170228.0,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Major depression,128084703.0,OT,,,128084703.0,1.0,20160106.0,,,,128084703.0,1.0,HIV infection
12815372,128153724,4,F,20160801.0,20161101.0,20161005,20161109,EXP,,UG-GILEAD-2016-0226992,GILEAD,,36.0,YR,A,M,Y,56.0,KG,20161109.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Encephalitis;Pulmonary embolism,128153724.0,HO,,,128153724.0,1.0,20151021.0,20160801.0,,,128153724.0,1.0,Acquired immunodeficiency syndrome
12817795,128177953,3,F,20160902.0,20180129.0,20161005,20180202,EXP,,FR-GILEAD-2016-0235829,GILEAD,,52.0,YR,A,M,Y,68.0,KG,20180202.0,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Rectal cancer,128177953.0,HO,,,128177953.0,1.0,20101105.0,,,,128177953.0,1.0,HIV infection
12821338,128213381,1,I,20160604.0,20160928.0,20161006,20161006,EXP,,ZA-GILEAD-2016-0236100,GILEAD,,34.0,YR,A,F,Y,58.0,KG,20161006.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ovarian cyst,128213381.0,HO,,,128213381.0,1.0,20150921.0,,,,128213381.0,1.0,HIV infection
12824077,128240771,1,I,20160715.0,20160928.0,20161006,20161006,EXP,,AU-GILEAD-2016-0235855,GILEAD,,31.0,YR,A,M,Y,78.0,KG,20161006.0,,MD,AU,AU,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Overdose;Suicide attempt,128240771.0,LT,,,128240771.0,1.0,20151015.0,,,,128240771.0,1.0,HIV infection
12827933,128279331,1,I,20160819.0,20160825.0,20161007,20161007,EXP,,ZW-GILEAD-2016-0231301,GILEAD,,29.0,YR,A,M,Y,,,20161007.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,128279331.0,HO,,,128279331.0,1.0,20150702.0,20160818.0,,,128279331.0,1.0,Acquired immunodeficiency syndrome
12837742,128377421,1,I,,20160930.0,20161012,20161012,EXP,,TZ-CIPLA LTD.-2016TZ19144,CIPLA,"SIKALENGO G, RAMIREZ A, FAINI D, MWAMELO K, BATTEGAY M, JUGHELI L ET AL.,. TUBERCULOUS SPONDYLITIS DIAGNOSED THROUGH XPERT MTB/RIF ASSAY IN URINE: A CASE REPORT. BMC INFECTIOUS DISEASES. 2016;16:514",,,,,Y,,,20161012.0,,OT,TZ,TZ,TENOFOVIR/LAMIVUDINE/EFAVIRENZ TABLET,Bone tuberculosis;Death;Treatment noncompliance,128377421.0,OT,,,128377421.0,1.0,2009.0,,,,128377421.0,1.0,HIV infection
12840571,128405711,1,I,,20161010.0,20161012,20161012,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084893,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161012.0,,OT,ZW,ZW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Malignant neoplasm progression,128405711.0,OT,,,128405711.0,1.0,20140318.0,20140630.0,,,128405711.0,1.0,Kaposi's sarcoma AIDS related
12852249,128522491,1,I,,20161005.0,20161017,20161017,EXP,,BR-HETERO LABS LTD-1058406,HETERO,,27.0,YR,,F,Y,,,20161017.0,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Exposure during pregnancy;Stillbirth,128522491.0,OT,,,128522491.0,1.0,20160412.0,,,,128522491.0,1.0,HIV infection
12853703,128537031,1,I,20160818.0,20161005.0,20161017,20161017,EXP,,BR-CIPLA LTD.-2016BR19245,CIPLA,,,,,,Y,,,20161017.0,,OT,BR,BR,TENOFOVIR/LAMIVUDINE/EFAVIRENZ TABLET,Exposure during pregnancy;Stillbirth,128537031.0,OT,,,128537031.0,1.0,20140412.0,,,,128537031.0,1.0,HIV infection
12855270,128552702,2,F,20160910.0,20161021.0,20161017,20161102,EXP,,ZW-GILEAD-2016-0237389,GILEAD,,41.0,YR,A,M,Y,104.5,KG,20161102.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lower limb fracture,128552702.0,HO,,,128552702.0,1.0,20140723.0,20141118.0,,,128552702.0,1.0,Kaposi's sarcoma AIDS related
12855273,128552734,4,F,20161003.0,20190116.0,20161017,20190123,EXP,,MW-GILEAD-2016-0237668,GILEAD,,25.0,YR,A,M,Y,,,20190123.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,128552734.0,OT,,,128552734.0,1.0,20160818.0,20161003.0,,,128552734.0,1.0,Kaposi's sarcoma AIDS related
12858261,128582611,1,I,20141216.0,20161009.0,20161018,20161018,EXP,,ZW-GILEAD-2016-0237882,GILEAD,,41.0,YR,A,F,Y,67.5,KG,20161018.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Malignant neoplasm progression;Weight decreased,128582611.0,DE,,,128582611.0,1.0,20140318.0,20160118.0,,,128582611.0,1.0,Kaposi's sarcoma AIDS related
12859233,128592331,1,I,20160917.0,20161003.0,20161018,20161018,EXP,,ZW-GILEAD-2016-0238316,GILEAD,,60.0,YR,A,M,Y,61.2,KG,20161018.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,128592331.0,DE,,,128592331.0,1.0,20150529.0,20150911.0,,,128592331.0,1.0,Acquired immunodeficiency syndrome
12878146,128781461,1,I,,20161015.0,20161024,20161024,EXP,,GB-GILEAD-2016-0239094,GILEAD,,54.0,YR,A,M,Y,,,20161024.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood cholesterol increased;Myocardial infarction;Renal impairment,128781461.0,OT,,,,,,,,,128781461.0,1.0,HIV infection
12882282,128822821,1,I,20131112.0,20151111.0,20161025,20161025,EXP,,ZW-GILEAD-2015-0182701,GILEAD,,33.0,YR,A,M,Y,65.2,KG,20161025.0,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Weight decreased,128822821.0,OT,,,128822821.0,1.0,20130314.0,20131111.0,,,128822821.0,1.0,HIV infection
12883396,128833961,1,I,,20161018.0,20161025,20161025,EXP,,US-GILEAD-2016-0239556,GILEAD,,77.0,YR,E,M,Y,,,20161025.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Visual impairment,128833961.0,OT,,,,,,,,,128833961.0,1.0,HIV infection
12890258,128902581,1,I,,20161021.0,20161027,20161027,EXP,,US-GILEAD-2016-0239986,GILEAD,,55.0,YR,A,M,Y,,,20161027.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Rheumatoid arthritis;Sciatic nerve injury,128902581.0,OT,,,128902581.0,1.0,20080101.0,,,,128902581.0,1.0,HIV infection
12903921,129039211,1,I,20131230.0,20140102.0,20161102,20161102,EXP,,MW-GILEAD-2014-0091377,GILEAD,,41.0,YR,A,M,Y,55.5,KG,20161102.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Bacterial sepsis,129039211.0,DE,,,129039211.0,1.0,20131111.0,20131229.0,,,129039211.0,1.0,HIV infection
12904155,129041551,1,I,,20161025.0,20161102,20161102,EXP,,US-GILEAD-2016-0240760,GILEAD,,55.0,YR,A,M,Y,,,20161102.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure congestive,129041551.0,HO,,,,,,,,,129041551.0,1.0,HIV infection
12904994,129049942,2,F,20161017.0,20161107.0,20161102,20161110,EXP,,UG-GILEAD-2016-0240974,GILEAD,,51.0,YR,A,F,Y,,,20161110.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129049942.0,LT,,,129049942.0,1.0,20131022.0,,,,129049942.0,1.0,HIV infection
12908657,129086571,1,I,20161009.0,20161028.0,20161103,20161103,EXP,,UG-GILEAD-2016-0241099,GILEAD,,54.0,YR,A,F,Y,79.0,KG,20161103.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatic encephalopathy,129086571.0,OT,,,129086571.0,1.0,20160215.0,20160928.0,,,129086571.0,1.0,HIV infection
12908760,129087601,1,I,20160827.0,20160928.0,20161103,20161103,EXP,,AR-GILEAD-2016-0236084,GILEAD,,49.0,YR,A,M,Y,72.0,KG,20161103.0,,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Herpes zoster,129087601.0,HO,,,129087601.0,1.0,20131107.0,,,,129087601.0,1.0,HIV infection
12913810,129138101,1,I,20161005.0,20161031.0,20161104,20161104,EXP,,GB-GILEAD-2016-0241459,GILEAD,,56.0,YR,A,M,Y,66.4,KG,20161104.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis perforated,129138101.0,HO,,,129138101.0,1.0,20110718.0,20161011.0,,,129138101.0,1.0,HIV infection
12926688,129266882,2,F,20161025.0,20161104.0,20161108,20161117,EXP,,UG-GILEAD-2016-0241990,GILEAD,,41.0,YR,A,M,Y,51.8,KG,20161117.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alcohol poisoning,129266882.0,OT,,,129266882.0,1.0,20160619.0,20161025.0,,,129266882.0,1.0,HIV infection
12928638,129286381,1,I,20160801.0,20160803.0,20161110,20161110,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-066293,BRISTOL MYERS SQUIBB,,36.0,YR,,M,Y,56.0,KG,20161110.0,,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Encephalitis;Pulmonary embolism,129286381.0,LT,,,129286381.0,1.0,20151021.0,20160323.0,,,129286381.0,1.0,Acquired immunodeficiency syndrome
12930507,129305074,4,F,20161027.0,20161203.0,20161110,20161213,EXP,,MW-GILEAD-2016-0242202,GILEAD,,41.0,YR,A,M,Y,75.8,KG,20161213.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129305074.0,HO,,,129305074.0,1.0,20150325.0,20150806.0,,,129305074.0,1.0,Acquired immunodeficiency syndrome
12931537,129315372,2,F,20160421.0,20161107.0,20161110,20161115,EXP,,UG-GILEAD-2016-0212079,GILEAD,,36.0,YR,A,M,Y,66.0,KG,20161115.0,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Encephalitis;Neutropenia,129315372.0,OT,,,129315372.0,1.0,20151021.0,20160801.0,,,129315372.0,1.0,Acquired immunodeficiency syndrome
12931953,129319531,1,I,2005.0,20161028.0,20161111,20161111,EXP,,GB-CIPLA LTD.-2016GB20742,CIPLA,,,,,,Y,,,20161111.0,,OT,US,GB,Tenofovir/Emtricitabine/Efavirenz,Drug level increased;Drug-induced liver injury;Encephalopathy;Lipodystrophy acquired;Pneumonia,129319531.0,HO,,,129319531.0,1.0,201001.0,,,,129319531.0,1.0,HIV infection
12951155,129511551,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243160,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",42.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129511551.0,OT,,,,,,,,,129511551.0,1.0,HIV infection
12951234,129512341,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243158,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",46.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129512341.0,OT,,,,,,,,,129512341.0,1.0,HIV infection
12951900,129519001,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243162,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",52.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129519001.0,OT,,,,,,,,,129519001.0,1.0,HIV infection
12952198,129521981,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243159,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",53.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129521981.0,OT,,,,,,,,,129521981.0,1.0,HIV infection
12952355,129523551,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243161,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",48.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129523551.0,OT,,,,,,,,,129523551.0,1.0,HIV infection
12953088,129530881,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243152,GILEAD,"V. ORANRAP, S. TREEPRESERTSUK,. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",47.0,YR,A,M,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129530881.0,OT,,,,,,,,,129530881.0,1.0,HIV infection
12953112,129531121,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243154,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",58.0,YR,A,M,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531121.0,OT,,,,,,,,,129531121.0,1.0,HIV infection
12953128,129531281,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243155,GILEAD,"V. ORANRAP, S. TREEPRASURTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",27.0,YR,A,M,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531281.0,OT,,,,,,,,,129531281.0,1.0,HIV infection
12953129,129531291,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243156,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",44.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531291.0,OT,,,,,,,,,129531291.0,1.0,HIV infection
12953147,129531471,1,I,,20161109.0,20161117,20161117,EXP,,TH-GILEAD-2016-0243157,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",46.0,YR,A,F,Y,,,20161117.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531471.0,OT,,,,,,,,,129531471.0,1.0,HIV infection
12953684,129536844,4,F,20161102.0,20180809.0,20161117,20180820,EXP,,MW-GILEAD-2016-0242786,GILEAD,,35.0,YR,A,M,Y,60.0,KG,20180820.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129536844.0,HO,,,129536844.0,1.0,20150714.0,20160926.0,,,129536844.0,1.0,Kaposi's sarcoma AIDS related
12953694,129536944,4,F,20161109.0,20170721.0,20161117,20170728,EXP,,ZW-GILEAD-2016-0243462,GILEAD,,36.0,YR,A,M,Y,77.5,KG,20170728.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Sepsis,129536944.0,HO,,,129536944.0,1.0,20150423.0,20161109.0,,,129536944.0,1.0,Kaposi's sarcoma AIDS related
12962495,129624952,2,F,,20161116.0,20161121,20161123,EXP,,NG-GILEAD-2016-0243617,GILEAD,,40.0,YR,A,M,Y,72.0,KG,20161123.0,,MD,NG,NG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Hypertensive heart disease;Myocardial infarction,129624952.0,DE,,,129624952.0,1.0,20130307.0,20160718.0,,,129624952.0,1.0,HIV infection
12975656,129756561,1,I,20161106.0,20161117.0,20161125,20161125,EXP,,AU-GILEAD-2016-0244540,GILEAD,,53.0,YR,A,M,Y,74.0,KG,20161125.0,,MD,AU,AU,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pilonidal cyst,129756561.0,HO,,,129756561.0,1.0,20110207.0,,,,129756561.0,1.0,HIV infection
12988432,129884321,1,I,20160828.0,20161117.0,20161130,20161130,EXP,,ZA-GILEAD-2016-0244554,GILEAD,,54.0,YR,A,F,Y,100.2,KG,20161130.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis,129884321.0,HO,,,129884321.0,1.0,20140312.0,201606.0,,,129884321.0,1.0,HIV infection
12992052,129920522,2,F,20160916.0,20161123.0,20161201,20161202,EXP,,KE-GILEAD-2016-0246137,GILEAD,,32.0,YR,A,F,Y,,,20161202.0,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Immune reconstitution inflammatory syndrome associated tuberculosis;Oral candidiasis;Virologic failure,129920522.0,HO,,,129920522.0,1.0,20160211.0,201610.0,,,129920522.0,1.0,Kaposi's sarcoma AIDS related
12992077,129920771,1,I,2009.0,20161123.0,20161201,20161201,EXP,,US-GILEAD-2016-0246064,GILEAD,,66.0,YR,E,M,Y,,,20161201.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness;Hodgkin's disease,129920771.0,OT,,,,,,,,,129920771.0,1.0,HIV infection
12999941,129999412,2,F,2016.0,20161206.0,20161205,20161215,EXP,,ZA-GILEAD-2016-0246391,GILEAD,,39.0,YR,A,F,Y,,,20161215.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy,129999412.0,OT,,,129999412.0,1.0,20140212.0,,,,129999412.0,1.0,HIV infection
12999963,129999633,3,F,20160930.0,20170120.0,20161205,20170130,EXP,,PE-GILEAD-2016-0245926,GILEAD,,55.0,YR,A,M,Y,71.0,KG,20170130.0,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion,129999633.0,HO,,,129999633.0,1.0,20160210.0,,,,129999633.0,1.0,HIV infection
12999969,129999692,2,F,20160920.0,20161205.0,20161205,20161215,EXP,,ZW-GILEAD-2016-0246007,GILEAD,,35.0,YR,A,M,Y,48.0,KG,20161215.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis cryptococcal,129999692.0,DE,,,129999692.0,1.0,20160617.0,20160906.0,,,129999692.0,1.0,Kaposi's sarcoma AIDS related
13007665,130076651,1,I,,20161201.0,20161207,20161207,EXP,,US-GILEAD-2016-0247283,GILEAD,,24.0,YR,A,M,Y,,,20161207.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anger;Anxiety;Fatigue;Haematemesis;Haematochezia;Lipoatrophy;Major depression;Malaise;Muscle atrophy;Sensation of foreign body;Vomiting;Weight decreased,130076651.0,OT,,,,,,,,,130076651.0,1.0,HIV infection
13013727,130137271,1,I,20160813.0,20161201.0,20161209,20161209,EXP,,US-GILEAD-2016-0247321,GILEAD,,63.0,YR,A,M,Y,79.0,KG,20161209.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Syncope,130137271.0,HO,,,130137271.0,1.0,20100704.0,,,,130137271.0,1.0,HIV infection
13014029,130140291,1,I,,20161205.0,20161209,20161209,EXP,,GB-GILEAD-2016-0247859,GILEAD,,65.0,YR,E,M,Y,,,20161209.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130140291.0,DE,,,,,,,,,130140291.0,1.0,HIV infection
13014614,130146141,1,I,20161130.0,20161205.0,20161209,20161209,EXP,,GB-GILEAD-2016-0247766,GILEAD,,48.0,YR,A,M,Y,,,20161209.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130146141.0,DE,,,,,,,,,130146141.0,1.0,HIV infection
13018663,130186633,3,F,20161123.0,20170104.0,20161212,20170105,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-105613,BRISTOL MYERS SQUIBB,,33.0,YR,,M,Y,53.3,KG,20170105.0,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Kaposi's sarcoma;Thrombocytopenia,130186633.0,DE,,,130186633.0,1.0,20151027.0,,,,130186633.0,1.0,HIV infection
13020118,130201181,1,I,,20161205.0,20161212,20161212,EXP,,US-GILEAD-2016-0248150,GILEAD,,52.0,YR,A,M,Y,,,20161212.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac assistance device user,130201181.0,OT,,,,,,,,,130201181.0,1.0,HIV infection
13060218,130602183,3,F,,20170509.0,20161223,20170512,EXP,,US-GILEAD-2016-0250332,GILEAD,,,,N,F,Y,,,20170512.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Atrial septal defect;Cardiac aneurysm;Exposure to communicable disease;Foetal exposure during pregnancy;Poor feeding infant;Small for dates baby;Toxoplasmosis,130602183.0,CA,,,,,,,,,130602183.0,1.0,HIV infection
13060255,130602552,2,F,,20170412.0,20161223,20170420,EXP,,US-GILEAD-2016-0250167,GILEAD,,,,N,M,Y,,,20170420.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diaphragmatic hernia;Foetal exposure during pregnancy;Otitis media;Pleural effusion,130602552.0,CA,,,130602552.0,1.0,20071205.0,2007.0,,,130602552.0,1.0,HIV infection
13062170,130621702,2,F,,20170518.0,20161226,20170524,EXP,,US-GILEAD-2016-0250336,GILEAD,,,,N,F,Y,,,20170524.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cataract;Foetal exposure during pregnancy;Laryngomalacia;Stridor,130621702.0,OT,,,,,,,,,130621702.0,1.0,HIV test positive
13077160,130771602,2,F,20161123.0,20170104.0,20161230,20170111,EXP,,MW-GILEAD-2016-0248704,GILEAD,,33.0,YR,A,M,Y,53.3,KG,20170111.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma;Thrombocytopenia,130771602.0,OT,,,130771602.0,1.0,20151027.0,20161206.0,,,130771602.0,1.0,Kaposi's sarcoma AIDS related
13077519,130775191,1,I,,20161216.0,20161231,20161231,EXP,,BR-HETERO LABS LTD-1061421,HETERO,,,,,F,Y,1.5,KG,20161231.0,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Foetal exposure during pregnancy;Weight increased,130775191.0,HO,,,130775191.0,1.0,20160831.0,,,,130775191.0,1.0,HIV infection
13084952,130849521,1,I,2015.0,20151215.0,20170104,20170104,EXP,,US-BMSGILMSD-2015-0188646,GILEAD,,68.0,YR,E,M,Y,,,20170104.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Dyspnoea,130849521.0,DE,,,,,,,,,130849521.0,1.0,HIV infection
13085241,130852411,1,I,,20161228.0,20170104,20170104,EXP,,US-GILEAD-2016-0251353,GILEAD,,45.0,YR,A,M,Y,,,20170104.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm,130852411.0,OT,,,,,,,,,130852411.0,1.0,HIV infection
13086191,130861911,1,I,201412.0,20161227.0,20170104,20170104,EXP,,US-GILEAD-2016-0251329,GILEAD,,59.0,YR,A,M,Y,,,20170104.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Influenza,130861911.0,HO,,,130861911.0,1.0,2013.0,,,,130861911.0,1.0,HIV infection
13099056,130990561,1,I,20160822.0,20160913.0,20170109,20170109,EXP,,UG-GILEAD-2016-0233568,GILEAD,,54.0,YR,A,F,Y,79.0,KG,20170109.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatitis acute,130990561.0,OT,,,130990561.0,1.0,20160215.0,201609.0,,,130990561.0,1.0,HIV infection
13109865,131098651,1,I,20170105.0,20170110.0,20170112,20170112,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001807,BRISTOL MYERS SQUIBB,,43.0,YR,,F,Y,40.0,KG,20170112.0,,OT,MZ,MZ,EFAVIRENZ;EFAVIRENZ+LAMIVUDINE+TENOFOVIR DISOPROXIL FUM,Anaemia;Malaria,131098651.0,OT,,,131098651.0,1.0,20161026.0,20170106.0,,,131098651.0,1.0,HIV infection
13111151,131111511,1,I,20161206.0,20170106.0,20170112,20170112,EXP,,US-GILEAD-2017-0252748,GILEAD,,61.0,YR,A,F,Y,93.6,KG,20170112.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bronchitis,131111511.0,HO,,,131111511.0,1.0,20130222.0,,,,131111511.0,1.0,HIV infection
13123491,131234914,4,F,20161130.0,20170222.0,20170117,20170228,EXP,,MW-GILEAD-2017-0253784,GILEAD,,30.0,YR,A,M,Y,69.7,KG,20170228.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system infection,131234914.0,OT,,,131234914.0,1.0,20160407.0,20161124.0,,,131234914.0,1.0,Kaposi's sarcoma AIDS related
13126035,131260352,2,F,,20170112.0,20170118,20170120,EXP,,US-GILEAD-2016-0248393,GILEAD,,63.0,YR,A,M,Y,65.76,KG,20170120.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Creatinine renal clearance decreased,131260352.0,OT,,,,,,,,,131260352.0,1.0,HIV infection
13151111,131511112,2,F,20170103.0,20170118.0,20170125,20170127,EXP,,ZW-GILEAD-2017-0254565,GILEAD,,53.0,YR,A,M,Y,,,20170127.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,131511112.0,OT,,,131511112.0,1.0,20151012.0,20170112.0,,,131511112.0,1.0,HIV infection
13160396,131603964,4,F,20161222.0,20170310.0,20170127,20170314,EXP,,ZA-GILEAD-2017-0252974,GILEAD,,37.0,YR,A,F,Y,91.6,KG,20170314.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pyelonephritis acute,131603964.0,OT,,,131603964.0,1.0,20110831.0,,,,131603964.0,1.0,HIV infection
13165193,131651931,1,I,,20170116.0,20170130,20170130,EXP,,MX-HETERO LABS LTD-1062542,HETERO,,40.0,YR,,M,Y,,,20170130.0,,OT,MX,MX,Efavirenz\ Emtricitabine\Tenofovir,Immune reconstitution inflammatory syndrome;Intestinal perforation,131651931.0,OT,,,,,,,,,131651931.0,1.0,HIV infection
13174269,131742691,1,I,,20170127.0,20170131,20170131,EXP,,US-GILEAD-2017-0255876,GILEAD,,45.0,YR,A,M,Y,,,20170131.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis;Immunodeficiency;Leukaemia;Malaise,131742691.0,OT,,,,,,,,,131742691.0,1.0,HIV infection
13175954,131759544,4,F,20170103.0,20171227.0,20170201,20180103,EXP,,MW-GILEAD-2017-0253792,GILEAD,,28.0,YR,A,F,Y,56.8,KG,20180103.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,131759544.0,DE,,,131759544.0,1.0,20161116.0,20170102.0,,,131759544.0,1.0,Kaposi's sarcoma AIDS related
13176826,131768262,2,F,20170117.0,20170216.0,20170201,20170227,EXP,,UG-GILEAD-2017-0255961,GILEAD,,44.0,YR,A,M,Y,,,20170227.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacteraemia,131768262.0,OT,,,131768262.0,1.0,20130703.0,20150504.0,,,131768262.0,1.0,Acquired immunodeficiency syndrome
13195796,131957961,1,I,,20170125.0,20170208,20170208,EXP,,CN-HETERO LABS LTD-1062868,HETERO,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10 (1):42-46",38.0,YR,,,Y,,,20170208.0,,OT,CN,CN,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Osteoporosis,131957961.0,OT,,,,,,,,,131957961.0,1.0,HIV infection
13199367,131993671,1,I,,20170202.0,20170208,20170208,EXP,,US-GILEAD-2017-0256926,GILEAD,,40.0,YR,A,M,Y,,,20170208.0,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system lesion,131993671.0,OT,,,,,,,,,131993671.0,1.0,HIV infection
13203766,132037665,5,F,20170110.0,20170320.0,20170208,20170328,EXP,,TH-GILEAD-2017-0256663,GILEAD,,28.0,YR,A,M,Y,69.9,KG,20170328.0,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Substance-induced psychotic disorder,132037665.0,HO,,,132037665.0,1.0,20160125.0,20170109.0,,,132037665.0,1.0,HIV infection
13204411,132044114,4,F,20170112.0,20170315.0,20170208,20170328,EXP,,GB-GILEAD-2017-0256895,GILEAD,,53.0,YR,A,M,Y,111.8,KG,20170328.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abscess limb,132044114.0,HO,,,132044114.0,1.0,20110225.0,,,,132044114.0,1.0,HIV infection
13205319,132053194,4,F,20170123.0,20170412.0,20170208,20170420,EXP,,PE-GILEAD-2017-0257015,GILEAD,,29.0,YR,A,M,Y,60.5,KG,20170420.0,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicidal ideation,132053194.0,OT,,,132053194.0,1.0,20140411.0,20161230.0,,,132053194.0,1.0,HIV infection
13215050,132150501,1,I,20160629.0,20160706.0,20170210,20170210,EXP,,MW-GILEAD-2016-0223379,GILEAD,,34.0,YR,A,M,Y,59.5,KG,20170210.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,132150501.0,OT,,,132150501.0,1.0,20160628.0,20160629.0,,,132150501.0,1.0,Kaposi's sarcoma AIDS related
13232769,132327691,1,I,20170203.0,20170207.0,20170214,20170214,EXP,,MW-GILEAD-2017-0257956,GILEAD,,29.0,YR,A,M,Y,,,20170214.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Sepsis,132327691.0,OT,,,132327691.0,1.0,20170202.0,20170202.0,,,132327691.0,1.0,Kaposi's sarcoma AIDS related
13240880,132408802,2,F,,20170227.0,20170216,20170303,EXP,,ES-GILEAD-2017-0258280,GILEAD,,,,A,,Y,,,20170303.0,,MD,ES,ES,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132408802.0,OT,,,,,,,,,132408802.0,1.0,HIV infection
13246572,132465721,1,I,20161202.0,20170207.0,20170217,20170217,EXP,,PL-GILEAD-2017-0257664,GILEAD,,35.0,YR,A,M,Y,81.1,KG,20170217.0,,OT,PL,PL,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Epididymitis;Orchitis noninfective,132465721.0,HO,,,132465721.0,1.0,20110204.0,,,,132465721.0,1.0,HIV infection
13258114,132581142,2,F,20160819.0,20180808.0,20170221,20180820,EXP,,MW-GILEAD-2017-0258042,GILEAD,,35.0,YR,A,M,Y,60.0,KG,20180820.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma,132581142.0,OT,,,132581142.0,1.0,20150715.0,20170206.0,,,132581142.0,1.0,Acquired immunodeficiency syndrome
13303645,133036452,2,F,20170301.0,20170706.0,20170307,20170720,EXP,,ZW-GILEAD-2017-0261170,GILEAD,,54.0,YR,A,M,Y,65.7,KG,20170720.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,133036452.0,HO,,,133036452.0,1.0,20140701.0,20160622.0,,,133036452.0,1.0,Kaposi's sarcoma AIDS related
13335529,133355291,1,I,,20170303.0,20170315,20170315,EXP,,BR-HETERO LABS LTD-1064248,HETERO,,,,,M,Y,,,20170315.0,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Congenital naevus;Foetal exposure during pregnancy,133355291.0,CA,,,,,,,,,133355291.0,1.0,HIV infection
13335634,133356341,1,I,,20170309.0,20170314,20170314,EXP,,US-GILEAD-2017-0262293,GILEAD,,56.0,YR,A,M,Y,,,20170314.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Affective disorder;Anxiety disorder;Bipolar disorder,133356341.0,OT,,,133356341.0,1.0,2009.0,,,,133356341.0,1.0,HIV infection
13339610,133396101,1,I,,20170310.0,20170315,20170315,EXP,,US-GILEAD-2017-0262237,GILEAD,,51.0,YR,A,M,Y,,,20170315.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,133396101.0,OT,,,,,,,,,133396101.0,1.0,HIV infection
13353790,133537901,1,I,,20170308.0,20170321,20170321,EXP,,US-CIPLA LTD.-2017US04544,CIPLA,,,,,,Y,,,20170321.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133537901.0,OT,,,,,,,,,133537901.0,1.0,HIV infection
13353796,133537961,1,I,,20170308.0,20170321,20170321,EXP,,US-CIPLA LTD.-2017US04546,CIPLA,,,,,,Y,,,20170321.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133537961.0,OT,,,,,,,,,133537961.0,1.0,HIV infection
13357112,133571121,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04548,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133571121.0,OT,,,,,,,,,133571121.0,1.0,HIV infection
13357116,133571161,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04547,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133571161.0,OT,,,,,,,,,133571161.0,1.0,HIV infection
13357117,133571171,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04558,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133571171.0,OT,,,,,,,,,133571171.0,1.0,HIV infection
13357206,133572061,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04554,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Road traffic accident,133572061.0,OT,,,,,,,,,133572061.0,1.0,HIV infection
13357456,133574561,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04553,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Ulcer haemorrhage,133574561.0,OT,,,,,,,,,133574561.0,1.0,HIV infection
13357463,133574631,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04556,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Virologic failure,133574631.0,OT,,,,,,,,,133574631.0,1.0,HIV infection
13358135,133581351,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04538,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133581351.0,OT,,,,,,,,,133581351.0,1.0,HIV infection
13358154,133581541,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04571,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581541.0,OT,,,,,,,,,133581541.0,1.0,HIV infection
13358186,133581861,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04569,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581861.0,OT,,,,,,,,,133581861.0,1.0,HIV infection
13358189,133581891,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04570,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581891.0,OT,,,,,,,,,133581891.0,1.0,HIV infection
13358201,133582011,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04567,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582011.0,OT,,,,,,,,,133582011.0,1.0,HIV infection
13358208,133582081,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04568,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582081.0,OT,,,,,,,,,133582081.0,1.0,HIV infection
13358215,133582151,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04563,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582151.0,OT,,,,,,,,,133582151.0,1.0,HIV infection
13358220,133582201,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04549,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Death,133582201.0,DE,,,,,,,,,133582201.0,1.0,HIV infection
13358238,133582381,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04542,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582381.0,OT,,,,,,,,,133582381.0,1.0,HIV infection
13358250,133582501,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04540,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582501.0,OT,,,,,,,,,133582501.0,1.0,HIV infection
13358261,133582611,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04539,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582611.0,OT,,,,,,,,,133582611.0,1.0,HIV infection
13358280,133582801,1,I,,20170308.0,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04537,CIPLA,,,,,,Y,,,20170322.0,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582801.0,OT,,,,,,,,,133582801.0,1.0,HIV infection
13366442,133664423,3,F,20110822.0,20170331.0,20170323,20170405,EXP,,GR-GILEAD-2017-0263312,GILEAD,,34.0,YR,A,M,Y,87.0,KG,20170405.0,,MD,GR,GR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,133664423.0,OT,,,133664423.0,1.0,200804.0,201109.0,,,133664423.0,1.0,HIV infection
13378144,133781441,1,I,2015.0,20170321.0,20170328,20170328,EXP,,US-GILEAD-2017-0263920,GILEAD,,44.0,YR,A,M,Y,,,20170328.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hodgkin's disease stage IV;Neuropathy peripheral,133781441.0,OT,,,133781441.0,1.0,201001.0,201612.0,,,133781441.0,1.0,HIV infection
13379518,133795184,4,F,20160515.0,20170421.0,20170328,20170426,EXP,,AR-GILEAD-2017-0263863,GILEAD,,36.0,YR,A,M,Y,68.0,KG,20170426.0,,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional overdose;Suicide attempt,133795184.0,LT,,,133795184.0,1.0,20150723.0,,,,133795184.0,1.0,HIV infection
13384057,133840572,2,F,20170315.0,20170407.0,20170329,20170413,EXP,,BR-GILEAD-2017-0264275,GILEAD,,,,,,Y,,,20170413.0,,OT,BR,BR,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Pyelocaliectasis,133840572.0,OT,,,133840572.0,2.0,20170317.0,,,,133840572.0,1.0,HIV infection
13402416,134024164,4,F,20170317.0,20170419.0,20170404,20170428,EXP,,MW-GILEAD-2017-0264667,GILEAD,,51.0,YR,A,M,Y,,,20170428.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaria;Neutropenia;Pneumonia bacterial;Renal failure,134024164.0,OT,,,134024164.0,1.0,20160816.0,20170312.0,,,134024164.0,1.0,Acquired immunodeficiency syndrome
13418549,134185493,3,F,20170321.0,20171110.0,20170406,20171121,EXP,,MW-GILEAD-2017-0266019,GILEAD,,34.0,YR,A,M,Y,68.0,KG,20171121.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal loss of weight;Extrapulmonary tuberculosis,134185493.0,HO,,,134185493.0,1.0,20140917.0,20170320.0,,,134185493.0,1.0,Kaposi's sarcoma AIDS related
13426671,134266711,1,I,,20170221.0,20170411,20170411,PER,,AR-LUPIN PHARMACEUTICALS INC.-2017-00905,LUPIN,,75.0,YR,,M,Y,,,20170411.0,,MD,AR,AR,EFAVIRENZ;EMTRICITABINE/TENOFOVIR/EFAVIRENZ,Drug interaction;Viral load increased,,,,,134266711.0,1.0,2004.0,,,,134266711.0,1.0,HIV infection
13433250,134332502,2,F,20160919.0,20170424.0,20170412,20170501,EXP,,CH-GILEAD-2017-0266937,GILEAD,,71.0,YR,E,M,Y,,,20170501.0,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Osteoporosis;Renal tubular dysfunction,134332502.0,OT,,,134332502.0,1.0,200805.0,,,,134332502.0,1.0,HIV infection
13444431,134444312,2,F,20170227.0,20170425.0,20170414,20170502,EXP,,GB-GILEAD-2017-0262235,GILEAD,,51.0,YR,A,M,Y,78.2,KG,20170502.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ankle fracture,134444312.0,DS,,,134444312.0,1.0,20121030.0,,,,134444312.0,1.0,HIV infection
13445335,134453352,2,F,20170213.0,20170428.0,20170414,20170503,EXP,,ZA-GILEAD-2017-0261904,GILEAD,,49.0,YR,A,F,Y,89.4,KG,20170503.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Demyelination,134453352.0,HO,,,134453352.0,1.0,20150709.0,,,,134453352.0,1.0,HIV infection
13449088,134490882,2,F,20170203.0,20170518.0,20170417,20170525,EXP,,FR-GILEAD-2017-0267012,GILEAD,,53.0,YR,A,M,Y,68.0,KG,20170525.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal stoma complication,134490882.0,HO,,,134490882.0,1.0,20101105.0,,,,134490882.0,1.0,HIV infection
13456460,134564604,4,F,20170203.0,20170524.0,20170418,20170531,EXP,,UG-GILEAD-2017-0267324,GILEAD,,56.0,YR,A,F,Y,83.0,KG,20170531.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Transient ischaemic attack,134564604.0,HO,,,134564604.0,1.0,20150608.0,,,,134564604.0,1.0,HIV infection
13462596,134625963,3,F,20160309.0,20170622.0,20170420,20170629,EXP,,UG-GILEAD-2017-0267647,GILEAD,,30.0,YR,A,F,Y,53.0,KG,20170629.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Maternal exposure during pregnancy,134625963.0,OT,,,134625963.0,1.0,20150922.0,20160920.0,,,134625963.0,1.0,HIV infection
13462608,134626082,2,F,20170306.0,20170518.0,20170420,20170523,EXP,,UG-GILEAD-2017-0268455,GILEAD,,32.0,YR,A,F,Y,53.0,KG,20170523.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion threatened;Maternal exposure during pregnancy,134626082.0,HO,,,134626082.0,1.0,20150922.0,20160920.0,,,134626082.0,1.0,HIV infection
13462645,134626451,1,I,,20170412.0,20170420,20170420,EXP,,US-GILEAD-2017-0268443,GILEAD,,,,,F,Y,123.0,KG,20170420.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Maternal exposure during pregnancy;Premature labour;Twin pregnancy,134626451.0,DE,,,134626451.0,1.0,,2007.0,,,134626451.0,1.0,HIV infection
13463867,134638673,3,F,20170115.0,20171018.0,20170420,20171025,EXP,,UG-GILEAD-2017-0268451,GILEAD,,32.0,YR,A,F,Y,53.0,KG,20171025.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion threatened;Maternal exposure before pregnancy,134638673.0,OT,,,134638673.0,1.0,20150922.0,20160920.0,,,134638673.0,1.0,HIV infection
13480067,134800673,3,F,20170320.0,20170517.0,20170425,20170522,EXP,,UG-GILEAD-2017-0269067,GILEAD,,51.0,YR,A,F,Y,51.0,KG,20170522.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Tumour haemorrhage,134800673.0,HO,,,134800673.0,1.0,20131022.0,,,,134800673.0,1.0,HIV infection
13497000,134970001,1,I,,20170421.0,20170428,20170428,EXP,,US-GILEAD-2017-0269985,GILEAD,,,,,F,Y,,,20170428.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebral toxoplasmosis;Maternal exposure during pregnancy;Oligohydramnios;Premature delivery;Seizure,134970001.0,OT,,,,,,,,,134970001.0,1.0,HIV infection
13499846,134998461,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0269949,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134998461.0,OT,,,,,,,,,134998461.0,1.0,Prophylaxis against HIV infection
13499884,134998842,2,F,,20170422.0,20170501,20170502,EXP,,BW-GILEAD-2017-0270333,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134998842.0,OT,,,,,,,,,134998842.0,1.0,Prophylaxis against HIV infection
13499887,134998871,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270338,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134998871.0,OT,,,,,,,,,134998871.0,1.0,Prophylaxis against HIV infection
13499903,134999032,2,F,,20170422.0,20170501,20170502,EXP,,BW-GILEAD-2017-0270334,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999032.0,OT,,,,,,,,,134999032.0,1.0,Prophylaxis against HIV infection
13499905,134999052,2,F,,20170422.0,20170501,20170502,EXP,,BW-GILEAD-2017-0270335,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999052.0,OT,,,,,,,,,134999052.0,1.0,Prophylaxis against HIV infection
13499906,134999061,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270283,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999061.0,OT,,,,,,,,,134999061.0,1.0,Prophylaxis against HIV infection
13499911,134999111,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270336,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999111.0,OT,,,,,,,,,134999111.0,1.0,Prophylaxis against HIV infection
13499918,134999181,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270261,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999181.0,OT,,,,,,,,,134999181.0,1.0,Prophylaxis against HIV infection
13499919,134999191,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270337,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999191.0,OT,,,,,,,,,134999191.0,1.0,Prophylaxis against HIV infection
13499923,134999231,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270260,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999231.0,OT,,,,,,,,,134999231.0,1.0,Prophylaxis against HIV infection
13499932,134999321,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270257,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999321.0,OT,,,,,,,,,134999321.0,1.0,Prophylaxis against HIV infection
13499946,134999461,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270309,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999461.0,OT,,,,,,,,,134999461.0,1.0,Prophylaxis against HIV infection
13499947,134999471,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270259,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999471.0,OT,,,,,,,,,134999471.0,1.0,Prophylaxis against HIV infection
13499948,134999481,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270258,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999481.0,OT,,,,,,,,,134999481.0,1.0,Prophylaxis against HIV infection
13499960,134999601,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270308,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999601.0,OT,,,,,,,,,134999601.0,1.0,Prophylaxis against HIV infection
13499961,134999611,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270329,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999611.0,OT,,,,,,,,,134999611.0,1.0,Prophylaxis against HIV infection
13499967,134999671,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270288,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999671.0,OT,,,,,,,,,134999671.0,1.0,Prophylaxis against HIV infection
13499968,134999681,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270304,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999681.0,OT,,,,,,,,,134999681.0,1.0,Prophylaxis against HIV infection
13499972,134999721,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270331,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999721.0,OT,,,,,,,,,134999721.0,1.0,Prophylaxis against HIV infection
13499975,134999751,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270303,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999751.0,OT,,,,,,,,,134999751.0,1.0,Prophylaxis against HIV infection
13499976,134999761,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270302,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999761.0,OT,,,,,,,,,134999761.0,1.0,Prophylaxis against HIV infection
13499984,134999841,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270300,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999841.0,OT,,,,,,,,,134999841.0,1.0,Prophylaxis against HIV infection
13499989,134999891,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270299,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999891.0,OT,,,,,,,,,134999891.0,1.0,Prophylaxis against HIV infection
13499997,134999971,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270340,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999971.0,OT,,,,,,,,,134999971.0,1.0,Prophylaxis against HIV infection
13499999,134999991,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270298,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999991.0,OT,,,,,,,,,134999991.0,1.0,Prophylaxis against HIV infection
13500000,135000001,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270347,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000001.0,OT,,,,,,,,,135000001.0,1.0,Prophylaxis against HIV infection
13500003,135000031,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270284,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000031.0,OT,,,,,,,,,135000031.0,1.0,Prophylaxis against HIV infection
13500015,135000151,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270301,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000151.0,OT,,,,,,,,,135000151.0,1.0,Prophylaxis against HIV infection
13500054,135000541,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270262,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000541.0,OT,,,,,,,,,135000541.0,1.0,Prophylaxis against HIV infection
13500089,135000891,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270263,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000891.0,OT,,,,,,,,,135000891.0,1.0,Prophylaxis against HIV infection
13500099,135000991,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270264,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000991.0,OT,,,,,,,,,135000991.0,1.0,Prophylaxis against HIV infection
13500112,135001121,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270265,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001121.0,OT,,,,,,,,,135001121.0,1.0,Prophylaxis against HIV infection
13500122,135001221,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270297,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001221.0,OT,,,,,,,,,135001221.0,1.0,Prophylaxis against HIV infection
13500125,135001251,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270280,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001251.0,OT,,,,,,,,,135001251.0,1.0,Prophylaxis against HIV infection
13500174,135001741,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270305,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001741.0,OT,,,,,,,,,135001741.0,1.0,Prophylaxis against HIV infection
13500196,135001961,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270310,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001961.0,OT,,,,,,,,,135001961.0,1.0,Prophylaxis against HIV infection
13500202,135002021,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270281,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002021.0,OT,,,,,,,,,135002021.0,1.0,Prophylaxis against HIV infection
13500216,135002161,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270282,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002161.0,OT,,,,,,,,,135002161.0,1.0,Prophylaxis against HIV infection
13500218,135002181,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270311,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002181.0,OT,,,,,,,,,135002181.0,1.0,Prophylaxis against HIV infection
13500223,135002231,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270312,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002231.0,OT,,,,,,,,,135002231.0,1.0,Prophylaxis against HIV infection
13500224,135002241,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270285,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002241.0,OT,,,,,,,,,135002241.0,1.0,Prophylaxis against HIV infection
13500238,135002381,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270314,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002381.0,OT,,,,,,,,,135002381.0,1.0,Prophylaxis against HIV infection
13500239,135002391,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270286,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002391.0,OT,,,,,,,,,135002391.0,1.0,Prophylaxis against HIV infection
13500241,135002411,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270313,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002411.0,OT,,,,,,,,,135002411.0,1.0,Prophylaxis against HIV infection
13500254,135002541,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270315,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002541.0,OT,,,,,,,,,135002541.0,1.0,Prophylaxis against HIV infection
13500255,135002551,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270287,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002551.0,OT,,,,,,,,,135002551.0,1.0,Prophylaxis against HIV infection
13500276,135002761,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270316,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002761.0,OT,,,,,,,,,135002761.0,1.0,Prophylaxis against HIV infection
13500287,135002871,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270323,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002871.0,OT,,,,,,,,,135002871.0,1.0,Prophylaxis against HIV infection
13500293,135002931,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270324,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002931.0,OT,,,,,,,,,135002931.0,1.0,Prophylaxis against HIV infection
13500307,135003071,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270325,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135003071.0,OT,,,,,,,,,135003071.0,1.0,Prophylaxis against HIV infection
13500527,135005271,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270326,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005271.0,OT,,,,,,,,,135005271.0,1.0,Prophylaxis against HIV infection
13500536,135005361,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270327,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005361.0,OT,,,,,,,,,135005361.0,1.0,Prophylaxis against HIV infection
13500543,135005431,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270328,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005431.0,OT,,,,,,,,,135005431.0,1.0,Prophylaxis against HIV infection
13500570,135005701,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270330,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005701.0,OT,,,,,,,,,135005701.0,1.0,Prophylaxis against HIV infection
13500587,135005871,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270400,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135005871.0,OT,,,,,,,,,135005871.0,1.0,Prophylaxis against HIV infection
13500616,135006161,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270401,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006161.0,OT,,,,,,,,,135006161.0,1.0,Prophylaxis against HIV infection
13500624,135006241,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270402,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006241.0,OT,,,,,,,,,135006241.0,1.0,Prophylaxis against HIV infection
13500645,135006451,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270341,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006451.0,OT,,,,,,,,,135006451.0,1.0,Prophylaxis against HIV infection
13500662,135006621,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270403,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006621.0,OT,,,,,,,,,135006621.0,1.0,Prophylaxis against HIV infection
13500683,135006831,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270411,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006831.0,OT,,,,,,,,,135006831.0,1.0,Prophylaxis against HIV infection
13500694,135006941,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270424,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006941.0,OT,,,,,,,,,135006941.0,1.0,Prophylaxis against HIV infection
13500696,135006961,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270423,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006961.0,OT,,,,,,,,,135006961.0,1.0,Prophylaxis against HIV infection
13500698,135006981,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270385,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006981.0,OT,,,,,,,,,135006981.0,1.0,Prophylaxis against HIV infection
13500701,135007011,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270418,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007011.0,OT,,,,,,,,,135007011.0,1.0,Prophylaxis against HIV infection
13500702,135007021,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270417,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007021.0,OT,,,,,,,,,135007021.0,1.0,Prophylaxis against HIV infection
13500705,135007051,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270416,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007051.0,OT,,,,,,,,,135007051.0,1.0,Prophylaxis against HIV infection
13500712,135007121,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270407,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007121.0,OT,,,,,,,,,135007121.0,1.0,Prophylaxis against HIV infection
13500714,135007141,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270408,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007141.0,OT,,,,,,,,,135007141.0,1.0,Prophylaxis against HIV infection
13500728,135007281,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270404,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007281.0,OT,,,,,,,,,135007281.0,1.0,Prophylaxis against HIV infection
13500729,135007291,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270412,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007291.0,OT,,,,,,,,,135007291.0,1.0,Prophylaxis against HIV infection
13500744,135007441,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270414,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007441.0,OT,,,,,,,,,135007441.0,1.0,Prophylaxis against HIV infection
13500745,135007451,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270409,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007451.0,OT,,,,,,,,,135007451.0,1.0,Prophylaxis against HIV infection
13500752,135007521,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270386,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007521.0,OT,,,,,,,,,135007521.0,1.0,Prophylaxis against HIV infection
13500759,135007591,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270390,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007591.0,OT,,,,,,,,,135007591.0,1.0,Prophylaxis against HIV infection
13500761,135007611,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270405,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007611.0,OT,,,,,,,,,135007611.0,1.0,Prophylaxis against HIV infection
13500762,135007621,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270410,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007621.0,OT,,,,,,,,,135007621.0,1.0,Prophylaxis against HIV infection
13500763,135007631,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270391,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007631.0,OT,,,,,,,,,135007631.0,1.0,Prophylaxis against HIV infection
13500764,135007641,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270388,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007641.0,OT,,,,,,,,,135007641.0,1.0,Prophylaxis against HIV infection
13500766,135007661,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270394,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007661.0,OT,,,,,,,,,135007661.0,1.0,Prophylaxis against HIV infection
13500791,135007911,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270406,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007911.0,OT,,,,,,,,,135007911.0,1.0,Prophylaxis against HIV infection
13500797,135007971,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270387,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007971.0,OT,,,,,,,,,135007971.0,1.0,Prophylaxis against HIV infection
13500803,135008031,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270413,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008031.0,OT,,,,,,,,,135008031.0,1.0,Prophylaxis against HIV infection
13500804,135008041,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270415,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008041.0,OT,,,,,,,,,135008041.0,1.0,Prophylaxis against HIV infection
13500834,135008341,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270392,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008341.0,OT,,,,,,,,,135008341.0,1.0,Prophylaxis against HIV infection
13500853,135008531,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270389,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008531.0,OT,,,,,,,,,135008531.0,1.0,Prophylaxis against HIV infection
13500890,135008901,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270393,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008901.0,OT,,,,,,,,,135008901.0,1.0,Prophylaxis against HIV infection
13501532,135015321,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0269948,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015321.0,OT,,,,,,,,,135015321.0,1.0,Prophylaxis against HIV infection
13501537,135015371,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270436,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015371.0,OT,,,,,,,,,135015371.0,1.0,Prophylaxis against HIV infection
13501539,135015391,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270437,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015391.0,OT,,,,,,,,,135015391.0,1.0,Prophylaxis against HIV infection
13501541,135015411,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270438,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015411.0,OT,,,,,,,,,135015411.0,1.0,Prophylaxis against HIV infection
13501544,135015441,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270439,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015441.0,OT,,,,,,,,,135015441.0,1.0,Prophylaxis against HIV infection
13501545,135015451,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270429,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015451.0,OT,,,,,,,,,135015451.0,1.0,Prophylaxis against HIV infection
13501546,135015461,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270430,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015461.0,OT,,,,,,,,,135015461.0,1.0,Prophylaxis against HIV infection
13501548,135015481,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270431,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015481.0,OT,,,,,,,,,135015481.0,1.0,Prophylaxis against HIV infection
13501552,135015521,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270432,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015521.0,OT,,,,,,,,,135015521.0,1.0,Prophylaxis against HIV infection
13501556,135015561,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270375,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015561.0,OT,,,,,,,,,135015561.0,1.0,Prophylaxis against HIV infection
13501557,135015571,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270370,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015571.0,OT,,,,,,,,,135015571.0,1.0,Prophylaxis against HIV infection
13501558,135015581,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270374,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015581.0,OT,,,,,,,,,135015581.0,1.0,Prophylaxis against HIV infection
13501559,135015591,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270373,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015591.0,OT,,,,,,,,,135015591.0,1.0,Prophylaxis against HIV infection
13501560,135015601,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270376,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015601.0,OT,,,,,,,,,135015601.0,1.0,Prophylaxis against HIV infection
13501561,135015611,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270369,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015611.0,OT,,,,,,,,,135015611.0,1.0,Prophylaxis against HIV infection
13501562,135015621,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270371,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015621.0,OT,,,,,,,,,135015621.0,1.0,Prophylaxis against HIV infection
13501563,135015631,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270372,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015631.0,OT,,,,,,,,,135015631.0,1.0,Prophylaxis against HIV infection
13501564,135015641,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270368,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015641.0,OT,,,,,,,,,135015641.0,1.0,Prophylaxis against HIV infection
13501566,135015661,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270367,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015661.0,OT,,,,,,,,,135015661.0,1.0,Prophylaxis against HIV infection
13501587,135015871,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270342,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015871.0,OT,,,,,,,,,135015871.0,1.0,Prophylaxis against HIV infection
13501588,135015881,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270425,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015881.0,OT,,,,,,,,,135015881.0,1.0,Prophylaxis against HIV infection
13501589,135015891,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270426,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015891.0,OT,,,,,,,,,135015891.0,1.0,Prophylaxis against HIV infection
13501590,135015901,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270427,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015901.0,OT,,,,,,,,,135015901.0,1.0,Prophylaxis against HIV infection
13501594,135015941,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270428,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015941.0,OT,,,,,,,,,135015941.0,1.0,Prophylaxis against HIV infection
13501595,135015951,1,I,,20170422.0,20170501,20170501,EXP,,BW-GILEAD-2017-0270339,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015951.0,OT,,,,,,,,,135015951.0,1.0,Prophylaxis against HIV infection
13504041,135040411,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270441,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040411.0,OT,,,,,,,,,135040411.0,1.0,Prophylaxis against HIV infection
13504044,135040441,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270443,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040441.0,OT,,,,,,,,,135040441.0,1.0,Prophylaxis against HIV infection
13504046,135040461,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270445,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040461.0,OT,,,,,,,,,135040461.0,1.0,Prophylaxis against HIV infection
13504065,135040651,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270452,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040651.0,OT,,,,,,,,,135040651.0,1.0,Prophylaxis against HIV infection
13504066,135040661,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270454,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040661.0,OT,,,,,,,,,135040661.0,1.0,Prophylaxis against HIV infection
13504067,135040671,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270450,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040671.0,OT,,,,,,,,,135040671.0,1.0,Prophylaxis against HIV infection
13504083,135040831,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270457,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040831.0,OT,,,,,,,,,135040831.0,1.0,Prophylaxis against HIV infection
13504092,135040921,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270462,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040921.0,OT,,,,,,,,,135040921.0,1.0,Prophylaxis against HIV infection
13504097,135040971,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270465,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040971.0,OT,,,,,,,,,135040971.0,1.0,Prophylaxis against HIV infection
13504107,135041071,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270468,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041071.0,OT,,,,,,,,,135041071.0,1.0,Prophylaxis against HIV infection
13504109,135041091,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270470,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041091.0,OT,,,,,,,,,135041091.0,1.0,Prophylaxis against HIV infection
13504134,135041341,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270477,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041341.0,OT,,,,,,,,,135041341.0,1.0,Prophylaxis against HIV infection
13504165,135041651,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270478,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041651.0,OT,,,,,,,,,135041651.0,1.0,Prophylaxis against HIV infection
13504167,135041671,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270512,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041671.0,OT,,,,,,,,,135041671.0,1.0,Prophylaxis against HIV infection
13504174,135041741,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270514,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041741.0,OT,,,,,,,,,135041741.0,1.0,Prophylaxis against HIV infection
13504188,135041881,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270518,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041881.0,OT,,,,,,,,,135041881.0,1.0,Prophylaxis against HIV infection
13504210,135042101,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270519,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042101.0,OT,,,,,,,,,135042101.0,1.0,Prophylaxis against HIV infection
13504225,135042251,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270515,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042251.0,OT,,,,,,,,,135042251.0,1.0,Prophylaxis against HIV infection
13504226,135042261,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270524,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042261.0,OT,,,,,,,,,135042261.0,1.0,Prophylaxis against HIV infection
13504232,135042321,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270526,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042321.0,OT,,,,,,,,,135042321.0,1.0,Prophylaxis against HIV infection
13504240,135042401,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270528,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042401.0,OT,,,,,,,,,135042401.0,1.0,Prophylaxis against HIV infection
13504273,135042731,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270442,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042731.0,OT,,,,,,,,,135042731.0,1.0,Prophylaxis against HIV infection
13504274,135042741,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270684,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042741.0,OT,,,,,,,,,135042741.0,1.0,Prophylaxis against HIV infection
13504275,135042751,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270529,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042751.0,OT,,,,,,,,,135042751.0,1.0,Prophylaxis against HIV infection
13504277,135042771,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270531,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042771.0,OT,,,,,,,,,135042771.0,1.0,Prophylaxis against HIV infection
13504278,135042781,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270682,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042781.0,OT,,,,,,,,,135042781.0,1.0,Prophylaxis against HIV infection
13504288,135042881,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270537,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042881.0,OT,,,,,,,,,135042881.0,1.0,Prophylaxis against HIV infection
13504289,135042891,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270671,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042891.0,OT,,,,,,,,,135042891.0,1.0,Prophylaxis against HIV infection
13504292,135042921,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270440,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042921.0,OT,,,,,,,,,135042921.0,1.0,Prophylaxis against HIV infection
13504294,135042941,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270670,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042941.0,OT,,,,,,,,,135042941.0,1.0,Prophylaxis against HIV infection
13504302,135043021,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270444,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043021.0,OT,,,,,,,,,135043021.0,1.0,Prophylaxis against HIV infection
13504312,135043121,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270669,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043121.0,OT,,,,,,,,,135043121.0,1.0,Prophylaxis against HIV infection
13504313,135043131,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270449,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043131.0,OT,,,,,,,,,135043131.0,1.0,Prophylaxis against HIV infection
13504314,135043141,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270672,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043141.0,OT,,,,,,,,,135043141.0,1.0,Prophylaxis against HIV infection
13504326,135043261,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270539,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043261.0,OT,,,,,,,,,135043261.0,1.0,Prophylaxis against HIV infection
13504334,135043341,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270665,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043341.0,OT,,,,,,,,,135043341.0,1.0,Prophylaxis against HIV infection
13504345,135043451,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270451,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043451.0,OT,,,,,,,,,135043451.0,1.0,Prophylaxis against HIV infection
13504346,135043461,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270668,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043461.0,OT,,,,,,,,,135043461.0,1.0,Prophylaxis against HIV infection
13504347,135043471,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270674,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043471.0,OT,,,,,,,,,135043471.0,1.0,Prophylaxis against HIV infection
13504349,135043491,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270667,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043491.0,OT,,,,,,,,,135043491.0,1.0,Prophylaxis against HIV infection
13504353,135043531,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270666,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043531.0,OT,,,,,,,,,135043531.0,1.0,Prophylaxis against HIV infection
13504354,135043541,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270678,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043541.0,OT,,,,,,,,,135043541.0,1.0,Prophylaxis against HIV infection
13504357,135043571,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270540,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043571.0,OT,,,,,,,,,135043571.0,1.0,Prophylaxis against HIV infection
13504358,135043581,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270676,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043581.0,OT,,,,,,,,,135043581.0,1.0,Prophylaxis against HIV infection
13504359,135043591,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270453,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043591.0,OT,,,,,,,,,135043591.0,1.0,Prophylaxis against HIV infection
13504360,135043601,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270661,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043601.0,OT,,,,,,,,,135043601.0,1.0,Prophylaxis against HIV infection
13504361,135043611,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270662,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043611.0,OT,,,,,,,,,135043611.0,1.0,Prophylaxis against HIV infection
13504362,135043621,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270648,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043621.0,OT,,,,,,,,,135043621.0,1.0,Prophylaxis against HIV infection
13504364,135043641,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270680,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043641.0,OT,,,,,,,,,135043641.0,1.0,Prophylaxis against HIV infection
13504365,135043651,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270663,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043651.0,OT,,,,,,,,,135043651.0,1.0,Prophylaxis against HIV infection
13504366,135043661,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270664,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043661.0,OT,,,,,,,,,135043661.0,1.0,Prophylaxis against HIV infection
13504368,135043681,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270543,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043681.0,OT,,,,,,,,,135043681.0,1.0,Prophylaxis against HIV infection
13504376,135043761,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270455,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043761.0,OT,,,,,,,,,135043761.0,1.0,Prophylaxis against HIV infection
13504377,135043771,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270660,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043771.0,OT,,,,,,,,,135043771.0,1.0,Prophylaxis against HIV infection
13504378,135043781,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270546,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043781.0,OT,,,,,,,,,135043781.0,1.0,Prophylaxis against HIV infection
13504387,135043871,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270549,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043871.0,OT,,,,,,,,,135043871.0,1.0,Prophylaxis against HIV infection
13504411,135044111,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270552,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044111.0,OT,,,,,,,,,135044111.0,1.0,Prophylaxis against HIV infection
13504413,135044131,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270456,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044131.0,OT,,,,,,,,,135044131.0,1.0,Prophylaxis against HIV infection
13504419,135044191,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270556,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044191.0,OT,,,,,,,,,135044191.0,1.0,Prophylaxis against HIV infection
13504431,135044311,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270559,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044311.0,OT,,,,,,,,,135044311.0,1.0,Prophylaxis against HIV infection
13504432,135044321,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270658,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044321.0,OT,,,,,,,,,135044321.0,1.0,Prophylaxis against HIV infection
13504433,135044331,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270659,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044331.0,OT,,,,,,,,,135044331.0,1.0,Prophylaxis against HIV infection
13504446,135044461,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270563,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044461.0,OT,,,,,,,,,135044461.0,1.0,Prophylaxis against HIV infection
13504447,135044471,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270656,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044471.0,OT,,,,,,,,,135044471.0,1.0,Prophylaxis against HIV infection
13504449,135044491,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270657,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044491.0,OT,,,,,,,,,135044491.0,1.0,Prophylaxis against HIV infection
13504456,135044561,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270655,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044561.0,OT,,,,,,,,,135044561.0,1.0,Prophylaxis against HIV infection
13504518,135045181,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270654,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135045181.0,OT,,,,,,,,,135045181.0,1.0,Prophylaxis against HIV infection
13504624,135046241,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270653,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135046241.0,OT,,,,,,,,,135046241.0,1.0,Prophylaxis against HIV infection
13504708,135047081,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270651,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047081.0,OT,,,,,,,,,135047081.0,1.0,Prophylaxis against HIV infection
13504709,135047091,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270650,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047091.0,OT,,,,,,,,,135047091.0,1.0,Prophylaxis against HIV infection
13504721,135047211,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270625,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047211.0,OT,,,,,,,,,135047211.0,1.0,Prophylaxis against HIV infection
13504725,135047251,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270649,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047251.0,OT,,,,,,,,,135047251.0,1.0,Prophylaxis against HIV infection
13504761,135047611,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270523,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047611.0,OT,,,,,,,,,135047611.0,1.0,Prophylaxis against HIV infection
13504762,135047621,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270475,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047621.0,OT,,,,,,,,,135047621.0,1.0,Prophylaxis against HIV infection
13504790,135047901,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270646,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047901.0,OT,,,,,,,,,135047901.0,1.0,Prophylaxis against HIV infection
13504791,135047911,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270647,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047911.0,OT,,,,,,,,,135047911.0,1.0,Prophylaxis against HIV infection
13504792,135047921,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270463,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047921.0,OT,,,,,,,,,135047921.0,1.0,Prophylaxis against HIV infection
13504835,135048351,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270525,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048351.0,OT,,,,,,,,,135048351.0,1.0,Prophylaxis against HIV infection
13504847,135048471,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270527,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048471.0,OT,,,,,,,,,135048471.0,1.0,Prophylaxis against HIV infection
13504849,135048491,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270561,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048491.0,OT,,,,,,,,,135048491.0,1.0,Prophylaxis against HIV infection
13504850,135048501,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270565,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048501.0,OT,,,,,,,,,135048501.0,1.0,Prophylaxis against HIV infection
13504851,135048511,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270553,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048511.0,OT,,,,,,,,,135048511.0,1.0,Prophylaxis against HIV infection
13504852,135048521,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270530,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048521.0,OT,,,,,,,,,135048521.0,1.0,Prophylaxis against HIV infection
13504853,135048531,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270516,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048531.0,OT,,,,,,,,,135048531.0,1.0,Prophylaxis against HIV infection
13504864,135048641,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270538,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048641.0,OT,,,,,,,,,135048641.0,1.0,Prophylaxis against HIV infection
13504865,135048651,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270517,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048651.0,OT,,,,,,,,,135048651.0,1.0,Prophylaxis against HIV infection
13504866,135048661,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270532,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048661.0,OT,,,,,,,,,135048661.0,1.0,Prophylaxis against HIV infection
13504874,135048741,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270464,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048741.0,OT,,,,,,,,,135048741.0,1.0,Prophylaxis against HIV infection
13504877,135048771,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270541,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048771.0,OT,,,,,,,,,135048771.0,1.0,Prophylaxis against HIV infection
13504878,135048781,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270564,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048781.0,OT,,,,,,,,,135048781.0,1.0,Prophylaxis against HIV infection
13504890,135048901,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270544,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048901.0,OT,,,,,,,,,135048901.0,1.0,Prophylaxis against HIV infection
13504891,135048911,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270557,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048911.0,OT,,,,,,,,,135048911.0,1.0,Prophylaxis against HIV infection
13504924,135049241,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270554,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049241.0,OT,,,,,,,,,135049241.0,1.0,Prophylaxis against HIV infection
13504925,135049251,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270458,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049251.0,OT,,,,,,,,,135049251.0,1.0,Prophylaxis against HIV infection
13504926,135049261,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270466,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049261.0,OT,,,,,,,,,135049261.0,1.0,Prophylaxis against HIV infection
13504929,135049291,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270548,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049291.0,OT,,,,,,,,,135049291.0,1.0,Prophylaxis against HIV infection
13504939,135049391,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270555,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049391.0,OT,,,,,,,,,135049391.0,1.0,Prophylaxis against HIV infection
13504945,135049451,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270467,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049451.0,OT,,,,,,,,,135049451.0,1.0,Prophylaxis against HIV infection
13504951,135049511,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270469,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049511.0,OT,,,,,,,,,135049511.0,1.0,Prophylaxis against HIV infection
13504952,135049521,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270679,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049521.0,OT,,,,,,,,,135049521.0,1.0,Prophylaxis against HIV infection
13504955,135049551,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270551,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049551.0,OT,,,,,,,,,135049551.0,1.0,Prophylaxis against HIV infection
13504956,135049561,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270566,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049561.0,OT,,,,,,,,,135049561.0,1.0,Prophylaxis against HIV infection
13504957,135049571,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270677,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049571.0,OT,,,,,,,,,135049571.0,1.0,Prophylaxis against HIV infection
13504958,135049581,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270675,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049581.0,OT,,,,,,,,,135049581.0,1.0,Prophylaxis against HIV infection
13504959,135049591,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270547,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049591.0,OT,,,,,,,,,135049591.0,1.0,Prophylaxis against HIV infection
13504960,135049601,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270550,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049601.0,OT,,,,,,,,,135049601.0,1.0,Prophylaxis against HIV infection
13504965,135049651,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270562,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049651.0,OT,,,,,,,,,135049651.0,1.0,Prophylaxis against HIV infection
13504969,135049691,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270471,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049691.0,OT,,,,,,,,,135049691.0,1.0,Prophylaxis against HIV infection
13504975,135049751,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270683,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049751.0,OT,,,,,,,,,135049751.0,1.0,Prophylaxis against HIV infection
13504995,135049951,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270476,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049951.0,OT,,,,,,,,,135049951.0,1.0,Prophylaxis against HIV infection
13504999,135049991,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270479,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049991.0,OT,,,,,,,,,135049991.0,1.0,Prophylaxis against HIV infection
13505014,135050141,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270542,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050141.0,OT,,,,,,,,,135050141.0,1.0,Prophylaxis against HIV infection
13505015,135050151,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270510,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050151.0,OT,,,,,,,,,135050151.0,1.0,Prophylaxis against HIV infection
13505020,135050201,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270482,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050201.0,OT,,,,,,,,,135050201.0,1.0,Prophylaxis against HIV infection
13505037,135050371,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270513,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050371.0,OT,,,,,,,,,135050371.0,1.0,Prophylaxis against HIV infection
13505171,135051711,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270681,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051711.0,OT,,,,,,,,,135051711.0,1.0,Prophylaxis against HIV infection
13505172,135051721,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270545,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051721.0,OT,,,,,,,,,135051721.0,1.0,Prophylaxis against HIV infection
13505173,135051731,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270560,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051731.0,OT,,,,,,,,,135051731.0,1.0,Prophylaxis against HIV infection
13505268,135052681,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270558,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135052681.0,OT,,,,,,,,,135052681.0,1.0,Prophylaxis against HIV infection
13505305,135053051,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270652,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135053051.0,OT,,,,,,,,,135053051.0,1.0,Prophylaxis against HIV infection
13505430,135054301,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270619,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054301.0,OT,,,,,,,,,135054301.0,1.0,Prophylaxis against HIV infection
13505488,135054881,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270620,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054881.0,OT,,,,,,,,,135054881.0,1.0,Prophylaxis against HIV infection
13505489,135054891,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270624,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054891.0,OT,,,,,,,,,135054891.0,1.0,Prophylaxis against HIV infection
13505598,135055981,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270626,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135055981.0,OT,,,,,,,,,135055981.0,1.0,Prophylaxis against HIV infection
13505607,135056071,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270627,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056071.0,OT,,,,,,,,,135056071.0,1.0,Prophylaxis against HIV infection
13505611,135056111,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270628,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056111.0,OT,,,,,,,,,135056111.0,1.0,Prophylaxis against HIV infection
13505617,135056171,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270645,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056171.0,OT,,,,,,,,,135056171.0,1.0,Prophylaxis against HIV infection
13505625,135056251,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270621,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056251.0,OT,,,,,,,,,135056251.0,1.0,Prophylaxis against HIV infection
13505738,135057381,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270623,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135057381.0,OT,,,,,,,,,135057381.0,1.0,Prophylaxis against HIV infection
13506246,135062461,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270480,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135062461.0,OT,,,,,,,,,135062461.0,1.0,Prophylaxis against HIV infection
13506247,135062471,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270481,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135062471.0,OT,,,,,,,,,135062471.0,1.0,Prophylaxis against HIV infection
13506464,135064641,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270483,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135064641.0,OT,,,,,,,,,135064641.0,1.0,Prophylaxis against HIV infection
13506498,135064981,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270484,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135064981.0,OT,,,,,,,,,135064981.0,1.0,Prophylaxis against HIV infection
13506594,135065941,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270511,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135065941.0,OT,,,,,,,,,135065941.0,1.0,Prophylaxis against HIV infection
13506753,135067531,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270622,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135067531.0,OT,,,,,,,,,135067531.0,1.0,Prophylaxis against HIV infection
13506754,135067541,1,I,,20170422.0,20170502,20170502,EXP,,BW-GILEAD-2017-0270673,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135067541.0,OT,,,,,,,,,135067541.0,1.0,Prophylaxis against HIV infection
13515130,135151301,1,I,,20170426.0,20170504,20170504,EXP,,US-GILEAD-2017-0270355,GILEAD,,48.0,YR,A,F,Y,,,20170504.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,135151301.0,OT,,,135151301.0,1.0,2009.0,,,,135151301.0,1.0,HIV infection
13523816,135238161,1,I,20170408.0,20170428.0,20170508,20170508,EXP,,ZA-GILEAD-2017-0270985,GILEAD,,43.0,YR,A,M,Y,60.6,KG,20170508.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Thermal burn,135238161.0,HO,,,135238161.0,1.0,20150817.0,,,,135238161.0,1.0,HIV infection
13536066,135360663,3,F,,20190411.0,20170511,20190412,EXP,,DE-GILEAD-2017-0272168,GILEAD,"RADMER S, KASTIRR I, ADRESEN JR, ANDRESEN R. RESOLUTION OF RECURRENT BONE MARROW EDEMA AND INSUFFICIENCY FRACTURES IN AN HIV PATIENT FOLLOWING ANTIVIRAL THERAPY SWITCH. 2019 CONGRESS ON OSTEOLOGY GERMAN SOCIETY FOR OSTEOLOGY E.V. (DGO). 2019;UNK:28",62.0,YR,A,M,Y,,,20190412.0,,OT,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema;Foot fracture;Renal failure,135360663.0,OT,,,,,,,,,135360663.0,1.0,HIV infection
13539634,135396341,1,I,,20170428.0,20170512,20170512,EXP,,US-MYLANLABS-2017M1028036,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Herpes zoster;Neutropenia,135396341.0,OT,,,,,,,,,135396341.0,1.0,Lymphoma AIDS related
13540226,135402261,1,I,,20170428.0,20170512,20170512,EXP,,US-MYLANLABS-2017M1028180,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,135402261.0,OT,,,,,,,,,135402261.0,1.0,Lymphoma AIDS related
13540227,135402271,1,I,,20170428.0,20170512,20170512,EXP,,US-MYLANLABS-2017M1028177,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased,135402271.0,OT,,,,,,,,,135402271.0,1.0,Lymphoma AIDS related
13546643,135466433,3,F,20170418.0,20170711.0,20170515,20170720,EXP,,GB-GILEAD-2017-0272377,GILEAD,,53.0,YR,A,F,Y,66.0,KG,20170720.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Peripheral ischaemia,135466433.0,HO,,,135466433.0,1.0,20100617.0,,,,135466433.0,1.0,HIV infection
13549436,135494361,1,I,,20170508.0,20170516,20170516,EXP,,US-TEVA-768207USA,TEVA,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",51.0,YR,,M,Y,,,20170516.0,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE",Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,135494361.0,OT,,,,,,,,,135494361.0,1.0,Lymphoma AIDS related
13549468,135494681,1,I,,20170508.0,20170516,20170516,EXP,,US-TEVA-768216USA,TEVA,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",65.0,YR,,M,Y,,,20170516.0,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE",Herpes zoster;Neutropenia,135494681.0,OT,,,,,,,,,135494681.0,1.0,Lymphoma AIDS related
13565295,135652954,4,F,,20190617.0,20170519,20190625,EXP,,ZA-MYLANLABS-2017M1029650,MYLAN,,,,N,F,Y,,,20190625.0,,OT,ZA,ZA,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Corneal opacity congenital;Foetal exposure during pregnancy,135652954.0,CA,,,,,,,,,135652954.0,1.0,HIV infection
13569392,135693921,1,I,,20170515.0,20170522,20170522,EXP,,US-GILEAD-2017-0273449,GILEAD,,50.0,YR,A,M,Y,,,20170522.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Diarrhoea,135693921.0,OT,,,,,,,,,135693921.0,1.0,HIV infection
13570909,135709091,1,I,,20170508.0,20170523,20170523,EXP,,US-HETERO LABS LTD-2021082,HETERO,,65.0,YR,,M,Y,,,20170523.0,,OT,US,US,Efavirenz\ Emtricitabine\Tenofovir,Herpes zoster;Neutropenia,135709091.0,OT,,,,,,,,,135709091.0,1.0,HIV infection
13582798,135827981,1,I,,20170517.0,20170525,20170525,EXP,,US-GILEAD-2017-0274081,GILEAD,,34.0,YR,A,M,Y,,,20170525.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise,135827981.0,HO,,,,,,,,,135827981.0,1.0,HIV infection
13583140,135831402,2,F,20160626.0,20170531.0,20170525,20170606,EXP,,ZA-GILEAD-2017-0273804,GILEAD,,34.0,YR,A,F,Y,,,20170606.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Subchorionic haemorrhage,135831402.0,OT,,,135831402.0,1.0,20130415.0,,,,135831402.0,1.0,HIV infection
13588726,135887261,1,I,,20170517.0,20170529,20170529,EXP,,KE-CIPLA LTD.-2017KE09227,CIPLA,,,,,,Y,,,20170529.0,,OT,KE,KE,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Left ventricular dysfunction;Neurosyphilis,135887261.0,HO,,,,,,,,,135887261.0,1.0,HIV infection
13589185,135891851,1,I,,20160718.0,20170529,20170529,PER,,US-STRIDES ARCOLAB LIMITED-2016SP010742,STRIDES,"MAKADZANGE AT, HIGGINS-BIDDLE M, CHIMUKANGARA B, BIRRI R, GORDON M, MAHLANZA T, MCHUGH G, VAN DIJK JH, BWAKURA-DANGAREMBIZI M, NDUNGU T, MASIMIREMBWA C, PHELPS B, AMZEL A, OJIKUTU BO, WALKER BD, NDHL. CLINICAL, VIROLOGIC, IMMUNOLOGIC OUTCOMES AND EMERGING HIV DRUG RESISTANCE PATTERNS IN CHILDREN AND ADOLESCENTS IN PUBLIC ART CARE IN ZIMBABWE.. PLOS ONE.. 2015;10(12):E0144057.",,,,,Y,,,20170529.0,,OT,US,US,EFAVIRENZ W/LAMIVUDINE/STAVUDINE;EFAVIRENZ W/LAMIVUDINE/ZIDOVUDINE,Virologic failure,135891851.0,OT,,,,,,,,,135891851.0,1.0,HIV infection
13595320,135953201,1,I,,20170516.0,20170531,20170531,EXP,,US-CIPLA LTD.-2017US09895,CIPLA,,,,,,Y,,,20170531.0,,CN,US,US,Tenofovir/Emtricitabine/Efavirenz,Beta haemolytic streptococcal infection;Exposure during pregnancy,135953201.0,OT,,,,,,,,,135953201.0,1.0,HIV infection
13599243,135992431,1,I,20170412.0,20170519.0,20170531,20170531,EXP,,MW-GILEAD-2017-0274939,GILEAD,,39.0,YR,A,M,Y,,,20170531.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,135992431.0,OT,,,135992431.0,1.0,20170328.0,20170411.0,,,135992431.0,1.0,Kaposi's sarcoma AIDS related
13610109,136101091,1,I,,20170524.0,20170604,20170604,EXP,,US-HETERO LABS LTD-2021534,HETERO,,,,,,Y,2.98,KG,20170604.0,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Maternal drugs affecting foetus;Polydactyly,136101091.0,OT,,,,,,,,,136101091.0,1.0,HIV infection
13631960,136319604,4,F,20170525.0,20171227.0,20170608,20180104,EXP,,KE-GILEAD-2017-0276578,GILEAD,,33.0,YR,A,M,Y,59.0,KG,20180104.0,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,136319604.0,HO,,,136319604.0,1.0,20170227.0,20170524.0,,,136319604.0,1.0,Kaposi's sarcoma AIDS related
13643941,136439411,1,I,,20160512.0,20170612,20170612,EXP,,US-GILEAD-2016-0214044,GILEAD,,49.0,YR,A,F,Y,,,20170612.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood potassium decreased;Drug dose omission;Facial paralysis;Headache;Hypertension,136439411.0,HO,,,136439411.0,1.0,2011.0,,,,136439411.0,1.0,HIV infection
13649428,136494281,1,I,,20170530.0,20170613,20170613,EXP,,US-AUROBINDO-AUR-APL-2017-35325,AUROBINDO,,,,N,,Y,2.9,KG,20170613.0,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Foetal exposure during pregnancy;Polydactyly,136494281.0,CA,,,,,,,,,136494281.0,1.0,HIV infection
13651384,136513841,1,I,20170504.0,20170602.0,20170614,20170614,EXP,,ZA-GILEAD-2017-0276651,GILEAD,,34.0,YR,A,F,Y,46.0,KG,20170614.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthma,136513841.0,HO,,,136513841.0,1.0,20160217.0,20151210.0,,,136513841.0,1.0,HIV infection
13656806,136568061,1,I,,20170605.0,20170615,20170615,EXP,,DE-GILEAD-2017-0277975,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568061.0,OT,,,,,,,,,136568061.0,1.0,HIV infection
13656826,136568261,1,I,,20170605.0,20170615,20170615,EXP,,DE-GILEAD-2017-0277977,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568261.0,OT,,,,,,,,,136568261.0,1.0,HIV infection
13656891,136568911,1,I,,20170605.0,20170615,20170615,EXP,,DE-GILEAD-2017-0277976,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568911.0,OT,,,,,,,,,136568911.0,1.0,HIV infection
13656893,136568931,1,I,,20170605.0,20170615,20170615,EXP,,DE-GILEAD-2017-0277244,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568931.0,OT,,,,,,,,,136568931.0,1.0,HIV infection
13657466,136574661,1,I,2015.0,20170608.0,20170615,20170615,EXP,,US-GILEAD-2017-0278017,GILEAD,,52.0,YR,A,M,Y,,,20170615.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Accident at work;Back injury,136574661.0,OT,,,,,,,,,136574661.0,1.0,HIV infection
13675730,136757303,3,F,20170518.0,20180403.0,20170621,20180411,EXP,,ZA-GILEAD-2017-0278617,GILEAD,,29.0,YR,A,M,Y,82.2,KG,20180411.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicide attempt,136757303.0,HO,,,136757303.0,1.0,20140605.0,201705.0,,,136757303.0,1.0,HIV infection
13679070,136790701,1,I,201512.0,20170615.0,20170622,20170622,EXP,,US-GILEAD-2017-0279140,GILEAD,,51.0,YR,A,M,Y,,,20170622.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety disorder due to a general medical condition;Cardiac failure congestive;Poor quality sleep,136790701.0,OT,,,136790701.0,1.0,2009.0,,,,136790701.0,1.0,HIV infection
13684970,136849702,2,F,20170608.0,20170616.0,20170623,20170628,EXP,,KE-GILEAD-2017-0279249,GILEAD,,21.0,YR,A,F,Y,,,20170628.0,,OT,KE,KE,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Skin ulcer,136849702.0,HO,,,136849702.0,1.0,20160728.0,20170518.0,,,136849702.0,1.0,Acquired immunodeficiency syndrome
13684980,136849805,5,F,20170608.0,20171227.0,20170623,20180104,EXP,,KE-GILEAD-2017-0279230,GILEAD,,53.0,YR,A,M,Y,56.4,KG,20180104.0,,OT,US,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,136849805.0,HO,,,136849805.0,1.0,20170322.0,20170511.0,,,136849805.0,1.0,Acquired immunodeficiency syndrome
13684981,136849812,2,F,20170608.0,20170706.0,20170623,20170719,EXP,,ZW-GILEAD-2017-0279194,GILEAD,,39.0,YR,A,M,Y,64.0,KG,20170719.0,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,136849812.0,HO,,,136849812.0,1.0,20161129.0,20170315.0,,,136849812.0,1.0,Kaposi's sarcoma AIDS related
13712779,137127792,2,F,201309.0,20170707.0,20170703,20170717,EXP,,DE-GILEAD-2017-0280889,GILEAD,,34.0,YR,A,M,Y,66.5,KG,20170717.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Acute hepatitis C;Burkitt's lymphoma;Hepatic mass;Splenomegaly,137127792.0,HO,,,137127792.0,1.0,2009.0,,,,137127792.0,1.0,HIV infection
13726632,137266321,1,I,,20170629.0,20170706,20170706,EXP,,US-GILEAD-2017-0281750,GILEAD,,,,,M,Y,,,20170706.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,137266321.0,OT,,,,,,,,,137266321.0,1.0,HIV infection
13743642,137436421,1,I,20160411.0,20170626.0,20170711,20170711,EXP,,GB-GILEAD-2017-0280691,GILEAD,,53.0,YR,A,M,Y,,,20170711.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cholecystitis acute,137436421.0,OT,,,,,,,,,137436421.0,1.0,HIV infection
13755549,137555491,1,I,,20170701.0,20170714,20170714,EXP,,IN-MYLANLABS-2017M1041666,MYLAN,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTI RETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN-J-DERMATOL-VENEREOL-LEPROL 2017;83(4):502-504.",48.0,YR,,F,Y,,,20170714.0,,OT,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Rash maculo-papular;Vomiting,137555491.0,OT,,,,,,,,,137555491.0,1.0,HIV infection
13755550,137555501,1,I,,20170701.0,20170714,20170714,EXP,,IN-MYLANLABS-2017M1041830,MYLAN,"AMRUTHA PC, RAKESH TP, KIDANGAZHIYATHMANA A, CHAKKUNNY SC, REWARI BB, ANDREWS AM. THE ENIGMA OF LAMIVUDINE RASH: EXPERIENCE ON RE-CHALLENGE FROM AN ANTI RETROVIRAL TREATMENT CENTER IN SOUTH INDIA. INDIAN-J-DERMATOL-VENEREOL-LEPROL 2017;83(4):502-504.",36.0,YR,,F,Y,,,20170714.0,,OT,IN,IN,EFAVIRENZ W/LAMIVUDINE/ZIDOVUDINE,Asthma;Dermatitis atopic,137555501.0,OT,,,,,,,,,137555501.0,1.0,HIV infection
13776017,137760173,3,F,20160719.0,20171102.0,20170720,20171108,EXP,,US-GILEAD-2017-0283660,GILEAD,,30.0,YR,A,F,Y,,,20171108.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,137760173.0,OT,,,137760173.0,2.0,20170428.0,,,,137760173.0,1.0,HIV infection
13776030,137760304,4,F,20160719.0,20171102.0,20170720,20171108,EXP,,US-GILEAD-2017-0283895,GILEAD,,0.0,YR,N,,Y,,,20171108.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital choroid plexus cyst;Foetal exposure during pregnancy;Trisomy 18,137760304.0,OT,,,137760304.0,1.0,20160719.0,20170428.0,,,137760304.0,1.0,HIV infection
13776794,137767942,2,F,,20170728.0,20170721,20170801,EXP,,PT-GILEAD-2017-0284206,GILEAD,,38.0,YR,A,F,Y,,,20170801.0,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,137767942.0,OT,,,137767942.0,1.0,201009.0,201210.0,,,137767942.0,1.0,HIV infection
13777053,137770532,2,F,20161007.0,20171214.0,20170721,20171220,EXP,,FR-GILEAD-2017-0283883,GILEAD,,,,,,Y,,,20171220.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypoplastic right heart syndrome;Ventricular septal defect,137770532.0,OT,,,137770532.0,1.0,20161007.0,20161007.0,,,137770532.0,1.0,HIV infection
13783297,137832971,1,I,,20170717.0,20170724,20170724,EXP,,US-GILEAD-2017-0284589,GILEAD,"ASSAD DS, TAHA W. SAFETY AND EFFICACY OF DENOSUMAB IN AN HIV-INFECTED PATIENT WITH OSTEOPOROSIS. ENDOCRINE REVIEWS. CONFERENCE:99TH ANNUAL MEETING OF THE ENDOCRINE SOCIETY, ENDO. 2017;38:UNKNOWN",73.0,YR,E,F,Y,,,20170724.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Osteoporosis,137832971.0,OT,,,,,,,,,137832971.0,1.0,HIV infection
13816035,138160352,2,F,20170714.0,20170728.0,20170731,20170807,EXP,,MW-GILEAD-2017-0285542,GILEAD,,60.0,YR,A,M,Y,,,20170807.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,138160352.0,OT,,,138160352.0,1.0,20160525.0,20170713.0,,,138160352.0,1.0,Acquired immunodeficiency syndrome
13873128,138731281,1,I,,20170803.0,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14090,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J, ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816.0,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Cervical dysplasia,138731281.0,OT,,,,,,,,,138731281.0,1.0,HIV infection
13873206,138732061,1,I,,20170803.0,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14087,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816.0,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Virologic failure,138732061.0,OT,,,,,,,,,138732061.0,1.0,HIV infection
13873279,138732791,1,I,,20170803.0,20170816,20170816,EXP,,TH-CIPLA LTD.-2017TH14091,CIPLA,"AVIHINGSANON A, MAEK-A-NANTAWAT W, GATECHOMPOL S, SAPSIRISAVAT V, THIANSANGUANKUL W, SOPHONPHAN J, ET AL;. EFFICACY AND SAFETY OF A ONCE-DAILY SINGLE-TABLET REGIMEN OF TENOFOVIR, LAMIVUDINE, AND EFAVIRENZ ASSESSED AT 144 WEEKS AMONG ANTIRETROVIRAL-NAIVE AND EXPERIENCED HIV-1-INFECTED THAI ADULTS. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;61:89 TO 96",,,,,Y,,,20170816.0,,OT,TH,TH,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Endocarditis enterococcal,138732791.0,HO,,,,,,,,,138732791.0,1.0,HIV infection
13877993,138779934,4,F,,20190726.0,20170817,20190805,EXP,,BW-GILEAD-2017-0288038,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKAMN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,F,Y,,,20190805.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,138779934.0,OT,,,,,,,,,138779934.0,1.0,HIV infection
13878029,138780294,4,F,,20190726.0,20170817,20190805,EXP,,BW-GILEAD-2017-0288039,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACOSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,N,,Y,,,20190805.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death neonatal;Foetal exposure during pregnancy,138780294.0,DE,,,,,,,,,138780294.0,1.0,HIV infection
13878060,138780603,3,F,,20190726.0,20170817,20190805,EXP,,BW-GILEAD-2017-0288037,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,,Y,,,20190805.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,138780603.0,OT,,,,,,,,,138780603.0,1.0,HIV infection
13928785,139287852,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14993,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75(5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Delirium;Diarrhoea;Drug level increased;Speech disorder;Vomiting,139287852.0,OT,,,,,,,,,139287852.0,1.0,HIV infection
13928788,139287882,2,F,,20170825.0,20170901,20170908,EXP,,ZA-CIPLA LTD.-2017ZA14994,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170908.0,,OT,ZA,ZA,Efavirenz;TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Cholestasis;Drug level increased;Speech disorder,139287882.0,HO,,,,,,,,,139287882.0,1.0,HIV infection
13928802,139288022,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14995,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,Efavirenz;TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Aggression;Asthenia;Ataxia;Burning sensation;Cerebellar syndrome;Delirium;Drug level increased;Dysarthria,139288022.0,HO,,,,,,,,,139288022.0,1.0,HIV infection
13928971,139289712,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14997,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75(5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Confusional state;Death;Drug level increased;Treatment noncompliance;Viral load increased,139289712.0,DE,,,,,,,,,139289712.0,1.0,HIV infection
13929001,139290012,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA15001,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Death;Drug level increased;Encephalopathy,139290012.0,DE,,,,,,,,,139290012.0,1.0,HIV infection
13929008,139290082,2,F,,20170825.0,20170901,20170907,EXP,,ZA-CIPLA LTD.-2017ZA14998,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL;. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Drug level increased;Seizure,139290082.0,HO,,,,,,,,,139290082.0,1.0,HIV infection
13938334,139383342,2,F,,20170906.0,20170905,20170914,EXP,,US-GILEAD-2017-0291942,GILEAD,,46.0,YR,A,F,Y,,,20170914.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Intentional product use issue,139383342.0,OT,,,139383342.0,1.0,1997.0,,,,139383342.0,1.0,HIV infection
13938958,139389582,2,F,,20170906.0,20170906,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16065,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Drug level increased,139389582.0,OT,,,,,,,,,139389582.0,1.0,Antiretroviral therapy
13943526,139435261,1,I,,20170825.0,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16060,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Abnormal behaviour;Ataxia;Cerebellar syndrome;Drug level increased;Malaise;Paraesthesia;Suicidal ideation;Tremor;Vomiting,139435261.0,HO,,,,,,,,,139435261.0,1.0,HIV infection
13944690,139446901,1,I,,20170825.0,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16040,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Cerebellar syndrome;Exposure during pregnancy;Fall;Speech disorder,139446901.0,OT,,,,,,,,,139446901.0,1.0,HIV infection
13944693,139446931,1,I,,20170825.0,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16059,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Abnormal behaviour;Acute psychosis;Ataxia;Confusional state;Death;Drug level increased;Dyskinesia,139446931.0,HO,,,,,,,,,139446931.0,1.0,HIV infection
13944697,139446972,2,F,,20171016.0,20170907,20171030,EXP,,ZA-CIPLA LTD.-2017ZA15424,CIPLA,,,,,,Y,,,20171030.0,,OT,GB,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Abnormal dreams;Ataxia;Drug level increased;Dysarthria;Neuroleptic malignant syndrome,139446972.0,HO,,,,,,,,,139446972.0,1.0,HIV infection
13944700,139447001,1,I,,20170825.0,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16058,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A ET AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Ataxia;Drug level increased;Encephalopathy;Immune reconstitution inflammatory syndrome,139447001.0,HO,,,,,,,,,139447001.0,1.0,HIV infection
13945823,139458231,1,I,,20170825.0,20170907,20170907,EXP,,ZA-CIPLA LTD.-2017ZA16062,CIPLA,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, ET.AL.,. BRIEF REPORT: LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75 (5):577 TO 579",,,,,Y,,,20170907.0,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Acute kidney injury;Ataxia;Drug level increased;Encephalopathy;International normalised ratio increased;Leukocytosis;Sepsis;Thrombocytopenia,139458231.0,HO,,,,,,,,,139458231.0,1.0,HIV infection
13951607,139516072,2,F,20161114.0,20170918.0,20170908,20170922,EXP,,ZA-GILEAD-2017-0292226,GILEAD,,31.0,YR,A,F,Y,,,20170922.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,139516072.0,OT,,,,,,,,,139516072.0,1.0,HIV infection
13993776,139937761,1,I,201612.0,20170911.0,20170920,20170920,EXP,,US-GILEAD-2017-0293547,GILEAD,,47.0,YR,A,M,Y,,,20170920.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amyotrophic lateral sclerosis,139937761.0,OT,,,139937761.0,1.0,2015.0,,,,139937761.0,1.0,HIV infection
14108835,141088352,2,F,,20190726.0,20171019,20190805,EXP,,BW-GILEAD-2017-0288035,GILEAD,"ZASH R, HOLMES L, DISEKO M, JACOBSON D, BRUMMEL S, MAYONDI G, ISAACSON A, DAVEY S, MABUTA J, MMALANE M, GAOLATHE T, ESSEX M, LOCKMAN S, MAKHEMA J, SHAPIRO R. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;UNK:1-14. DOI:10.1056/NEJMOA1905230",,,,F,Y,,,20190805.0,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature baby,141088352.0,OT,,,,,,,,,141088352.0,1.0,HIV infection
14111391,141113913,3,F,20170726.0,20180131.0,20171020,20180202,EXP,,UG-GILEAD-2017-0299190,GILEAD,,42.0,YR,A,M,Y,65.0,KG,20180202.0,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tibia fracture,141113913.0,HO,,,141113913.0,1.0,20120309.0,,,,141113913.0,1.0,HIV infection
14143278,141432781,1,I,,20171023.0,20171030,20171030,EXP,,CG-GILEAD-2017-0300896,GILEAD,,,,,F,Y,,,20171030.0,,CN,FR,CG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aphasia;Blindness;Deafness;Diarrhoea;Tuberculosis,141432781.0,OT,,,141432781.0,1.0,2017.0,,,,141432781.0,1.0,HIV infection
14147931,141479312,2,F,,20180628.0,20171031,20180706,EXP,,CA-GILEAD-2017-0301425,GILEAD,,,,N,,Y,,,20180706.0,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,141479312.0,CA,,,,,,,,,141479312.0,1.0,Prophylaxis against HIV infection
14154597,141545971,1,I,20161006.0,20171024.0,20171102,20171102,EXP,,GB-GILEAD-2017-0301748,GILEAD,,80.0,YR,E,M,Y,77.0,KG,20171102.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone graft lysis;Lower limb fracture,141545971.0,OT,,,141545971.0,4.0,20161006.0,,,,141545971.0,1.0,HIV infection
14176261,141762613,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303003,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",52.0,YR,A,F,Y,26.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762613.0,OT,,,,,,,,,141762613.0,1.0,HIV infection
14176264,141762643,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303488,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",30.0,YR,A,F,Y,30.4,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762643.0,OT,,,,,,,,,141762643.0,1.0,HIV infection
14176265,141762653,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303500,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",30.0,YR,A,F,Y,36.4,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762653.0,OT,,,,,,,,,141762653.0,1.0,HIV infection
14176266,141762663,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303498,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",28.0,YR,A,F,Y,27.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug ineffective;Drug level increased;Encephalopathy;Treatment noncompliance,141762663.0,OT,,,,,,,,,141762663.0,1.0,HIV infection
14176267,141762673,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303499,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",44.0,YR,A,F,Y,34.2,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy;Immune reconstitution inflammatory syndrome associated tuberculosis,141762673.0,HO,,,,,,,,,141762673.0,1.0,HIV infection
14176268,141762683,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303501,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",35.0,YR,A,F,Y,40.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Ataxia;Drug level increased;Encephalopathy,141762683.0,OT,,,,,,,,,141762683.0,1.0,HIV infection
14176269,141762693,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303503,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",18.0,YR,A,F,Y,38.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762693.0,OT,,,,,,,,,141762693.0,1.0,HIV infection
14176270,141762703,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303502,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",56.0,YR,A,F,Y,37.8,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Chronic kidney disease;Drug level increased;Encephalopathy,141762703.0,OT,,,,,,,,,141762703.0,1.0,HIV infection
14176271,141762713,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303489,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",47.0,YR,A,F,Y,29.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762713.0,HO,,,,,,,,,141762713.0,1.0,HIV infection
14176274,141762743,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303491,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",20.0,YR,A,F,Y,36.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy;Maternal exposure during pregnancy,141762743.0,DS,,,,,,,,,141762743.0,1.0,HIV infection
14176275,141762753,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303492,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",32.0,YR,A,F,Y,37.0,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762753.0,OT,,,,,,,,,141762753.0,1.0,HIV infection
14176276,141762763,3,F,,20171211.0,20171109,20171219,EXP,,ZA-GILEAD-2017-0303490,GILEAD,"VARIAVA E, SIGAUKE FR, NORMAN J, RAKGOKONG M, MUCHICHWA P, MOCHAN A, MAARTENS G, MARTINSON NA,. LATE EFAVIRENZ-INDUCED ATAXIA AND ENCEPHALOPATHY: A CASE SERIES. J ACQUIR IMMUNE DEFIC SYNDR. 2017;75:577-579",24.0,YR,A,F,Y,35.3,KG,20171219.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ataxia;Drug level increased;Encephalopathy,141762763.0,OT,,,,,,,,,141762763.0,1.0,HIV infection
14176282,141762821,1,I,,20171103.0,20171109,20171109,EXP,,US-GILEAD-2017-0303863,GILEAD,,62.0,YR,A,M,Y,,,20171109.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Paralysis;Speech disorder,141762821.0,OT,,,141762821.0,1.0,20170215.0,,,,141762821.0,1.0,HIV infection
14184921,141849211,1,I,20161031.0,20171107.0,20171113,20171113,EXP,,US-GILEAD-2017-0304358,GILEAD,,0.0,YR,,M,Y,3.22,KG,20171113.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrops foetalis;Umbilical cord around neck,141849211.0,OT,,,141849211.0,1.0,20161031.0,20170801.0,,,141849211.0,1.0,HIV infection
14184957,141849571,1,I,20161031.0,20171107.0,20171113,20171113,EXP,,US-GILEAD-2017-0304346,GILEAD,,38.0,YR,A,F,Y,,,20171113.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,141849571.0,OT,,,,,,,,,141849571.0,1.0,HIV infection
14217502,142175022,2,F,,20171209.0,20171123,20171212,EXP,,US-GILEAD-2017-0306515,GILEAD,,52.0,YR,A,M,Y,,,20171212.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aphasia;Cerebrovascular accident,142175022.0,OT,,,142175022.0,1.0,20170218.0,,,,142175022.0,1.0,HIV infection
14220900,142209001,1,I,201711.0,20171113.0,20171124,20171124,EXP,,US-GILEAD-2017-0305573,GILEAD,,83.0,YR,E,M,Y,,,20171124.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,142209001.0,DE,,,,,,,,,142209001.0,1.0,HIV infection
14244075,142440751,1,I,,20171121.0,20171201,20171201,EXP,,US-GILEAD-2017-0307133,GILEAD,,42.0,YR,A,M,Y,,,20171201.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder;Product use issue,142440751.0,DS,,,142440751.0,1.0,2002.0,,,,142440751.0,1.0,HIV infection
14249128,142491281,1,I,,20171127.0,20171204,20171204,EXP,,US-GILEAD-2017-0308083,GILEAD,,48.0,YR,A,F,Y,,,20171204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,142491281.0,OT,,,,,,,,,142491281.0,1.0,HIV infection
14254234,142542341,1,I,20170504.0,20171127.0,20171205,20171205,EXP,,ZA-GILEAD-2017-0307942,GILEAD,,26.0,YR,A,F,Y,,,20171205.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy;Ruptured ectopic pregnancy,142542341.0,OT,,,142542341.0,1.0,20170608.0,20170602.0,,,142542341.0,1.0,HIV infection
14265339,142653392,2,F,,20171212.0,20171208,20171227,EXP,,BR-MYLANLABS-2017M1075774,MYLAN,,,,,M,Y,,,20171217.0,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Spina bifida occulta,142653392.0,CA,,,142653392.0,1.0,20170517.0,20171111.0,,,142653392.0,1.0,HIV infection
14291328,142913282,2,F,20170120.0,20171215.0,20171215,20171221,EXP,,US-GILEAD-2017-0310773,GILEAD,,0.0,YR,N,M,Y,,,20171221.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital megaureter;Foetal exposure during pregnancy;Pyelocaliectasis;Single umbilical artery;Talipes,142913282.0,CA,,,142913282.0,1.0,20170120.0,20171012.0,,,142913282.0,1.0,HIV infection
14329498,143294981,1,I,,20171212.0,20171227,20171227,EXP,,US-MYLANLABS-2017M1080661,MYLAN,,46.0,YR,,M,Y,,,20171227.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myositis;Steatohepatitis,143294981.0,OT,,,,,,,,,143294981.0,1.0,Antiretroviral therapy
14332029,143320292,2,F,,20171218.0,20171228,20180109,EXP,,BR-MYLANLABS-2017M1078574,MYLAN,,,,,M,Y,3.13,KG,20180109.0,,CN,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Cryptorchism;Foetal exposure during pregnancy,143320292.0,OT,,,143320292.0,1.0,20170607.0,,,,143320292.0,1.0,HIV infection
14332216,143322161,1,I,20150714.0,20171227.0,20171228,20171228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-118823,BRISTOL MYERS SQUIBB,,34.0,YR,,M,Y,63.0,KG,20171228.0,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenic sepsis,143322161.0,LT,,,143322161.0,1.0,20150305.0,20150713.0,,,143322161.0,1.0,HIV infection
14385936,143859361,1,I,20141118.0,20180105.0,20180115,20180115,EXP,,GB-GILEAD-2018-0314495,GILEAD,,,,,F,Y,80.1,KG,20180115.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,143859361.0,HO,,,,,,,,,143859361.0,1.0,Antiretroviral therapy
14450746,144507461,1,I,,20180124.0,20180129,20180129,EXP,,US-GILEAD-2018-0317999,GILEAD,,62.0,YR,A,M,Y,,,20180129.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,144507461.0,DE,,,,,,,,,144507461.0,1.0,HIV infection
14459633,144596331,1,I,,20180124.0,20180130,20180130,EXP,,US-GILEAD-2018-0317976,GILEAD,,31.0,YR,A,M,Y,,,20180130.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Impaired work ability;Surgery,144596331.0,OT,,,,,,,,,144596331.0,1.0,HIV infection
14470002,144700021,1,I,2015.0,20180117.0,20180131,20180131,EXP,,GB-MYLANLABS-2018M1005555,MYLAN,,40.0,YR,,F,Y,,,20180122.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug prescribing error;Ectopic pregnancy with contraceptive device;Immunodeficiency;Internal haemorrhage;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Unintended pregnancy,144700021.0,LT,,,144700021.0,3.0,20130901.0,20160107.0,,,144700021.0,1.0,HIV infection
14482673,144826731,1,I,,20180129.0,20180203,20180203,EXP,,US-HETERO CORPORATE-HET2018US00083,HETERO,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE. J-INT-ASSOC-PROVID-AIDS-CARE. 2017;16(6):540-545",37.0,YR,,F,Y,,,20180203.0,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Coccidioidomycosis;Condition aggravated;Immune reconstitution inflammatory syndrome,144826731.0,OT,,,,,,,,,144826731.0,1.0,HIV infection
14494789,144947892,2,F,,20180123.0,20180206,20180216,EXP,,US-MYLANLABS-2018M1007325,MYLAN,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE. J-INT-ASSOC-PROVID-AIDS-CARE 2017;16(6):540-545.",37.0,YR,,F,Y,,,20180216.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Coccidioidomycosis;Immune reconstitution inflammatory syndrome;Infection,144947892.0,OT,,,,,,,,,144947892.0,1.0,HIV infection
14540463,145404631,1,I,20180209.0,20180210.0,20180216,20180216,EXP,,BR-GLAXOSMITHKLINE-BR2018GSK026499,GLAXOSMITHKLINE,,31.0,YR,,F,Y,,,20180216.0,,CN,US,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145404631.0,OT,,,145404631.0,1.0,20180103.0,20180103.0,,,145404631.0,1.0,HIV infection
14541015,145410151,1,I,20180209.0,20180210.0,20180216,20180216,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2018GSK026499,VIIV,,31.0,YR,,F,Y,,,20180216.0,,CN,US,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145410151.0,OT,,,145410151.0,1.0,20180103.0,20180103.0,,,145410151.0,1.0,HIV infection
14544345,145443453,3,F,20180209.0,20181121.0,20180216,20181202,EXP,,BR-ABBVIE-18P-020-2255672-00,ABBVIE,,31.0,YR,,F,Y,,,20181202.0,,OT,BR,BR,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145443453.0,OT,,,145443453.0,1.0,20180103.0,20180103.0,,,145443453.0,1.0,HIV infection
14544633,145446331,1,I,,20180210.0,20180217,20180217,EXP,,BR-HETERO CORPORATE-HET2018BR00111,HETERO,,31.0,YR,,F,Y,,,20180217.0,,OT,BR,BR,EFAVIRENZ+LAMIVUDINE+TENOFOVIR,Abortion spontaneous;Exposure during pregnancy,145446331.0,OT,,,145446331.0,1.0,20180103.0,20180103.0,,,145446331.0,1.0,HIV infection
14547748,145477481,1,I,20180209.0,20180209.0,20180219,20180219,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-014334,BRISTOL MYERS SQUIBB,,31.0,YR,,F,Y,,,20180219.0,,OT,BR,BR,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,145477481.0,OT,,,145477481.0,1.0,20180103.0,20180103.0,,,145477481.0,1.0,HIV infection
14554216,145542161,1,I,2012.0,20180215.0,20180220,20180220,EXP,,GB-GILEAD-2018-0321689,GILEAD,,,,,F,Y,,,20180220.0,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,145542161.0,OT,,,,,,,,,145542161.0,1.0,HIV infection
14555618,145556181,1,I,,20180212.0,20180221,20180221,EXP,,IN-HETERO CORPORATE-HET2018IN00127,HETERO,,31.0,YR,,M,Y,,,20180220.0,,OT,IN,IN,STAVUDINE+LAMIVUDINE+EFAVIRENZ,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,145556181.0,DE,,,,,,,,,145556181.0,1.0,HIV infection
14568246,145682462,2,F,20180209.0,20180821.0,20180223,20180831,EXP,,BR-CIPLA LTD.-2018BR06248,CIPLA,,,,,,Y,,,20180831.0,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Contraindicated product administered;Exposure during pregnancy,145682462.0,OT,,,145682462.0,1.0,20180103.0,20180103.0,,,145682462.0,1.0,HIV infection
14586226,145862262,2,F,20170606.0,20181121.0,20180301,20181207,EXP,,UG-MYLANLABS-2018M1012525,MYLAN,,26.0,YR,,F,Y,,,20181207.0,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Malaria;Maternal exposure during pregnancy;Stillbirth,145862262.0,OT,,,145862262.0,1.0,20170118.0,,,,145862262.0,1.0,HIV infection
14595397,145953971,1,I,,20170802.0,20180302,20180302,EXP,,US-GILEAD-2017-0287264,GILEAD,,49.0,YR,A,F,Y,,,20180302.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Back pain;Loss of consciousness;Pneumonia,145953971.0,OT,,,145953971.0,1.0,2017.0,,,,145953971.0,1.0,HIV infection
14598424,145984241,1,I,,20180219.0,20180305,20180305,EXP,,US-MYLANLABS-2018M1013573,MYLAN,"MORGAN MK, HARTZELL JD, BLAYLOCK JM. SEPSIS MIMICKER IN AN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENT. MIL-MED 2017;182:E1861-E1863.",22.0,YR,,M,Y,,,20180305.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Hypersensitivity;Hypotension,145984241.0,HO,,,,,,,,,145984241.0,1.0,HIV infection
14598555,145985551,1,I,,20180209.0,20180305,20180305,EXP,,BR-MYLANLABS-2018M1011927,MYLAN,,,,,M,Y,2.37,KG,20180305.0,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital skin dimples;Foetal exposure during pregnancy,145985551.0,CA,,,145985551.0,1.0,20170821.0,,,,145985551.0,1.0,HIV infection
14711220,147112201,1,I,,20180329.0,20180403,20180403,EXP,,US-GILEAD-2018-0330613,GILEAD,,24.0,YR,A,F,Y,,,20180403.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Disability,147112201.0,DS,,,147112201.0,1.0,20150202.0,,,,147112201.0,1.0,HIV infection
14776155,147761552,2,F,,20180411.0,20180418,20180420,EXP,,US-GILEAD-2018-0333115,GILEAD,,54.0,YR,A,M,Y,,,20180420.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Hip arthroplasty;Thrombosis,147761552.0,OT,,,147761552.0,2.0,2018.0,,,,147761552.0,1.0,HIV infection
14794849,147948491,1,I,,20180413.0,20180423,20180423,EXP,,FR-MYLANLABS-2018M1025689,MYLAN,,35.0,YR,,M,Y,,,20180423.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,No adverse event;Treatment failure,147948491.0,OT,,,,,,,,,147948491.0,1.0,HIV infection
14801460,148014602,2,F,20120101.0,20220617.0,20180424,20220622,EXP,,GB-MYLANLABS-2018M1025061,MYLAN,,59.0,YR,,F,Y,,,20220622.0,,CN,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,148014602.0,OT,,,,,,,,,148014602.0,1.0,HIV infection
14812908,148129081,1,I,,20180412.0,20180426,20180426,EXP,,US-CIPLA (EU) LIMITED-2018US16687,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016;1-21",,,,,Y,,,20180426.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Blood creatinine increased,148129081.0,OT,,,,,,,,,148129081.0,1.0,HIV infection
14819140,148191401,1,I,,20180206.0,20180427,20180427,EXP,,US-CIPLA LTD.-2018US05613,CIPLA,"MU A, SHEIN TT, JAYACHANDRAN P, PAUL S.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN PATIENTS WITH AIDS AND DISSEMINATED COCCIDIOIDOMYCOSIS: A CASE SERIES AND REVIEW OF THE LITERATURE.. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (6):540 TO 545",,,,,Y,,,20180427.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Alopecia;Coccidioidomycosis;Death;Immune reconstitution inflammatory syndrome;Nervous system disorder;Transaminases increased,148191401.0,OT,,,,,,,,,148191401.0,1.0,HIV infection
14819152,148191522,2,F,,20180622.0,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16723,CIPLA,"SAX PE, DEJESUS E, MILLS A, ZOLOPA A, COHEN C, WOHL D ET AL. CO?FORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR VERSUS CO?FORMULATED EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR FOR INITIAL TREATMENT OF HIV?1 INFECTION:A RANDOMISED, DOUBLE?BLIND, PHASE 3 TRIAL, ANALYSIS OF RESULTS AFTER 48 WEEKS. LANCET. 2012?379:2439?2448",,,,,Y,,,20180706.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Metastatic neoplasm,148191522.0,DE,,,,,,,,,148191522.0,1.0,HIV infection
14836583,148365833,3,F,201801.0,20180509.0,20180502,20180522,EXP,,ZA-CIPLA LTD.-2018ZA16946,CIPLA,,,,,,Y,,,20180522.0,,CN,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Liver injury;Musculoskeletal chest pain,148365833.0,OT,,,148365833.0,1.0,2013.0,,,,148365833.0,1.0,HIV infection
14881855,148818553,3,F,,20180614.0,20180511,20180806,PER,,US-009507513-1805USA003795,MERCK,,30.0,YR,,F,Y,,,20180806.0,,CN,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Maternal exposure during pregnancy,,,,,,,,,,,148818553.0,1.0,Antiretroviral therapy
14897500,148975003,3,F,20171103.0,20180525.0,20180515,20180604,EXP,,ZA-GILEAD-2018-0338320,GILEAD,,0.0,YR,N,M,Y,3.81,KG,20180604.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,148975003.0,OT,,,148975003.0,1.0,20171103.0,20171108.0,,,148975003.0,1.0,HIV infection
14920196,149201961,1,I,,20180514.0,20180521,20180521,EXP,,US-GILEAD-2018-0339129,GILEAD,,52.0,YR,A,M,Y,,,20180521.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Osteoporosis;Viral load increased,149201961.0,OT,,,,,,,,,149201961.0,1.0,HIV infection
14961910,149619104,4,F,,20191104.0,20180601,20191115,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17784,CIPLA,,,,,,Y,,,20191115.0,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619104.0,OT,,,,,,,,,149619104.0,1.0,HIV infection WHO clinical stage II
14961911,149619112,2,F,,20191104.0,20180601,20191118,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17786,CIPLA,,,,,,Y,,,20191118.0,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619112.0,OT,,,,,,,,,149619112.0,1.0,HIV infection WHO clinical stage IV
14994542,149945423,3,F,,20180626.0,20180611,20180630,PER,,BR-HETERO CORPORATE-HET2018BR00512,HETERO,,,,,F,Y,2.25,KG,20180630.0,,OT,BR,BR,EFAVIRENZ+LAMIVUDINE+TENOFOVIR DISOPROXIL FUM,Acrochordon;Foetal exposure during pregnancy,,,,,149945423.0,1.0,20171128.0,20180504.0,,,149945423.0,1.0,HIV infection
15013095,150130951,1,I,,20180604.0,20180614,20180614,EXP,,PT-GILEAD-2018-0343029,GILEAD,"LOUREIRO RV, COSTA MN, GERMANO I, CALINAS F. PSEUDORESISTANCE OF HEPATITIS B VIRUS TO TENOFOVIR WITH EMTRICITABINE. AIDS. 2018;32(10):1387-1388",52.0,YR,A,M,Y,,,20180614.0,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Drug ineffective for unapproved indication;Drug interaction;Genotype drug resistance test positive,150130951.0,OT,,,150130951.0,1.0,201206.0,,,,150130951.0,1.0,HIV infection
15046619,150466191,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0346525,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466191.0,OT,,,,,,,,,150466191.0,1.0,HIV infection
15046628,150466281,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0346527,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466281.0,OT,,,,,,,,,150466281.0,1.0,HIV infection
15046631,150466311,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0346526,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466311.0,OT,,,,,,,,,150466311.0,1.0,HIV infection
15046648,150466481,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0346529,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466481.0,OT,,,,,,,,,150466481.0,1.0,HIV infection
15046649,150466491,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0346528,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150466491.0,OT,,,,,,,,,150466491.0,1.0,HIV infection
15046740,150467401,1,I,,20180611.0,20180621,20180621,EXP,,IT-GILEAD-2018-0344332,GILEAD,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ZACCARELLI M, CARAMELLO P, COSTANTINI A, VISCOLI C, D?ARMINIO MONFORTE A, COZZI-LEPRI A. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE. 2018;UNK:DOI: 10.1111/HIV.12628",,,A,,Y,,,20180621.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,150467401.0,OT,,,,,,,,,150467401.0,1.0,HIV infection
15058934,150589342,2,F,,20200629.0,20180625,20200708,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018111756,VIIV,,52.0,YR,,M,Y,,,20200708.0,,HP,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective for unapproved indication;Drug interaction;Genotype drug resistance test positive;Infection,150589342.0,OT,,,,,,,,,150589342.0,1.0,HIV infection
15060764,150607641,1,I,20180115.0,20180613.0,20180625,20180625,EXP,,CA-MYLANLABS-2018M1043961,MYLAN,,44.0,YR,,M,Y,61.0,KG,20180620.0,,PH,CA,CA,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Drug ineffective,150607641.0,OT,,,150607641.0,1.0,20171117.0,,,,150607641.0,1.0,HIV infection
15103404,151034041,1,I,20180625.0,20180625.0,20180703,20180703,EXP,,BR-MYLANLABS-2018M1048343,MYLAN,,30.0,YR,,F,Y,,,20180703.0,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Abortion spontaneous;Maternal exposure during pregnancy,151034041.0,OT,,,151034041.0,1.0,20150110.0,,,,151034041.0,1.0,HIV infection
15112462,151124621,1,I,,20180627.0,20180705,20180705,EXP,,IT-GILEAD-2018-0347888,GILEAD,,,,A,,Y,,,20180705.0,,OT,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiotoxicity,151124621.0,OT,,,,,,,,,151124621.0,1.0,HIV infection
15120389,151203891,1,I,,20171023.0,20180709,20180709,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2017203843,VIIV,"BERARD A, ET AL.. ANTIRETROVIRAL COMBINATION USE DURING PREGNANCYAND THE RISK OF MAJOR CONGENITAL MALFORMATIONS.. AIDS.. 2017?31:2267?2277",,,N,,Y,,,20180709.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,151203891.0,OT,,,,,,,,,151203891.0,1.0,HIV infection
15120396,151203961,1,I,,20171023.0,20180709,20180709,EXP,,CA-GLAXOSMITHKLINE-CA2017203843,GLAXOSMITHKLINE,"BERARD A, ET AL.. ANTIRETROVIRAL COMBINATION USE DURING PREGNANCYAND THE RISK OF MAJOR CONGENITAL MALFORMATIONS.. AIDS.. 2017?31:2267?2277",,,N,,Y,,,20180709.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,151203961.0,OT,,,,,,,,,151203961.0,1.0,HIV infection
15127888,151278881,1,I,201803.0,20180709.0,20180710,20180710,EXP,,US-GILEAD-2018-0349380,GILEAD,,50.0,YR,A,M,Y,,,20180710.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,151278881.0,OT,,,,,,,,,151278881.0,1.0,HIV infection
15158165,1515816551,51,F,20100629.0,20230524.0,20180718,20230526,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43.0,YR,,F,Y,43.0,KG,20230526.0,,MD,GB,GB,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Drug abuse;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,1515816551.0,CA,,,1515816551.0,1.0,20100610.0,20180205.0,4.0,MON,1515816551.0,1.0,HIV infection
15169266,151692664,4,F,20160209.0,20180924.0,20180720,20180927,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-068119,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,67.3,KG,20180927.0,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Blood creatinine increased;Malaria,151692664.0,LT,,,151692664.0,1.0,20150527.0,20160208.0,,,151692664.0,1.0,Antiretroviral therapy
15190757,151907575,5,F,20151104.0,20180822.0,20180724,20180831,EXP,,MW-GILEAD-2018-0351189,GILEAD,,36.0,YR,A,M,Y,70.6,KG,20180831.0,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Carbon dioxide abnormal;Platelet count decreased;Transaminases increased,151907575.0,OT,,,151907575.0,1.0,20150305.0,20160323.0,,,151907575.0,1.0,Antiretroviral therapy
15190772,151907721,1,I,20160209.0,20180717.0,20180724,20180724,EXP,,MW-GILEAD-2018-0351226,GILEAD,,34.0,YR,A,M,Y,67.3,KG,20180724.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased,151907721.0,LT,,,151907721.0,1.0,20150527.0,20150916.0,,,151907721.0,1.0,Antiretroviral therapy
15217110,152171101,1,I,20141011.0,20180726.0,20180730,20180730,EXP,,ZA-GILEAD-2018-0352419,GILEAD,,28.0,YR,A,F,Y,,,20180730.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,152171101.0,OT,,,152171101.0,1.0,20140604.0,,,,152171101.0,1.0,HIV infection
15239551,152395511,1,I,20100210.0,20180720.0,20180803,20180803,EXP,,PT-MYLANLABS-2018M1057421,MYLAN,,27.0,YR,,M,Y,91.0,KG,20180802.0,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;No adverse event,152395511.0,OT,,,152395511.0,1.0,20100210.0,20100818.0,,,152395511.0,1.0,HIV infection
15265709,152657091,1,I,20150509.0,20180801.0,20180810,20180810,EXP,,ZA-GILEAD-2018-0353888,GILEAD,,34.0,YR,A,F,Y,,,20180810.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,152657091.0,OT,,,152657091.0,1.0,20140226.0,,,,152657091.0,1.0,HIV infection
15266069,152660691,1,I,,20180801.0,20180810,20180810,EXP,,BW-GILEAD-2018-0353848,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810.0,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152660691.0,OT,,,,,,,,,152660691.0,1.0,HIV infection
15266106,152661061,1,I,,20180801.0,20180810,20180810,EXP,,BW-GILEAD-2018-0355047,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810.0,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152661061.0,OT,,,,,,,,,152661061.0,1.0,HIV infection
15266110,152661101,1,I,,20180801.0,20180810,20180810,EXP,,BW-GILEAD-2018-0355048,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810.0,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152661101.0,OT,,,,,,,,,152661101.0,1.0,HIV infection
15273902,152739022,2,F,,20190408.0,20180813,20190411,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-040296",BOEHRINGER INGELHEIM,,,,,,Y,,,20190411.0,,OT,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOP,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,152739022.0,CA,,,,,,,,,152739022.0,1.0,HIV infection
15296511,152965111,1,I,,20180808.0,20180820,20180820,EXP,,US-MYLANLABS-2018M1061714,MYLAN,"SHAIKH B, SOHAIB M, ALSHANTTI R, BARRERA F, MURVELASHVILI N. A FAST END TO A SLOW DISEASE. J-CLIN-TRANSL-ENDOCRINOL-CASE-REP 2018;9:9-11.",50.0,YR,,M,Y,,,20180820.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bradycardia;Cardiac arrest;Electrocardiogram QT prolonged;Ventricular arrhythmia,152965111.0,DE,,,,,,,,,152965111.0,1.0,HIV infection
15297669,152976691,1,I,,20180816.0,20180820,20180820,EXP,,TW-GILEAD-2018-0357319,GILEAD,,40.0,YR,A,F,Y,,,20180820.0,,MD,TW,TW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypersensitivity;Insomnia;Osteoporosis,152976691.0,OT,,,,,,,,,152976691.0,1.0,HIV infection
15299845,152998452,2,F,,20180813.0,20180821,20180827,EXP,,US-HETERO CORPORATE-HET2018US00806,HETERO,"SHAIKH B, SOHAIB M, ALSHANTTI R, BARRERA F, MURVELASHVILI N.. A FAST END TO A SLOW DISEASE.. J?CLIN?TRANSL?ENDOCRINOL?CASE?REP. 2018?9?11",50.0,YR,,M,Y,,,20180823.0,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Myxoedema coma,152998452.0,OT,,,,,,,,,152998452.0,1.0,HIV infection
15330805,153308052,2,F,,20180824.0,20180829,20180906,EXP,,BR-MYLANLABS-2018M1063732,MYLAN,,,,,M,Y,3.52,KG,20180906.0,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Foetal exposure during pregnancy;Hydrocele,153308052.0,OT,,,153308052.0,1.0,20150601.0,,,,153308052.0,1.0,HIV infection
15376017,153760171,1,I,,20180906.0,20180912,20180912,EXP,,US-GILEAD-2018-0361988,GILEAD,,37.0,YR,A,M,Y,,,20180912.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder,153760171.0,HO,,,153760171.0,1.0,20150429.0,,,,153760171.0,1.0,HIV infection
15435619,154356192,2,F,20150708.0,20181005.0,20180927,20181009,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-047172,BRISTOL MYERS SQUIBB,,35.0,YR,,M,Y,59.1,KG,20181009.0,,CN,US,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neutropenia;Pneumonia bacterial,154356192.0,DE,,,154356192.0,1.0,20150324.0,20160201.0,,,154356192.0,1.0,Kaposi's sarcoma AIDS related
15493462,154934622,2,F,20150708.0,20181012.0,20181012,20181031,EXP,,MW-GILEAD-2015-0163489,GILEAD,,35.0,YR,A,M,Y,60.4,KG,20181031.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aspartate aminotransferase increased;Kaposi's sarcoma;Pneumonia bacterial,154934622.0,OT,,,154934622.0,1.0,20150324.0,20150324.0,,,154934622.0,1.0,Kaposi's sarcoma AIDS related
15507656,155076561,1,I,,20181010.0,20181016,20181016,EXP,,US-GILEAD-2018-0368492,GILEAD,,56.0,YR,A,F,Y,,,20181016.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,CD4 lymphocytes decreased;Drug ineffective;Viral load increased,155076561.0,OT,,,,,,,,,155076561.0,1.0,HIV infection
15527156,155271562,2,F,20181001.0,20181027.0,20181020,20181105,EXP,,ZA-AUROBINDO-AUR-APL-2018-051204,AUROBINDO,,43.0,YR,,F,Y,,,20181105.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Exposure during pregnancy;Foetal death,155271562.0,OT,,,155271562.0,1.0,20140101.0,,,,155271562.0,1.0,HIV infection
15530658,155306581,1,I,,20181012.0,20181018,20181018,EXP,,US-GILEAD-2018-0369027,GILEAD,,49.0,YR,A,M,Y,,,20181018.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Product use issue,155306581.0,OT,,,155306581.0,1.0,2007.0,,,,155306581.0,1.0,HIV infection
15530756,155307562,2,F,20151021.0,20181018.0,20181018,20181025,EXP,,MW-GILEAD-2018-0368297,GILEAD,,31.0,YR,A,M,Y,,,20181025.0,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,155307562.0,OT,,,155307562.0,1.0,20150527.0,20151020.0,,,155307562.0,1.0,Kaposi's sarcoma AIDS related
15576131,155761311,1,I,,20181026.0,20181101,20181101,EXP,,FR-MYLANLABS-2018M1081787,MYLAN,,43.0,YR,,F,Y,,,20181101.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,155761311.0,OT,,,,,,,,,155761311.0,1.0,HIV infection
15590305,155903051,1,I,,20181029.0,20181106,20181106,EXP,,FR-MYLANLABS-2018M1082415,MYLAN,,27.0,YR,,F,Y,,,20181101.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,155903051.0,OT,,,,,,,,,155903051.0,1.0,HIV infection
15597106,155971061,1,I,,20181029.0,20181108,20181108,EXP,,UG-HETERO CORPORATE-HET2018UG01164,HETERO,"MAHSA ABASSI, JOSHUA RHEIN, DAVID B. MEYA, AND DAVID R. BOULWARE. CRYPTOCOCCAL DISEASE IN THE ERA OF ?TEST AND TREAT?: IS THERE CAUSE FOR CONCERN?. OPEN FORUM INFECTIOUS DISEASES. 2018;5(1)",45.0,YR,,M,Y,,,20181108.0,,OT,UG,UG,Efavirenz+Lamivudine+Tenofovir,Condition aggravated;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,155971061.0,OT,,,,,,,,,155971061.0,1.0,HIV infection
15603654,156036542,2,F,20180115.0,20181213.0,20181109,20181218,EXP,,FR-MYLANLABS-2018M1084620,MYLAN,,53.0,YR,,F,Y,76.0,KG,20181218.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gene mutation identification test positive;Treatment failure;Virologic failure,156036542.0,OT,,,156036542.0,1.0,20100120.0,20180215.0,,,156036542.0,1.0,HIV infection
15606261,156062611,1,I,,20181105.0,20181112,20181112,EXP,,MW-HETERO CORPORATE-HET2018MW01308,HETERO,"ELLIS JP, KALATA N, JOEKES EC, KAMPONDENI S, BENJAMIN LA, HARRISON TS, ET AL.. ISCHEMIC STROKE AS A COMPLICATION OF CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CASE REPORT 11 MEDICAL AND HEALTH SCIENCES 1103 CLINICAL SCIENCES.. BMC-INFECT-DIS. 2018;18(1):520",38.0,YR,,M,Y,,,20181112.0,,OT,MW,MW,Efavirenz+Lamivudine+Tenofovir,Central nervous system vasculitis;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke,156062611.0,OT,,,,,,,,,156062611.0,1.0,HIV infection
15607511,156075111,1,I,,20181031.0,20181112,20181112,EXP,,MW-MYLANLABS-2018M1084000,MYLAN,"ELLIS JP, KALATA N, JOEKES EC, KAMPONDENI S, BENJAMIN LA, HARRISON TS, ET AL. ISCHEMIC STROKE AS A COMPLICATION OF CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: A CASE REPORT 11 MEDICAL AND HEALTH SCIENCES 1103 CLINICAL SCIENCES. BMC-INFECT-DIS 2018;18(1):520.",38.0,YR,,M,Y,,,20181112.0,,OT,MW,MW,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Central nervous system vasculitis;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke;Paradoxical drug reaction,156075111.0,HO,,,,,,,,,156075111.0,1.0,HIV infection
15609108,156091083,3,F,2018.0,20190129.0,20181112,20190205,EXP,,UG-MYLANLABS-2018M1084907,MYLAN,,,,,F,Y,3.8,KG,20190205.0,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy;Sepsis neonatal;Umbilical granuloma,156091083.0,OT,,,156091083.0,1.0,20180518.0,,,,156091083.0,1.0,HIV infection
15609119,156091191,1,I,20180831.0,20181102.0,20181112,20181112,EXP,,UG-MYLANLABS-2018M1084914,MYLAN,,31.0,YR,,F,Y,,,20181111.0,,CN,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Stillbirth,156091191.0,OT,,,,,,,,,156091191.0,1.0,HIV infection
15617422,156174223,3,F,,20190131.0,20181114,20190208,EXP,,UG-MYLANLABS-2018M1086638,MYLAN,,,,,F,Y,2.93,KG,20190208.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174223.0,CA,,,156174223.0,1.0,20180510.0,,,,156174223.0,1.0,HIV infection
15617481,156174813,3,F,,20190205.0,20181114,20190219,EXP,,UG-MYLANLABS-2018M1086627,MYLAN,,,,N,F,Y,,,20190219.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174813.0,OT,,,156174813.0,1.0,20180510.0,,,,156174813.0,1.0,HIV infection
15617825,156178252,2,F,2018.0,20181214.0,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086708,MYLAN,,,,,M,Y,3.0,KG,20181226.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156178252.0,CA,,,156178252.0,1.0,20180524.0,,,,156178252.0,1.0,HIV infection
15617826,156178261,1,I,,20181107.0,20181114,20181114,EXP,,UG-MYLANLABS-2018M1086661,MYLAN,,,,,M,Y,2.6,KG,20181114.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156178261.0,OT,,,156178261.0,1.0,20180523.0,,,,156178261.0,1.0,HIV infection
15617827,156178272,2,F,,20181214.0,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086680,MYLAN,,,,N,M,Y,3.0,KG,20181226.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Birth mark;Congenital umbilical hernia;Conjunctivitis bacterial;Foetal exposure during pregnancy;Sepsis neonatal,156178272.0,CA,,,156178272.0,1.0,20180409.0,,,,156178272.0,1.0,HIV infection
15617828,156178282,2,F,2018.0,20181214.0,20181114,20181226,EXP,,UG-MYLANLABS-2018M1086699,MYLAN,,,,N,M,Y,,,20181226.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156178282.0,OT,,,156178282.0,1.0,20180516.0,,,,156178282.0,1.0,HIV infection
15618298,156182983,3,F,2018.0,20190201.0,20181114,20190211,EXP,,UG-MYLANLABS-2018M1086636,MYLAN,,0.0,YR,,F,Y,,,20190211.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Foetal exposure during pregnancy;Premature baby;Talipes,156182983.0,CA,,,156182983.0,1.0,20180521.0,,,,156182983.0,1.0,HIV infection
15621334,156213342,2,F,2018.0,20190815.0,20181115,20190819,EXP,,UG-MYLANLABS-2018M1086709,MYLAN,,,,,M,Y,2.93,KG,20190819.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156213342.0,OT,,,156213342.0,1.0,20180417.0,,,,156213342.0,1.0,HIV infection
15621336,156213363,3,F,2018.0,20190501.0,20181115,20190513,EXP,,UG-MYLANLABS-2018M1086706,MYLAN,,,,,M,Y,3.5,KG,20190513.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213363.0,OT,,,156213363.0,1.0,20180709.0,,,,156213363.0,1.0,HIV infection
15621343,156213432,2,F,2018.0,20190131.0,20181115,20190208,EXP,,UG-MYLANLABS-2018M1086698,MYLAN,,0.0,YR,,M,Y,,,20190208.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213432.0,OT,,,156213432.0,1.0,20180412.0,,,,156213432.0,1.0,HIV infection
15621345,156213452,2,F,2018.0,20181214.0,20181115,20181220,EXP,,UG-MYLANLABS-2018M1086697,MYLAN,,0.0,YR,,M,Y,3.2,KG,20181220.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213452.0,OT,,,156213452.0,1.0,20180522.0,,,,156213452.0,1.0,HIV infection
15621346,156213462,2,F,2018.0,20181214.0,20181115,20181226,EXP,,UG-MYLANLABS-2018M1086705,MYLAN,,,,N,M,Y,2.7,KG,20181226.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213462.0,OT,,,156213462.0,1.0,20180523.0,,,,156213462.0,1.0,HIV infection
15621559,156215593,3,F,2018.0,20190205.0,20181115,20190218,EXP,,UG-MYLANLABS-2018M1086624,MYLAN,,,,N,F,Y,3.5,KG,20190218.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156215593.0,CA,,,156215593.0,1.0,20180404.0,,,,156215593.0,1.0,HIV infection
15622123,156221233,3,F,2018.0,20190823.0,20181115,20190828,EXP,,UG-MYLANLABS-2018M1086992,MYLAN,,,,N,M,Y,4.2,KG,20190828.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221233.0,CA,,,156221233.0,1.0,20180406.0,,,,156221233.0,1.0,HIV infection
15622136,156221364,4,F,2018.0,20190823.0,20181115,20190828,EXP,,UG-MYLANLABS-2018M1086990,MYLAN,,0.0,YR,,F,Y,3.0,KG,20190828.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221364.0,CA,,,156221364.0,1.0,20180412.0,,,,156221364.0,1.0,HIV infection
15622137,156221371,1,I,,20181109.0,20181115,20181115,EXP,,UG-MYLANLABS-2018M1086682,MYLAN,,,,I,F,Y,3.2,KG,20181115.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221371.0,OT,,,156221371.0,1.0,20180607.0,,,,156221371.0,1.0,HIV infection
15622838,156228382,2,F,2018.0,20181214.0,20181115,20181220,EXP,,UG-MYLANLABS-2018M1086642,MYLAN,,0.0,YR,,F,Y,2.7,KG,20181220.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156228382.0,OT,,,156228382.0,1.0,20180619.0,,,,156228382.0,1.0,HIV infection
15622930,156229303,3,F,2018.0,20190205.0,20181115,20190218,EXP,,UG-MYLANLABS-2018M1086629,MYLAN,,,,,M,Y,3.13,KG,20190218.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156229303.0,OT,,,156229303.0,1.0,20180328.0,,,,156229303.0,1.0,HIV infection
15626107,156261072,2,F,2018.0,20181214.0,20181116,20181226,EXP,,UG-MYLANLABS-2018M1086700,MYLAN,,,,N,M,Y,,,20181226.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156261072.0,CA,,,156261072.0,1.0,20180626.0,,,,156261072.0,1.0,HIV infection
15627005,156270054,4,F,2018.0,20190129.0,20181116,20190205,EXP,,UG-MYLANLABS-2018M1087001,MYLAN,,,,N,M,Y,3.21,KG,20190205.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy;Polydactyly,156270054.0,CA,,,156270054.0,1.0,20180605.0,,,,156270054.0,1.0,HIV infection
15627054,156270542,2,F,2018.0,20181214.0,20181116,20181220,EXP,,UG-MYLANLABS-2018M1086694,MYLAN,,,,,F,Y,3.11,KG,20181220.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156270542.0,CA,,,156270542.0,1.0,20180604.0,,,,156270542.0,1.0,HIV infection
15628175,156281752,2,F,2018.0,20190820.0,20181116,20190826,EXP,,UG-MYLANLABS-2018M1086989,MYLAN,,,,I,F,Y,,,20190826.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156281752.0,CA,,,156281752.0,1.0,20180607.0,,,,156281752.0,1.0,HIV infection
15629934,156299343,3,F,,20190815.0,20181117,20190820,EXP,,UG-MYLANLABS-2018M1086681,MYLAN,,,,,M,Y,2.8,KG,20190820.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156299343.0,OT,,,156299343.0,1.0,20180503.0,,,,156299343.0,1.0,HIV infection
15636953,156369531,1,I,,20181107.0,20181120,20181120,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018GSK209110,VIIV,"CARDOSO M, BAPTISTA T,  DIOGO I,  ALEIXO MJ, MARQUES N, MANSINHO K. ET AL. TWO CASES OF DOLUTEGRAVIR FAILURE WITH R263K MUTATION. AIDS. 2018;32:2639-2642",29.0,YR,,F,Y,,,20181120.0,,OT,PT,PT,EFAVIRENZ + EMTRICITABINA + TENOFOVIR DISOPROXIL,Exposure during pregnancy;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,156369531.0,OT,,,,,,,,,156369531.0,1.0,HIV infection
15644174,156441741,1,I,,20181119.0,20181121,20181121,EXP,,US-GILEAD-2018-0375281,GILEAD,,52.0,YR,A,M,Y,,,20181121.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pain;Varicose vein,156441741.0,HO,,,156441741.0,1.0,201406.0,,,,156441741.0,1.0,HIV infection
15647145,156471451,1,I,,20181112.0,20181122,20181122,EXP,,MW-AUROBINDO-AUR-APL-2018-055640,AUROBINDO,,38.0,YR,,M,Y,,,20181122.0,,OT,MW,MW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Asthenia;Central nervous system vasculitis;Headache;Hemiparesis;Immune reconstitution inflammatory syndrome;Ischaemic stroke;Pyrexia,156471451.0,OT,,,,,,,,,156471451.0,1.0,Antiretroviral therapy
15660781,156607811,1,I,2018.0,20181121.0,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087718,MYLAN,,,,,M,Y,2.6,KG,20181127.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156607811.0,CA,,,156607811.0,1.0,20180523.0,,,,156607811.0,1.0,HIV infection
15660783,156607831,1,I,2018.0,20181121.0,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087713,MYLAN,,,,,M,Y,3.21,KG,20181127.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy;Polydactyly,156607831.0,CA,,,156607831.0,1.0,20180605.0,2018.0,,,156607831.0,1.0,HIV infection
15661847,156618471,1,I,2018.0,20181121.0,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087721,MYLAN,,,,,F,Y,3.0,KG,20181127.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156618471.0,CA,,,156618471.0,1.0,20180412.0,2018.0,,,156618471.0,1.0,HIV infection
15662329,156623291,1,I,2018.0,20181121.0,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087719,MYLAN,,,,,M,Y,3.2,KG,20181127.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156623291.0,CA,,,156623291.0,1.0,20180626.0,20180814.0,,,156623291.0,1.0,HIV infection
15662452,156624521,1,I,201801.0,20181120.0,20181127,20181127,EXP,,US-GILEAD-2018-0375490,GILEAD,,69.0,YR,E,M,Y,,,20181127.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ocular neoplasm;Product use issue,156624521.0,OT,,,,,,,,,156624521.0,1.0,HIV infection
15662513,156625131,1,I,2018.0,20181114.0,20181127,20181127,EXP,,UG-MYLANLABS-2018M1087644,MYLAN,,,,,F,Y,3.2,KG,20181127.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Congenital umbilical hernia;Foetal exposure during pregnancy,156625131.0,OT,,,156625131.0,1.0,20180607.0,,,,156625131.0,1.0,HIV infection
15669630,156696301,1,I,2018.0,20181114.0,20181129,20181129,EXP,,UG-MYLANLABS-2018M1087639,MYLAN,,,,I,F,Y,2.7,KG,20181129.0,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156696301.0,CA,,,156696301.0,1.0,20180619.0,,,,156696301.0,1.0,HIV infection
15677872,156778721,1,I,,20181127.0,20181130,20181130,EXP,,US-GILEAD-2018-0377165,GILEAD,,73.0,YR,E,M,Y,,,20181130.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Breast neoplasm,156778721.0,OT,,,,,,,,,156778721.0,1.0,HIV infection
15678006,156780061,1,I,2018.0,20181115.0,20181130,20181130,EXP,,UG-MYLANLABS-2018M1089888,MYLAN,,,,,F,Y,2.4,KG,20181130.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Foetal exposure during pregnancy;Talipes,156780061.0,CA,,,156780061.0,1.0,20180521.0,,,,156780061.0,1.0,HIV infection
15682068,156820681,1,I,20180503.0,20181108.0,20181203,20181203,EXP,,UG-MYLANLABS-2018M1089629,MYLAN,,0.0,YR,,M,Y,2.8,KG,20181203.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156820681.0,CA,,,156820681.0,1.0,20180503.0,,,,156820681.0,1.0,HIV infection
15696292,156962921,1,I,,20181123.0,20181206,20181206,EXP,,PK-MYLANLABS-2018M1088855,MYLAN,"TARIQ U, PARVEEN A, AKHTAR F, MAHMOOD F, ALI S, ABIDI SH. EMERGENCE OF CIRCULATING RECOMBINANT FORM 56-CPX IN PAKISTAN. AIDS-RES-HUM-RETROVIRUSES 2018;34(11):1002-1004.",29.0,YR,,M,Y,,,20181206.0,,OT,PK,PK,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Therapeutic response decreased,156962921.0,OT,,,,,,,,,156962921.0,1.0,HIV infection
15711389,157113891,1,I,,20181207.0,20181211,20181211,EXP,,FR-MYLANLABS-2018M1091785,MYLAN,,44.0,YR,,M,Y,,,20181211.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,157113891.0,OT,,,,,,,,,157113891.0,1.0,HIV infection
15722987,157229871,1,I,,20181210.0,20181214,20181214,EXP,,FR-MYLANLABS-2018M1092827,MYLAN,,23.0,YR,,M,Y,,,20181214.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,157229871.0,OT,,,,,,,,,157229871.0,1.0,HIV infection
15730076,157300763,3,F,20180309.0,20190114.0,20181217,20190122,EXP,,ZA-GILEAD-2018-0380355,GILEAD,,0.0,YR,N,M,Y,3.84,KG,20190122.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus,157300763.0,CA,,,157300763.0,1.0,20180309.0,20180504.0,,,157300763.0,1.0,HIV infection
15732856,157328562,2,F,201810.0,20190501.0,20181217,20190510,EXP,,ZA-MYLANLABS-2018M1093652,MYLAN,,,,,M,Y,0.83,KG,20190510.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Intraventricular haemorrhage neonatal;Neonatal respiratory distress syndrome;Premature separation of placenta,157328562.0,OT,,,157328562.0,1.0,20181003.0,,,,157328562.0,1.0,HIV infection
15736184,157361843,3,F,20180531.0,20190114.0,20181218,20190122,EXP,,ZA-GILEAD-2018-0380804,GILEAD,,0.0,YR,N,F,Y,3.42,KG,20190122.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157361843.0,OT,,,157361843.0,1.0,20180531.0,20180914.0,,,157361843.0,1.0,HIV infection
15737050,157370503,3,F,20180405.0,20190115.0,20181218,20190122,EXP,,ZA-GILEAD-2018-0380717,GILEAD,,,,N,M,Y,1.85,KG,20190122.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157370503.0,CA,,,157370503.0,1.0,20180405.0,20180408.0,,,157370503.0,1.0,HIV infection
15740581,157405814,4,F,20180405.0,20190118.0,20181219,20190122,EXP,,ZA-GILEAD-2018-0380549,GILEAD,,26.0,YR,A,F,Y,,,20190122.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature delivery,157405814.0,OT,,,157405814.0,1.0,20180405.0,,,,157405814.0,1.0,HIV infection
15740770,157407704,4,F,20180412.0,20190131.0,20181219,20190228,EXP,,ZA-GILEAD-2018-0380807,GILEAD,,0.0,YR,N,M,Y,4.0,KG,20190228.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157407704.0,CA,,,157407704.0,1.0,20180412.0,,,,157407704.0,1.0,HIV infection
15744828,157448281,1,I,,20181217.0,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094534,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET.AL.. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE. 2018",,,A,,Y,,,20181220.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448281.0,OT,,,,,,,,,157448281.0,1.0,HIV infection
15744833,157448331,1,I,,20181217.0,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094530,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET.AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE.. 2018",,,A,,Y,,,20181220.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448331.0,OT,,,,,,,,,157448331.0,1.0,HIV infection
15744865,157448651,1,I,,20181217.0,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094495,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S ET AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON. HIV MEDICINE.. HIV MEDICINE. 2018",,,A,,Y,,,20181220.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157448651.0,OT,,,,,,,,,157448651.0,1.0,HIV infection
15745897,157458973,3,F,20180320.0,20181224.0,20181220,20190122,EXP,,ZA-GILEAD-2018-0380946,GILEAD,,0.0,YR,N,M,Y,3.66,KG,20190122.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,157458973.0,CA,,,157458973.0,1.0,20180320.0,20180702.0,,,157458973.0,1.0,HIV infection
15746215,157462152,2,F,,20190206.0,20181220,20190213,EXP,,ZA-MYLANLABS-2018M1094943,MYLAN,,,,N,F,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157462152.0,OT,,,157462152.0,1.0,20180531.0,,,,157462152.0,1.0,HIV infection
15746229,157462291,1,I,,20181217.0,20181220,20181220,EXP,,IT-MYLANLABS-2018M1094526,MYLAN,"TARAMASSO L, DI BIAGIO A, MAGGIOLO F, TAVELLI A, LO CAPUTO S, BONORA S, ET,AL. FIRST-LINE ANTIRETROVIRAL THERAPY WITH EFAVIRENZ PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE OR RILPIVIRINE PLUS TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE: A DURABILITY COMPARISON.. HIV MEDICINE.. 2018",,,A,,Y,,,20181220.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,157462291.0,OT,,,,,,,,,157462291.0,1.0,HIV infection
15747640,157476401,1,I,,20181218.0,20181220,20181220,EXP,,US-GILEAD-2018-0380897,GILEAD,,47.0,YR,A,F,Y,,,20181220.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Fat tissue increased;Hysterectomy,157476401.0,HO,,,157476401.0,1.0,1992.0,,,,157476401.0,1.0,HIV infection
15751682,157516821,1,I,20180208.0,20181217.0,20181221,20181221,EXP,,ZA-GILEAD-2018-0381235,GILEAD,,0.0,YR,N,M,Y,4.02,KG,20181221.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,157516821.0,CA,,,157516821.0,1.0,20180208.0,,,,157516821.0,1.0,HIV infection
15751695,157516953,3,F,,20181224.0,20181221,20190311,EXP,,ZA-GILEAD-2018-0381253,GILEAD,,,,N,F,Y,3.28,KG,20190311.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157516953.0,CA,,,157516953.0,1.0,20180524.0,,,,157516953.0,1.0,HIV infection
15763590,157635902,2,F,,20190115.0,20181227,20190117,EXP,,ZA-GILEAD-2018-0381712,GILEAD,,,,N,F,Y,2.86,KG,20190117.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157635902.0,CA,,,157635902.0,1.0,20180614.0,,,,157635902.0,1.0,HIV infection
15763598,157635983,3,F,20180629.0,20190114.0,20181227,20190118,EXP,,ZA-GILEAD-2018-0381700,GILEAD,,0.0,YR,N,M,Y,3.44,KG,20190118.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157635983.0,OT,,,157635983.0,1.0,20180629.0,20180811.0,,,157635983.0,1.0,HIV infection
15766913,157669133,3,F,,20190114.0,20181227,20190117,EXP,,IT-MYLANLABS-2018M1095303,MYLAN,,,,A,,Y,,,20190117.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiotoxicity;Toxicity to various agents,157669133.0,OT,,,,,,,,,157669133.0,1.0,HIV infection
15767049,157670493,3,F,,20190114.0,20181227,20190125,EXP,,IT-MYLANLABS-2018M1095299,MYLAN,,,,A,,Y,,,20190125.0,,MD,IT,IT,EFAVIRENZ.;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Cardiotoxicity;Drug intolerance;Lipodystrophy acquired,157670493.0,OT,,,,,,,,,157670493.0,1.0,HIV infection
15767297,157672971,1,I,201112.0,20181220.0,20181227,20181227,EXP,,GB-GILEAD-2018-0381479,GILEAD,,,,A,M,Y,,,20181227.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Osteoporosis,157672971.0,OT,,,157672971.0,1.0,201112.0,201810.0,,,157672971.0,1.0,HIV infection
15773439,157734392,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382250,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734392.0,OT,,,,,,,,,157734392.0,1.0,HIV infection
15773441,157734412,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382549,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734412.0,OT,,,,,,,,,157734412.0,1.0,HIV infection
15773442,157734422,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382539,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734422.0,OT,,,,,,,,,157734422.0,1.0,HIV infection
15773443,157734432,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382538,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734432.0,OT,,,,,,,,,157734432.0,1.0,HIV infection
15773444,157734442,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382512,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734442.0,OT,,,,,,,,,157734442.0,1.0,HIV infection
15773446,157734462,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382511,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734462.0,OT,,,,,,,,,157734462.0,1.0,HIV infection
15773452,157734522,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382510,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734522.0,OT,,,,,,,,,157734522.0,1.0,HIV infection
15773453,157734533,3,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382509,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734533.0,OT,,,,,,,,,157734533.0,1.0,HIV infection
15773463,157734632,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382550,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734632.0,OT,,,,,,,,,157734632.0,1.0,HIV infection
15773464,157734643,3,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382523,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734643.0,OT,,,,,,,,,157734643.0,1.0,HIV infection
15773465,157734652,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382527,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734652.0,OT,,,,,,,,,157734652.0,1.0,HIV infection
15773466,157734662,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382541,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734662.0,OT,,,,,,,,,157734662.0,1.0,HIV infection
15773467,157734672,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382524,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734672.0,OT,,,,,,,,,157734672.0,1.0,HIV infection
15773468,157734682,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382537,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734682.0,OT,,,,,,,,,157734682.0,1.0,HIV infection
15773469,157734692,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382525,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734692.0,OT,,,,,,,,,157734692.0,1.0,HIV infection
15773470,157734702,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382551,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734702.0,OT,,,,,,,,,157734702.0,1.0,HIV infection
15773471,157734712,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382526,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734712.0,OT,,,,,,,,,157734712.0,1.0,HIV infection
15773482,157734822,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382508,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734822.0,OT,,,,,,,,,157734822.0,1.0,HIV infection
15773483,157734832,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382540,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734832.0,OT,,,,,,,,,157734832.0,1.0,HIV infection
15773484,157734842,2,F,,20190205.0,20181228,20190213,EXP,,ZA-GILEAD-2018-0382548,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734842.0,OT,,,,,,,,,157734842.0,1.0,HIV infection
15779141,157791414,4,F,,20190201.0,20190101,20190211,EXP,,ZA-MYLANLABS-2018M1095419,MYLAN,,,,N,F,Y,3.28,KG,20190211.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157791414.0,CA,,,157791414.0,1.0,20180524.0,,,,157791414.0,1.0,HIV infection
15780547,157805471,1,I,,20181217.0,20190102,20190102,EXP,,ZA-MYLANLABS-2018M1095422,MYLAN,,,,,M,Y,,,20190101.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,157805471.0,CA,,,157805471.0,1.0,20180208.0,,,,157805471.0,1.0,HIV infection
15796694,157966942,2,F,,20181228.0,20190108,20190108,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-122768,BRISTOL MYERS SQUIBB,,39.0,YR,,M,Y,,,20190108.0,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Immune reconstitution inflammatory syndrome;Psoriasis,157966942.0,OT,,,,,,,,,157966942.0,1.0,HIV infection
15813826,158138262,2,F,,20190108.0,20190111,20190121,EXP,,CA-MYLANLABS-2019M1002112,MYLAN,,44.0,YR,,M,Y,61.0,KG,20190121.0,,PH,CA,CA,Mylan-Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Drug ineffective,158138262.0,OT,,,,,,,,,158138262.0,1.0,HIV infection
15835920,158359204,4,F,,20220304.0,20190117,20220317,EXP,,ZA-AUROBINDO-AUR-APL-2019-001256,AUROBINDO,,,,I,M,Y,4.0,KG,20220317.0,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Strabismus congenital,158359204.0,CA,,,158359204.0,1.0,20180208.0,,,,158359204.0,1.0,HIV infection
15836280,158362804,4,F,,20220304.0,20190117,20220317,EXP,,ZA-AUROBINDO-AUR-APL-2019-001293,AUROBINDO,,,,,M,Y,4.0,KG,20220317.0,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,158362804.0,CA,,,158362804.0,1.0,20180208.0,,,,158362804.0,1.0,HIV infection
15836338,158363383,3,F,,20190128.0,20190117,20190208,EXP,,ZA-AUROBINDO-AUR-APL-2019-001255,AUROBINDO,,,,,,Y,,,20190208.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital acrochordon;Foetal exposure during pregnancy,158363383.0,CA,,,158363383.0,1.0,20180524.0,,,,158363383.0,1.0,HIV infection
15836406,158364063,3,F,,20190206.0,20190117,20190218,EXP,,ZA-AUROBINDO-AUR-APL-2019-001288,AUROBINDO,,,,,,Y,,,20190219.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy,158364063.0,CA,,,158364063.0,1.0,20180531.0,,,,158364063.0,1.0,HIV infection
15836618,158366182,2,F,,20190115.0,20190117,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001251,AUROBINDO,,,,,M,Y,1.8,KG,20190129.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158366182.0,OT,,,158366182.0,1.0,20180405.0,,,,158366182.0,1.0,HIV infection
15839001,158390011,1,I,,20181212.0,20190117,20190117,EXP,,ZA-GILEAD-2018-0380353,GILEAD,,,,I,M,Y,33.3,KG,20190117.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hernia congenital,158390011.0,CA,,,158390011.0,1.0,20180307.0,,,,158390011.0,1.0,HIV infection
15847615,158476152,2,F,,20190121.0,20190121,20190203,EXP,,TZ-AUROBINDO-AUR-APL-2019-001287,AUROBINDO,,,,,M,Y,2.3,KG,20190204.0,,MD,TZ,TZ,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Foetal exposure during pregnancy;Haemangioma,158476152.0,CA,,,158476152.0,1.0,20180510.0,20180516.0,,,158476152.0,1.0,HIV infection
15847693,158476932,2,F,,20190115.0,20190121,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001247,AUROBINDO,,42.0,WK,,M,Y,3.6,KG,20190129.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,158476932.0,CA,,,158476932.0,1.0,20180320.0,,,,158476932.0,1.0,HIV infection
15856736,158567362,2,F,,20190121.0,20190123,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-002466,AUROBINDO,,,,,,Y,,,20190202.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Foetal exposure during pregnancy;Hernia congenital,158567362.0,OT,,,158567362.0,1.0,20180307.0,,,,158567362.0,1.0,HIV infection
15866879,158668792,2,F,,20190121.0,20190125,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-002420,AUROBINDO,,,,,,Y,,,20190202.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Foetal exposure during pregnancy;Strabismus,158668792.0,CA,,,158668792.0,1.0,20180309.0,,,,158668792.0,1.0,HIV infection
15882518,158825182,2,F,,20190115.0,20190129,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001283,AUROBINDO,,,,,F,Y,2.8,KG,20190129.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158825182.0,OT,,,158825182.0,1.0,20180614.0,,,,158825182.0,1.0,HIV infection
15903849,159038493,3,F,,20190207.0,20190204,20190213,EXP,,ZA-AUROBINDO-AUR-APL-2019-005752,AUROBINDO,,,,,,Y,,,20190213.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital acrochordon;Foetal exposure during pregnancy,159038493.0,CA,,,159038493.0,1.0,20180412.0,,,,159038493.0,1.0,HIV infection
15906784,159067841,1,I,20181215.0,20190124.0,20190204,20190204,EXP,,KE-GILEAD-2019-0387226,GILEAD,,66.0,YR,E,F,Y,54.6,KG,20190204.0,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,159067841.0,OT,,,159067841.0,1.0,20170515.0,20181215.0,,,159067841.0,1.0,Antiretroviral therapy
15953624,159536241,1,I,,20190207.0,20190212,20190212,EXP,,US-GILEAD-2019-0389881,GILEAD,,,,,M,Y,,,20190212.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Muscle disorder;Wheelchair user,159536241.0,DS,,,159536241.0,1.0,2010.0,,,,159536241.0,1.0,HIV infection
15963115,159631151,1,I,,20190207.0,20190214,20190214,EXP,,US-GILEAD-2019-0390611,GILEAD,,,,A,M,Y,,,20190214.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amnesia;Unevaluable event,159631151.0,HO,,,,,,,,,159631151.0,1.0,HIV infection
15964658,159646582,2,F,,20190829.0,20190215,20190912,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019020010,MACLEODS,,,,,,Y,,,20190912.0,,CN,US,UG,"Lamivudine, Efavirenz + Tenofovir",Foetal exposure during pregnancy;Foot deformity;Talipes,159646582.0,OT,,,159646582.0,1.0,20180521.0,,,,159646582.0,1.0,HIV infection
15982810,159828101,1,I,20181022.0,20190213.0,20190219,20190219,EXP,,GB-GILEAD-2019-0391318,GILEAD,,35.0,YR,A,F,Y,,,20190219.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,159828101.0,OT,,,,,,,,,159828101.0,1.0,HIV infection
15991981,159919812,2,F,,20190307.0,20190221,20190312,EXP,,GB-MYLANLABS-2019M1015365,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,159919812.0,OT,,,,,,,,,159919812.0,1.0,HIV infection
16006520,160065201,1,I,,20190215.0,20190226,20190226,EXP,,GB-MYLANLABS-2019M1016072,MYLAN,,,,A,,Y,,,20190226.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Treatment noncompliance;Virologic failure,160065201.0,OT,,,,,,,,,160065201.0,1.0,HIV infection
16012986,160129861,1,I,,20190225.0,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018226,MYLAN,,,,A,,Y,,,20190227.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160129861.0,OT,,,,,,,,,160129861.0,1.0,HIV infection
16012988,160129881,1,I,,20190225.0,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018187,MYLAN,,,,A,,Y,,,20190227.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160129881.0,OT,,,,,,,,,160129881.0,1.0,HIV infection
16013050,160130501,1,I,,20190225.0,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018279,MYLAN,,,,A,,Y,,,20190227.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160130501.0,OT,,,,,,,,,160130501.0,1.0,HIV infection
16018750,160187501,1,I,,20190225.0,20190228,20190228,EXP,,GB-MYLANLABS-2019M1018254,MYLAN,,,,A,,Y,,,20190228.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160187501.0,OT,,,,,,,,,160187501.0,1.0,HIV infection
16035546,160355461,1,I,,20190225.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018688,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160355461.0,OT,,,,,,,,,160355461.0,1.0,HIV infection
16035702,160357021,1,I,,20190225.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018778,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160357021.0,OT,,,,,,,,,160357021.0,1.0,HIV infection
16037477,160374771,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018805,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160374771.0,OT,,,,,,,,,160374771.0,1.0,HIV infection
16037732,160377321,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018882,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160377321.0,OT,,,,,,,,,160377321.0,1.0,HIV infection
16037738,160377381,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018883,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160377381.0,OT,,,,,,,,,160377381.0,1.0,HIV infection
16037815,160378151,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018941,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160378151.0,OT,,,,,,,,,160378151.0,1.0,HIV infection
16037817,160378171,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018934,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160378171.0,OT,,,,,,,,,160378171.0,1.0,HIV infection
16037903,160379031,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019188,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160379031.0,OT,,,,,,,,,160379031.0,1.0,HIV infection
16038062,160380621,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019113,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160380621.0,OT,,,,,,,,,160380621.0,1.0,HIV infection
16038135,160381351,1,I,,20190226.0,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019050,MYLAN,,,,A,,Y,,,20190305.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160381351.0,OT,,,,,,,,,160381351.0,1.0,HIV infection
16040438,160404381,1,I,,20190226.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1019075,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160404381.0,OT,,,,,,,,,160404381.0,1.0,HIV infection
16040439,160404391,1,I,,20190226.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1019079,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160404391.0,OT,,,,,,,,,160404391.0,1.0,HIV infection
16043220,160432201,1,I,2018.0,20181212.0,20190306,20190306,EXP,,ZA-MYLANLABS-2018M1093637,MYLAN,,,,,M,Y,3.84,KG,20190306.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,160432201.0,CA,,,160432201.0,1.0,20180309.0,,,,160432201.0,1.0,HIV infection
16043405,160434051,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020563,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal impairment;Virologic failure,160434051.0,OT,,,,,,,,,160434051.0,1.0,HIV infection
16044070,160440701,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020520,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160440701.0,OT,,,,,,,,,160440701.0,1.0,HIV infection
16044074,160440741,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020536,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lipids increased;Nervous system disorder;Virologic failure,160440741.0,OT,,,,,,,,,160440741.0,1.0,HIV infection
16044317,160443171,1,I,,20190301.0,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020577,MYLAN,,,,A,,Y,,,20190306.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160443171.0,OT,,,,,,,,,160443171.0,1.0,HIV infection
16057849,160578492,2,F,2019.0,20190321.0,20190311,20190329,EXP,,BR-MYLANLABS-2019M1021741,MYLAN,,,,,M,Y,2.37,KG,20190329.0,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Hydrocele;Patent ductus arteriosus;Pericardial effusion,160578492.0,OT,,,160578492.0,1.0,20150815.0,,,,160578492.0,1.0,HIV infection
16063329,160633291,1,I,,20190305.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1021748,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160633291.0,OT,,,,,,,,,160633291.0,1.0,HIV infection
16064283,160642831,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022445,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Lipids increased;Virologic failure,160642831.0,OT,,,,,,,,,160642831.0,1.0,HIV infection
16064392,160643921,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022461,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160643921.0,OT,,,,,,,,,160643921.0,1.0,HIV infection
16064397,160643971,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022464,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160643971.0,OT,,,,,,,,,160643971.0,1.0,HIV infection
16064431,160644311,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022490,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160644311.0,OT,,,,,,,,,160644311.0,1.0,HIV infection
16064450,160644501,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022501,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160644501.0,OT,,,,,,,,,160644501.0,1.0,HIV infection
16064451,160644511,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022506,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160644511.0,OT,,,,,,,,,160644511.0,1.0,HIV infection
16064480,160644801,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022518,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160644801.0,OT,,,,,,,,,160644801.0,1.0,HIV infection
16064534,160645341,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022540,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645341.0,OT,,,,,,,,,160645341.0,1.0,HIV infection
16064554,160645541,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022563,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645541.0,OT,,,,,,,,,160645541.0,1.0,HIV infection
16064577,160645771,1,I,,20190307.0,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022612,MYLAN,,,,A,,Y,,,20190312.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645771.0,OT,,,,,,,,,160645771.0,1.0,HIV infection
16066987,160669871,1,I,,20190307.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022905,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160669871.0,OT,,,,,,,,,160669871.0,1.0,HIV infection
16066988,160669881,1,I,,20190307.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022906,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160669881.0,OT,,,,,,,,,160669881.0,1.0,HIV infection
16067916,160679161,1,I,,20190308.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023099,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dermatitis allergic;Virologic failure,160679161.0,OT,,,,,,,,,160679161.0,1.0,HIV infection
16067918,160679181,1,I,,20190308.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023102,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Treatment noncompliance;Virologic failure,160679181.0,OT,,,,,,,,,160679181.0,1.0,HIV infection
16068024,160680241,1,I,,20190308.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023107,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160680241.0,OT,,,,,,,,,160680241.0,1.0,HIV infection
16068026,160680261,1,I,,20190308.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023109,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160680261.0,OT,,,,,,,,,160680261.0,1.0,HIV infection
16068027,160680271,1,I,,20190308.0,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023112,MYLAN,,,,A,,Y,,,20190313.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160680271.0,OT,,,,,,,,,160680271.0,1.0,HIV infection
16068384,160683842,2,F,,20190507.0,20190313,20190513,EXP,,CA-MYLANLABS-2019M1023388,MYLAN,,,,,,Y,,,20190513.0,,OT,CA,CA,Mylan-Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,160683842.0,OT,,,,,,,,,160683842.0,1.0,Prophylaxis against HIV infection
16077788,160777881,1,I,2018.0,20181105.0,20190315,20190315,EXP,,UG-MYLANLABS-2018M1086621,MYLAN,,,,N,F,Y,3.07,KG,20190315.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,160777881.0,CA,,,160777881.0,1.0,20180625.0,,,,160777881.0,1.0,HIV infection
16154432,161544321,1,I,,20190331.0,20190403,20190403,EXP,,US-GILEAD-2019-0400328,GILEAD,,59.0,YR,A,M,Y,,,20190403.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow toxicity;Renal disorder,161544321.0,OT,,,,,,,,,161544321.0,1.0,HIV infection
16154442,161544421,1,I,,20190331.0,20190403,20190403,EXP,,US-GILEAD-2019-0400337,GILEAD,,65.0,YR,E,F,Y,,,20190403.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,161544421.0,OT,,,,,,,,,161544421.0,1.0,HIV infection
16155546,161555462,2,F,,20200117.0,20190404,20200127,EXP,,PT-AUROBINDO-AUR-APL-2019-017912,AUROBINDO,,29.0,YR,,F,Y,,,20200127.0,,HP,PT,PT,Efavirenz;Emtricitabine;Tenofovir disoproxil fumarate,Exposure during pregnancy;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,161555462.0,OT,,,161555462.0,7.0,201707.0,,,,161555462.0,1.0,HIV infection
16159047,161590471,1,I,,20190307.0,20190404,20190404,EXP,,GB-MYLANLABS-2019M1022572,MYLAN,,,,A,,Y,,,20190404.0,,MD,GB,GB,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,161590471.0,OT,,,,,,,,,161590471.0,1.0,HIV infection
16185726,161857261,1,I,,20190401.0,20190411,20190411,EXP,,ZA-GILEAD-2019-0400485,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Low birth weight baby,161857261.0,OT,,,,,,,,,161857261.0,1.0,HIV infection
16186606,161866062,2,F,,20190401.0,20190411,20200331,EXP,,ZA-GILEAD-2019-0401093,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200331.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161866062.0,CA,,,,,,,,,161866062.0,1.0,HIV infection
16186618,161866182,2,F,,20190401.0,20190411,20200331,EXP,,ZA-GILEAD-2019-0401788,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200331.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161866182.0,CA,,,,,,,,,161866182.0,1.0,HIV infection
16186720,161867202,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401790,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867202.0,CA,,,,,,,,,161867202.0,1.0,HIV infection
16186723,161867232,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401796,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867232.0,OT,,,,,,,,,161867232.0,1.0,HIV infection
16186724,161867242,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401789,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867242.0,OT,,,,,,,,,161867242.0,1.0,HIV infection
16186725,161867252,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401792,GILEAD,,,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867252.0,OT,,,,,,,,,161867252.0,1.0,HIV infection
16186726,161867262,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401791,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867262.0,OT,,,,,,,,,161867262.0,1.0,HIV infection
16186727,161867272,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401797,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867272.0,CA,,,,,,,,,161867272.0,1.0,HIV infection
16186735,161867352,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401793,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867352.0,OT,,,,,,,,,161867352.0,1.0,HIV infection
16186736,161867362,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401794,GILEAD,,,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867362.0,OT,,,,,,,,,161867362.0,1.0,HIV infection
16186737,161867372,2,F,,20190401.0,20190411,20200323,EXP,,ZA-GILEAD-2019-0401795,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867372.0,CA,,,,,,,,,161867372.0,1.0,HIV infection
16202935,162029351,1,I,,20190406.0,20190416,20190416,EXP,,UG-MYLANLABS-2019M1035391,MYLAN,"MUNDERI P, WERE E, AVIHINGSANON A, ABENA MESSOMO MBIDA P, MOHAPI L, SAMBA BM, ET AL. SALIF TRIAL: SWITCHING SUPPRESSED FIRST-LINE PATIENTS TO TENOFOVIR/EMTRICITABINE/RILPIVIRINE (TDF/FTC/RPV) IS NON-INFERIOR TO TDF/FTC/EFAVIRENZ (TDF/FTC/EFV) AND COULD BE AN ALTERNATIVE TREATMENT OPTION IN LMICS. J-INT-AIDS-SOC 2016;19 (SUPPL. 5)(6):76-77 ABSTR. THAB0104.",,,A,,Y,,,20190416.0,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,162029351.0,OT,,,,,,,,,162029351.0,1.0,HIV infection
16204531,162045311,1,I,,20190307.0,20190416,20190416,EXP,,GB-MYLANLABS-2019M1022557,MYLAN,,,,A,,Y,,,20190416.0,,MD,GB,GB,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,162045311.0,OT,,,,,,,,,162045311.0,1.0,HIV infection
16208651,162086511,1,I,,20190412.0,20190417,20190417,EXP,,CA-GILEAD-2019-0402293,GILEAD,,48.0,YR,A,M,Y,,,20190417.0,,CN,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Osteoporosis,162086511.0,OT,,,162086511.0,1.0,2009.0,2012.0,,,162086511.0,1.0,HIV infection
16213433,162134333,3,F,20161105.0,20200320.0,20190418,20200415,EXP,,US-GILEAD-2019-0402857,GILEAD,,38.0,YR,A,M,Y,95.69,KG,20200415.0,,CN,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Femur fracture;Hip arthroplasty;Osteomalacia;Osteonecrosis;Pain,162134333.0,OT,,,162134333.0,1.0,201003.0,201809.0,,,162134333.0,1.0,HIV infection
16257946,162579461,1,I,,20190422.0,20190430,20190430,EXP,,BR-MYLANLABS-2019M1039917,MYLAN,,24.0,YR,,F,Y,,,20190430.0,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Anembryonic gestation;Maternal exposure during pregnancy,162579461.0,OT,,,162579461.0,1.0,20170609.0,20171231.0,,,162579461.0,1.0,HIV infection
16258145,162581452,2,F,,20200429.0,20190430,20200501,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK074257,GLAXOSMITHKLINE,,,,,,Y,,,20200501.0,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581452.0,OT,,,,,,,,,162581452.0,1.0,HIV infection
16258147,162581472,2,F,,20200429.0,20190430,20200501,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK074257,VIIV,,,,,,Y,,,20200501.0,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581472.0,CA,,,,,,,,,162581472.0,1.0,HIV infection
16261847,162618476,6,F,,20191202.0,20190501,20191213,EXP,,CA-GILEAD-2019-0405133,GILEAD,,,,I,,Y,,,20191213.0,,OT,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162618476.0,OT,,,,,,,,,162618476.0,1.0,HIV infection
16266600,162666003,3,F,20181214.0,20190605.0,20190502,20190606,EXP,,BR-GILEAD-2019-0405171,GILEAD,,23.0,YR,A,F,Y,,,20190606.0,,OT,BR,BR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,162666003.0,OT,,,162666003.0,1.0,20181214.0,,,,162666003.0,1.0,HIV infection
16266686,162666862,2,F,20181214.0,20190520.0,20190502,20190522,EXP,,BR-GILEAD-2019-0405383,GILEAD,,,,,F,Y,,,20190522.0,,OT,BR,BR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrops foetalis,162666862.0,OT,,,162666862.0,1.0,20181214.0,,,,162666862.0,1.0,HIV infection
16267058,162670581,1,I,,20190430.0,20190502,20190502,EXP,,ZA-GILEAD-2019-0405182,GILEAD,,,,N,F,Y,,,20190502.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Corneal opacity congenital;Foetal exposure during pregnancy,162670581.0,OT,,,,,,,,,162670581.0,1.0,HIV infection
16269410,162694102,2,F,,20190506.0,20190503,20190510,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019078125,VIIV,,,,I,,Y,,,20190510.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Ventricular septal defect,162694102.0,OT,,,,,,,,,162694102.0,1.0,HIV infection
16269419,162694192,2,F,,20190506.0,20190503,20190510,EXP,,CA-GLAXOSMITHKLINE-CA2019078125,GLAXOSMITHKLINE,,,,I,,Y,,,20190510.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Ventricular septal defect,162694192.0,OT,,,,,,,,,162694192.0,1.0,HIV infection
16271657,162716571,1,I,,20190408.0,20190506,20190506,PER,,US-HETERO CORPORATE-HET2019US00509,HETERO,,,,,F,Y,,,20190506.0,,CN,US,US,Efavirenz+Lamivudine+Tenofovir,Asthenia;Feeling abnormal,,,,,,,,,,,162716571.0,1.0,Prophylaxis against HIV infection
16271660,162716601,1,I,,20190429.0,20190503,20190503,EXP,,GB-MYLANLABS-2019M1042031,MYLAN,,,,A,F,Y,,,20190503.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,162716601.0,OT,,,,,,,,,162716601.0,1.0,HIV infection
16274115,162741151,1,I,,20190419.0,20190504,20190504,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021082,MACLEODS,,,,,,Y,,,20190504.0,,OT,GB,BR,LAMIVUDINE+ EFAVIRENZ + TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,162741151.0,OT,,,162741151.0,1.0,20170609.0,20171231.0,,,162741151.0,1.0,HIV infection
16280003,162800032,2,F,,20190507.0,20190507,20190514,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-020086",BOEHRINGER INGELHEIM,,,,N,,Y,,,20190514.0,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR D,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162800032.0,CA,,,,,,,,,162800032.0,1.0,HIV infection
16284485,162844855,5,F,,20190910.0,20190508,20191120,EXP,,CA-AUROBINDO-AUR-APL-2019-025238,AUROBINDO,,,,I,,Y,,,20191120.0,,OT,CA,CA,Tenofovir + efavirenz + emtricitabine,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162844855.0,OT,,,,,,,,,162844855.0,1.0,HIV infection
16291871,162918712,2,F,,20190506.0,20190509,20190516,EXP,,CA-TEVA-2019-CA-1047631,TEVA,,,,I,,Y,,,20190516.0,,OT,CA,CA,EFAVIRENZ+TENOFOVIR DISOPROXIL MALEATE+EMTRICITABINE GENERIC -MYLAN,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162918712.0,OT,,,,,,,,,162918712.0,1.0,HIV infection
16297606,162976064,4,F,,20190611.0,20190510,20190624,EXP,,ZA-AUROBINDO-AUR-APL-2019-025243,AUROBINDO,,,,,,Y,,,20190624.0,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Corneal opacity congenital;Foetal exposure during pregnancy,162976064.0,CA,,,,,,,,,162976064.0,1.0,HIV infection
16307804,163078041,1,I,,20190430.0,20190514,20190514,EXP,,CA-MACLEODS PHARMACEUTICALS US LTD-MAC2019021173,MACLEODS,,,,,,Y,,,20190514.0,,OT,CA,CA,EFAVIRENZ/TENOFOVIR/MALEATE/EMTRICITABINE,Maternal exposure during pregnancy,163078041.0,OT,,,,,,,,,163078041.0,1.0,HIV infection
16307806,163078061,1,I,,20190430.0,20190514,20190514,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019021174,MACLEODS,,,,,,Y,,,20190514.0,,OT,US,CA,EFAVIRENZ/TENOFOVIR/MALEATE/EMTRICITABINE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163078061.0,OT,,,,,,,,,163078061.0,1.0,HIV infection
16312970,163129701,1,I,,20190430.0,20190515,20190515,EXP,,CA-HETERO CORPORATE-HET2019CA00639,HETERO,,,,I,,Y,,,20190515.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163129701.0,OT,,,,,,,,,163129701.0,1.0,HIV infection
16314485,163144851,1,I,,20190507.0,20190515,20190515,EXP,,NG-MYLANLABS-2019M1045681,MYLAN,"AKASE IE, OLOWOYO O, OLADELE RO, OBIAKO RO, WARRIS A, AKANMU SA. CRYPTOCOCCAL MENINGITIS AFTER ART: NEED FOR PROPER BASELINE EVALUATION IN THE ERA OF ^TEST + TREAT^. MED-MYCOL-CASE-REPORTS 2019;24:58-60.",52.0,YR,,M,Y,,,20190515.0,,OT,NG,NG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Facial paralysis;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Paralysis,163144851.0,OT,,,,,,,,,163144851.0,1.0,HIV infection
16316293,163162931,1,I,,20190510.0,20190515,20190515,EXP,,US-GILEAD-2019-0407096,GILEAD,,63.0,YR,A,M,Y,,,20190515.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Metastatic lymphoma;Prostate cancer,163162931.0,HO,,,,,,,,,163162931.0,1.0,HIV infection
16320900,163209001,1,I,,20190509.0,20190516,20190516,EXP,,US-GILEAD-2019-0407404,GILEAD,,52.0,YR,A,M,Y,,,20190516.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alcohol poisoning;Economic problem,163209001.0,OT,,,,,,,,,163209001.0,1.0,HIV infection
16323548,163235483,3,F,200809.0,20190527.0,20190517,20190528,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047409,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,69.5,KG,20190528.0,,MD,ES,ES,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE;EFAVIRENZ.",Prescribed overdose;Pulmonary tuberculosis,163235483.0,OT,,,163235483.0,1.0,200805.0,200809.0,,,163235483.0,1.0,HIV infection
16325136,163251362,2,F,,20210126.0,20190517,20210205,EXP,,CA-APOTEX-2019AP013869,APOTEX,,,,,,Y,,,20210205.0,,CN,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL MALEATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163251362.0,CA,,,,,,,,,163251362.0,1.0,HIV infection
16336953,163369531,1,I,,20190516.0,20190521,20190521,EXP,,US-GILEAD-2019-0408673,GILEAD,,34.0,YR,A,M,Y,,,20190521.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tooth fracture,163369531.0,OT,,,,,,,,,163369531.0,1.0,HIV infection
16337837,163378371,1,I,20180303.0,20190516.0,20190521,20190521,EXP,,GB-GILEAD-2019-0408345,GILEAD,,31.0,YR,A,F,Y,,,20190521.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,163378371.0,OT,,,,,,,,,163378371.0,1.0,HIV infection
16344775,163447751,1,I,,20190513.0,20190522,20190522,EXP,,CA-TEVA-2019-CA-1051062,TEVA,,,,,,Y,,,20190522.0,,OT,CA,CA,MYLANEFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163447751.0,CA,,,,,,,,,163447751.0,1.0,HIV infection
16351614,163516141,1,I,,20190513.0,20190524,20190524,EXP,,NG-HETERO CORPORATE-HET2019NG00720,HETERO,"AKASE IE, OLOWOYO O, OLADELE RO, OBIAKO RO, WARRIS A, AKANMU SA. CRYPTOCOCCAL MENINGITIS AFTER ART: NEED FOR PROPER BASELINE EVALUATION IN THE ERA OF ?TEST + TREAT?. MEDICAL MYCOLOGY CASE REPORTS. 2019;24:58-60",52.0,YR,,M,Y,,,20190524.0,,OT,NG,NG,Efavirenz+Lamivudine+Tenofovir,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163516141.0,HO,,,,,,,,,163516141.0,1.0,HIV infection
16351796,163517961,1,I,,20190520.0,20190524,20190524,EXP,,NG-AUROBINDO-AUR-APL-2019-030291,AUROBINDO,,,,,,Y,,,20190524.0,,OT,NG,NG,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Blindness;Blood HIV RNA increased;Blood pressure increased;CSF protein increased;Diplopia;Facial paralysis;Facial paresis;Headache;Kernig's sign;Meningitis cryptococcal;Musculoskeletal stiffness;Pallor;Papilloedema;Paralysis;Photophobia;Pyrexia;Restlessness;Sluggishness;Vision blurred;Visual impairment,163517961.0,OT,,,,,,,,,163517961.0,1.0,HIV antibody positive
16369908,163699081,1,I,,20190522.0,20190530,20190530,EXP,,CA-TEVA-2019-CA-1055283,TEVA,,60.0,YR,,M,Y,81.72,KG,20190530.0,,MD,CA,CA,TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Abdominal discomfort;Nausea,163699081.0,DS,,,,,,,,,163699081.0,1.0,HIV test positive
16394356,163943564,4,F,20180802.0,20190611.0,20190605,20190614,EXP,,DE-GILEAD-2019-0411767,GILEAD,,40.0,YR,A,M,Y,92.0,KG,20190614.0,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression,163943564.0,OT,,,163943564.0,10.0,20141012.0,20181121.0,,,163943564.0,1.0,HIV infection
16395888,163958882,2,F,20190224.0,20190703.0,20190605,20190704,EXP,,US-GILEAD-2019-0411957,GILEAD,,48.0,YR,A,M,Y,113.0,KG,20190704.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,163958882.0,DE,,,,,,,,,163958882.0,1.0,HIV infection
16402847,164028471,1,I,,20190604.0,20190607,20190607,EXP,,US-GILEAD-2019-0411788,GILEAD,,,,A,F,Y,,,20190607.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,164028471.0,HO,,,,,,,,,164028471.0,1.0,HIV infection
16411782,164117821,1,I,,20190530.0,20190610,20190610,EXP,,IN-MYLANLABS-2019M1053778,MYLAN,,42.0,YR,,M,Y,,,20190610.0,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Pneumocystis jirovecii pneumonia;Respiratory failure,164117821.0,OT,,,,,,,,,164117821.0,1.0,HIV infection
16441111,164411111,1,I,201112.0,20190610.0,20190617,20190617,EXP,,GB-MYLANLABS-2019M1056682,MYLAN,,,,A,M,Y,,,20190617.0,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Osteoporosis,164411111.0,OT,,,164411111.0,1.0,201112.0,201810.0,,,164411111.0,1.0,HIV infection
16446422,164464222,2,F,201805.0,20190611.0,20190618,20190731,EXP,,US-GILEAD-2019-0413810,GILEAD,,54.0,YR,A,M,Y,111.3,KG,20190731.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Depression;Mental disorder;Substance abuse,164464222.0,OT,,,164464222.0,2.0,1999.0,,,,164464222.0,1.0,HIV infection
16465683,164656831,1,I,20181101.0,20190613.0,20190621,20190621,EXP,,UG-MYLANLABS-2019M1058215,MYLAN,,33.0,YR,,F,Y,,,20190621.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Foetal death,164656831.0,OT,,,164656831.0,1.0,20170724.0,,,,164656831.0,1.0,HIV infection
16470787,164707872,2,F,,20191118.0,20190624,20191122,EXP,,UG-MYLANLABS-2019M1058214,MYLAN,,20.0,YR,,F,Y,,,20191122.0,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Foetal death,164707872.0,OT,,,164707872.0,1.0,20141022.0,,,,164707872.0,1.0,HIV infection
16470789,164707898,8,F,,20210517.0,20190624,20210524,EXP,,UG-MYLANLABS-2019M1058216,MYLAN,,,,,F,Y,3.7,KG,20210524.0,,HP,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Congenital skin dimples;Congenital umbilical hernia;Foetal exposure during pregnancy,164707898.0,OT,,,164707898.0,1.0,20170721.0,20180614.0,,,164707898.0,1.0,HIV infection
16473489,164734891,1,I,,20190610.0,20190625,20190625,EXP,,IN-AUROBINDO-AUR-APL-2019-035791,AUROBINDO,,,,,,Y,,,20190625.0,,MD,IN,IN,TENOFOVIR+LAMIVUDINE+EFAVIRENZ,Abdominal pain;Asthenia;Blood HIV RNA decreased;CD4 lymphocytes decreased;Cough;Decreased appetite;Dysphagia;Dyspnoea;Early satiety;HIV infection CDC group IV;Haemoglobin decreased;Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Leishmaniasis;Lymphadenopathy;Odynophagia;Oesophageal candidiasis;Pallor;Pancytopenia;Pneumocystis jirovecii pneumonia;Productive cough;Pyrexia;Respiratory failure;Tachycardia;Tachypnoea;Visceral leishmaniasis;Vomiting;Weight decreased,164734891.0,HO,,,,,,,,,164734891.0,1.0,HIV infection
16499390,164993901,1,I,,20190618.0,20190701,20190701,EXP,,ZA-CIPLA LTD.-2019ZA04630,CIPLA,,,,,,Y,,,20190701.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Exposure during pregnancy;No adverse event,164993901.0,OT,,,,,,,,,164993901.0,1.0,HIV infection
16500823,165008231,1,I,2013.0,20190626.0,20190701,20190701,EXP,,US-GILEAD-2019-0415961,GILEAD,,45.0,YR,A,M,Y,,,20190701.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,"Hallucination, visual;Intentional dose omission",165008231.0,OT,,,165008231.0,1.0,2013.0,2014.0,,,165008231.0,1.0,HIV infection
16536490,165364902,2,F,20190325.0,20190705.0,20190706,20190711,EXP,,BR-HETERO-HET2019BR00902,HETERO,,0.0,DY,,M,Y,2.78,KG,20190711.0,,OT,BR,BR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPRO (EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE),Ankyloglossia congenital;Foetal exposure during pregnancy;Premature baby,165364902.0,CA,,,165364902.0,1.0,20181018.0,20181024.0,,,165364902.0,1.0,HIV infection
16536496,165364962,2,F,20190325.0,20190705.0,20190706,20190711,EXP,,BR-HETERO-HET2019BR00903,HETERO,,24.0,YR,,F,Y,,,20190711.0,,OT,BR,BR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Exposure during pregnancy;Premature delivery,165364962.0,OT,,,165364962.0,1.0,20181018.0,20181024.0,,,165364962.0,1.0,HIV infection
16539046,165390461,1,I,,20190703.0,20190708,20190708,EXP,,US-GILEAD-2019-0416714,GILEAD,,,,A,F,Y,,,20190708.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Coronary arterial stent insertion,165390461.0,OT,,,165390461.0,1.0,2019.0,2019.0,,,165390461.0,1.0,HIV infection
16541950,165419501,1,I,201802.0,20190705.0,20190708,20190708,EXP,,US-GILEAD-2019-0416980,GILEAD,,54.0,YR,A,M,Y,,,20190708.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness;Meningitis;Product use issue,165419501.0,OT,,,,,,,,,165419501.0,1.0,HIV infection
16553196,165531961,1,I,,20190708.0,20190710,20190710,EXP,,US-GILEAD-2019-0417343,GILEAD,,,,A,M,Y,,,20190710.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal injury,165531961.0,OT,,,,,,,,,165531961.0,1.0,HIV infection
16559338,165593381,1,I,,20190708.0,20190711,20190711,EXP,,CH-GILEAD-2019-0417596,GILEAD,"MALIKOVA J, ZINGG T, FINGERHUT R, SLUKA S, GROSSL M, BRIXIUS-ANDERKO S, BERNHARDT R, MCDOUGALL J, PANDEY AV, FLUCK CE. HIV DRUG EFAVIRENZ INHIBITS CYP21A2 ACTIVITY WITH POSSIBLE CLINICAL IMPLICATIONS. HORM RES PAEDIATR.. 2019;1-9:UNK. DOI:10.1159/000500522",,,N,F,Y,,,20190711.0,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Adrenal insufficiency neonatal;Foetal exposure during pregnancy,165593381.0,OT,,,,,,,,,165593381.0,1.0,HIV infection
16559365,165593652,2,F,,20190411.0,20190711,20190716,PER,,US-GILEAD-2019-0417804,GILEAD,,34.0,YR,A,M,Y,,,20190716.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nausea,,,,,165593652.0,1.0,201902.0,,,,165593652.0,1.0,HIV infection
16559366,165593662,2,F,201801.0,20190411.0,20190711,20190716,PER,,US-GILEAD-2019-0417806,GILEAD,,35.0,YR,A,,Y,,,20190716.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety;Dizziness;Fear;Rash,,,,,165593662.0,1.0,201801.0,,,,165593662.0,1.0,HIV infection
16559560,165595601,1,I,,20190708.0,20190711,20190711,EXP,,CH-GILEAD-2019-0417593,GILEAD,"MALIKOVA J, ZINGG T, FINGERHUT R, SLUKA S, GROSSL M, BRIXIUS-ANDERKO S, BERNHARDT R, MCDOUGALL J, PANDEY AV, FLUCK CE. HIV DRUG EFAVIRENZ INHIBITS CYP21A2 ACTIVITY WITH POSSIBLE CLINICAL IMPLICATIONS. HORM RES PAEDIATR.. 2019;1-9:UNK. DOI:10.1159/000500522",,,,F,Y,,,20190711.0,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature baby,165595601.0,OT,,,,,,,,,165595601.0,1.0,HIV infection
16568467,165684671,1,I,,20190711.0,20190712,20190712,EXP,,US-GILEAD-2019-0418150,GILEAD,,,,,M,Y,,,20190712.0,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,165684671.0,DE,,,,,,,,,165684671.0,1.0,HIV infection
16576907,165769071,1,I,,20190715.0,20190716,20190716,EXP,,US-GILEAD-2019-0418414,GILEAD,,,,A,M,Y,,,20190716.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,165769071.0,OT,,,,,,,,,165769071.0,1.0,HIV infection
16582236,165822362,2,F,,20191010.0,20190717,20191017,EXP,,CA-AUROBINDO-AUR-APL-2019-039430,AUROBINDO,,,,,,Y,,,20191017.0,,OT,CA,CA,Mylan efavirenz/emtricitabine/tenofovir disoproxil fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,165822362.0,OT,,,,,,,,,165822362.0,1.0,HIV infection
16588204,165882042,2,F,,20190814.0,20190717,20190815,EXP,,CA-GILEAD-2019-0418318,GILEAD,,,,N,,Y,,,20190815.0,,OT,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,165882042.0,CA,,,,,,,,,165882042.0,1.0,Prophylaxis against HIV infection
16594834,165948341,1,I,20190701.0,20190718.0,20190718,20190718,EXP,,US-GILEAD-2019-0418990,GILEAD,,58.0,YR,A,M,Y,,,20190718.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Oral candidiasis,165948341.0,DS,,,165948341.0,1.0,2015.0,,,,165948341.0,1.0,HIV infection
16601723,166017232,2,F,,20190814.0,20190719,20190819,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019129907,VIIV,,,,N,,Y,,,20190819.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,166017232.0,CA,,,,,,,,,166017232.0,1.0,HIV infection
16601744,166017442,2,F,,20190814.0,20190719,20190819,EXP,,CA-GLAXOSMITHKLINE-CA2019129907,GLAXOSMITHKLINE,,,,N,,Y,,,20190819.0,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,166017442.0,CA,,,,,,,,,166017442.0,1.0,HIV infection
16628927,166289271,1,I,,20190716.0,20190725,20190725,EXP,,US-MYLANLABS-2019M1068635,MYLAN,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K, ET AL. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS 2018;5:NO. 10.",30.0,YR,,F,Y,,,20190725.0,,MD,US,US,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Castleman's disease;Immune reconstitution inflammatory syndrome associated tuberculosis;Lymph node abscess;Paradoxical drug reaction,166289271.0,OT,,,,,,,,,166289271.0,1.0,HIV infection
16638680,166386805,5,F,,20201113.0,20190726,20201123,EXP,,UG-MYLANLABS-2019M1069122,MYLAN,,,,,F,Y,,,20201123.0,,HP,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,166386805.0,CA,,,166386805.0,1.0,20140818.0,20190524.0,,,166386805.0,1.0,HIV infection
16641527,166415271,1,I,,20190722.0,20190729,20190729,EXP,,US-HETERO-HET2019US01004,HETERO,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K,METZGER D, MICAN JM, PAU A, LISCO A, LAIDLAW E, HAMMOUD DA, WHITBY D, YARCHOAN R, SERETI I. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS. 2018;5 NO",30.0,YR,,F,Y,,,20190729.0,,MD,US,US,Efavirenz+Emtricitabine+Tenofovir,Anaemia;Clostridium difficile colitis;Immune reconstitution inflammatory syndrome associated tuberculosis;Thrombocytopenia,166415271.0,OT,,,,,,,,,166415271.0,1.0,HIV infection
16645051,166450511,1,I,,20190725.0,20190729,20190729,EXP,,GB-MYLANLABS-2019M1071055,MYLAN,"ORKIN C, SQUIRES KE, MOLINA JM, SAX PE, WONG WW, SUSSMANN O ETAL. DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE IS NON-INFERIOR TO EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE ADULTS WITH  HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTION: WEEK 48 RESULTS OF THE DRIVE-AHEAD TRIAL.. CLINICAL INFECTIOUS DISEASES. 2019;68:535-544",,,A,,Y,,,20190729.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Psychotic disorder;Suicide attempt,166450511.0,OT,,,,,,,,,166450511.0,1.0,HIV infection
16647133,166471332,2,F,20190501.0,20191028.0,20190730,20191031,EXP,GB-MHRA-EYC 00203835,GB-GILEAD-2019-0420758,GILEAD,,47.0,YR,A,F,Y,,,20191031.0,,PH,GB,GB,EFAVIRENZ/EMTRICITABIN/TENOFOVIR DISOPROXIL MYLAN,Diarrhoea;Product substitution issue,166471332.0,DS,,,166471332.0,1.0,20190401.0,,,,166471332.0,1.0,HIV infection
16648472,166484722,2,F,,20190801.0,20190730,20190808,EXP,,US-TEVA-2019-US-1084141,TEVA,"MANION M, ULDRICK T, POLIZZOTTO MN, SHEIKH V, ROBY G, LURAIN K, ET AL. EMERGENCE OF KAPOSI^S SARCOMA HERPESVIRUS-ASSOCIATED COMPLICATIONS FOLLOWING CORTICOSTEROID USE IN TB-IRIS. OPEN-FORUM-INFECT-DIS 2018;5:NO. 10.",30.0,YR,,F,Y,,,20190808.0,,MD,US,US,Efavirenz/tenofovir/emtricitabine,Anaemia;Castleman's disease;Immune reconstitution inflammatory syndrome associated tuberculosis;Lymph node abscess;Paradoxical drug reaction,166484722.0,HO,,,,,,,,,166484722.0,1.0,Immune reconstitution inflammatory syndrome associated tuberculosis
16666818,166668181,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421672,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,166668181.0,CA,,,,,,,,,166668181.0,1.0,HIV infection
16667411,166674111,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421667,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Holoprosencephaly,166674111.0,CA,,,,,,,,,166674111.0,1.0,HIV infection
16667558,166675581,1,I,20181022.0,20190725.0,20190805,20190805,EXP,,GB-MYLANLABS-2019M1072307,MYLAN,,35.0,YR,,F,Y,,,20190805.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,166675581.0,OT,,,,,,,,,166675581.0,1.0,HIV infection
16667632,166676322,2,F,,20190726.0,20190805,20191212,EXP,,BW-GILEAD-2019-0421543,GILEAD,,,,N,,Y,,,20191212.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166676322.0,OT,,,,,,,,,166676322.0,1.0,HIV infection
16667679,166676792,2,F,,20190726.0,20190805,20191212,EXP,,BW-GILEAD-2019-0421975,GILEAD,,,,N,,Y,,,20191212.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166676792.0,OT,,,,,,,,,166676792.0,1.0,HIV infection
16667707,166677071,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421968,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677071.0,CA,,,,,,,,,166677071.0,1.0,HIV infection
16667754,166677541,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421692,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677541.0,CA,,,,,,,,,166677541.0,1.0,HIV infection
16667778,166677782,2,F,,20190726.0,20190805,20191212,EXP,,BW-GILEAD-2019-0421978,GILEAD,,,,N,,Y,,,20191212.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677782.0,CA,,,,,,,,,166677782.0,1.0,HIV infection
16667779,166677791,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421969,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Multiple congenital abnormalities,166677791.0,CA,,,,,,,,,166677791.0,1.0,HIV infection
16667780,166677802,2,F,,20190726.0,20190805,20191212,EXP,,BW-GILEAD-2019-0421976,GILEAD,,,,N,,Y,,,20191212.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677802.0,CA,,,,,,,,,166677802.0,1.0,HIV infection
16667782,166677822,2,F,,20190726.0,20190805,20191212,EXP,,BW-GILEAD-2019-0421977,GILEAD,,,,N,,Y,,,20191212.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydrocephalus;Foetal exposure during pregnancy,166677822.0,CA,,,,,,,,,166677822.0,1.0,HIV infection
16667916,166679161,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421705,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,166679161.0,CA,,,,,,,,,166679161.0,1.0,HIV infection
16667918,166679181,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421972,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Skeletal dysplasia,166679181.0,OT,,,,,,,,,166679181.0,1.0,HIV infection
16667954,166679541,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421994,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679541.0,CA,,,,,,,,,166679541.0,1.0,HIV infection
16667961,166679611,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421673,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679611.0,OT,,,,,,,,,166679611.0,1.0,HIV infection
16667962,166679621,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421993,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166679621.0,OT,,,,,,,,,166679621.0,1.0,HIV infection
16668007,166680071,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421995,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Genitalia external ambiguous,166680071.0,OT,,,,,,,,,166680071.0,1.0,HIV infection
16668028,166680281,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421973,GILEAD,,,,,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningocele;Meningomyelocele,166680281.0,CA,,,,,,,,,166680281.0,1.0,HIV infection
16668040,166680401,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421528,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningocele;Meningomyelocele,166680401.0,OT,,,,,,,,,166680401.0,1.0,HIV infection
16668105,166681051,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421683,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681051.0,OT,,,,,,,,,166681051.0,1.0,HIV infection
16668159,166681591,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421997,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681591.0,CA,,,,,,,,,166681591.0,1.0,HIV infection
16668160,166681601,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421998,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Syndactyly,166681601.0,CA,,,,,,,,,166681601.0,1.0,HIV infection
16668169,166681691,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421982,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166681691.0,CA,,,,,,,,,166681691.0,1.0,HIV infection
16668170,166681701,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421984,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166681701.0,OT,,,,,,,,,166681701.0,1.0,HIV infection
16668202,166682021,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421983,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682021.0,OT,,,,,,,,,166682021.0,1.0,HIV infection
16668203,166682031,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421670,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682031.0,CA,,,,,,,,,166682031.0,1.0,HIV infection
16668212,166682121,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421985,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682121.0,OT,,,,,,,,,166682121.0,1.0,HIV infection
16668263,166682631,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421693,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb malformation,166682631.0,CA,,,,,,,,,166682631.0,1.0,HIV infection
16668269,166682691,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421684,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital foot malformation;Congenital hand malformation;Foetal exposure during pregnancy,166682691.0,CA,,,,,,,,,166682691.0,1.0,HIV infection
16668282,166682821,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421986,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166682821.0,CA,,,,,,,,,166682821.0,1.0,HIV infection
16668318,166683181,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421695,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb reduction defect,166683181.0,OT,,,,,,,,,166683181.0,1.0,HIV infection
16668342,166683421,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421987,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683421.0,OT,,,,,,,,,166683421.0,1.0,HIV infection
16668343,166683431,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421988,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683431.0,CA,,,,,,,,,166683431.0,1.0,HIV infection
16668356,166683561,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421989,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683561.0,CA,,,,,,,,,166683561.0,1.0,HIV infection
16668357,166683571,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421696,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Limb reduction defect,166683571.0,CA,,,,,,,,,166683571.0,1.0,HIV infection
16668381,166683811,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421990,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683811.0,CA,,,,,,,,,166683811.0,1.0,HIV infection
16668397,166683971,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421991,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166683971.0,CA,,,,,,,,,166683971.0,1.0,HIV infection
16668399,166683991,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421682,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amniotic band syndrome;Exposure during pregnancy,166683991.0,OT,,,,,,,,,166683991.0,1.0,HIV infection
16668516,166685161,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421694,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital inguinal hernia;Foetal exposure during pregnancy,166685161.0,OT,,,,,,,,,166685161.0,1.0,HIV infection
16668521,166685211,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422003,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166685211.0,CA,,,,,,,,,166685211.0,1.0,HIV infection
16668526,166685261,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421535,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Foetal exposure during pregnancy,166685261.0,CA,,,,,,,,,166685261.0,1.0,HIV infection
16668568,166685681,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421669,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip;Foetal exposure during pregnancy,166685681.0,OT,,,,,,,,,166685681.0,1.0,HIV infection
16668697,166686971,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422004,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166686971.0,OT,,,,,,,,,166686971.0,1.0,HIV infection
16668717,166687171,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422002,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687171.0,OT,,,,,,,,,166687171.0,1.0,HIV infection
16668723,166687231,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421980,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip;Foetal exposure during pregnancy,166687231.0,OT,,,,,,,,,166687231.0,1.0,HIV infection
16668770,166687701,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422005,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687701.0,OT,,,,,,,,,166687701.0,1.0,HIV infection
16668771,166687711,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421671,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,166687711.0,CA,,,,,,,,,166687711.0,1.0,HIV infection
16668772,166687721,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422012,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,166687721.0,OT,,,,,,,,,166687721.0,1.0,HIV infection
16668784,166687841,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422007,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166687841.0,CA,,,,,,,,,166687841.0,1.0,HIV infection
16668800,166688001,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422006,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166688001.0,CA,,,,,,,,,166688001.0,1.0,HIV infection
16668812,166688121,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421685,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688121.0,OT,,,,,,,,,166688121.0,1.0,HIV infection
16668829,166688291,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422000,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688291.0,OT,,,,,,,,,166688291.0,1.0,HIV infection
16668867,166688671,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421686,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688671.0,OT,,,,,,,,,166688671.0,1.0,HIV infection
16668872,166688721,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422001,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688721.0,OT,,,,,,,,,166688721.0,1.0,HIV infection
16668873,166688731,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422010,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Polydactyly,166688731.0,OT,,,,,,,,,166688731.0,1.0,HIV infection
16668876,166688761,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0422008,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Talipes,166688761.0,OT,,,,,,,,,166688761.0,1.0,HIV infection
16668889,166688891,1,I,,20190726.0,20190805,20190805,EXP,,BW-GILEAD-2019-0421967,GILEAD,,,,N,,Y,,,20190805.0,,MD,US,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Holoprosencephaly,166688891.0,CA,,,,,,,,,166688891.0,1.0,HIV infection
16702036,167020361,1,I,,20190813.0,20190814,20190814,EXP,,US-GILEAD-2019-0423268,GILEAD,,59.0,YR,A,M,Y,,,20190814.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder;Fatigue;Nightmare;Vision blurred,167020361.0,OT,,,167020361.0,1.0,200401.0,,,,167020361.0,1.0,HIV infection
16728651,167286511,1,I,,20190808.0,20190822,20190822,EXP,,CA-AUROBINDO-AUR-APL-2019-054602,AUROBINDO,,,,,,Y,,,20190822.0,,OT,CA,CA,Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,167286511.0,CA,,,,,,,,,167286511.0,1.0,HIV infection
16747443,167474431,1,I,,20190822.0,20190827,20190827,EXP,,CA-TEVA-2019-CA-1099318,TEVA,,57.0,YR,,M,Y,,,20190827.0,,PH,CA,CA,TEVA-EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Agitation;Anxiety;Depression;Diarrhoea;Feeling of despair;Mania;Product substitution issue;Suicidal ideation,167474431.0,LT,,,,,,,,,167474431.0,1.0,HIV infection
16747469,167474691,1,I,,20190822.0,20190827,20190827,EXP,,CA-TEVA-2019-CA-1099329,TEVA,,56.0,YR,,M,Y,,,20190827.0,,PH,CA,CA,TEVA-EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Abdominal discomfort;Product substitution issue,167474691.0,OT,,,,,,,,,167474691.0,1.0,HIV infection
16751630,167516301,1,I,,20190822.0,20190828,20190828,EXP,,CA-TEVA-2019-CA-1099324,TEVA,,,,,M,Y,64.0,KG,20190828.0,,PH,CA,CA,TEVA- EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Alanine aminotransferase increased;Aspartate aminotransferase increased;Nervous system disorder;Product substitution issue;Rash;Transaminases increased;Urticaria,167516301.0,OT,,,,,,,,,167516301.0,1.0,HIV infection
16794386,167943861,1,I,,20190902.0,20190911,20190911,EXP,,ES-TEVA-2019-ES-1105202,TEVA,"KWON M, BAILEN R, BALSALOBRE P, JURADO M, BERMUDEZ A, BADIOLA J, ET AL. ALLOGENEIC STEM-CELL TRANSPLANTATION IN HIV-1-INFECTED PATIENTS WITH HIGH-RISK HEMATOLOGICAL DISORDERS. AIDS 2019;33(9):1441-1447.",,,A,,Y,,,20190911.0,,MD,ES,ES,EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Drug interaction;Hepatotoxicity;Neurotoxicity,167943861.0,OT,,,,,,,,,167943861.0,1.0,HIV infection
16799645,167996452,2,F,,20190916.0,20190912,20190918,EXP,,ZA-GILEAD-2019-0427152,GILEAD,,18.0,YR,A,F,Y,,,20190918.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Bradycardia foetal;Drug interaction;Foetal distress syndrome;Maternal exposure during pregnancy,167996452.0,OT,,,,,,,,,167996452.0,1.0,HIV infection
16801916,168019161,1,I,,20190906.0,20190912,20190912,EXP,,DE-MYLANLABS-2019M1084461,MYLAN,"RADMER S, KASTIRR I, ANDERSEN R.. OBSERVATION OF RECURRENT BONE MARROW OEDEMAS IN HIV PATIENTS ON ANTIVIRAL THERAPY. 2016 (ASBMR). ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH. 2016",62.0,YR,,M,Y,,,20190912.0,,,COUNTRY NOT SPECIFIED,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema;Foot fracture;Renal failure,168019161.0,OT,,,,,,,,,168019161.0,1.0,HIV infection
16803928,168039282,2,F,20190717.0,20191009.0,20190913,20191011,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019022900,MACLEODS,,,,,,Y,,,20191011.0,,CN,US,BR,LAMIVUDINE+ EFAVIRENZ + TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,168039282.0,OT,,,168039282.0,1.0,20170927.0,,,,168039282.0,1.0,HIV infection
16824327,168243271,1,I,200809.0,20190910.0,20190918,20190918,EXP,,ES-MYLANLABS-2019M1086577,MYLAN,,68.0,YR,,M,Y,69.5,KG,20190918.0,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis,168243271.0,OT,,,168243271.0,1.0,200805.0,,,,168243271.0,1.0,HIV infection
16831092,168310921,1,I,20190201.0,20190917.0,20190920,20190920,EXP,,US-GILEAD-2019-0428991,GILEAD,,54.0,YR,A,M,Y,,,20190920.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,168310921.0,OT,,,,,,,,,168310921.0,1.0,HIV infection
16832095,1683209510,10,F,,20231117.0,20190920,20231127,EXP,,ES-AUROBINDO-AUR-APL-2019-060571,AUROBINDO,"Kwon M, Bailen R, Balsalobre P, Jurado M, Bermudez A, Badiola J et.. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. AIDS. 2019;33(9):1441-1447",,,A,,Y,,,20231127.0,,MD,ES,ES,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA;Disseminated tuberculosis;Drug ineffective;Drug interaction;Hepatotoxicity;Neurotoxicity;Viral infection,1683209510.0,OT,,,1683209510.0,2.0,2008.0,,,,1683209510.0,1.0,HIV infection
16852039,168520391,1,I,,20190920.0,20190925,20190925,EXP,,US-GILEAD-2019-0429840,GILEAD,,,,,M,Y,,,20190925.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety;Depression;Diabetes mellitus;Pain,168520391.0,OT,,,,,,,,,168520391.0,1.0,HIV infection
16860477,168604772,2,F,200809.0,20191104.0,20190927,20191107,EXP,,ES-MYLANLABS-2019M1089643,MYLAN,,68.0,YR,,M,Y,69.5,KG,20191107.0,,MD,ES,ES,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN;EFAVIRENZ.",Pulmonary tuberculosis,168604772.0,OT,,,168604772.0,1.0,200805.0,200905.0,,,168604772.0,1.0,HIV infection
16862780,168627801,1,I,,20190925.0,20190927,20190927,EXP,,US-GILEAD-2019-0430355,GILEAD,,35.0,YR,A,M,Y,,,20190927.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gun shot wound,168627801.0,OT,,,,,,,,,168627801.0,1.0,HIV infection
16863601,168636012,2,F,20190806.0,20191017.0,20190927,20191023,EXP,GB-MHRA-EYC 00208628,GB-MYLANLABS-2019M1090380,MYLAN,,69.0,YR,,M,Y,,,20191023.0,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal pain upper;Diarrhoea;Product substitution issue,168636012.0,DS,,,168636012.0,1.0,20190806.0,20190821.0,,,168636012.0,1.0,HIV infection
16867501,168675012,2,F,20190301.0,20191017.0,20190930,20191022,EXP,GB-MHRA-EYC 00208612,GB-MYLANLABS-2019M1090169,MYLAN,,47.0,YR,,M,Y,,,20191022.0,,PH,GB,GB,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Abdominal distension;Depression;Diarrhoea;Product substitution issue;Suicidal ideation,168675012.0,DS,,,168675012.0,1.0,20190301.0,20190501.0,,,168675012.0,1.0,HIV infection
16884756,168847563,3,F,,20220414.0,20191004,20220419,EXP,,PT-MYLANLABS-2019M1091779,MYLAN,"Cardoso M, Baptista T,  Diogo I,  Aleixo MJ, Marques N, Mansinho K. et al.. Two cases of dolutegravir failure with R263K mutation. AIDS. 2018;32:2639-2642",29.0,YR,,F,Y,,,20220419.0,,HP,PT,PT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Gastrointestinal disorder;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,168847563.0,OT,,,,,,,,,168847563.0,1.0,HIV infection
16895338,168953381,1,I,20180303.0,20191001.0,20191008,20191008,EXP,,GB-MYLANLABS-2019M1092758,MYLAN,,31.0,YR,,F,Y,,,20191008.0,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,168953381.0,OT,,,,,,,,,168953381.0,1.0,HIV infection
16902940,169029401,1,I,,20190903.0,20191010,20191010,EXP,,BR-MYLANLABS-2019M1094721,MYLAN,,37.0,YR,,F,Y,,,20191010.0,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Maternal exposure during pregnancy,169029401.0,OT,,,169029401.0,1.0,20170927.0,,,,169029401.0,1.0,HIV infection
16931549,169315491,1,I,20191015.0,20191015.0,20191017,20191017,EXP,,US-GILEAD-2019-0433322,GILEAD,,43.0,YR,A,F,Y,,,20191017.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Unevaluable event,169315491.0,HO,,,169315491.0,1.0,201803.0,,,,169315491.0,1.0,HIV infection
16941947,169419471,1,I,20190620.0,20190923.0,20191021,20191021,EXP,GB-MHRA-EYC 00207191,GB-MYLANLABS-2019M1090161,MYLAN,,33.0,YR,,M,Y,,,20191021.0,,PH,GB,GB,Efavirenz/Emtricitabin/Tenofovirdisoproxil Mylan,Diarrhoea;Product substitution issue,169419471.0,DS,,,169419471.0,1.0,20190620.0,20190808.0,,,169419471.0,1.0,HIV infection
16960846,169608461,1,I,,20191017.0,20191025,20191025,EXP,,ZA-GILEAD-2019-0434475,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,3.1,KG,20191025.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningomyelocele,169608461.0,OT,,,,,,,,,169608461.0,1.0,HIV infection
16960853,169608532,2,F,,20191105.0,20191025,20191106,EXP,,ZA-GILEAD-2019-0434473,GILEAD,,,,N,,Y,,,20191106.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Low set ears;Talipes,169608532.0,CA,,,,,,,,,169608532.0,1.0,HIV infection
16961106,169611062,2,F,,20191105.0,20191025,20191107,EXP,,ZA-GILEAD-2019-0434476,GILEAD,,,,N,,Y,,,20191107.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft lip and palate;Foetal exposure during pregnancy,169611062.0,OT,,,,,,,,,169611062.0,1.0,HIV infection
16961170,169611701,1,I,,20191017.0,20191025,20191025,EXP,,ZA-GILEAD-2019-0434477,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,,,20191025.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dysmorphism;Foetal exposure during pregnancy;Micrognathia;Polydactyly,169611701.0,CA,,,,,,,,,169611701.0,1.0,HIV infection
16961241,169612412,2,F,,20191105.0,20191025,20191107,EXP,,ZA-GILEAD-2019-0434478,GILEAD,,,,N,,Y,,,20191107.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exomphalos;Foetal exposure during pregnancy,169612412.0,OT,,,,,,,,,169612412.0,1.0,HIV infection
16961463,169614632,2,F,,20191104.0,20191025,20191106,EXP,,ZA-GILEAD-2019-0434479,GILEAD,,,,N,,Y,,,20191106.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,169614632.0,CA,,,,,,,,,169614632.0,1.0,HIV infection
16962939,169629392,2,F,,20200129.0,20191025,20200131,EXP,,ZA-GILEAD-2019-0434474,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,,,20200131.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningomyelocele,169629392.0,OT,,,,,,,,,169629392.0,1.0,HIV infection
16970634,169706342,2,F,,20191029.0,20191029,20191101,EXP,,US-GILEAD-2019-0435047,GILEAD,,58.0,YR,A,M,Y,,,20191101.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Depression;Suicidal ideation,169706342.0,OT,,,169706342.0,1.0,2009.0,2015.0,,,169706342.0,1.0,HIV infection
16975294,169752941,1,I,20190501.0,20191025.0,20191030,20191030,EXP,GB-EMA-DD-20191023-KHARE_I-123904,GB-MYLANLABS-2019M1102559,MYLAN,,47.0,YR,,F,Y,,,20191030.0,,PH,GB,GB,Efavirenz/Emtricitabin/Tenofovirdisoproxil Mylan,Diarrhoea;Product substitution issue,169752941.0,DS,,,,,,,,,169752941.0,1.0,HIV infection
16978172,169781721,1,I,,20191029.0,20191031,20191031,EXP,,US-GILEAD-2019-0435343,GILEAD,,,,E,M,Y,,,20191031.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,169781721.0,HO,,,,,,,,,169781721.0,1.0,HIV infection
16989675,169896751,1,I,,20191029.0,20191104,20191104,EXP,,ZA-GILEAD-2019-0435459,GILEAD,,,,I,,Y,,,20191104.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hypospadias,169896751.0,OT,,,,,,,,,169896751.0,1.0,HIV infection
17075956,170759564,4,F,20031224.0,20211007.0,20191126,20211015,EXP,,US-GILEAD-2019-0439500,GILEAD,,63.0,YR,A,M,Y,,,20211014.0,,LW,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Foot fracture;Hand fracture;Hip fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure;Rib fracture,170759564.0,OT,,,170759564.0,1.0,20020730.0,20050901.0,1129.0,DAY,170759564.0,1.0,HIV infection
17086665,170866653,3,F,,20201204.0,20191128,20201216,EXP,,CA-APOTEX-2018AP015491,APOTEX,,,,,,Y,,,20201216.0,,CN,CA,CA,EMTRICITABINE/TENOFOVIR/EFAVIRENZ,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,170866653.0,CA,,,,,,,,,170866653.0,1.0,Prophylaxis against HIV infection
17111075,171110751,1,I,20191101.0,20191202.0,20191204,20191204,EXP,,US-GILEAD-2019-0440898,GILEAD,,42.0,YR,A,M,Y,,,20191204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Pneumonia;Product use issue;Pyrexia,171110751.0,OT,,,171110751.0,1.0,200912.0,,,,171110751.0,1.0,HIV infection
17127367,171273678,8,F,,20231216.0,20191209,20231226,EXP,,FR-AUROBINDO-AUR-APL-2019-103586,AUROBINDO,Gregorie M.. Les interactions m?dicamenteuses chez le patient ?g? vivant avec le VIH.[ Drug-drug interactions in older patients living with HIV]. La letter de l?infectiologie (Lett Infectiologue). 2019;34(5):212-7,64.0,YR,,F,Y,,,20231226.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cushing's syndrome;Drug interaction;Product administration error,171273678.0,HO,,,,,,,,,171273678.0,1.0,HIV infection
17160832,171608321,1,I,20171101.0,20191211.0,20191216,20191216,EXP,,ZA-GILEAD-2019-0442396,GILEAD,,25.0,YR,A,F,Y,,,20191216.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171608321.0,OT,,,171608321.0,1.0,20170606.0,,,,171608321.0,1.0,HIV infection
17160877,171608771,1,I,20181203.0,20191211.0,20191216,20191216,EXP,,ZA-GILEAD-2019-0442840,GILEAD,,32.0,YR,A,F,Y,,,20191216.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171608771.0,OT,,,171608771.0,1.0,20180315.0,,,,171608771.0,1.0,HIV infection
17163638,171636381,1,I,,20191216.0,20191217,20191217,EXP,,US-GILEAD-2019-0443063,GILEAD,,42.0,YR,A,M,Y,,,20191217.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,171636381.0,HO,,,,,,,,,171636381.0,1.0,HIV infection
17163716,171637161,1,I,2018.0,20191213.0,20191217,20191217,EXP,,US-GILEAD-2019-0442894,GILEAD,,65.0,YR,E,M,Y,,,20191217.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Prostate cancer,171637161.0,HO,,,,,,,,,171637161.0,1.0,HIV infection
17165297,171652971,1,I,20170813.0,20191211.0,20191217,20191217,EXP,,ZA-GILEAD-2019-0442856,GILEAD,,43.0,YR,A,F,Y,,,20191217.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171652971.0,OT,,,171652971.0,1.0,20170330.0,,,,171652971.0,1.0,HIV infection
17165320,171653201,1,I,20170501.0,20191211.0,20191217,20191217,EXP,,ZA-GILEAD-2019-0442388,GILEAD,,30.0,YR,A,F,Y,,,20191217.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171653201.0,OT,,,171653201.0,1.0,20170224.0,,,,171653201.0,1.0,HIV infection
17165324,171653241,1,I,20190506.0,20191212.0,20191217,20191217,EXP,,ZA-GILEAD-2019-0442860,GILEAD,,35.0,YR,A,F,Y,,,20191217.0,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,171653241.0,OT,,,171653241.0,1.0,20180117.0,,,,171653241.0,1.0,HIV infection
17166275,171662751,1,I,,20191210.0,20191217,20191217,EXP,,ES-MYLANLABS-2019M1123320,MYLAN,"RUIZ-ALGUERO M, SUAREZ-GARCIA I, ALVAREZ-DEL ARCO D, LAZARO P, MORENO S, JARRIN I.. USE OF HEALTH RESOURCES AND COSTS ASSOCIATED TO FIRST-LINE ANTIRETROVIRAL THERAPY IN THE ERA OF INTEGRASE INHIBITORS.. PHARMACEUTICAL CARE ESPANA.. 2019;21:86-109",,,A,,Y,,,20191217.0,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,171662751.0,OT,,,,,,,,,171662751.0,1.0,HIV infection
17220559,172205598,8,F,,20231127.0,20191231,20231201,EXP,,ES-MYLANLABS-2019M1132018,MYLAN,"Kwon M, Bailen R, Balsalobre P, Jurado M, Bermudez A, Badiola J, et al.. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. AIDS. 2019;33(9):1441-1447",,,A,,Y,,,20231201.0,,MD,ES,ES,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA;Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,172205598.0,OT,,,172205598.0,1.0,2008.0,,,,172205598.0,1.0,HIV infection
17297167,172971671,1,I,,20200116.0,20200121,20200121,EXP,,CA-TEVA-2020-CA-1172080,TEVA,,58.0,YR,,M,Y,,,20200121.0,,PH,CA,CA,TEVA EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Bone density decreased;Osteopenia;Pathological fracture,172971671.0,HO,,,,,,,,,172971671.0,1.0,HIV infection
17308135,173081351,1,I,,20200122.0,20200123,20200123,EXP,,US-GILEAD-2020-0447959,GILEAD,,44.0,YR,A,M,Y,,,20200123.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,173081351.0,OT,,,,,,,,,173081351.0,1.0,HIV infection
17345483,173454831,1,I,201706.0,20200128.0,20200129,20200129,EXP,,US-GILEAD-2020-0448846,GILEAD,,57.0,YR,A,M,Y,,,20200129.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aortic bypass;Walking aid user,173454831.0,HO,,,,,,,,,173454831.0,1.0,HIV infection
17347799,173477991,1,I,20170821.0,20200121.0,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010799,MYLAN,,25.0,YR,,M,Y,78.0,KG,20200130.0,,MD,MD,MD,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lip oedema;Pruritus;Rash,173477991.0,LT,,,173477991.0,1.0,20170815.0,,,,173477991.0,1.0,HIV infection
17347802,173478021,1,I,20171109.0,20200121.0,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010804,MYLAN,,38.0,YR,,M,Y,98.0,KG,20200130.0,,MD,MD,MD,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Pruritus;Pyrexia;Rash,173478021.0,LT,,,173478021.0,1.0,20171107.0,,,,173478021.0,1.0,HIV infection
17347841,173478411,1,I,20171004.0,20200121.0,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010803,MYLAN,,35.0,YR,,F,Y,97.0,KG,20200130.0,,MD,MD,MD,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Dyspnoea;Eyelid oedema;Lip oedema;Pruritus,173478411.0,LT,,,173478411.0,1.0,20171003.0,20171004.0,,,173478411.0,1.0,HIV infection
17438344,174383441,1,I,,20200217.0,20200220,20200220,EXP,,PH-AUROBINDO-AUR-APL-2020-009707,AUROBINDO,,22.0,YR,,M,Y,,,20200220.0,,HP,PH,PH,EFAVIRENZ+LAMIVUDINE +TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,174383441.0,OT,,,,,,,,,174383441.0,1.0,HIV infection
17440919,174409191,1,I,,20200212.0,20200220,20200220,EXP,,MM-MYLANLABS-2020M1018492,MYLAN,,50.0,YR,,F,Y,,,20200220.0,,HP,MM,MM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Haemolytic anaemia,174409191.0,HO,,,,,,,,,174409191.0,1.0,HIV infection
17452252,174522521,1,I,,20200221.0,20200224,20200224,EXP,,US-GILEAD-2020-0452212,GILEAD,,,,A,M,Y,,,20200224.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder;Post-traumatic stress disorder,174522521.0,OT,,,,,,,,,174522521.0,1.0,HIV infection
17463889,174638891,1,I,,20200213.0,20200226,20200226,EXP,,IN-MYLANLABS-2020M1019539,MYLAN,"GUPTA A, VERMA A, KASHYAP M, GAUTAM P. ART IN PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV. J-OBSTET-GYNECOL-INDIA 2020;70(1):18-22.",,,N,,Y,,,20200226.0,,MD,IN,IN,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Drug ineffective;Foetal exposure during pregnancy,174638891.0,OT,,,,,,,,,174638891.0,1.0,Prophylaxis against HIV infection
17463890,174638901,1,I,,20200213.0,20200226,20200226,EXP,,IN-MYLANLABS-2020M1019538,MYLAN,"GUPTA A, VERMA A, KASHYAP M, GAUTAM P. ART IN PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV. J-OBSTET-GYNECOL-INDIA 2020;70(1):18-22.",,,N,,Y,,,20200226.0,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Drug ineffective;Foetal exposure during pregnancy,174638901.0,OT,,,,,,,,,174638901.0,1.0,Prophylaxis against HIV infection
17466150,174661501,1,I,,20200220.0,20200227,20200227,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010629",BOEHRINGER INGELHEIM,,,,,,Y,,,20200227.0,,MD,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Ventricular septal defect,174661501.0,OT,,,,,,,,,174661501.0,1.0,HIV infection
17489680,174896802,2,F,2017.0,20200527.0,20200303,20200602,EXP,,PT-GILEAD-2020-0452706,GILEAD,,45.0,YR,A,M,Y,,,20200602.0,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,174896802.0,OT,,,174896802.0,1.0,2011.0,2017.0,,,174896802.0,1.0,HIV infection
17497427,174974272,2,F,20180301.0,20200723.0,20200304,20200728,EXP,,ZA-GILEAD-2020-0453451,GILEAD,,,,A,F,Y,,,20200728.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,174974272.0,OT,,,174974272.0,1.0,20170625.0,,,,174974272.0,1.0,HIV infection
17497566,174975661,1,I,20170918.0,20200303.0,20200304,20200304,EXP,,ZA-GILEAD-2020-0453453,GILEAD,,27.0,YR,A,F,Y,,,20200304.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,174975661.0,OT,,,174975661.0,1.0,20170821.0,,,,174975661.0,1.0,HIV infection
17502703,175027031,1,I,20180523.0,20200303.0,20200305,20200305,EXP,,ZA-GILEAD-2020-0453452,GILEAD,,30.0,YR,A,F,Y,,,20200305.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175027031.0,OT,,,175027031.0,1.0,20170830.0,,,,175027031.0,1.0,HIV infection
17511757,175117572,2,F,,20200306.0,20200307,20200317,EXP,,IN-AUROBINDO-AUR-APL-2020-012663,AUROBINDO,,1.0,MON,,,Y,,,20200317.0,,HP,IN,IN,Tenofovir+Lamivudine+Efavirenz 300mg+300mg+600mg,Foetal exposure during pregnancy;HIV test positive,175117572.0,OT,,,,,,,,,175117572.0,1.0,Prophylaxis against HIV infection
17512904,175129042,2,F,,20200306.0,20200308,20200319,EXP,,IN-AUROBINDO-AUR-APL-2020-012664,AUROBINDO,,12.0,MON,,,Y,,,20200319.0,,HP,IN,IN,Tenofovir+Lamivudine+Efavirenz 300mg+300mg+600mg,Congenital HIV infection;Drug ineffective;Foetal exposure during pregnancy,175129042.0,OT,,,,,,,,,175129042.0,1.0,Prophylaxis against HIV infection
17516037,175160371,1,I,,20200225.0,20200309,20200309,EXP,,BR-MYLANLABS-2020M1025758,MYLAN,,,,I,F,Y,2.1,KG,20200309.0,,HP,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Talipes,175160371.0,CA,,,175160371.0,1.0,20150302.0,,,,175160371.0,1.0,HIV infection
17534028,175340281,1,I,20190201.0,20200311.0,20200312,20200312,EXP,,US-GILEAD-2020-0454656,GILEAD,,56.0,YR,A,M,Y,,,20200312.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal disorder;Renal impairment,175340281.0,DS,,,,,,,,,175340281.0,1.0,HIV infection
17550710,175507101,1,I,20190719.0,20200316.0,20200317,20200317,EXP,,ZA-GILEAD-2020-0455237,GILEAD,,27.0,YR,A,F,Y,,,20200317.0,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175507101.0,OT,,,175507101.0,1.0,20180503.0,,,,175507101.0,1.0,HIV infection
17578374,175783741,1,I,,20200316.0,20200324,20200324,EXP,,US-GILEAD-2020-0455585,GILEAD,"KROWN SE, MOSER CB, MACPHAIL P, MATINING RM, GODFREY C, CARUSO SR, HOSSEINIPOUR MC, SAMANEKA W, NYIRENDA M, BUSAKHALA NW, OKUKU FM,. TREATMENT OF ADVANCED AIDS-ASSOCIATED KAPOSI SARCOMA IN RESOURCE-LIMITED SETTINGS: A THREE-ARM, OPEN-LABEL, RANDOMISED, NON-INFERIORITY TRIAL. LANCET. 2020;UNK:UNK. DOI:HTTPS://DOI.ORG/10.1016/S0140-6736(19)33222-2",,,A,F,Y,,,20200324.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175783741.0,OT,,,,,,,,,175783741.0,1.0,HIV infection
17587129,175871292,2,F,2017.0,20200609.0,20200326,20200611,EXP,,PT-MYLANLABS-2020M1031812,MYLAN,,45.0,YR,,M,Y,,,20200611.0,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,175871292.0,HO,,,175871292.0,1.0,2011.0,2017.0,,,175871292.0,1.0,HIV infection
17688433,176884331,1,I,,20200407.0,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068225,GLAXOSMITHKLINE,,41.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR;EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176884331.0,OT,,,,,,,,,176884331.0,1.0,HIV infection
17688440,176884401,1,I,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068225,VIIV,,41.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR;EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,176884401.0,OT,,,,,,,,,176884401.0,1.0,HIV infection
17689185,176891851,1,I,,20200407.0,20200421,20200421,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2020GSK068226,VIIV,,29.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Pathogen resistance;Viral mutation identified;Virologic failure,176891851.0,OT,,,,,,,,,176891851.0,1.0,HIV infection
17689186,176891861,1,I,,20200407.0,20200421,20200421,EXP,,TW-GLAXOSMITHKLINE-TW2020GSK068226,GLAXOSMITHKLINE,,29.0,YR,,M,Y,,,20200421.0,,HP,TW,TW,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Pathogen resistance;Viral mutation identified;Virologic failure,176891861.0,OT,,,,,,,,,176891861.0,1.0,HIV infection
17709802,177098021,1,I,,20200420.0,20200427,20200427,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020596",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200427.0,,HP,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177098021.0,OT,,,,,,,,,177098021.0,1.0,HIV infection
17716006,177160061,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020921",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428.0,,HP,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177160061.0,OT,,,,,,,,,177160061.0,1.0,HIV infection
17716091,177160911,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020886",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428.0,,MD,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL MALEATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177160911.0,OT,,,,,,,,,177160911.0,1.0,HIV infection
17716385,177163851,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020997",BOEHRINGER INGELHEIM,,,,,F,Y,,,20200428.0,,HP,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177163851.0,OT,,,,,,,,,177163851.0,1.0,HIV infection
17716551,177165511,1,I,,20200421.0,20200428,20200428,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-020873",BOEHRINGER INGELHEIM,,,,,,Y,,,20200428.0,,HP,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,177165511.0,OT,,,,,,,,,177165511.0,1.0,HIV infection
17812978,178129781,1,I,,20200514.0,20200521,20200521,EXP,,ID-MYLANLABS-2020M1050863,MYLAN,,,,A,,Y,,,20200521.0,,HP,ID,ID,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Hypothyroidism,178129781.0,OT,,,,,,,,,178129781.0,1.0,Acquired immunodeficiency syndrome
17818786,178187861,1,I,,20200520.0,20200522,20200522,EXP,,US-GILEAD-2020-0468026,GILEAD,,,,A,M,Y,,,20200522.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal distension;Chromaturia;Intentional product use issue;Jaundice;Malaise;Pruritus;Renal disorder,178187861.0,OT,,,,,,,,,178187861.0,1.0,HIV infection
17822580,178225801,1,I,,20200520.0,20200526,20200526,EXP,,US-GILEAD-2020-0468275,GILEAD,,64.0,YR,A,F,Y,,,20200526.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Liver injury,178225801.0,OT,,,,,,,,,178225801.0,1.0,HIV infection
17835877,178358771,1,I,201305.0,20200526.0,20200528,20200528,EXP,,US-GILEAD-2020-0468908,GILEAD,,61.0,YR,A,M,Y,,,20200528.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Type 2 diabetes mellitus,178358771.0,OT,,,178358771.0,1.0,201201.0,201801.0,,,178358771.0,1.0,HIV infection
17875895,178758951,1,I,202003.0,20200608.0,20200609,20200609,EXP,,US-GILEAD-2020-0470925,GILEAD,,66.0,YR,A,M,Y,,,20200609.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Intentional product use issue,178758951.0,OT,,,,,,,,,178758951.0,1.0,HIV infection
17893955,178939553,3,F,,20200728.0,20200615,20200805,EXP,,FR-AUROBINDO-AUR-APL-2020-028781,AUROBINDO,M. GREGOIRE. DRUG?DRUG INTERACTIONS IN ELDERLY PATIENTS LIVING WITH HIV. LA LETTRE DE L^LNFECTIOLOGUE. 2019?5:212?7,64.0,YR,,F,Y,,,20200805.0,,MD,FR,FR,Efavirenz+Emtricitabine+Tenofovir,Cushing's syndrome;Drug interaction,178939553.0,OT,,,,,,,,,178939553.0,1.0,HIV infection
17894471,178944711,1,I,2017.0,20200605.0,20200615,20200615,EXP,,PT-AUROBINDO-AUR-APL-2020-028611,AUROBINDO,,45.0,YR,,M,Y,,,20200615.0,,MD,PT,PT,EFAVIRENZ+EMTRICITABINE+TENOFOVIR FILM COATED TABLETS,Acute myocardial infarction;Blood creatinine abnormal;Cardiac failure acute;Cardiorenal syndrome;Dyslipidaemia;Headache;Hepatic function abnormal;Insomnia;Renal disorder;Renal impairment,178944711.0,OT,,,178944711.0,1.0,2011.0,2017.0,,,178944711.0,1.0,HIV infection
17898801,178988011,1,I,20190724.0,20200610.0,20200615,20200615,EXP,,ZA-GILEAD-2020-0472264,GILEAD,,22.0,YR,A,F,Y,,,20200615.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,178988011.0,OT,,,178988011.0,1.0,20180319.0,,,,178988011.0,1.0,HIV infection
17913197,179131971,1,I,,20200615.0,20200618,20200618,EXP,,US-GILEAD-2020-0473214,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS.. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):1845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618.0,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dyspnoea;Immune reconstitution inflammatory syndrome associated tuberculosis;Pleural effusion,179131971.0,OT,,,,,,,,,179131971.0,1.0,HIV infection
17913215,179132151,1,I,,20200615.0,20200618,20200618,EXP,,US-GILEAD-2020-0473215,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS.. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):1845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618.0,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Intestinal obstruction,179132151.0,OT,,,,,,,,,179132151.0,1.0,HIV infection
17913217,179132171,1,I,,20200615.0,20200618,20200618,EXP,,US-GILEAD-2020-0473216,GILEAD,"RAVIMOHAN S, AULD S.C, MAENETJE P, RATSELA N, MLOTSHWA M, NCUBE I, SMITH J.P, VANGU M.-D.-T, SEBE M, KOSSENKOV A, WEISSMAN D, WALLIS R.S, CHURCHYARD G, KORNFELD H. BISSON G.P.. LUNG INJURY ON ANTIRETROVIRAL THERAPY IN ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS/TUBERCULOSIS. CLINICAL INFECTIOUS DISEASES. 2020;70 (9):845-1854. DOI:10.1093/CID/CIZ560",,,A,,Y,,,20200618.0,,MD,US,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenopathy,179132171.0,OT,,,,,,,,,179132171.0,1.0,HIV infection
17915851,179158511,1,I,,20200608.0,20200619,20200619,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-045409,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,,,20200619.0,,HP,FR,FR,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Cushing's syndrome;Labelled drug-drug interaction medication error,179158511.0,OT,,,,,,,,,179158511.0,1.0,HIV infection
17941267,179412671,1,I,201908.0,20200619.0,20200624,20200624,EXP,,US-GILEAD-2020-0475282,GILEAD,,59.0,YR,A,M,Y,,,20200624.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Eye disorder,179412671.0,HO,,,179412671.0,1.0,201806.0,201806.0,,,179412671.0,1.0,HIV infection
17969930,179699301,1,I,,20200629.0,20200701,20200701,EXP,,US-GILEAD-2020-0477732,GILEAD,,,,A,M,Y,,,20200701.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;HIV infection,179699301.0,OT,,,,,,,,,179699301.0,1.0,Prophylaxis against HIV infection
18047788,180477883,3,F,20191001.0,20200731.0,20200721,20200807,EXP,,ZA-AUROBINDO-AUR-APL-2020-036019,AUROBINDO,,20.0,YR,,F,Y,,,20200807.0,,HP,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Maternal exposure during pregnancy,180477883.0,OT,,,180477883.0,1.0,20180710.0,,,,180477883.0,1.0,HIV infection
18047798,180477983,3,F,20200410.0,20200731.0,20200721,20200807,EXP,,ZA-AUROBINDO-AUR-APL-2020-036030,AUROBINDO,,30.0,YR,,F,Y,,,20200807.0,,HP,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Maternal exposure during pregnancy,180477983.0,OT,,,180477983.0,1.0,20180510.0,,,,180477983.0,1.0,HIV infection
18064001,180640011,1,I,,20200713.0,20200724,20200724,EXP,,UG-CIPLA LTD.-2020UG04953,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21: 232:1 TO 6",,,,,Y,,,20200724.0,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180640011.0,OT,,,,,,,,,180640011.0,1.0,HIV infection WHO clinical stage II
18064080,180640801,1,I,,20200713.0,20200724,20200724,EXP,,UG-CIPLA LTD.-2020UG04954,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P.. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21(232):1 TO 6",,,,,Y,,,20200724.0,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hyperphosphataemia;Hypocalcaemia,180640801.0,OT,,,,,,,,,180640801.0,1.0,HIV infection WHO clinical stage II
18078182,180781821,1,I,,20200713.0,20200728,20200728,EXP,,UG-CIPLA LTD.-2020UG04957,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200728.0,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia,180781821.0,OT,,,,,,,,,180781821.0,1.0,HIV infection WHO clinical stage II
18079395,180793951,1,I,,20200713.0,20200728,20200728,EXP,,UG-CIPLA LTD.-2020UG04989,CIPLA,"NYENDE L, KALYESUBULA R, SEKASANVU E, BYAKIKA?KIBWIKA P. PREVALENCE OF RENAL DYSFUNCTION AMONG HIV INFECTED PATIENTS RECEIVING TENOFOVIR AT MULAGO: A CROSS?SECTIONAL STUDY. BMC NEPHROLOGY. 2020?21 (232):1 TO 6",,,,,Y,,,20200728.0,,HP,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Hyperkalaemia;Hypocalcaemia,180793951.0,OT,,,,,,,,,180793951.0,1.0,HIV infection WHO clinical stage II
18095441,180954411,1,I,2016.0,20200723.0,20200730,20200730,EXP,,TZ-MYLANLABS-2020M1068658,MYLAN,"BACHA JM, EL?MALLAWANY NK, SLONE JS, WILKINSON JP, MEHTA PS, CAMPBELL LR. RECOMMENDATIONS FOR TREATING LIFE?THREATENING KAPOSI SARCOMA DURING PREGNANCY IN HIV?POSITIVE WOMEN IN LOW INCOME COUNTRIES. INT?J?STD?AIDS 2020?31(8):724?734.",31.0,YR,,F,Y,,,20200730.0,,HP,TZ,TZ,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abdominal pain;Dysphagia;Dyspnoea;Exposure via breast milk;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Lymphadenopathy;Maternal exposure during pregnancy;Obstructive airways disorder;Oral candidiasis,180954411.0,OT,,,180954411.0,1.0,2016.0,2016.0,,,180954411.0,1.0,HIV infection
18117153,181171531,1,I,201909.0,20200731.0,20200805,20200805,EXP,,US-GILEAD-2020-0488858,GILEAD,,50.0,YR,A,F,Y,,,20200805.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Product use issue,181171531.0,OT,,,181171531.0,1.0,2007.0,201909.0,,,181171531.0,1.0,HIV infection
18133234,181332341,1,I,,20200803.0,20200811,20200811,EXP,,TZ-AUROBINDO-AUR-APL-2020-038325,AUROBINDO,,31.0,YR,,F,Y,,,20200811.0,,HP,TZ,TZ,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Abdominal pain;Condition aggravated;Dysphagia;Dyspnoea;Exposure during pregnancy;Haematemesis;Haematochezia;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Lymphadenopathy;Oral candidiasis,181332341.0,OT,,,,,,,,,181332341.0,1.0,HIV infection
18147382,181473824,4,F,20130101.0,20230402.0,20200813,20230406,EXP,,US-GILEAD-2020-0489260,GILEAD,,41.0,YR,A,M,Y,111.11,KG,20230406.0,,LW,US,US,EFAVIRENZ;EFAVIRENZ;EMTRICITABINE;TENOFOVIR;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal impairment,181473824.0,HO,,,181473824.0,1.0,2001.0,201607.0,,,181473824.0,1.0,HIV infection
18412028,184120281,1,I,,20201015.0,20201021,20201021,EXP,,US-GILEAD-2020-0500156,GILEAD,,,,,F,Y,,,20201021.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatic cirrhosis;Mental disorder;Product use issue,184120281.0,OT,,,184120281.0,1.0,200611.0,201111.0,,,184120281.0,1.0,HIV infection
18415398,184153981,1,I,,20201015.0,20201022,20201022,EXP,,US-GILEAD-2020-0500374,GILEAD,,,,A,M,Y,,,20201022.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Fatigue;Inflammation;Lower limb fracture,184153981.0,OT,,,,,,,,,184153981.0,1.0,HIV infection
18441543,184415431,1,I,20201007.0,20201021.0,20201029,20201029,EXP,,US-GILEAD-2020-0500587,GILEAD,,48.0,YR,A,M,Y,,,20201029.0,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis;Product use issue,184415431.0,OT,,,184415431.0,1.0,,20201007.0,,,184415431.0,1.0,HIV infection
18462213,184622131,1,I,,20201026.0,20201104,20201104,EXP,,IT-MYLANLABS-2020M1092154,MYLAN,,,,,,Y,,,20201104.0,,HP,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Virologic failure,184622131.0,OT,,,,,,,,,184622131.0,1.0,HIV infection
18487650,184876507,7,F,20201027.0,20220317.0,20201111,20220321,EXP,,CN-GILEAD-2020-0503255,GILEAD,,,,A,M,Y,80.0,KG,20220321.0,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Pneumonia,184876507.0,OT,,,184876507.0,1.0,20201014.0,20201027.0,13.0,DAY,184876507.0,1.0,HIV infection
18499093,184990932,2,F,20200831.0,20201111.0,20201112,20201120,EXP,,TH-GILEAD-2020-0502294,GILEAD,,,,A,F,Y,49.8,KG,20201120.0,,HP,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,False labour;Maternal exposure during pregnancy,184990932.0,HO,,,184990932.0,1.0,20200831.0,20201106.0,,,184990932.0,1.0,HIV infection
18509915,185099151,1,I,,20201110.0,20201117,20201117,EXP,,FR-GILEAD-2020-0504313,GILEAD,,54.0,YR,A,M,Y,,,20201117.0,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,185099151.0,OT,,,185099151.0,1.0,2009.0,,,,185099151.0,1.0,HIV infection
18514093,185140931,1,I,,20201105.0,20201118,20201118,EXP,,US-CIPLA LTD.-2020ZM08732,CIPLA,"NAVIS A, DALLAH I, MABETA C, MUSUKUMA K, SIDDIQI OK, BOSITIS CM ET AL.. EVALUATING THE IMPACT OF ANTIRETROVIRAL AND ANTISEIZURE MEDICATION INTERACTIONS ON TREATMENT EFFECTIVENESS AMONG OUTPATIENT CLINIC ATTENDEES WITH HIV IN ZAMBIA. EPILEPSIA. 2020;00:1 TO 7",,,,,Y,,,20201118.0,,HP,US,ZM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Drug interaction;Drug resistance;Virologic failure,185140931.0,OT,,,,,,,,,185140931.0,1.0,HIV infection
18514534,185145341,1,I,,20201105.0,20201118,20201118,EXP,,ZM-CIPLA LTD.-2020ZM08731,CIPLA,"NAVIS A, DALLAH I, MABETA C, MUSUKUMA K, SIDDIQI OK, BOSITIS CM ET AL.. EVALUATING THE IMPACT OF ANTIRETROVIRAL AND ANTISEIZURE MEDICATION INTERACTIONS ON TREATMENT EFFECTIVENESS AMONG OUTPATIENT CLINIC ATTENDEES WITH HIV IN ZAMBIA. EPILEPSIA. 2020;00:1 TO 7",,,,,Y,,,20201118.0,,HP,ZM,ZM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Condition aggravated;Drug interaction;Drug resistance;Seizure;Virologic failure,185145341.0,OT,,,,,,,,,185145341.0,1.0,HIV infection
18549520,185495201,1,I,,20201123.0,20201126,20201126,EXP,,BR-AUROBINDO-AUR-APL-2020-058745,AUROBINDO,,,,I,F,Y,2.1,KG,20201126.0,,HP,BR,BR,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Foetal exposure during pregnancy;Talipes,185495201.0,CA,,,,,,,,,185495201.0,1.0,HIV infection
18552079,185520791,1,I,,20201118.0,20201127,20201127,EXP,,FR-AUROBINDO-AUR-APL-2020-058453,AUROBINDO,,54.0,YR,,M,Y,,,20201127.0,,CN,FR,FR,EFAVIRENZ+EMTRICITABINE+TENOFOVIR FILM COATEDTABLETS,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,185520791.0,OT,,,185520791.0,1.0,2012.0,,,,185520791.0,1.0,HIV infection
18557618,185576181,1,I,,20201118.0,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08985,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11 (4):158 TO 163",,,,,Y,,,20201130.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185576181.0,OT,,,,,,,,,185576181.0,1.0,HIV infection
18557619,185576191,1,I,,20201118.0,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08987,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB.. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI.. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11(4):158 TO 163",,,,,Y,,,20201130.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185576191.0,OT,,,,,,,,,185576191.0,1.0,HIV infection
18557976,185579761,1,I,,20201118.0,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08986,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11(4):158 TO 163",,,,,Y,,,20201130.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185579761.0,OT,,,,,,,,,185579761.0,1.0,HIV infection
18590594,185905941,1,I,1992.0,20201201.0,20201208,20201208,EXP,,US-GILEAD-2020-0506915,GILEAD,,57.0,YR,A,F,Y,,,20201208.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,185905941.0,OT,,,185905941.0,1.0,1990.0,1992.0,,,185905941.0,1.0,HIV infection
18601829,186018291,1,I,,20201202.0,20201210,20201210,EXP,,FR-MYLANLABS-2020M1100726,MYLAN,,54.0,YR,,M,Y,,,20201210.0,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,186018291.0,OT,,,186018291.0,1.0,2009.0,,,,186018291.0,1.0,HIV infection
18654345,186543454,4,F,20200731.0,20210831.0,20201223,20210902,EXP,,ZA-GILEAD-2020-0494586,GILEAD,,40.0,YR,A,F,Y,70.7,KG,20210902.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Transaminases increased,186543454.0,OT,,,186543454.0,1.0,20170309.0,20200909.0,,,186543454.0,1.0,HIV infection
18654547,186545471,1,I,2015.0,20201216.0,20201223,20201223,EXP,,US-GILEAD-2020-0509577,GILEAD,,,,E,M,Y,,,20201223.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Ligament sprain;Near death experience,186545471.0,OT,,,,,,,,,186545471.0,1.0,HIV infection
18659618,186596181,1,I,201901.0,20201218.0,20201223,20201223,EXP,,US-GILEAD-2020-0510286,GILEAD,,46.0,YR,A,M,Y,,,20201223.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Rash;Renal injury;Weight increased,186596181.0,OT,,,186596181.0,1.0,20190201.0,201812.0,,,186596181.0,1.0,HIV infection
18710148,187101483,3,F,20201125.0,20210219.0,20210107,20210329,EXP,,FR-AUROBINDO-AUR-APL-2021-000435,AUROBINDO,,57.0,YR,,M,Y,60.0,KG,20210329.0,,MD,FR,FR,Efavirenz+Emtricitabine+Tenofovir Film  coated Tablets,Drug ineffective;Drug interaction;Viral load increased,187101483.0,OT,,,,,,,,,187101483.0,1.0,HIV infection
18714732,187147322,2,F,20100215.0,20210202.0,20210107,20210205,EXP,,US-GILEAD-2021-0511881,GILEAD,,48.0,YR,A,F,Y,,,20210205.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deep vein thrombosis,187147322.0,OT,,,187147322.0,2.0,201607.0,,,,187147322.0,1.0,HIV infection
18724742,187247422,2,F,,20210108.0,20210111,20210204,EXP,,US-GILEAD-2021-0512233,GILEAD,,,,A,F,Y,,,20210204.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Colon cancer,187247422.0,OT,,,,,,,,,187247422.0,1.0,HIV infection
18727592,187275924,4,F,20191201.0,20211209.0,20210111,20211228,EXP,,US-GILEAD-2021-0511928,GILEAD,,74.0,YR,E,F,Y,,,20211228.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Arthralgia;CD4 lymphocytes abnormal;CD4 lymphocytes decreased;Cataract;Chronic obstructive pulmonary disease;Coronavirus infection;Dry age-related macular degeneration;Hiatus hernia;Memory impairment;Pulmonary function test decreased;Rib fracture;Visual impairment;Weight increased,187275924.0,DS,,,187275924.0,1.0,20210301.0,,,,187275924.0,1.0,HIV infection
18731963,187319631,1,I,,20210104.0,20210112,20210112,EXP,,US-GILEAD-2021-0512196,GILEAD,,36.0,YR,A,M,Y,,,20210112.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gait inability;Hallucination;Insomnia;Loss of consciousness;Multiple sclerosis relapse,187319631.0,OT,,,,,,,,,187319631.0,1.0,HIV infection
18750981,187509811,1,I,2009.0,20210113.0,20210118,20210118,EXP,,US-GILEAD-2021-0513037,GILEAD,,58.0,YR,A,M,Y,,,20210118.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone disorder;Nightmare;Osteoporosis,187509811.0,OT,,,187509811.0,1.0,,2018.0,,,187509811.0,1.0,HIV infection
18768016,187680161,1,I,,20210115.0,20210121,20210121,EXP,,US-GILEAD-2021-0513663,GILEAD,,56.0,YR,A,M,Y,,,20210121.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Hip arthroplasty;Knee arthroplasty;Tooth fracture,187680161.0,OT,,,,,,,,,187680161.0,1.0,HIV infection
18775907,187759071,1,I,20191201.0,20201218.0,20210122,20210122,EXP,,US-GILEAD-2020-0510261,GILEAD,,46.0,YR,A,M,Y,,,20210122.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Rash;Renal injury;Weight increased,187759071.0,OT,,,187759071.0,1.0,20090501.0,20191231.0,,,187759071.0,1.0,HIV infection
18819739,188197391,1,I,,20210125.0,20210202,20210202,EXP,,IT-AUROBINDO-AUR-APL-2021-004140,AUROBINDO,,51.0,YR,,,Y,,,20210202.0,,CN,IT,IT,Efavirenz+Emtricitabine+Tenofovir Film  coated Tablets,Drug ineffective,188197391.0,OT,,,,,,,,,188197391.0,1.0,HIV infection
18864315,188643151,1,I,,20210201.0,20210209,20210209,EXP,,ZA-GILEAD-2021-0515778,GILEAD,"MOUTON J, JOBANPUTRA N, NJUGUNA C, GUNTER H, STEWART A, MEHTA U, LAHRI S, COURT R, IGUMBOR E, MAARTENS G, COHEN K. ADULT MEDICAL EMERGENCY UNIT PRESENTATIONS DUE TO ADVERSE DRUG REACTIONS IN A SETTING OF HIGH HIV PREVALENCE. AFR J EMERG MED.. 2021?UNK:46?52. DOI:10.1016/J.AFJEM.2020.10.010",45.0,YR,A,F,Y,,,20210209.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Drug-induced liver injury,188643151.0,OT,,,,,,,,,188643151.0,1.0,HIV infection
18864398,188643981,1,I,,20210201.0,20210209,20210209,EXP,,ZA-GILEAD-2021-0516372,GILEAD,"MOUTON J, JOBANPUTRA N, NJUGUNA C, GUNTER H, STEWART A, MEHTA U, LAHRI S, COURT R, IGUMBOR E, MAARTENS G, COHEN K. ADULT MEDICAL EMERGENCY UNIT PRESENTATIONS DUE TO ADVERSE DRUG REACTIONS IN A SETTING OF HIGH HIV PREVALENCE. AFR J EMERG MED.. 2021?UNK:46?52. DOI:10.1016/J.AFJEM.2020.10.010",33.0,YR,A,F,Y,,,20210209.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,188643981.0,OT,,,,,,,,,188643981.0,1.0,HIV infection
18864489,188644891,1,I,,20210201.0,20210209,20210209,EXP,,ZA-GILEAD-2021-0516373,GILEAD,"MOUTON J, JOBANPUTRA N, NJUGUNA C, GUNTER H, STEWART A, MEHTA U, LAHRI S, COURT R, IGUMBOR E, MAARTENS G, COHEN K. ADULT MEDICAL EMERGENCY UNIT PRESENTATIONS DUE TO ADVERSE DRUG REACTIONS IN A SETTING OF HIGH HIV PREVALENCE. AFR J EMERG MED.. 2021?UNK:46?52. DOI:10.1016/J.AFJEM.2020.10.010",38.0,YR,A,F,Y,,,20210209.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,188644891.0,OT,,,,,,,,,188644891.0,1.0,HIV infection
18864664,188646641,1,I,,20210201.0,20210209,20210209,EXP,,ZA-GILEAD-2021-0516374,GILEAD,"MOUTON J, JOBANPUTRA N, NJUGUNA C, GUNTER H, STEWART A, MEHTA U, LAHRI S, COURT R, IGUMBOR E, MAARTENS G, COHEN K. ADULT MEDICAL EMERGENCY UNIT PRESENTATIONS DUE TO ADVERSE DRUG REACTIONS IN A SETTING OF HIGH HIV PREVALENCE. AFR J EMERG MED.. 2021?UNK:46?52. DOI:10.1016/J.AFJEM.2020.10.010",32.0,YR,A,F,Y,,,20210209.0,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,188646641.0,OT,,,,,,,,,188646641.0,1.0,HIV infection
18870387,188703878,8,F,20210101.0,20220530.0,20210209,20220603,EXP,,CN-GILEAD-2021-0515844,GILEAD,,,,A,M,Y,62.0,KG,20220603.0,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Liver injury,188703878.0,HO,,,188703878.0,1.0,20201229.0,20210112.0,14.0,DAY,188703878.0,1.0,HIV infection
18898554,188985542,2,F,,20210213.0,20210216,20210226,EXP,,US-MYLANLABS-2021M1009639,MYLAN,,,,,M,Y,,,20210226.0,,LW,US,US,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abnormal dreams;Blood creatinine increased;Blood lactic acid increased;Dizziness;Insomnia;Liver disorder;Liver injury;Mental disorder;Nightmare;Renal failure,188985542.0,OT,,,188985542.0,1.0,20181012.0,202007.0,,,188985542.0,1.0,HIV infection
18994764,189947641,1,I,201901.0,20210302.0,20210310,20210310,EXP,,US-GILEAD-2021-0519571,GILEAD,,59.0,YR,A,M,Y,,,20210310.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bedridden;Coronary artery surgery;Depression;Gait disturbance;Underweight,189947641.0,OT,,,189947641.0,1.0,199001.0,,,,189947641.0,1.0,HIV infection
18997529,189975291,1,I,,20210303.0,20210311,20210311,EXP,,US-MYLANLABS-2021M1014513,MYLAN,"HANDOKO RC, CHAN P, JAGODZINSKI L, PINYAKORN S, PHANUPHAK N, SACDALAN C, ET AL. MINIMAL INCIDENCE OF CSF ESCAPE AFTER INITIATION OF ART IN ACUTE HIV INFECTION. TOP?ANTIVIR?MED 2019?27 (SUPPL. 1):163S?164S ABSTR. 450.",,,,M,Y,,,20210311.0,,HP,US,US,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Treatment failure,189975291.0,OT,,,,,,,,,189975291.0,1.0,Antiretroviral therapy
19012996,190129961,1,I,20200127.0,20210309.0,20210315,20210315,EXP,,UG-ORGANON-O2103UGA001729,ORGANON,,,,,F,Y,,,20210315.0,,CN,UG,UG,EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,190129961.0,OT,,,190129961.0,1.0,20190403.0,,,,190129961.0,2.0,Antiretroviral therapy
19040462,190404621,1,I,,20210310.0,20210323,20210323,EXP,,IN-CIPLA LTD.-2021IN02132,CIPLA,,,,,,Y,,,20210323.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Treatment failure;Viral load increased,190404621.0,OT,,,,,,,,,190404621.0,1.0,Acquired immunodeficiency syndrome
19063172,190631722,2,F,2016.0,20210325.0,20210326,20210330,EXP,,US-MYLANLABS-2021M1017154,MYLAN,,52.0,YR,,M,Y,,,20210330.0,,LW,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anhedonia;Arthralgia;Bone density decreased;Hip fracture;Multiple fractures;Osteoporosis;Pain;Renal injury;Skeletal injury;Spinal compression fracture,190631722.0,OT,,,190631722.0,1.0,20150126.0,20181204.0,,,190631722.0,1.0,HIV infection
19069028,190690281,1,I,,20210321.0,20210329,20210329,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-028187,BRISTOL MYERS SQUIBB,,58.0,YR,,M,Y,,,20210329.0,,MD,GB,GB,EFAVIRENZ + EMTRICITABINE + TENOFOVIR [EFAVIRENZ;EMTRICITABINE;TENOFOVIR];EFAVIRENZ.,Nephropathy toxic,190690281.0,OT,,,,,,,,,190690281.0,1.0,HIV infection
19131435,191314352,2,F,20210224.0,20210408.0,20210413,20210415,EXP,PT-INFARMED-E202103-1731,PT-GILEAD-2021-0524807,GILEAD,,40.0,YR,A,F,Y,,,20210415.0,,PH,PT,PT,EFAVIRENZ + EMTRICITABINA + TENOFOVIR TEVA,Dizziness;Insomnia;Malaise;Nausea;Vomiting,191314352.0,OT,,,191314352.0,1.0,20210224.0,20210224.0,,,191314352.0,1.0,HIV infection
19151364,191513641,1,I,,20210413.0,20210419,20210419,EXP,,DE-GILEAD-2021-0525554,GILEAD,,,,,M,Y,,,20210419.0,,HP,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypophosphataemia;Renal salt-wasting syndrome,191513641.0,OT,,,191513641.0,1.0,200706.0,201704.0,,,191513641.0,1.0,HIV infection
19159610,191596102,2,F,20210224.0,20210425.0,20210420,20210504,EXP,PT-INFARMED-E202103-1731,PT-TEVA-2021-PT-1901567,TEVA,,40.0,YR,A,F,Y,,,20210504.0,,PH,PT,PT,Efavirenz + Emtricitabina + Tenofovir Teva,Dizziness;Insomnia;Malaise;Nausea;Vomiting,191596102.0,OT,,,191596102.0,1.0,20210224.0,20210224.0,,,191596102.0,1.0,HIV infection
19194327,191943271,1,I,,20210422.0,20210429,20210429,EXP,,US-GILEAD-2021-0527118,GILEAD,,60.0,YR,A,M,Y,,,20210429.0,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis;Renal failure,191943271.0,OT,,,191943271.0,1.0,2010.0,,,,191943271.0,1.0,HIV infection
19228048,192280483,3,F,202007.0,20210527.0,20210506,20210603,EXP,,AR-ORGANON-O2105ARG000146,ORGANON,,28.0,YR,,F,Y,,,20210603.0,,CN,AR,AR,EFAVIRENZ + EMTRICITABINE + TENOFOVIR [EFAVIRENZ;EMTRICITABINE;TENOFOV,Abortion induced;Inappropriate schedule of product administration;Pregnancy with implant contraceptive;Unintended pregnancy,192280483.0,HO,,,192280483.0,1.0,202007.0,20210427.0,,,192280483.0,2.0,HIV infection
19256891,192568911,1,I,,20210510.0,20210514,20210514,EXP,,IN-AUROBINDO-AUR-APL-2021-019684,AUROBINDO,,,,,,Y,,,20210514.0,,HP,IN,IN,Tenofovir+Lamivudine+Efavirenz,Acute kidney injury;Renal tubular disorder,192568911.0,OT,,,,,,,,,192568911.0,1.0,HIV infection
19258173,192581731,1,I,2006.0,20210512.0,20210514,20210514,EXP,,US-GILEAD-2021-0530516,GILEAD,,,,A,F,Y,,,20210514.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebral disorder;Cerebrovascular accident,192581731.0,OT,,,,,,,,,192581731.0,1.0,HIV infection
19307378,193073781,1,I,20210520.0,20210521.0,20210526,20210526,EXP,,US-GILEAD-2021-0532524,GILEAD,,43.0,YR,A,F,Y,,,20210526.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Brain neoplasm;Dementia;Gait inability;Renal cyst;Spinal disorder,193073781.0,OT,,,,,,,,,193073781.0,1.0,HIV infection
19350179,193501791,1,I,20190909.0,,20210531,20210531,DIR,,,FDA-CTU,,28.0,YR,,M,N,63.0,KG,20210531.0,N,CN,PE,PE,AVONZA (EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE);EFAVIRENZ.,Dizziness;Dysphagia;Pruritus;Rash macular;Tachycardia,193501791.0,DS,193501791.0,FGN,193501791.0,1.0,20190831.0,,,,193501791.0,1.0,HIV infection
19375560,193755601,1,I,,20210528.0,20210604,20210604,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME116388,VIIV,,65.0,YR,,M,Y,,,20210604.0,,CN,GB,GB,EFAVIRENZ + EMTRICITABINE + TENOFOVIR;EFAVIRENZ.,Renal impairment,193755601.0,OT,,,193755601.0,1.0,20120601.0,,,,193755601.0,1.0,HIV infection
19377487,193774872,2,F,,20210531.0,20210604,20210609,EXP,,US-GILEAD-2021-0534438,GILEAD,"CHINULA L., BRUMMEL S., ZIEMBA L., MCCARTHY K., JOHNSTON B., CHAKHTOURA N., ET AL. SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/ POSTPARTUM: IMPAACT 2010 TRIAL.. TOPICS IN ANTIVIRAL MEDICINE.. 2021?29(1):56",,,I,,Y,,,20210609.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital anomaly;Foetal exposure during pregnancy,193774872.0,CA,,,,,,,,,193774872.0,1.0,HIV infection
19377488,193774882,2,F,,20210531.0,20210604,20210609,EXP,,US-GILEAD-2021-0534437,GILEAD,"CHINULA L., BRUMMEL S., ZIEMBA L., MCCARTHY K., JOHNSTON B., CHAKHTOURA N., ET AL. SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/ POSTPARTUM: IMPAACT 2010 TRIAL.. TOPICS IN ANTIVIRAL MEDICINE.. 2021?29(1):56",,,I,,Y,,,20210609.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital anomaly;Foetal exposure during pregnancy,193774882.0,CA,,,,,,,,,193774882.0,1.0,HIV infection
19386144,193861441,1,I,,20210531.0,20210608,20210608,EXP,,US-GILEAD-2021-0534459,GILEAD,"HOFFMAN R, ZIEMBA L, BRUMMEL S, CHINULA L, NEMATADZIRA T, NAKAYIWA F, STRINGER J, KROTJE C, JEAN?PHILIPPE P, COLETTI A, ZASH R, SHAPIRO R, SAX P, CURRIER J, LOCKMAN S. ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010. UNK. 2021?29 (1):55?56",,,I,,Y,,,20210608.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Stillbirth,193861441.0,OT,,,,,,,,,193861441.0,1.0,HIV infection
19389493,193894931,1,I,,20210531.0,20210608,20210608,EXP,,US-GILEAD-2021-0534458,GILEAD,"HOFFMAN R, ZIEMBA L, BRUMMEL S, CHINULA L, NEMATADZIRA T, NAKAYIWA F, STRINGER J, KROTJE C, JEAN?PHILIPPE P, COLETTI A, ZASH R, SHAPIRO R, SAX P, CURRIER J, LOCKMAN S. ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010. UNK. 2021?29 (1):55?56",,,I,,Y,,,20210608.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Stillbirth,193894931.0,OT,,,,,,,,,193894931.0,1.0,HIV infection
19392241,193922411,1,I,,20210531.0,20210608,20210608,EXP,,US-GILEAD-2021-0534457,GILEAD,"HOFFMAN R, ZIEMBA L, BRUMMEL S, CHINULA L, NEMATADZIRA T, NAKAYIWA F, STRINGER J, KROTJE C, JEAN?PHILIPPE P, COLETTI A, ZASH R, SHAPIRO R, SAX P, CURRIER J, LOCKMAN S. ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010. UNK. 2021?29 (1):55?56",,,I,,Y,,,20210608.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,193922411.0,OT,,,,,,,,,193922411.0,1.0,HIV infection
19395246,193952461,1,I,,20210602.0,20210609,20210609,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME123104,VIIV,,76.0,YR,,M,Y,,,20210609.0,,CN,GB,GB,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Renal impairment,193952461.0,OT,,,193952461.0,1.0,20121101.0,,,,193952461.0,1.0,HIV infection
19396371,193963711,1,I,,20210602.0,20210609,20210609,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME123182,VIIV,,61.0,YR,,M,Y,,,20210609.0,,CN,GB,GB,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Renal impairment,193963711.0,OT,,,193963711.0,1.0,20121101.0,,,,193963711.0,1.0,HIV infection
19399734,193997342,2,F,20201125.0,20210804.0,20210610,20210809,EXP,,FR-MYLANLABS-2021M1033868,MYLAN,,57.0,YR,,M,Y,60.0,KG,20210809.0,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Drug interaction;Viral load increased,193997342.0,OT,,,,,,,,,193997342.0,1.0,HIV infection
19452098,194520981,1,I,,20210611.0,20210623,20210623,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-057798,BRISTOL MYERS SQUIBB,,61.0,YR,,M,Y,,,20210623.0,,MD,GB,GB,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL,Renal impairment,194520981.0,OT,,,194520981.0,1.0,20121101.0,,,,194520981.0,1.0,HIV infection
19470007,194700071,1,I,,20210519.0,20210628,20210628,EXP,,IT-GILEAD-2021-0537622,GILEAD,,36.0,YR,A,M,Y,,,20210628.0,,HP,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,194700071.0,OT,,,,,,,,,194700071.0,1.0,HIV infection
19470053,194700531,1,I,,20210519.0,20210628,20210628,EXP,,IT-GILEAD-2021-0537627,GILEAD,,52.0,YR,A,F,Y,,,20210628.0,,HP,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,194700531.0,OT,,,,,,,,,194700531.0,1.0,HIV infection
19476449,194764491,1,I,20190315.0,20210616.0,20210630,20210630,EXP,,BR-CIPLA LTD.-2021BR04414,CIPLA,,,,,,Y,,,20210630.0,,HP,US,BR,EFAVIRENZ.;EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Premature delivery,194764491.0,OT,,,,,,,,,194764491.0,1.0,Antiretroviral therapy
19519915,195199151,1,I,,20210701.0,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040945,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",6.0,DEC,,F,Y,,,20210712.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195199151.0,OT,,,,,,,,,195199151.0,1.0,HIV infection
19519945,195199451,1,I,,20210701.0,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040950,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",,,,F,Y,,,20210712.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195199451.0,OT,,,,,,,,,195199451.0,1.0,HIV infection
19520596,195205961,1,I,,20210701.0,20210712,20210712,EXP,,IN-MYLANLABS-2021M1040984,MYLAN,"RUKMANGATHEN R, BRAHMANAPALLI V, THAMMISETTY D, PEMMASANI D, GALI S, ATMAKURU R. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECT?CLIN?RES 2020?11(4):158?163.",4.0,DEC,,F,Y,,,20210712.0,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness;Hypoacusis,195205961.0,OT,,,,,,,,,195205961.0,1.0,HIV infection
19566683,195666831,1,I,,20210712.0,20210716,20210716,EXP,,IT-MYLANLABS-2021M1042601,MYLAN,,51.0,YR,,,Y,,,20210716.0,,CN,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,195666831.0,OT,,,,,,,,,195666831.0,1.0,HIV infection
19604002,196040021,1,I,,20210715.0,20210723,20210723,EXP,,ES-MYLANLABS-2021M1043717,MYLAN,,40.0,YR,,M,Y,,,20210723.0,,CN,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone disorder;Renal failure,196040021.0,OT,,,,,,,,,196040021.0,1.0,HIV infection
19636915,196369151,1,I,2017.0,20210726.0,20210729,20210729,EXP,,US-GILEAD-2021-0542208,GILEAD,,,,A,M,Y,,,20210729.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatitis C;Sleep disorder,196369151.0,OT,,,,,,,,,196369151.0,1.0,HIV infection
19646677,196466771,1,I,,20210419.0,20210802,20210802,EXP,,DE-GILEAD-2021-0526291,GILEAD,"RADMER S, ANDRESEN J, ANDRESEN R. DIMINISHED BONE MARROW OEDEMA AND HEALING OF INSUFFICIENCY FRACTURES IN A HIV PATIENT AFTER SWITCHING ANTIVIRAL THERAPIES. UNK. 2021?15(3):UNK. DOI:10.7860/JCDR/2020/46523.14738",64.0,YR,A,M,Y,,,20210802.0,,HP,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema syndrome;Foot fracture;Renal failure,196466771.0,OT,,,,,,,,,196466771.0,1.0,HIV infection
19680350,196803501,1,I,,20210809.0,20210810,20210810,EXP,,US-GILEAD-2021-0543607,GILEAD,,,,A,M,Y,,,20210810.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypovolaemic shock;Intentional dose omission,196803501.0,OT,,,,,,,,,196803501.0,1.0,HIV infection
19688961,196889611,1,I,,20210730.0,20210812,20210812,EXP,,US-CIPLA LTD.-2021US05449,CIPLA,,,,,,Y,,,20210812.0,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Herpes zoster;Neutropenia,196889611.0,OT,,,,,,,,,196889611.0,1.0,Lymphoma AIDS related
19707503,197075031,1,I,,20210809.0,20210817,20210817,EXP,,TH-MYLANLABS-2021M1052686,MYLAN,,45.0,YR,,F,Y,,,20210817.0,,HP,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome;Paradoxical drug reaction,197075031.0,HO,,,,,,,,,197075031.0,1.0,HIV infection
19779968,197799681,1,I,,20210830.0,20210902,20210902,EXP,,US-GILEAD-2021-0546565,GILEAD,,42.0,YR,A,M,Y,,,20210902.0,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Infection;Pain;Renal disorder;Sleep terror;Tachyphrenia;Transfusion,197799681.0,OT,,,197799681.0,1.0,201309.0,201411.0,,,197799681.0,1.0,HIV infection
19799530,197995301,1,I,,20210831.0,20210907,20210907,EXP,,IT-MYLANLABS-2021M1058128,MYLAN,,31.0,YR,,F,Y,,,20210907.0,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL,Drug ineffective;Virologic failure,197995301.0,OT,,,,,,,,,197995301.0,1.0,HIV infection
19845057,198450571,1,I,,20210910.0,20210916,20210916,EXP,,ZA-GILEAD-2021-0548799,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",48.0,YR,A,F,Y,,,20210916.0,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450571.0,OT,,,,,,,,,198450571.0,1.0,HIV infection
19845091,198450911,1,I,,20210910.0,20210916,20210916,EXP,,ZA-GILEAD-2021-0548800,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",55.0,YR,A,F,Y,,,20210916.0,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450911.0,OT,,,,,,,,,198450911.0,1.0,HIV infection
19845099,198450992,2,F,,20210910.0,20210916,20220405,EXP,,ZA-GILEAD-2021-0548801,GILEAD,"Manickchund N, du Plessis C, John MA, Manzini TC, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. unk. 2021;22(1):1-4. doi:10.4102/sajhivmed.v22i1.1271",37.0,YR,A,F,Y,,,20220405.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450992.0,HO,,,,,,,,,198450992.0,1.0,HIV infection
19845107,198451071,1,I,,20210910.0,20210916,20210916,EXP,,ZA-GILEAD-2021-0548802,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",23.0,YR,A,F,Y,,,20210916.0,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198451071.0,OT,,,,,,,,,198451071.0,1.0,HIV infection
19849692,198496921,1,I,,20210910.0,20210917,20210917,EXP,,ZA-GILEAD-2021-0548136,GILEAD,"MANICKCHUND N, DU PLESSIS C, JOHN MA, MANZINI TC, MOOSA M?YS. A CASE SERIES OF EMTRICITABINE?INDUCED PURE RED CELL APLASIA. UNK. 2021?22(1):1?4. DOI:10.4102/SAJHIVMED.V22I1.1271",61.0,YR,A,F,Y,,,20210917.0,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198496921.0,OT,,,,,,,,,198496921.0,1.0,HIV infection
19884907,198849071,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032761,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198849071.0,OT,,,,,,,,,198849071.0,1.0,Antiretroviral therapy
19885066,198850661,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032763,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198850661.0,OT,,,,,,,,,198850661.0,1.0,Antiretroviral therapy
19885196,198851961,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032764,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198851961.0,OT,,,,,,,,,198851961.0,1.0,Antiretroviral therapy
19885285,198852851,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032765,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198852851.0,OT,,,,,,,,,198852851.0,1.0,Antiretroviral therapy
19885394,198853941,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032766,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198853941.0,OT,,,,,,,,,198853941.0,1.0,HIV infection
19885531,198855311,1,I,,20210916.0,20210927,20210927,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2021032762,MACLEODS,,,,,,Y,,,20210927.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198855311.0,OT,,,,,,,,,198855311.0,1.0,Antiretroviral therapy
19903764,199037642,2,F,,20220510.0,20211001,20220520,EXP,,IN-CIPLA LTD.-2021IN06420,CIPLA,"Soneja M, Gupta N, Aggarwal A, Kodan P. Human immunodeficiency virus infection with multiple opportunistic infections: lessons learnt from a non-adherent patient. Oxford Medical Case Reports. 2021;3:79 to 81",,,,,Y,,,20220520.0,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Cachexia;Dehydration;Depression;Diarrhoea;Dysphagia;Electrolyte imbalance;Ichthyosis;Oral candidiasis;Treatment failure;Treatment noncompliance,199037642.0,HO,,,,,,,,,199037642.0,1.0,Antiretroviral therapy
19923817,199238171,1,I,,20211004.0,20211006,20211006,EXP,,US-GILEAD-2021-0551366,GILEAD,,,,A,F,Y,,,20211006.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Lung disorder;Pneumocystis jirovecii pneumonia,199238171.0,OT,,,199238171.0,1.0,,2018.0,,,199238171.0,1.0,HIV infection
19953657,199536571,1,I,,20211008.0,20211013,20211013,EXP,,IT-MYLANLABS-2021M1071657,MYLAN,,65.0,YR,,M,Y,,,20211013.0,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,199536571.0,OT,,,,,,,,,199536571.0,1.0,HIV infection
19959618,199596181,1,I,,20211011.0,20211015,20211015,EXP,,IT-MYLANLABS-2021M1071995,MYLAN,,52.0,YR,,F,Y,,,20211015.0,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,199596181.0,OT,,,,,,,,,199596181.0,1.0,HIV infection
19959620,199596201,1,I,,20211011.0,20211015,20211015,EXP,,IT-MYLANLABS-2021M1071993,MYLAN,,36.0,YR,,M,Y,,,20211015.0,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,199596201.0,OT,,,,,,,,,199596201.0,1.0,HIV infection
19994721,199947211,1,I,,20211025.0,20211026,20211026,EXP,,US-GILEAD-2021-0554050,GILEAD,,,,E,F,Y,,,20211026.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Near death experience;Pneumonia,199947211.0,HO,,,,,,,,,199947211.0,1.0,HIV infection
20034515,200345151,1,I,20110201.0,20211029.0,20211104,20211104,EXP,,US-GILEAD-2021-0554805,GILEAD,,38.0,YR,A,M,Y,,,20211104.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Back pain;Cardiac failure;Depression;Dyspnoea exertional;Fatigue;Fluid retention;Hyperhidrosis;Intracardiac thrombus;Stress;Tuberculosis;Weight decreased,200345151.0,OT,,,200345151.0,1.0,,20140101.0,,,200345151.0,1.0,HIV infection
20041342,200413421,1,I,,20211029.0,20211107,20211107,EXP,,KZ-HETERO-HET2021KZ02059,HETERO,,,,,,Y,,,20211108.0,,HP,KZ,KZ,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Depressed level of consciousness;Headache;Malaise,200413421.0,OT,,,,,,,,,200413421.0,1.0,HIV infection WHO clinical stage I
20044583,200445831,1,I,,20211029.0,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081056,MYLAN,,,,,M,Y,,,20211108.0,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445831.0,OT,,,,,,,,,200445831.0,1.0,HIV infection
20044584,200445841,1,I,,20211029.0,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081059,MYLAN,,,,,M,Y,,,20211108.0,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445841.0,OT,,,,,,,,,200445841.0,1.0,HIV infection
20044586,200445861,1,I,,20211029.0,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081058,MYLAN,,,,,M,Y,,,20211108.0,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445861.0,OT,,,,,,,,,200445861.0,1.0,HIV infection
20081561,200815611,1,I,,20211108.0,20211117,20211117,EXP,,ZA-GILEAD-2021-0556201,GILEAD,"Malaba TR, Myer L, Gray C, Newell ML. Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS). BMJ Open.. 2021;11(9):unk. doi:10.1136/bmjopen-2020-047133",,,A,F,Y,,,20211117.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Maternal exposure during pregnancy,200815611.0,OT,,,,,,,,,200815611.0,1.0,HIV infection
20090380,200903801,1,I,20160301.0,20211108.0,20211119,20211119,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-119682,BRISTOL MYERS SQUIBB,"Pohlman FW, McGee KS, McKellar MS. Case report: reversal of integrase inhibitor- and tenofovir alafenamide-related weight gain after switching back to efavirenz/emtricitabine/tenofovir DF. Open Forum Infectious Diseases. 2021;8(8):1-3",33.0,YR,,M,Y,,,20211119.0,,HP,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abnormal dreams;Diarrhoea;Sleep disorder;Weight decreased,,,,,200903801.0,1.0,201212.0,201603.0,,,200903801.0,1.0,HIV infection
20125879,201258794,4,F,,20220608.0,20211129,20220616,EXP,,UG-MYLANLABS-2021M1086327,MYLAN,,,,,F,Y,3.4,KG,20220616.0,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,201258794.0,OT,,,201258794.0,1.0,20210204.0,20210203.0,1032.0,DAY,201258794.0,1.0,HIV infection
20142455,201424552,2,F,,20211206.0,20211202,20211216,EXP,,US-TEVA-2021-US-1982405,TEVA,"Pohlman FW, Mcgee KS, Mckellar MS. Case Report: Reversal of Integrase Inhibitor- A nd Tenofovir Alafenamide-Related Weight Gain after Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open-Forum-Infect-Dis 2021;8(8):ofab403.",33.0,YR,A,M,Y,66.7,KG,20211216.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Diarrhoea;Sleep disorder;Weight decreased;Weight increased,201424552.0,OT,,,201424552.0,2.0,201603.0,,,,201424552.0,1.0,HIV infection
20144797,201447975,5,F,,20220118.0,20211203,20220201,EXP,,UG-AUROBINDO-AUR-APL-2021-050077,AUROBINDO,,,,I,F,Y,3.4,KG,20220201.0,,HP,UG,UG,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Foetal exposure during pregnancy;Umbilical hernia,201447975.0,CA,,,201447975.0,1.0,20180409.0,20210203.0,1032.0,DAY,201447975.0,1.0,HIV infection
20336620,203366201,1,I,20210820.0,20220112.0,20220114,20220114,EXP,,ZA-GILEAD-2022-0565310,GILEAD,,27.0,YR,A,F,Y,,,20220114.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203366201.0,OT,,,203366201.0,1.0,20161116.0,20211020.0,1799.0,DAY,203366201.0,1.0,HIV infection
20340755,203407552,2,F,20210615.0,20220202.0,20220117,20220204,EXP,,ZA-GILEAD-2022-0565607,GILEAD,,23.0,YR,A,F,Y,,,20220204.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203407552.0,OT,,,203407552.0,1.0,20180118.0,20210301.0,1138.0,DAY,203407552.0,1.0,HIV infection
20346383,203463832,2,F,20211121.0,20220602.0,20220118,20220607,EXP,,ZA-MYLANLABS-2022M1003728,MYLAN,,27.0,YR,,F,Y,,,20220607.0,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203463832.0,OT,,,203463832.0,1.0,20161116.0,20211020.0,1800.0,DAY,203463832.0,1.0,HIV infection
20373955,203739551,1,I,20211121.0,20220113.0,20220125,20220125,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022034125,MACLEODS,,,,,,Y,,,20220125.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203739551.0,OT,,,203739551.0,1.0,20161116.0,20211020.0,1799.0,DAY,203739551.0,1.0,HIV infection
20379777,203797772,2,F,20210615.0,20220201.0,20220126,20220215,EXP,,ZA-MYLANLABS-2022M1003734,MYLAN,,23.0,YR,,F,Y,,,20220215.0,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203797772.0,OT,,,203797772.0,1.0,20210301.0,20210301.0,1139.0,DAY,203797772.0,1.0,HIV infection
20381106,203811062,2,F,,20220201.0,20220127,20220214,EXP,,ZA-AUROBINDO-AUR-APL-2022-001596,AUROBINDO,,23.0,YR,,F,Y,,,20220214.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203811062.0,OT,,,203811062.0,1.0,20210118.0,20210301.0,43.0,DAY,203811062.0,1.0,HIV infection
20381882,203818823,3,F,20210615.0,20220202.0,20220127,20220216,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022034157,MACLEODS,,,,,,Y,,,20220216.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Maternal exposure during pregnancy;Stillbirth,203818823.0,OT,,,203818823.0,1.0,20180118.0,20210301.0,1138.0,DAY,203818823.0,1.0,HIV infection
20438722,204387221,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010506,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",23.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell;Cross sensitivity reaction,204387221.0,HO,,,,,,,,,204387221.0,1.0,HIV infection
20438723,204387231,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010486,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",61.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387231.0,HO,,,,,,,,,204387231.0,1.0,HIV infection
20438724,204387241,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010502,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",37.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387241.0,HO,,,,,,,,,204387241.0,1.0,HIV infection
20438725,204387251,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010501,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",35.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387251.0,HO,,,,,,,,,204387251.0,1.0,HIV infection
20438726,204387261,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010487,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",48.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387261.0,HO,,,,,,,,,204387261.0,1.0,HIV infection
20438727,204387271,1,I,,20220202.0,20220207,20220207,EXP,,ZA-MYLANLABS-2022M1010500,MYLAN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. South-Afr-J-HIV-Med 2021;22:No. 1.",55.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204387271.0,HO,,,,,,,,,204387271.0,1.0,HIV infection
20439449,204394491,1,I,,20220202.0,20220207,20220207,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2022-01516,LUPIN,"Manickchund N, Du Plessis C, John MA-A, Manzini TC, Gosnell BI, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",23.0,YR,,F,Y,,,20220207.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell;Cross sensitivity reaction,204394491.0,OT,,,,,,,,,204394491.0,1.0,HIV infection
20448184,204481841,1,I,,20220126.0,20220209,20220209,EXP,,KZ-AUROBINDO-AUR-APL-2022-002874,AUROBINDO,,41.0,YR,,M,Y,,,20220209.0,,CN,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Connective tissue disorder;Injury;Musculoskeletal disorder;Poisoning;Procedural complication,204481841.0,OT,,,204481841.0,1.0,20210505.0,20211205.0,215.0,DAY,204481841.0,1.0,HIV infection
20478799,204787991,1,I,20130101.0,20220210.0,20220216,20220216,EXP,,US-GILEAD-2022-0569621,GILEAD,,62.0,YR,A,M,Y,,,20220216.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Leg amputation,204787991.0,DS,,,204787991.0,1.0,2013.0,2015.0,,,204787991.0,1.0,HIV infection
20482301,204823011,1,I,,20220207.0,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00342,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, Moosa MY. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",61.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823011.0,OT,,,204823011.0,1.0,,,8.0,MON,204823011.0,1.0,HIV infection
20482318,204823181,1,I,,20220207.0,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00343,HETERO,"Manickchund N, Du Plessis C, John MA, Manzini TC, Gosnell BI, Moosa M-YS.. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",48.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823181.0,OT,,,204823181.0,1.0,,,5.0,MON,204823181.0,1.0,HIV infection
20482319,204823191,1,I,,20220207.0,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00345,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",35.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823191.0,OT,,,204823191.0,1.0,,,5.0,MON,204823191.0,1.0,HIV infection
20482325,204823251,1,I,,20220207.0,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00346,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI,et al.. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine.. 2021;22(1):1-4",37.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823251.0,OT,,,204823251.0,1.0,,,2.0,MON,204823251.0,1.0,HIV infection
20482343,204823431,1,I,,20220207.0,20220216,20220216,EXP,,ZA-HETERO-HET2022ZA00347,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):1-4",23.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204823431.0,OT,,,204823431.0,1.0,,,4.0,MON,204823431.0,1.0,HIV infection
20482474,204824741,1,I,,20220207.0,20220217,20220217,EXP,,ZA-HETERO-HET2022ZA00344,HETERO,"Manickchund N, Du PC, John MA, Manzini TC, Gosnell BI, et al.,. A case series of emtricitabine-induced pure red cell aplasia. Southern African Journal of HIV Medicine. 2021;22(1):a1271",55.0,YR,,F,Y,,,20220217.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,204824741.0,OT,,,,,,,,,204824741.0,1.0,HIV infection
20601388,206013882,2,F,20201201.0,20220316.0,20220316,20220318,EXP,,ZA-GILEAD-2022-0573405,GILEAD,,21.0,YR,A,F,Y,,,20220318.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,206013882.0,OT,,,206013882.0,1.0,20180212.0,,,,206013882.0,1.0,HIV infection
20641852,206418521,1,I,20150329.0,20220318.0,20220328,20220328,EXP,,US-GILEAD-2016-0242362,GILEAD,,,,,M,Y,,,20220328.0,,MD,US,PE,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug eruption,206418521.0,OT,,,,,,,,,206418521.0,1.0,HIV infection
20683138,206831381,1,I,,20220404.0,20220407,20220407,EXP,,US-GILEAD-2022-0576344,GILEAD,,23.0,YR,A,M,Y,,,20220407.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Drug ineffective;Feeling abnormal;Illness;Motion sickness;Nausea;Staphylococcal infection,206831381.0,DS,,,,,,,,,206831381.0,1.0,HIV infection
20738589,207385892,2,F,20131029.0,20220501.0,20220422,20220504,EXP,,ZA-GILEAD-2022-0578517,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",39.0,YR,A,M,Y,,,20220504.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207385892.0,OT,,,207385892.0,1.0,20131003.0,20131029.0,26.0,DAY,207385892.0,1.0,HIV infection
20738611,207386111,1,I,,20220418.0,20220422,20220422,EXP,,ZA-GILEAD-2022-0578712,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",37.0,YR,A,M,Y,,,20220422.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207386111.0,OT,,,,,,,,,207386111.0,1.0,HIV infection
20738710,207387101,1,I,,20220418.0,20220422,20220422,EXP,,ZA-GILEAD-2022-0578713,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",33.0,YR,A,M,Y,,,20220422.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207387101.0,OT,,,,,,,,,207387101.0,1.0,HIV infection
20738779,207387791,1,I,,20220418.0,20220422,20220422,EXP,,ZA-GILEAD-2022-0578714,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36.0,YR,A,M,Y,,,20220422.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207387791.0,OT,,,,,,,,,207387791.0,1.0,HIV infection
20738861,207388611,1,I,,20220418.0,20220422,20220422,EXP,,ZA-GILEAD-2022-0578715,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",44.0,YR,A,F,Y,,,20220422.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207388611.0,OT,,,,,,,,,207388611.0,1.0,HIV infection
20738947,207389471,1,I,,20220418.0,20220422,20220422,EXP,,ZA-GILEAD-2022-0578716,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36.0,YR,A,F,Y,,,20220422.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207389471.0,OT,,,,,,,,,207389471.0,1.0,HIV infection
20739137,207391372,2,F,,20220418.0,20220422,20220504,EXP,,ZA-GILEAD-2022-0578717,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36.0,YR,A,M,Y,,,20220504.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207391372.0,DE,,,,,,,,,207391372.0,1.0,HIV infection
20739332,207393322,2,F,,20220418.0,20220422,20220428,EXP,,ZA-GILEAD-2022-0578718,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36.0,YR,A,F,Y,,,20220428.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207393322.0,OT,,,,,,,,,207393322.0,1.0,HIV infection
20780734,207807341,1,I,,20220420.0,20220504,20220504,EXP,,KE-CIPLA LTD.-2022KE02833,CIPLA,"Khamadi S, Wexler C, Lwembe R, Maosa N, Maloba M, Sandbulte M et.al. HIV Drug Resistance in Kenyan Infants Diagnosed with HIV and Their Mothers. The Pediatric Infectious Disease Journal. 2022;41:4:312 to 314",,,,,Y,,,20220504.0,,HP,KE,KE,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,207807341.0,OT,,,,,,,,,207807341.0,1.0,HIV infection CDC category B
20842957,208429571,1,I,,20220504.0,20220518,20220518,EXP,,IN-CIPLA LTD.-2022IN03053,CIPLA,"Mangal V, Murari T, Gaikwad SN, Kaur K.. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report. Indian Journal of Nephrology. 2022;32:2:175 to 178",,,,,Y,,,20220518.0,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Femur fracture;Hydronephrosis;Nephrolithiasis;Osteomalacia;Pyelitis,208429571.0,HO,,,,,,,,,208429571.0,1.0,HIV infection
20868399,208683991,1,I,20160101.0,20220523.0,20220524,20220524,EXP,,US-GILEAD-2022-0582842,GILEAD,,37.0,YR,A,M,Y,,,20220524.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bladder cancer;Hodgkin's disease stage III,208683991.0,OT,,,208683991.0,1.0,201407.0,2018.0,,,208683991.0,1.0,HIV infection
20884822,208848222,2,F,20220424.0,20220608.0,20220527,20220615,EXP,ES-AEMPS-1191015,ES-PFIZER INC-202200757835,PFIZER,,55.0,YR,,F,Y,,,20220615.0,,MD,ES,ES,EFAVIRENZ/EMTRICITABINA/TENOFOVIR DISOPROXILO TEVA,Drug withdrawal syndrome;Overdose;Seizure;Syncope,208848222.0,HO,,,208848222.0,1.0,20220424.0,20220430.0,7.0,DAY,208848222.0,5.0,HIV infection
20902432,209024322,2,F,,20221208.0,20220601,20221214,EXP,,UG-MYLANLABS-2022M1041517,MYLAN,,37.0,YR,,F,Y,,,20221214.0,,HP,UG,UG,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209024322.0,OT,,,209024322.0,1.0,20210106.0,20210105.0,958.0,DAY,209024322.0,1.0,HIV infection
20916899,209168991,1,I,,20220529.0,20220605,20220605,EXP,,IN-Laurus-001256,LAURUS LABS LIMITED,IN-Laurus-001256-01_Initial Source Document,54.0,YR,A,F,Y,,,20220603.0,,HP,IN,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Calculus urinary;Condition aggravated;Fanconi syndrome;Femoral neck fracture;Metabolic acidosis;Nephrolithiasis;Osteomalacia;Pulmonary embolism;Sepsis;Urinary tract infection,209168991.0,HO,,,,,,,,,209168991.0,1.0,HIV infection
20929273,209292732,2,F,,20220607.0,20220608,20220620,EXP,,ZA-LAURUS LABS LIMITED-2022LAU000004,LAURUS LABS LIMITED,,28.0,YR,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,209292732.0,OT,,,209292732.0,1.0,20180711.0,,,,209292732.0,1.0,Asymptomatic HIV infection
20929353,209293531,1,I,,20220529.0,20220608,20220608,EXP,,IN-HETERO-HET2022IN01229,HETERO,"Mangal V, Murari T, Gaikwad SN, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy-A case report. Indian Journal of Nephrology. 2022;32(2):175-178",54.0,YR,,F,Y,,,20220608.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Nephrolithiasis;Osteomalacia,209293531.0,OT,,,209293531.0,1.0,,,6.0,YR,209293531.0,1.0,HIV infection
20929565,209295651,1,I,,20220525.0,20220608,20220608,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2022035899,MACLEODS,"Mangal V, Murari T, Gaikwad SN, Kaur K.. Simultaneous Occurrence of Nephrolithiasis, Fanconi Syndrome, and Nephro-osteopathy in a Patient onFirst-line Antiretroviral Therapy - A Case Report. Indian Journal of Nephrology. 2022;32(2):175?178",,,,,Y,,,20220607.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Femoral neck fracture;Hydronephrosis;Nephrolithiasis;Nephropathy;Osteomalacia;Pulmonary embolism;Pyelitis;Urinary tract infection,209295651.0,HO,,,,,,,,,209295651.0,1.0,HIV infection
20940247,209402471,1,I,20120101.0,20180805.0,20220609,20220609,EXP,,GB-TEVA-2018-GB-939324,TEVA,,59.0,YR,A,F,Y,,,20220609.0,,CN,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,209402471.0,OT,,,,,,,,,209402471.0,1.0,HIV infection
20941866,209418661,1,I,,20220527.0,20220610,20220610,EXP,,UG-AUROBINDO-AUR-APL-2022-020360,AUROBINDO,,37.0,YR,,F,Y,,,20220610.0,,HP,UG,UG,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,209418661.0,OT,,,209418661.0,1.0,20210106.0,20210105.0,958.0,DAY,209418661.0,1.0,HIV infection
20947752,209477522,2,F,20210421.0,20220608.0,20220611,20220621,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022035919,MACLEODS,,,,,,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,209477522.0,OT,,,209477522.0,1.0,20180711.0,,,,209477522.0,1.0,HIV infection
20950243,209502431,1,I,,20220601.0,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03698,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613.0,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug interaction;Drug resistance,209502431.0,OT,,,,,,,,,209502431.0,1.0,HIV infection CDC category C
20950246,209502461,1,I,,20220601.0,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03695,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613.0,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209502461.0,OT,,,,,,,,,209502461.0,1.0,HIV infection CDC category C
20950790,209507901,1,I,,20220601.0,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03694,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613.0,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507901.0,OT,,,,,,,,,209507901.0,1.0,HIV infection CDC category C
20950791,209507911,1,I,,20220601.0,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03700,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613.0,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507911.0,OT,,,,,,,,,209507911.0,1.0,HIV infection CDC category C
20950793,209507931,1,I,,20220601.0,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03697,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613.0,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507931.0,OT,,,,,,,,,209507931.0,1.0,HIV infection CDC category C
20983251,209832511,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586430,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,209832511.0,OT,,,,,,,,,209832511.0,1.0,HIV infection
20983263,209832631,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586429,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,209832631.0,OT,,,,,,,,,209832631.0,1.0,HIV infection
20983271,209832711,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586431,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832711.0,OT,,,,,,,,,209832711.0,1.0,HIV infection
20983273,209832731,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586428,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832731.0,OT,,,,,,,,,209832731.0,1.0,HIV infection
20983274,209832741,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586427,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832741.0,OT,,,,,,,,,209832741.0,1.0,HIV infection
20983277,209832771,1,I,,20220613.0,20220620,20220620,EXP,,ZA-GILEAD-2022-0586407,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832771.0,OT,,,,,,,,,209832771.0,1.0,HIV infection
21002372,210023721,1,I,,20220622.0,20220624,20220624,EXP,,US-GILEAD-2022-0587028,GILEAD,,,,E,M,Y,,,20220624.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cognitive disorder,210023721.0,OT,,,,,,,,,210023721.0,1.0,HIV infection
21039020,210390201,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04099,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390201.0,OT,,,,,,,,,210390201.0,1.0,HIV infection
21039024,210390241,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04094,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390241.0,OT,,,,,,,,,210390241.0,1.0,HIV infection
21039027,210390271,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04085,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390271.0,OT,,,,,,,,,210390271.0,1.0,HIV infection
21039030,210390301,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04087,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids research and human retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390301.0,OT,,,,,,,,,210390301.0,1.0,HIV infection
21039033,210390331,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04090,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390331.0,OT,,,,,,,,,210390331.0,1.0,HIV infection
21039034,210390341,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04092,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390341.0,OT,,,,,,,,,210390341.0,1.0,HIV infection
21039035,210390351,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04100,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38:6:455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390351.0,OT,,,,,,,,,210390351.0,1.0,HIV infection
21039038,210390381,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04093,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38:6:455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390381.0,OT,,,,,,,,,210390381.0,1.0,HIV infection
21039039,210390391,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04096,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug resistance, rather than low Tenofovir levels in blood or urine, is associated with Tenofovir, Emtricitabine, and Efavirenz failure in resource-limited settings. Aids research and human retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390391.0,OT,,,,,,,,,210390391.0,1.0,HIV infection
21039040,210390401,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04097,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390401.0,OT,,,,,,,,,210390401.0,1.0,HIV infection
21039041,210390411,1,I,,20220620.0,20220704,20220704,EXP,,ZA-CIPLA LTD.-2022ZA04091,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220704.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210390411.0,OT,,,,,,,,,210390411.0,1.0,HIV infection
21041731,210417311,1,I,,20220620.0,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04095,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701.0,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417311.0,OT,,,,,,,,,210417311.0,1.0,HIV infection
21041732,210417321,1,I,,20220620.0,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04098,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et.al. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417321.0,OT,,,,,,,,,210417321.0,1.0,HIV infection
21041733,210417331,1,I,,20220620.0,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04089,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. Aids Research And Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701.0,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417331.0,OT,,,,,,,,,210417331.0,1.0,HIV infection
21041734,210417341,1,I,,20220620.0,20220705,20220705,EXP,,ZA-CIPLA LTD.-2022ZA04088,CIPLA,"Jennings L, Gandhi M, Kellermann T, Spinelli M, Nkantsu Z, Cogill D et al.. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses. 2022;38 (6):455 to 462",,,,,Y,,,20220701.0,,MD,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210417341.0,OT,,,,,,,,,210417341.0,1.0,HIV infection
21042191,210421911,1,I,,20220622.0,20220705,20220705,EXP,,NA-CIPLA LTD.-2022NA04150,CIPLA,"Kakubu AMM, Katoto PDMC, Bikinesi T, Liswaniso ES.. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102 to 106",53.0,YR,,M,Y,,,20220705.0,,MD,,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Virologic failure,210421911.0,OT,,,,,,,,,210421911.0,1.0,HIV infection WHO clinical stage I
21045327,210453271,1,I,,20220628.0,20220706,20220706,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP008232,STRIDES,"Mangal V, Murari T, Gaikwad S, Kaur K.. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report.. Indian-J-Nephrol. 2022;32(2):175-178",54.0,YR,,F,Y,,,20220706.0,,HP,IN,IN,EFAVIRENZ;EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis,210453271.0,HO,,,210453271.0,2.0,,,6.0,YR,210453271.0,1.0,HIV infection
21047841,210478411,1,I,,20220628.0,20220706,20220706,EXP,,IN-MYLANLABS-2022M1050534,MYLAN,"Mangal V, Murari T, Gaikwad S, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report. Indian-J-Nephrol 2022;32(2):175-178.",54.0,YR,,F,Y,,,20220706.0,,HP,IN,IN,EFAVIRENZ;EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome acquired;Femoral neck fracture;Hydronephrosis;Nephrolithiasis;Osteomalacia,210478411.0,HO,,,210478411.0,1.0,,,6.0,YR,210478411.0,1.0,HIV infection
21062995,210629951,1,I,,20220707.0,20220711,20220711,EXP,,US-GILEAD-2022-0588833,GILEAD,,,,A,M,Y,,,20220711.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bone disorder,210629951.0,DS,,,,,,,,,210629951.0,1.0,HIV infection
21097237,210972371,1,I,,20220704.0,20220719,20220719,EXP,,ZA-CIPLA LTD.-2022ZA04311,CIPLA,"Thomson KF, Mahlobo F, Reddy DL. Splenic hydatid disease in pregnancy. Southern African Journal of HIV Medicine. 2022;23 (1):1 to 4",41.0,YR,,F,Y,,,20220714.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Premature delivery,210972371.0,OT,,,210972371.0,2.0,,,5.0,DAY,210972371.0,1.0,HIV infection
21170673,211706731,1,I,,20220725.0,20220804,20220804,EXP,,CH-MYLANLABS-2022M1082160,MYLAN,"Greiner M, Treichler G, Morela C, Camenzincia D, Neumayr A. Blum J et al.. Panzytopenie und akutes Nierenversagen. Swiss Medical forum. 2022;1-6",62.0,YR,,M,Y,54.0,KG,20220804.0,,MD,CH,CH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Kidney fibrosis;Renal failure,211706731.0,OT,,,,,,,,,211706731.0,1.0,HIV infection
21242637,212426371,1,I,,20220812.0,20220823,20220823,EXP,,IN-CIPLA LTD.-2022IN05058,CIPLA,"Harjani RG, Hinduja RH, Iyer AK.. Intracranial lymphoma in human immunodeficiency virus-infected patients: A diagnostic dilemma?. Indian Journal of Sexually Transmitted Diseases and AIDS. 2022;43:1:82 to 84",42.0,YR,,M,Y,,,20220823.0,,MD,IN,IN,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,212426371.0,OT,,,,,,,,,212426371.0,1.0,HIV infection
21280873,212808731,1,I,20210927.0,20220825.0,20220901,20220901,EXP,,GB-GILEAD-2022-0595790,GILEAD,,31.0,YR,A,F,Y,,,20220901.0,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,212808731.0,OT,,,,,,,,,212808731.0,1.0,HIV infection
21281188,212811881,1,I,,20220823.0,20220901,20220901,EXP,,IN-MYLANLABS-2022M1090014,MYLAN,"Patra PC, Samal P, Bhola RK, Pradhan S. An event of Evans even in HIV. India-J-Sex-Transm-Dis 2022;43(1):64-66.",32.0,YR,,F,Y,,,20220901.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Evans syndrome,212811881.0,HO,,,212811881.0,2.0,,,3.0,DAY,212811881.0,1.0,Antiretroviral therapy
21336494,213364941,1,I,,20220904.0,20220915,20220915,EXP,,TH-HETERO-HET2022TH02235,HETERO,"Wongjirattikarn R, Sriaram A, Pemcharoen J, Asawanonda P, Boontaveeyuwat E. Anti-retroviral drugs induced Photosensitivity may be Two culprits in Mixed formulation, a case report and literature review. Photodiagnosis and Photodynamic Therapy. 2022",63.0,YR,,F,Y,,,20220915.0,,MD,TH,TH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Photosensitivity reaction;Pseudoporphyria,213364941.0,OT,,,,,,,,,213364941.0,1.0,Asymptomatic HIV infection
21380740,213807401,1,I,,20220920.0,20220927,20220927,EXP,,US-MYLANLABS-2022M1096775,MYLAN,"Barnett SK, Armas-Kolostroubis L, Sension M, Riedel DJ. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient. AIDS 2022;36(10):1475-1476.",,,A,F,Y,,,20220927.0,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Treatment failure,213807401.0,OT,,,213807401.0,1.0,,,94.0,MON,213807401.0,1.0,HIV infection
21419290,214192902,2,F,,20221011.0,20221006,20221021,EXP,,US-TEVA-2022-US-2078748,TEVA,,,,A,F,Y,,,20221021.0,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Treatment failure,214192902.0,OT,,,214192902.0,1.0,,,96.0,MON,214192902.0,1.0,HIV infection
21442302,214423022,2,F,,20221025.0,20221011,20221028,EXP,,AU-GILEAD-2022-0600776,GILEAD,,,,A,F,Y,,,20221028.0,,CN,AU,AU,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Depression;Diabetes mellitus;Lipodystrophy acquired,214423022.0,OT,,,214423022.0,1.0,2000.0,2017.0,,,214423022.0,1.0,HIV infection
21478900,214789001,1,I,,20221014.0,20221019,20221019,EXP,,US-GILEAD-2022-0601923,GILEAD,,53.0,YR,A,M,Y,,,20221019.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Necrosis,214789001.0,OT,,,214789001.0,3.0,2020.0,,,,214789001.0,1.0,HIV infection
21512650,215126502,2,F,20090101.0,20221102.0,20221027,20221113,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-123975,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20221114.0,,MD,PT,PT,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215126502.0,OT,,,215126502.0,13.0,2022.0,,,,215126502.0,1.0,HIV infection
21519822,215198221,1,I,20220828.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86114,,FDA-CTU,,65.0,YR,,F,N,50.0,KG,20221021.0,N,HP,US,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Fanconi syndrome,215198221.0,HO,215198221.0,HP,215198221.0,1.0,20210715.0,20220829.0,,,215198221.0,1.0,HIV infection
21520696,215206961,1,I,20090101.0,20221021.0,20221028,20221028,EXP,,PT-PFIZER INC-202201256052,PFIZER,,,,,F,Y,,,20221028.0,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Myalgia;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215206961.0,DS,,,215206961.0,12.0,2022.0,,,,215206961.0,5.0,HIV infection
21524724,215247241,1,I,20090101.0,20221018.0,20221030,20221030,EXP,,PT-AUROBINDO-AUR-APL-2022-044879,AUROBINDO,,,,,F,Y,,,20221030.0,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215247241.0,OT,,,215247241.0,5.0,2022.0,,,,215247241.0,1.0,HIV infection
21601543,216015431,1,I,20220101.0,20221102.0,20221116,20221116,EXP,,PT-AUROBINDO-AUR-APL-2022-047575,AUROBINDO,,,,,F,Y,,,20221116.0,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,216015431.0,OT,,,216015431.0,9.0,2022.0,,,,216015431.0,1.0,HIV infection
21726772,217267721,1,I,20040101.0,20221212.0,20221214,20221214,EXP,,US-VIIV HEALTHCARE LIMITED-US2022AMR185796,VIIV,,,,,,Y,,,20221214.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Metastatic lymphoma;Prostate cancer,217267721.0,OT,,,,,,,,,217267721.0,1.0,HIV infection
21838893,218388931,1,I,,20170710.0,20230109,20230109,EXP,,IN-HETERO-2017HINLIT0642,HETERO,"Amrutha PC, Rakesh TP, Kidangazhiyathmana A, Chakkunny SC, Rewari BB, Andrews AM.. The enigma of lamivudine rash: Experience on re?challenge from an anti retroviral treatment center in South India.. Indian-J-Dermatol-Venereol-Leprol. 2017;83(4):502-504",48.0,YR,,F,Y,,,20230109.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Drug reaction with eosinophilia and systemic symptoms;Oral disorder;Rash,218388931.0,OT,,,,,,,,,218388931.0,1.0,HIV infection
21841940,218419402,2,F,20190101.0,20230215.0,20230110,20230227,EXP,,NA-CIPLA LTD.-2023NA00060,CIPLA,"Mpalang Kakubu MA, Frans K, Gibutai N, Katoto PDMC. A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions. SAGE Open Medical Case Reports. 2022;10:1 to 4",,,,,Y,,,20230227.0,,HP,,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,218419402.0,OT,,,218419402.0,1.0,20150129.0,20170406.0,,,218419402.0,1.0,HIV infection WHO clinical stage I
21867159,218671591,1,I,,20230104.0,20230116,20230116,EXP,,US-CIPLA LTD.-2023US00170,CIPLA,"Good BL, Fulco PP, Gomes DC,. An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. AIDS. 2015;29 (8):985 to 986",42.0,YR,,M,Y,,,20230116.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Anticoagulation drug level below therapeutic;Drug interaction;Dysphoria,218671591.0,OT,,,,,,,,,218671591.0,1.0,HIV infection
21884801,218848011,1,I,,20230113.0,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006169,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119.0,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218848011.0,OT,,,,,,,,,218848011.0,1.0,HIV infection
21886790,218867901,1,I,,20230113.0,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006177,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119.0,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218867901.0,OT,,,,,,,,,218867901.0,1.0,HIV infection
21886792,218867921,1,I,,20230113.0,20230119,20230119,EXP,,ZW-MYLANLABS-2023M1006176,MYLAN,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS-Res-Treat 2022;null:null.",,,,F,Y,,,20230119.0,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,218867921.0,OT,,,,,,,,,218867921.0,1.0,HIV infection
21889491,218894911,1,I,20230108.0,20230109.0,20230120,20230120,EXP,,IN-CIPLA LTD.-2023IN00246,CIPLA,,,,,M,Y,,,20230120.0,,CN,IN,IN,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Hangover;Nausea;Off label use;Product use in unapproved indication;Syncope,218894911.0,OT,,,218894911.0,1.0,20230108.0,,,,218894911.0,1.0,Prophylaxis against HIV infection
21934380,219343801,1,I,,20230123.0,20230201,20230201,EXP,,ZW-AUROBINDO-AUR-APL-2023-004075,AUROBINDO,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS Research and Treatment. 2022;13",,,,F,Y,,,20230201.0,,HP,ZW,ZW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Virologic failure,219343801.0,OT,,,,,,,,,219343801.0,1.0,HIV infection
21934926,219349261,1,I,,20230123.0,20230201,20230201,EXP,,ZW-AUROBINDO-AUR-APL-2023-004076,AUROBINDO,"Mutambanengwe-Jacob MT, Maponga CC, Amico KR, Ngara B, Yende-Zuma N, Chawana TD, et al.. Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study. AIDS Research and Treatment. 2022;13",,,,F,Y,,,20230201.0,,HP,ZW,ZW,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Virologic failure,219349261.0,OT,,,,,,,,,219349261.0,1.0,HIV infection
21953103,219531031,1,I,,20230129.0,20230204,20230204,EXP,,IN-HETERO-HET2023IN00206,HETERO,"Simon M, Meah A. Tenofovir as a cause of acquired fanconi^s syndrome. Annals of African Medicine. 2023;22:128-130",53.0,YR,,F,Y,,,20230204.0,,HP,IN,IN,EFAVIRENZ;LAMIVUDINE,Fanconi syndrome;Metabolic encephalopathy,219531031.0,HO,,,,,,,,,219531031.0,1.0,HIV infection
21997590,219975901,1,I,,20230201.0,20230216,20230216,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2023039759,MACLEODS,"Simon M, Meah A.. Tenofovir as a cause of acquired fanconi^s syndrome. Annals of African Medicine. 2023;22(1):128",,,,,Y,,,20230213.0,,HP,IN,IN,Lamivudine/ efavirenz,Addison's disease;Fanconi syndrome,219975901.0,HO,,,,,,,,,219975901.0,1.0,HIV infection
22097346,220973461,1,I,,20230302.0,20230315,20230315,EXP,,US-CIPLA LTD.-2023US01384,CIPLA,"Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD et al. National landscape of human immunodeficiency virus-positive deceased organ donors in the United States. Clinical Infectious Diseases. 2022;74(11):2010 to 2019",,,,,Y,,,20230315.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Multiple-drug resistance,220973461.0,OT,,,,,,,,,220973461.0,1.0,HIV infection
22111608,221116081,1,I,20230222.0,20230308.0,20230318,20230318,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2023040299,MACLEODS,,,,,,Y,,,20230317.0,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Depressed mood;Diarrhoea;Hyperhidrosis;Product dispensing error;Vertigo;Vomiting,221116081.0,OT,,,221116081.0,1.0,20230213.0,20230228.0,15.0,DAY,221116081.0,1.0,Prophylaxis against HIV infection
22113779,221137791,1,I,20230222.0,20230309.0,20230320,20230320,EXP,,FR-AUROBINDO-AUR-APL-2023-011860,AUROBINDO,,25.0,YR,,M,Y,65.0,KG,20230320.0,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Depressed mood;Diarrhoea;Hyperhidrosis;Product dispensing error;Vertigo;Vomiting,221137791.0,OT,,,221137791.0,1.0,20230213.0,20230228.0,15.0,DAY,221137791.0,1.0,Prophylaxis against HIV infection
22162331,221623313,3,F,,20230313.0,20230331,20230515,EXP,,ES-GILEAD-2023-0620975,GILEAD,"Kwon M, Bailen R, Balsalobre P, Jurado M, Bermudez A, Badiola J et al.. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders.. AIDS. 2019;33(9):1441-1447. doi:10.1097\QAD.0000000000002209",,,A,,Y,,,20230515.0,,HP,ES,ES,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Hepatotoxicity;Neurotoxicity,221623313.0,OT,,,221623313.0,1.0,2008.0,,,,221623313.0,1.0,HIV infection
22227500,222275002,2,F,20170901.0,20230804.0,20230419,20230818,EXP,,ZA-CIPLA (EU) LIMITED-2023ZA02014,CIPLA,"Khan A, Pillay M, Chimukangara B, Gounder L, Manyana S, Francois KL et al.. Identification of HIV-1 subtype CRF18_cpx in a patient with multidrug resistance in KwaZulu-Natal, South Africa: An epidemiological worry?. Journal of Clinical Virology Plus. 2023;1 to 7",,,,,Y,,,20230818.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Multiple-drug resistance;Normochromic normocytic anaemia;Treatment noncompliance;Virologic failure,222275002.0,HO,,,222275002.0,1.0,20170109.0,20181204.0,694.0,DAY,222275002.0,1.0,HIV infection
22256075,222560751,1,I,,20230424.0,20230426,20230426,EXP,,US-GILEAD-2023-0625877,GILEAD,,,,A,F,Y,,,20230426.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Lower limb fracture;Osteoporosis,222560751.0,OT,,,,,,,,,222560751.0,1.0,HIV infection
22313192,223131921,1,I,20180101.0,20230501.0,20230512,20230512,EXP,,MM-CIPLA LTD.-2023MM02463,CIPLA,"Lin KS, Nyein PP, Win S.. Drug-induced immune hemolytic anemia because of Efavirenz: A case report. AIDS. 2020;34 (2):326 to 328",,,,,Y,,,20230512.0,,HP,MM,MM,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Haemolytic anaemia,223131921.0,HO,,,223131921.0,1.0,2015.0,20180123.0,,,223131921.0,1.0,HIV infection
22330837,223308371,1,I,,20230214.0,20230517,20230517,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-381133,RANBAXY,"Aja-Okorie U, Ngene NC. Atypical preeclampsia-eclampsia syndrome at 18 weeks of gestation: A case report. Case Rep Women Health. 2022;36:e00470",,,,,Y,0.2,KG,20230517.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Premature baby,223308371.0,OT,,,,,,,,,223308371.0,1.0,HIV infection
22330846,223308461,1,I,,20230214.0,20230517,20230517,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-381131,RANBAXY,"Aja-Okorie U, Ngene NC. Atypical preeclampsia-eclampsia syndrome at 18 weeks of gestation: A case report. Case Rep Women Health. 2022;36:e00470",29.0,YR,,F,Y,,,20230517.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;HELLP syndrome;Posterior reversible encephalopathy syndrome;Premature delivery,223308461.0,OT,,,,,,,,,223308461.0,1.0,HIV infection
22335837,223358371,1,I,20210101.0,20230507.0,20230518,20230518,EXP,,IN-HETERO-HET2023IN01272,HETERO,"Choudhary S, Rangasamy K, Naidu S, Sachdeva RK, Sharma A. Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient  on Tenofovir-based antiretroviral therapy: A Case Report and Review of  the Literature. Journal of Orthopaedic Case Reports. 2023;13(2):14-20",40.0,YR,,F,Y,,,20230518.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Femur fracture;Osteomalacia,223358371.0,HO,,,,,,,,,223358371.0,1.0,HIV infection
22338353,223383532,2,F,,20230419.0,20230518,20230526,EXP,,GB-GILEAD-2023-0625168,GILEAD,,,,,M,Y,,,20230526.0,,MD,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Agitation;Diabetes mellitus;Insomnia;Weight increased,223383532.0,OT,,,223383532.0,1.0,2013.0,2013.0,8.0,YR,223383532.0,1.0,HIV infection
22346881,223468811,1,I,,20230511.0,20230520,20230520,EXP,,KZ-HETERO-HET2023KZ01274,HETERO,,59.0,YR,,,Y,,,20230520.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,223468811.0,OT,,,,,,,,,223468811.0,1.0,Asymptomatic HIV infection
22349614,223496141,1,I,,20230510.0,20230522,20230522,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2023041396,MACLEODS,"Choudhary S, Rangasamy K , Naidu S, Sachdeva RK , Sharma A. Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient on Tenofovir-based antiretroviral therapy: A Case Report and Review of the Literature. Journal of Orthopaedic Case Reports. 2023;13(2):14-20",,,,,Y,,,20230522.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Femur fracture;Osteomalacia,223496141.0,HO,,,223496141.0,1.0,,,6.0,YR,223496141.0,1.0,Antiretroviral therapy
22372054,223720541,1,I,,20230519.0,20230526,20230526,EXP,,IN-MYLANLABS-2023M1054860,MYLAN,"Joseph A, Cherian KE, Kapoor N, Paul TV. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?. Endocrinol-Diabetes-Metab-Case-Rep 2023;2023:No. 1.",46.0,YR,,F,Y,,,20230526.0,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Glycosuria;Hypokalaemia;Hypophosphataemic osteomalacia;Hypouricaemia;Metabolic acidosis;Osteopenia;Osteoporosis;Renal tubular acidosis,223720541.0,OT,,,,,,,,,223720541.0,1.0,HIV infection
22373399,223733992,2,F,,20230528.0,20230526,20230602,EXP,,GB-MYLANLABS-2023M1044973,MYLAN,,,,,M,Y,,,20230602.0,,MD,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Agitation;Diabetes mellitus;Insomnia;Weight increased,223733992.0,OT,,,223733992.0,1.0,2013.0,,2920.0,DAY,223733992.0,1.0,HIV infection
22587671,225876711,1,I,,20230529.0,20230612,20230612,EXP,,IN-AUROBINDO-AUR-APL-2023-041672,AUROBINDO,"Joseph A, Cherian KE, Kapoor N, Paul TV. Tenofovir-induced hypophosphatemic osteomalacia: how do bone mineral density, trabecular bone score and proximal hip geometry change with treatment?. Endocrinology Diabetes and Metabolism Case Reports. 2023",46.0,YR,,F,Y,,,20230612.0,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Glycosuria;Hypokalaemia;Hypophosphataemic osteomalacia;Hypouricaemia;Renal tubular acidosis,225876711.0,OT,,,,,,,,,225876711.0,1.0,HIV infection
22599581,225995812,2,F,20201101.0,20230622.0,20230614,20230627,EXP,,TH-ORGANON-O2306THA001548,ORGANON,,24.0,YR,,F,Y,,,20230627.0,,HP,TH,TH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Inappropriate schedule of product administration;Pregnancy with implant contraceptive;Unintended pregnancy,225995812.0,OT,,,225995812.0,1.0,202011.0,,,,225995812.0,2.0,HIV infection
22601077,226010772,2,F,20200224.0,20230622.0,20230614,20230627,EXP,,TH-ORGANON-O2306THA001559,ORGANON,,18.0,YR,,F,Y,,,20230627.0,,HP,TH,TH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Inappropriate schedule of product administration;Pregnancy with implant contraceptive;Unintended pregnancy,226010772.0,OT,,,226010772.0,1.0,20200224.0,,,,226010772.0,2.0,HIV infection
22624037,226240371,1,I,,20230614.0,20230621,20230621,EXP,,CO-MYLANLABS-2023M1064659,MYLAN,"Urbano-Alban DC, Orozco-Burbano JD, Andrade-Eraso AF, Cabrera-Velasco CE, Lozano-Fernandez VH. Strongyloides stercoralis in the bone marrow of a person living with HIV: Case report. [Spanish]. Iatreia 2022;35(4):475-479.",30.0,YR,,M,Y,,,20230621.0,,HP,CO,CO,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,226240371.0,DE,,,,,,,,,226240371.0,1.0,Antiretroviral therapy
22642348,226423481,1,I,,20230621.0,20230626,20230626,EXP,,US-GILEAD-2023-0634105,GILEAD,,,,A,M,Y,,,20230626.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Back pain;Balance disorder;Candida infection;Depression;Fatigue;Hemiparesis;Mood swings;Neurosyphilis;Sensory disturbance;Transient ischaemic attack;Weight decreased,226423481.0,OT,,,,,,,,,226423481.0,1.0,HIV infection
22692568,226925681,1,I,,20230704.0,20230711,20230711,EXP,,IN-MYLANLABS-2023M1073099,MYLAN,"Lad SG, Kolhe K, Chauhan S, Gattani M, Sethiya P, Singh GK, et al. AIH in HIV: A Very Much Possible Entity. J-Clin-Exp-Hepatol 2022;12(5):1388-1392.",48.0,YR,,F,Y,,,20230711.0,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,226925681.0,OT,,,,,,,,,226925681.0,1.0,HIV infection
22771667,227716671,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1080980,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,227716671.0,OT,,,,,,,,,227716671.0,1.0,HIV infection
22773857,227738571,1,I,,20230724.0,20230801,20230801,EXP,,ET-MYLANLABS-2023M1081027,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230801.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,227738571.0,OT,,,,,,,,,227738571.0,1.0,HIV infection
22776056,227760561,1,I,,20230723.0,20230802,20230802,EXP,,IN-HETERO-HET2023IN02166,HETERO,"Singh B, Guliani A, Hanumanthu V, Narang T, Dogra S, Handa S et.al. A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine). Indian Journal of Sexually Transmitted Diseases and AIDS. 2023;44(1):6-10",,,,M,Y,,,20230802.0,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug reaction with eosinophilia and systemic symptoms,227760561.0,OT,,,,,,,,,227760561.0,1.0,HIV infection
22776214,227762141,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081066,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Treatment failure,227762141.0,OT,,,,,,,,,227762141.0,1.0,HIV infection
22776220,227762201,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081108,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,227762201.0,OT,,,,,,,,,227762201.0,1.0,HIV infection
22776225,227762251,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081179,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Treatment failure,227762251.0,OT,,,,,,,,,227762251.0,1.0,HIV infection
22776233,227762331,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1080988,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Treatment failure,227762331.0,OT,,,,,,,,,227762331.0,1.0,HIV infection
22776515,227765151,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081152,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment failure,227765151.0,OT,,,,,,,,,227765151.0,1.0,HIV infection
22778544,227785441,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081189,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia,227785441.0,OT,,,,,,,,,227785441.0,1.0,HIV infection
22778552,227785521,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081085,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,M,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Treatment failure,227785521.0,OT,,,,,,,,,227785521.0,1.0,HIV infection
22778554,227785541,1,I,,20230724.0,20230802,20230802,EXP,,ET-MYLANLABS-2023M1081081,MYLAN,"Fentie Wendie T, Mengistu G. Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study. PLOS-One 2022;17(3):1-11.",,,A,F,Y,,,20230802.0,,HP,ET,ET,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Maternal exposure during pregnancy;Treatment failure,227785541.0,OT,,,,,,,,,227785541.0,1.0,HIV infection
22892383,228923831,1,I,20230802.0,20230829.0,20230901,20230901,EXP,,UA-MYLANLABS-2023M1091767,MYLAN,,55.0,YR,,M,Y,,,20230901.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Creatinine renal clearance decreased,228923831.0,LT,,,228923831.0,1.0,20211123.0,20230803.0,619.0,DAY,228923831.0,1.0,HIV infection
23008626,230086261,1,I,20230830.0,20230926.0,20230929,20230929,EXP,,UA-MYLANLABS-2023M1103083,MYLAN,,66.0,YR,,F,Y,,,20230929.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,230086261.0,OT,,,230086261.0,1.0,20220310.0,20230830.0,539.0,DAY,230086261.0,1.0,HIV infection
23080963,230809631,1,I,20230912.0,20231010.0,20231018,20231018,EXP,,UA-MYLANLABS-2023M1109533,MYLAN,,39.0,YR,,F,Y,,,20231018.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Creatinine renal clearance decreased,230809631.0,LT,,,230809631.0,1.0,20210908.0,20230912.0,735.0,DAY,230809631.0,1.0,HIV infection CDC Group IV subgroup C2
23215205,232152053,3,F,,20231218.0,20231122,20231221,EXP,,KZ-HETERO-HET2023KZ03293,HETERO,,39.0,YR,,M,Y,67.0,KG,20231221.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Glomerular filtration rate decreased;Neurotoxicity,232152053.0,OT,,,232152053.0,1.0,20230918.0,20230928.0,11.0,DAY,232152053.0,1.0,Asymptomatic HIV infection
23220096,232200963,3,F,,20231218.0,20231123,20231221,EXP,,KZ-HETERO-HET2023KZ03287,HETERO,,40.0,YR,,F,Y,79.0,KG,20231221.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,232200963.0,OT,,,232200963.0,1.0,20180817.0,20230912.0,1853.0,DAY,232200963.0,1.0,Asymptomatic HIV infection
23220252,232202523,3,F,,20231218.0,20231123,20231220,EXP,,KZ-HETERO-HET2023KZ03295,HETERO,,40.0,YR,,F,Y,68.0,KG,20231220.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Dyspnoea;Headache;Neurotoxicity,232202523.0,OT,,,232202523.0,1.0,20230217.0,20230912.0,208.0,DAY,232202523.0,1.0,Asymptomatic HIV infection
23220342,232203423,3,F,,20231218.0,20231123,20231220,EXP,,KZ-HETERO-HET2023KZ03290,HETERO,,,,,M,Y,58.0,KG,20231220.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Poisoning,232203423.0,OT,,,232203423.0,1.0,20220707.0,20230904.0,425.0,DAY,232203423.0,1.0,HIV infection WHO clinical stage II
23220414,232204143,3,F,,20231218.0,20231123,20231221,EXP,,KZ-HETERO-HET2023KZ03302,HETERO,,39.0,YR,,M,Y,47.0,KG,20231221.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Neurotoxicity,232204143.0,OT,,,232204143.0,1.0,20230630.0,20231019.0,112.0,DAY,232204143.0,1.0,Asymptomatic HIV infection
23284320,232843201,1,I,20231115.0,20231205.0,20231211,20231211,EXP,,UA-MYLANLABS-2023M1130496,MYLAN,,48.0,YR,,F,Y,,,20231211.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR,Nephropathy toxic,232843201.0,OT,,,232843201.0,1.0,20220613.0,20231116.0,540.0,DAY,232843201.0,1.0,HIV infection
23310036,233100361,1,I,20231216.0,20231218.0,20231218,20231218,DIR,684883,,FDA-CTU,,60.0,YR,,M,N,,,20231218.0,N,HP,US,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,HIV infection,233100361.0,DE,233100361.0,HP,233100361.0,1.0,20220301.0,20231216.0,,,233100361.0,1.0,HIV infection
23315666,233156661,1,I,20231216.0,20231218.0,20231219,20231219,DIR,FDA-CDER-CTU-2023-93014,,FDA-CTU,,60.0,YR,,M,N,,,20231218.0,Y,PH,US,,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",HIV infection,233156661.0,DE,233156661.0,HP,233156661.0,1.0,20220301.0,20231216.0,,,233156661.0,1.0,HIV infection
23425407,234254072,2,F,,20240217.0,20240122,20240221,EXP,,KZ-HETERO-HET2024KZ00160,HETERO,,23.0,YR,,F,Y,,,20240221.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Neurotoxicity,234254072.0,OT,,,,,,,,,234254072.0,1.0,Asymptomatic HIV infection
23573800,235738001,1,I,,20240215.0,20240228,20240228,EXP,,PT-AUROBINDO-AUR-APL-2024-008477,AUROBINDO,,58.0,YR,,M,Y,,,20240228.0,,MD,PT,PT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Fanconi syndrome;Renal tubular injury;Tubulointerstitial nephritis,235738001.0,OT,,,,,,,,,235738001.0,1.0,HIV infection
23655252,236552521,1,I,20230602.0,20240315.0,20240320,20240320,EXP,ES-AEMPS-1496163,ES-009507513-2403ESP005621,MERCK,,29.0,YR,,F,Y,58.0,KG,20240320.0,,CN,ES,ES,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acne;Androgenetic alopecia;Blindness transient;Constipation;Heavy menstrual bleeding;Skin candida;Weight increased,236552521.0,OT,,,236552521.0,1.0,20230601.0,20230627.0,27.0,DAY,236552521.0,1.0,Prophylaxis against HIV infection
23689705,236897051,1,I,,20240319.0,20240331,20240331,EXP,,US-JNJFOC-20240378279,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20240401.0,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Accident at work;Adverse drug reaction;Bronchitis;COVID-19;Depression;Dermatitis;Diarrhoea;Fall;Family stress;Hypercalcaemia;Hypertension;Intertrigo;Ligament sprain;Lumbar spinal stenosis;Menopausal symptoms;Neuropathy peripheral;Osteonecrosis;Pigmentation disorder;Pneumonia,236897051.0,OT,,,236897051.0,1.0,20231114.0,,,,236897051.0,1.0,HIV infection
23693254,236932541,1,I,20230801.0,20240326.0,20240401,20240401,EXP,,UA-MYLANLABS-2024M1028641,MYLAN,,44.0,YR,,M,Y,,,20240401.0,,HP,UA,UA,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL",Nephropathy toxic,236932541.0,OT,,,236932541.0,1.0,20220815.0,20240305.0,569.0,DAY,236932541.0,1.0,HIV infection CDC Group IV subgroup E
23697489,236974891,1,I,,20240327.0,20240402,20240402,EXP,,CA-MYLANLABS-2024M1029479,MYLAN,"DeKoven S, Naccarato M, Brumme CJ, Tan DHS. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. HIV-Med 2023; 24 (11): 1137-1143.",45.0,YR,,F,Y,,,20240402.0,,HP,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance,236974891.0,OT,,,,,,,,,236974891.0,1.0,HIV infection
23703973,237039731,1,I,,20240327.0,20240403,20240403,EXP,,CA-STRIDES ARCOLAB LIMITED-2024SP003830,STRIDES,"DeKoven S, Naccarato M, Brumme CJ, Tan DHS.. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.. HIV-Med. 2023;24 (11):1137-1143.",45.0,YR,,F,Y,,,20240404.0,,HP,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Treatment noncompliance,237039731.0,OT,,,,,,,,,237039731.0,1.0,HIV infection
23709559,237095591,1,I,,20240328.0,20240404,20240404,EXP,,DE-STRIDES ARCOLAB LIMITED-2024SP003931,STRIDES,"Foerster Y, Sollfrank L, Rechtien L, Harrer T, Berking C, Sticherling M.. Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature.. Front-Immunol. 2023;14:1-6",74.0,YR,,F,Y,,,20240405.0,,HP,DE,DE,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Pemphigoid,237095591.0,HO,,,,,,,,,237095591.0,1.0,HIV infection
23746723,237467232,2,F,,20240415.0,20240416,20240430,EXP,,CA-AUROBINDO-AUR-APL-2024-016888,AUROBINDO,"DeKoven S, Naccarato M, Brumme CJ, Tan DHS. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. HIV-Med. 2023;24(11):1137-1143",45.0,YR,,F,Y,,,20240430.0,,HP,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Treatment noncompliance;Virologic failure,237467232.0,OT,,,,,,,,,237467232.0,1.0,HIV infection
23792851,237928512,2,F,,20240518.0,20240429,20240524,EXP,,KZ-HETERO-HET2024KZ01205,HETERO,,,,A,F,Y,,,20240524.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,237928512.0,OT,,,237928512.0,1.0,20200604.0,20240307.0,1373.0,DAY,237928512.0,1.0,HIV infection
23792942,237929421,1,I,20240306.0,20240426.0,20240429,20240429,EXP,FR-AFSSAPS-MA2024000713,FR-VIIV HEALTHCARE LIMITED-FR2024053948,VIIV,,,,,,Y,,,20240429.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hepatic cytolysis,237929421.0,LT,,,237929421.0,1.0,20240212.0,20240306.0,23.0,DAY,237929421.0,1.0,HIV infection
23824661,238246612,2,F,20231009.0,20240805.0,20240507,20240812,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2023EME167263,VIIV,,,,,,Y,,,20240812.0,,MD,DE,DE,TENOFOVIR + EMTRICITABINE + EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,238246612.0,DS,,,238246612.0,1.0,20210805.0,20231009.0,795.0,DAY,238246612.0,1.0,HIV infection
23844058,238440581,1,I,20240306.0,20240430.0,20240510,20240510,EXP,FR-AFSSAPS-MA2024000713,FR-TEVA-VS-3193854,TEVA,,29.0,YR,,M,Y,,,20240510.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hepatic cytolysis,238440581.0,LT,,,238440581.0,1.0,20240212.0,20240306.0,23.0,DAY,238440581.0,1.0,HIV infection
23858202,238582021,1,I,20240415.0,20240508.0,20240515,20240515,EXP,,UA-MYLANLABS-2024M1042522,MYLAN,,45.0,YR,,M,Y,,,20240515.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,238582021.0,OT,,,238582021.0,1.0,20220523.0,20240416.0,695.0,DAY,238582021.0,1.0,HIV infection
23862190,238621901,1,I,20060101.0,20240510.0,20240516,20240516,EXP,,US-GILEAD-2024-0672501,GILEAD,,35.0,YR,A,F,Y,,,20240516.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Back disorder;Musculoskeletal discomfort;Pain,238621901.0,DS,,,,,,,,,238621901.0,1.0,HIV infection
24064501,240645011,1,I,,20240702.0,20240709,20240709,EXP,,ZA-MYLANLABS-2024M1063699,MYLAN,"Khan A, Pillay M, Chimukangara B, Gounder L, Manyana S, Francois K-L, et al. Identification of HIV-1 subtype CRF18_cpx in a patient with multidrug resistance in KwaZulu-Natal, South Africa: An epidemiological worry?. J-Clin-Virol-Plus 2023; 3 (2):.",31.0,YR,,F,Y,,,20240709.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Pathogen resistance,240645011.0,HO,,,240645011.0,1.0,20170109.0,,,,240645011.0,1.0,HIV infection
24089720,240897201,1,I,,20240702.0,20240715,20240715,EXP,,ZA-STRIDES ARCOLAB LIMITED-2024SP008069,STRIDES,"Khan A, Pillay M, Chimukangara B, Gounder L, Manyana S, Francois K-L, et al.. Identification of HIV-1 subtype CRF18_cpx in a patient with multidrug resistance in KwaZulu-Natal, South Africa: An epidemiological worry?.. J-Clin-Virol-Plus. 2023;3 (2)",31.0,YR,,F,Y,,,20240715.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Pathogen resistance;Treatment failure,240897201.0,OT,,,240897201.0,1.0,20170109.0,,,,240897201.0,1.0,HIV infection
24101321,241013212,2,F,,20240803.0,20240717,20240813,EXP,,KZ-HETERO-HET2024KZ02251,HETERO,,,,,M,Y,,,20240813.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Poisoning,241013212.0,OT,,,241013212.0,1.0,20240125.0,20240222.0,29.0,DAY,241013212.0,1.0,HIV infection WHO clinical stage I
24101731,241017312,2,F,,20240803.0,20240717,20240809,EXP,,KZ-HETERO-HET2024KZ02252,HETERO,,,,,F,Y,,,20240809.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Cough;Dizziness;Fatigue;Poisoning;Product dose omission issue,241017312.0,OT,,,241017312.0,1.0,20231106.0,20240214.0,101.0,DAY,241017312.0,1.0,HIV infection
24104734,241047342,2,F,,20240723.0,20240717,20240731,EXP,,US-MYLANLABS-2024M1065887,MYLAN,"Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, et al. Characterizing HIV drug resistance in cases of vertical transmission in the VesTed randomized antiretroviral treatment trial. J-Acquir-Immune-Defic-Syndr 2024; 96 (4): 385-392.",,,I,,Y,,,20240731.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,241047342.0,OT,,,,,,,,,241047342.0,1.0,Prophylaxis against HIV infection
24107199,241071992,2,F,,20240803.0,20240718,20240812,EXP,,KZ-HETERO-HET2024KZ02248,HETERO,,,,,M,Y,,,20240812.0,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Poisoning,241071992.0,OT,,,241071992.0,1.0,20210802.0,20240212.0,925.0,DAY,241071992.0,1.0,HIV infection WHO clinical stage II
24120939,241209391,1,I,,20240716.0,20240722,20240722,EXP,,ZW-MYLANLABS-2024M1068078,MYLAN,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. South-Afr-J-HIV-Med 2022; 23 (1): a1435.",29.0,YR,,F,Y,,,20240722.0,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Drug resistance mutation;Treatment failure,241209391.0,OT,,,241209391.0,1.0,201706.0,202006.0,,,241209391.0,1.0,HIV infection
24131564,241315641,1,I,,20240716.0,20240724,20240724,EXP,,ZW-MYLANLABS-2024M1068111,MYLAN,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. South-Afr-J-HIV-Med 2022; 23 (1): a1435.",7.0,YR,,M,Y,,,20240724.0,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\STAVUDINE;EFAVIRENZ\LAMIVUDINE\ZIDOVUDINE,Drug resistance mutation;Treatment failure,241315641.0,OT,,,241315641.0,1.0,201009.0,201501.0,,,241315641.0,1.0,HIV infection
24156903,241569031,1,I,,20240722.0,20240731,20240731,EXP,,US-MYLANLABS-2024M1069413,MYLAN,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.",51.0,YR,,F,Y,,,20240731.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Endocrine ophthalmopathy;Graves' disease,241569031.0,HO,,,,,,,,,241569031.0,1.0,HIV infection
24191423,241914232,2,F,,20240812.0,20240808,20240820,EXP,,US-TEVA-VS-3228835,TEVA,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.; Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.",51.0,YR,,F,Y,,,20240820.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Endocrine ophthalmopathy;Graves' disease,241914232.0,HO,,,,,,,,,241914232.0,1.0,HIV infection
24191587,241915872,2,F,,20240819.0,20240808,20240831,EXP,,US-AUROBINDO-AUR-APL-2024-038821,AUROBINDO,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K.. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci. 2024;367 (Suppl. 1):S9-S10",51.0,YR,,F,Y,,,20240831.0,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Endocrine ophthalmopathy;Graves' disease;Immune reconstitution inflammatory syndrome,241915872.0,OT,,,,,,,,,241915872.0,1.0,HIV infection
24208773,242087731,1,I,20180601.0,20240802.0,20240814,20240814,EXP,,UG-MYLANLABS-2024M1073734,MYLAN,"Lubega G, Lutaakome J, Kibirige M, Opoka D, Atukunda I, Ruzagira E. Vitamin B12 deficiency presenting as progressive blindness in a 33-year-old HIV-positive female patient on Efavirenz-based regimen: case report. Pan-Afr-Med-J 2024; 47 (0): 164.",30.0,YR,,F,Y,,,20240814.0,,HP,UG,UG,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Neuropathy peripheral;Optic neuritis;Vitamin B12 deficiency,242087731.0,OT,,,242087731.0,1.0,201301.0,2015.0,2.0,WK,242087731.0,1.0,HIV infection
24210181,242101811,1,I,,20240813.0,20240814,20240814,EXP,,US-GILEAD-2024-0684151,GILEAD,,39.0,YR,A,M,Y,,,20240814.0,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Feeling abnormal;Rash,242101811.0,HO,,,242101811.0,1.0,2016.0,2016.0,,,242101811.0,1.0,HIV infection
24253884,242538842,2,F,,20240823.0,20240827,20240829,EXP,,ID-PFIZER INC-202400242265,PFIZER,"Sufiawati, I.. Case Series of HIV-Associated Oral Lesions Across Different Clinical Stages in People Living with HIV. HIV/AIDS - Research and Palliative Care. 2024;16:289-299",34.0,YR,,F,Y,,,20240829.0,,MD,ID,ID,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Angular cheilitis;Drug eruption;Erythema multiforme,242538842.0,OT,,,,,,,,,242538842.0,6.0,Antiretroviral therapy
24267665,242676651,1,I,,20240819.0,20240830,20240830,EXP,,US-MACLEODS PHARMA-MAC2024048991,MACLEODS,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K..Delayed onset Graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency  virus: A case series.American Journal of the Medical Sciences.2024;367(Suppl 1):S9-10",,,,,Y,,,20240830.0,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR,Endocrine ophthalmopathy;Graves' disease;Immune reconstitution inflammatory syndrome,242676651.0,OT,,,,,,,,,242676651.0,1.0,HIV infection
24391558,243915581,1,I,,20240923.0,20241003,20241003,EXP,,ZA-GILEAD-2024-0688887,GILEAD,"Bronkhorst E., Joseph-Busby M., Bezuidenhout S. Reducing medication errors in HIV-positive patients: Influence of a clinical pharmacist. Southern African Journal of HIV Medicine. 2024;25(1):a1594. doi:10.4102/sajhivmed.v25i1.1594",,,A,,Y,,,20241003.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury;Prescription drug used without a prescription,243915581.0,OT,,,,,,,,,243915581.0,1.0,HIV infection
24434425,244344251,1,I,20231024.0,20241008.0,20241014,20241014,EXP,,UA-MYLANLABS-2024M1092250,MYLAN,,67.0,YR,,M,Y,,,20241014.0,,HP,UA,UA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,244344251.0,OT,,,244344251.0,1.0,20190604.0,20240903.0,63.0,MON,244344251.0,1.0,HIV infection
24440369,244403691,1,I,,20241007.0,20241016,20241016,EXP,,ZA-STRIDES ARCOLAB LIMITED-2024SP013237,STRIDES,"Chimbetete T, Choshi P, Pedretti S, Porter M, Roberts R, Lehloenya R, et al.. Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients.. Front-Med. 2023;10",35.0,YR,,M,Y,,,20241016.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug reaction with eosinophilia and systemic symptoms,244403691.0,HO,,,,,,,,,244403691.0,1.0,HIV infection
24463015,244630151,1,I,,20241007.0,20241018,20241018,EXP,,ZA-MYLANLABS-2024M1092687,MYLAN,"Chimbetete T, Choshi P, Pedretti S, Porter M, Roberts R, Lehloenya R, et al. Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients. Front-Med 2023; 10.",35.0,YR,,M,Y,,,20241018.0,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug reaction with eosinophilia and systemic symptoms,244630151.0,LT,,,,,,,,,244630151.0,1.0,HIV infection
24534910,245349101,1,I,,20240722.0,20241022,20241022,PER,,US-STRIDES ARCOLAB LIMITED-2024SP009289,STRIDES,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K.. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci. 2024;367 (Suppl. 1):S9-S10",51.0,YR,,F,Y,,,20241022.0,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Endocrine ophthalmopathy;Graves' disease,245349101.0,HO,,,,,,,,,245349101.0,1.0,HIV infection
24606827,246068271,1,I,,20241031.0,20241112,20241112,EXP,,ID-HETERO-HET2024ID04081,HETERO,,,,,M,Y,,,20241112.0,,PH,ID,ID,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Lung disorder;Nausea;Vomiting,246068271.0,HO,,,246068271.0,1.0,20241015.0,,,,246068271.0,1.0,HIV infection
24652091,246520911,1,I,20241120.0,20241121.0,20241121,20241121,DIR,FDA-CDER-CTU-2024-80625,,FDA-CTU,,64.0,YR,,M,N,,,20241121.0,N,PH,US,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Death,246520911.0,DE,246520911.0,HP,246520911.0,1.0,20240406.0,20241120.0,,,246520911.0,1.0,HIV infection
24684357,246843571,1,I,20240205.0,20241202.0,20241202,20241202,EXP,FR-AFSSAPS-NT2024001436,"FR-B.I. Pharmaceuticals,Inc./Ridgefield-2024-BI-066009",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20241202.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Osteoporosis,246843571.0,OT,,,246843571.0,1.0,20090824.0,20240205.0,5278.0,DAY,246843571.0,1.0,HIV infection
24695424,246954241,1,I,20240205.0,20241203.0,20241204,20241204,EXP,FR-AFSSAPS-NT2024001436,FR-GILEAD-2024-0695837,GILEAD,,61.0,YR,A,F,Y,,,20241204.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Osteoporosis,246954241.0,OT,,,246954241.0,1.0,20090824.0,20240205.0,5278.0,DAY,246954241.0,1.0,HIV infection
24700032,247000321,1,I,20241113.0,20241203.0,20241205,20241205,EXP,FR-AFSSAPS-PA2024001835,FR-GILEAD-2024-0695833,GILEAD,,,,A,M,Y,,,20241205.0,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Delirium;Hemiparesis;Wrong drug,247000321.0,HO,,,247000321.0,1.0,20241113.0,20241116.0,3.0,DAY,247000321.0,1.0,Prophylaxis against HIV infection
24719750,247197501,1,I,20240205.0,20241129.0,20241211,20241211,EXP,,FR-CIPLA LTD.-2024FR14393,CIPLA,,,,,,Y,,,20241211.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL MALEATE,Osteoporosis,247197501.0,OT,,,247197501.0,1.0,20090824.0,20240205.0,5278.0,DAY,247197501.0,1.0,HIV infection
24719888,247198881,1,I,20241113.0,20241129.0,20241211,20241211,EXP,,FR-CIPLA LTD.-2024FR14646,CIPLA,,,,,,Y,,,20241211.0,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Delirium;Hemiparesis;Wrong drug,247198881.0,HO,,,247198881.0,2.0,20241113.0,20241116.0,3.0,DAY,247198881.0,1.0,Prophylaxis against HIV infection
24722325,247223251,1,I,20240205.0,20241205.0,20241211,20241211,EXP,FR-AFSSAPS-NT2024001436,FR-MYLANLABS-2024M1110553,MYLAN,,61.0,YR,,F,Y,,,20241211.0,,MD,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,247223251.0,OT,,,247223251.0,1.0,20200302.0,20240205.0,1436.0,DAY,247223251.0,1.0,HIV infection
24722334,247223341,1,I,20241113.0,20241205.0,20241211,20241211,EXP,FR-AFSSAPS-PA2024001835,FR-MYLANLABS-2024M1110506,MYLAN,,,,A,M,Y,,,20241211.0,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL SUCCINATE,Delirium;Hemiparesis;Wrong drug,247223341.0,HO,,,247223341.0,2.0,20241113.0,20241116.0,4.0,DAY,247223341.0,1.0,Prophylaxis against HIV infection
